# ESC Guidelines: Pulmonary Hypertension (2022)

**Source**: `2022_Pulmonary_Hypertension.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 114

---

## Table of Contents

- [2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension](#2022-esc/ers-guidelines-for-the-diagnosis-and-trea) *(p. 1)*
  - [Abbreviations and acronyms](#abbreviations-and-acronyms) *(p. 5)*
  - [1. Preamble](#1-preamble) *(p. 7)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. What is new](#21-what-is-new) *(p. 8)*
    - [2.2. Methods](#22-methods) *(p. 18)*
  - [3. Definitions and classifications](#3-definitions-and-classifications) *(p. 19)*
    - [3.1. Definitions](#31-definitions) *(p. 19)*
    - [3.2. Classifications](#32-classifications) *(p. 20)*
  - [4. Epidemiology and risk factors](#4-epidemiology-and-risk-factors) *(p. 21)*
    - [4.1. Group 1, pulmonary arterial hypertension](#41-group-1,-pulmonary-arterial-hypertension) *(p. 21)*
    - [4.2. Group 2, pulmonary hypertension associated with left heart disease](#42-group-2,-pulmonary-hypertension-associated-with) *(p. 23)*
    - [4.3. Group 3, pulmonary hypertension associated with lung diseases and/or hypoxia](#43-group-3,-pulmonary-hypertension-associated-with) *(p. 23)*
    - [4.4. Group 4, pulmonary hypertension associated with chronic pulmonary artery obstruction](#44-group-4,-pulmonary-hypertension-associated-with) *(p. 23)*
    - [4.5. Group 5, pulmonary hypertension with unclear and/or multifactorial mechanisms](#45-group-5,-pulmonary-hypertension-with-unclear-an) *(p. 23)*
  - [5. Pulmonary hypertension diagnosis](#5-pulmonary-hypertension-diagnosis) *(p. 23)*
    - [5.1. Diagnosis](#51-diagnosis) *(p. 23)*
      - [5.1.1. Clinical presentation](#511-clinical-presentation) *(p. 23)*
      - [5.1.2. Electrocardiogram](#512-electrocardiogram) *(p. 23)*
      - [5.1.3. Chest radiography](#513-chest-radiography) *(p. 24)*
      - [5.1.4. Pulmonary function tests and arterial blood gases](#514-pulmonary-function-tests-and-arterial-blood-ga) *(p. 24)*
      - [5.1.5. Echocardiography](#515-echocardiography) *(p. 25)*
      - [5.1.6. Ventilation/perfusion lung scan](#516-ventilation/perfusion-lung-scan) *(p. 26)*
      - [5.1.7. Non-contrast and contrast-enhanced chest computed tomography examinations, and digital subtraction angiography](#517-non-contrast-and-contrast-enhanced-chest-compu) *(p. 27)*
      - [5.1.8. Cardiac magnetic resonance imaging](#518-cardiac-magnetic-resonance-imaging) *(p. 28)*
      - [5.1.9. Blood tests and immunology](#519-blood-tests-and-immunology) *(p. 29)*
      - [5.1.10. Abdominal ultrasound](#5110-abdominal-ultrasound) *(p. 29)*
      - [5.1.11. Cardiopulmonary exercise testing](#5111-cardiopulmonary-exercise-testing) *(p. 29)*
      - [5.1.12. Right heart catheterization, vasoreactivity, exercise, and fluid challenge](#5112-right-heart-catheterization,-vasoreactivity,-) *(p. 29)*
        - [5.1.12.1. Right heart catheterization](#51121-right-heart-catheterization) *(p. 29)*
        - [5.1.12.2. Vasoreactivity testing](#51122-vasoreactivity-testing) *(p. 30)*
        - [5.1.12.3. Exercise right heart catheterization](#51123-exercise-right-heart-catheterization) *(p. 30)*
        - [5.1.12.4. Fluid challenge](#51124-fluid-challenge) *(p. 30)*
      - [5.1.13. Genetic counselling and testing](#5113-genetic-counselling-and-testing) *(p. 31)*
    - [5.2. Diagnostic algorithm](#52-diagnostic-algorithm) *(p. 31)*
      - [5.2.1 Step 1 (suspicion)](#521-step-1-(suspicion)) *(p. 31)*
      - [5.2.2. Step 2 (detection)](#522-step-2-(detection)) *(p. 31)*
      - [5.2.3. Step 3 (confirmation)](#523-step-3-(confirmation)) *(p. 33)*
    - [5.3. Screening and early detection](#53-screening-and-early-detection) *(p. 35)*
      - [5.3.1. Systemic sclerosis](#531-systemic-sclerosis) *(p. 36)*
      - [5.3.2. BMPR2 mutation carriers](#532-bmpr2-mutation-carriers) *(p. 36)*
      - [5.3.3. Portal hypertension](#533-portal-hypertension) *(p. 36)*
      - [5.3.4. Pulmonary embolism](#534-pulmonary-embolism) *(p. 36)*
  - [6. Pulmonary arterial hypertension (group 1)](#6-pulmonary-arterial-hypertension-(group-1)) *(p. 38)*
    - [6.1. Clinical characteristics](#61-clinical-characteristics) *(p. 38)*
    - [6.2. Severity and risk assessment](#62-severity-and-risk-assessment) *(p. 38)*
      - [6.2.1. Clinical parameters](#621-clinical-parameters) *(p. 38)*
      - [6.2.2. Imaging](#622-imaging) *(p. 39)*
        - [6.2.2.1. Echocardiography](#6221-echocardiography) *(p. 39)*
        - [6.2.2.2. Cardiac magnetic resonance imaging](#6222-cardiac-magnetic-resonance-imaging) *(p. 39)*
      - [6.2.3. Haemodynamics](#623-haemodynamics) *(p. 39)*
      - [6.2.4. Exercise capacity](#624-exercise-capacity) *(p. 40)*
      - [6.2.5. Biochemical markers](#625-biochemical-markers) *(p. 41)*
      - [6.2.6. Patient-reported outcome measures](#626-patient-reported-outcome-measures) *(p. 41)*
      - [6.2.7. Comprehensive prognostic evaluation, risk assessment, and treatment goals](#627-comprehensive-prognostic-evaluation,-risk-asse) *(p. 42)*
    - [6.3. Therapy](#63-therapy) *(p. 43)*
      - [6.3.1. General measures](#631-general-measures) *(p. 43)*
        - [6.3.1.1. Physical activity and supervised rehabilitation](#6311-physical-activity-and-supervised-rehabilitati) *(p. 43)*
        - [6.3.1.2. Anticoagulation](#6312-anticoagulation) *(p. 43)*
        - [6.3.1.3. Diuretics](#6313-diuretics) *(p. 44)*
        - [6.3.1.4. Oxygen](#6314-oxygen) *(p. 44)*
        - [6.3.1.5. Cardiovascular drugs](#6315-cardiovascular-drugs) *(p. 44)*
        - [6.3.1.6. Anaemia and iron status](#6316-anaemia-and-iron-status) *(p. 44)*
        - [6.3.1.7. Vaccination](#6317-vaccination) *(p. 44)*
        - [6.3.1.8. Psychosocial support](#6318-psychosocial-support) *(p. 44)*
        - [6.3.1.9. Adherence to treatments](#6319-adherence-to-treatments) *(p. 44)*
      - [6.3.2. Special circumstances](#632-special-circumstances) *(p. 45)*
        - [6.3.2.1. Pregnancy and birth control](#6321-pregnancy-and-birth-control) *(p. 45)*
          - [6.3.2.1.1. Pregnancy](#63211-pregnancy) *(p. 45)*
          - [6.3.2.1.2. Contraception](#63212-contraception) *(p. 45)*
        - [6.3.2.2. Surgical procedures](#6322-surgical-procedures) *(p. 45)*
        - [6.3.2.3. Travel and altitude](#6323-travel-and-altitude) *(p. 45)*
      - [6.3.3. Pulmonary arterial hypertension therapies](#633-pulmonary-arterial-hypertension-therapies) *(p. 46)*
        - [6.3.3.1. Calcium channel blockers](#6331-calcium-channel-blockers) *(p. 46)*
        - [6.3.3.2. Endothelin receptor antagonists](#6332-endothelin-receptor-antagonists) *(p. 47)*
          - [6.3.3.2.1. Ambrisentan](#63321-ambrisentan) *(p. 48)*
          - [6.3.3.2.2. Bosentan](#63322-bosentan) *(p. 48)*
          - [6.3.3.2.3. Macitentan](#63323-macitentan) *(p. 49)*
        - [6.3.3.3. Phosphodiesterase 5 inhibitors and guanylate cyclase stimulators](#6333-phosphodiesterase-5-inhibitors-and-guanylate-) *(p. 49)*
          - [6.3.3.3.1. Sildenafil](#63331-sildenafil) *(p. 50)*
          - [6.3.3.3.2. Tadalafil](#63332-tadalafil) *(p. 50)*
          - [6.3.3.3.3. Riociguat](#63333-riociguat) *(p. 50)*
        - [6.3.3.4. Prostacyclin analogues and prostacyclin receptor agonists](#6334-prostacyclin-analogues-and-prostacyclin-recep) *(p. 50)*
          - [6.3.3.4.1. Epoprostenol](#63341-epoprostenol) *(p. 50)*
          - [6.3.3.4.2. Iloprost](#63342-iloprost) *(p. 50)*
          - [6.3.3.4.3. Treprostinil](#63343-treprostinil) *(p. 50)*
          - [6.3.3.4.4. Beraprost](#63344-beraprost) *(p. 50)*
          - [6.3.3.4.5. Selexipag](#63345-selexipag) *(p. 50)*
      - [6.3.4. Treatment strategies for patients with idiopathic, heritable, drug-associated, or connective tissue disease-associated pulmonary arterial hypertension](#634-treatment-strategies-for-patients-with-idiopat) *(p. 50)*
        - [6.3.4.1. Initial treatment decision in patients without cardiopulmonary comorbidities](#6341-initial-treatment-decision-in-patients-withou) *(p. 51)*
        - [6.3.4.2. Treatment decisions during follow-up in patients without cardiopulmonary comorbidities](#6342-treatment-decisions-during-follow-up-in-patie) *(p. 52)*
        - [6.3.4.3. Pulmonary arterial hypertension with cardiopulmonary comorbidities](#6343-pulmonary-arterial-hypertension-with-cardiopu) *(p. 53)*
      - [6.3.5. Drug interactions](#635-drug-interactions) *(p. 54)*
      - [6.3.6. Interventional therapy](#636-interventional-therapy) *(p. 54)*
        - [6.3.6.1. Balloon atrial septostomy and Potts shunt](#6361-balloon-atrial-septostomy-and-potts-shunt) *(p. 54)*
        - [6.3.6.2. Pulmonary artery denervation](#6362-pulmonary-artery-denervation) *(p. 54)*
      - [6.3.7. Advanced right ventricular failure](#637-advanced-right-ventricular-failure) *(p. 55)*
        - [6.3.7.1. Intensive care unit management](#6371-intensive-care-unit-management) *(p. 55)*
        - [6.3.7.2. Mechanical circulatory support](#6372-mechanical-circulatory-support) *(p. 55)*
      - [6.3.8. Lung and heart–lung transplantation](#638-lung-and-heart–lung-transplantation) *(p. 55)*
      - [6.3.9. Evidence-based treatment algorithm](#639-evidence-based-treatment-algorithm) *(p. 56)*
      - [6.3.10. Diagnosis and treatment of pulmonary arterial hypertension complications](#6310-diagnosis-and-treatment-of-pulmonary-arterial) *(p. 56)*
        - [6.3.10.1. Arrhythmias](#63101-arrhythmias) *(p. 56)*
        - [6.3.10.2. Haemoptysis](#63102-haemoptysis) *(p. 56)*
        - [6.3.10.3. Mechanical complications](#63103-mechanical-complications) *(p. 56)*
      - [6.3.11. End-of-life care and ethical issues](#6311-end-of-life-care-and-ethical-issues) *(p. 57)*
      - [6.3.12. New drugs in advanced clinical development (phase 3 studies)](#6312-new-drugs-in-advanced-clinical-development-(p) *(p. 57)*
  - [7. Specific pulmonary arterial hypertension subsets](#7-specific-pulmonary-arterial-hypertension-subsets) *(p. 57)*
    - [7.1. Pulmonary arterial hypertension associated with drugs and toxins](#71-pulmonary-arterial-hypertension-associated-with) *(p. 57)*
    - [7.2. Pulmonary arterial hypertension associated with connective tissue disease](#72-pulmonary-arterial-hypertension-associated-with) *(p. 58)*
      - [7.2.1. Epidemiology and diagnosis](#721-epidemiology-and-diagnosis) *(p. 58)*
      - [7.2.2. Therapy](#722-therapy) *(p. 58)*
    - [7.3. Pulmonary arterial hypertension associated with human immunodeficiency virus infection](#73-pulmonary-arterial-hypertension-associated-with) *(p. 59)*
      - [7.3.1. Diagnosis](#731-diagnosis) *(p. 59)*
      - [7.3.2. Therapy](#732-therapy) *(p. 59)*
    - [7.4. Pulmonary arterial hypertension associated with portal hypertension](#74-pulmonary-arterial-hypertension-associated-with) *(p. 60)*
      - [7.4.1. Diagnosis](#741-diagnosis) *(p. 60)*
      - [7.4.2. Therapy](#742-therapy) *(p. 60)*
        - [7.4.2.1. Liver transplantation](#7421-liver-transplantation) *(p. 60)*
    - [7.5. Pulmonary arterial hypertension associated with adult congenital heart disease](#75-pulmonary-arterial-hypertension-associated-with) *(p. 61)*
      - [7.5.1. Diagnosis and risk assessment](#751-diagnosis-and-risk-assessment) *(p. 61)*
      - [7.5.2. Therapy](#752-therapy) *(p. 62)*
    - [7.6. Pulmonary arterial hypertension associated with schistosomiasis](#76-pulmonary-arterial-hypertension-associated-with) *(p. 63)*
    - [7.7. Pulmonary arterial hypertension with signs of venous/capillary involvement](#77-pulmonary-arterial-hypertension-with-signs-of-v) *(p. 63)*
      - [7.7.1. Diagnosis](#771-diagnosis) *(p. 64)*
      - [7.7.2. Therapy](#772-therapy) *(p. 64)*
    - [7.8. Paediatric pulmonary hypertension](#78-paediatric-pulmonary-hypertension) *(p. 64)*
      - [7.8.1. Epidemiology and classification](#781-epidemiology-and-classification) *(p. 64)*
      - [7.8.2. Diagnosis and risk assessment](#782-diagnosis-and-risk-assessment) *(p. 66)*
      - [7.8.3. Therapy](#783-therapy) *(p. 66)*
  - [8. Pulmonary hypertension associated with left heart disease (group 2)](#8-pulmonary-hypertension-associated-with-left-hear) *(p. 68)*
    - [8.1. Definition, prognosis, and pathophysiology](#81-definition,-prognosis,-and-pathophysiology) *(p. 68)*
    - [8.2. Diagnosis](#82-diagnosis) *(p. 70)*
      - [8.2.1. Diagnosis and control of the underlying left heart disease](#821-diagnosis-and-control-of-the-underlying-left-) *(p. 70)*
      - [8.2.2. Evaluation of pulmonary hypertension and patient phenotyping](#822-evaluation-of-pulmonary-hypertension-and-patie) *(p. 70)*
      - [8.2.3. Invasive assessment of haemodynamics](#823-invasive-assessment-of-haemodynamics) *(p. 70)*
    - [8.3. Therapy](#83-therapy) *(p. 71)*
      - [8.3.1. Pulmonary hypertension associated with left-sided heart failure](#831-pulmonary-hypertension-associated-with-left-si) *(p. 71)*
        - [8.3.1.1. Heart failure with reduced ejection fraction](#8311-heart-failure-with-reduced-ejection-fraction) *(p. 71)*
        - [8.3.1.2. Heart failure with preserved ejection fraction](#8312-heart-failure-with-preserved-ejection-fractio) *(p. 71)*
        - [8.3.1.3. Interatrial shunt devices](#8313-interatrial-shunt-devices) *(p. 72)*
        - [8.3.1.4. Remote pulmonary arterial pressure monitoring in heart failure](#8314-remote-pulmonary-arterial-pressure-monitoring) *(p. 72)*
      - [8.3.2. Pulmonary hypertension associated with valvular heart disease](#832-pulmonary-hypertension-associated-with-valvula) *(p. 72)*
        - [8.3.2.1. Mitral valve disease](#8321-mitral-valve-disease) *(p. 72)*
        - [8.3.2.2. Aortic stenosis](#8322-aortic-stenosis) *(p. 72)*
        - [8.3.2.3. Tricuspid regurgitation](#8323-tricuspid-regurgitation) *(p. 72)*
      - [8.3.3. Recommendations on the use of drugs approved for PAH in PH-LHD](#833-recommendations-on-the-use-of-drugs-approved-f) *(p. 72)*
  - [9. Pulmonary hypertension associated with lung diseases and/or hypoxia (group 3)](#9-pulmonary-hypertension-associated-with-lung-dise) *(p. 73)*
    - [9.1. Diagnosis](#91-diagnosis) *(p. 75)*
    - [9.2. Therapy](#92-therapy) *(p. 75)*
      - [9.2.1. Pulmonary hypertension associated with chronic obstructive pulmonary disease or emphysema](#921-pulmonary-hypertension-associated-with-chronic) *(p. 75)*
      - [9.2.2. Pulmonary hypertension associated with interstitial lung disease](#922-pulmonary-hypertension-associated-with-interst) *(p. 75)*
      - [9.2.3. Recommendations on the use of drugs approved for PAH in PH associated with lung disease](#923-recommendations-on-the-use-of-drugs-approved-f) *(p. 76)*
  - [10. Chronic thrombo-embolic pulmonary hypertension (group 4)](#10-chronic-thrombo-embolic-pulmonary-hypertension-) *(p. 76)*
    - [10.1. Diagnosis](#101-diagnosis) *(p. 77)*
    - [10.2. Therapy](#102-therapy) *(p. 78)*
      - [10.2.1. Surgical treatment](#1021-surgical-treatment) *(p. 78)*
      - [10.2.2. Medical therapy](#1022-medical-therapy) *(p. 78)*
      - [10.2.3. Interventional treatment](#1023-interventional-treatment) *(p. 79)*
      - [10.2.4. Multimodal treatment](#1024-multimodal-treatment) *(p. 80)*
      - [10.2.5. Follow-up](#1025-follow-up) *(p. 81)*
    - [10.3. Chronic thrombo-embolic pulmonary hypertension team and experience criteria](#103-chronic-thrombo-embolic-pulmonary-hypertension) *(p. 81)*
  - [11. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5)](#11-pulmonary-hypertension-with-unclear-and/or-mult) *(p. 82)*
    - [11.1. Haematological disorders](#111-haematological-disorders) *(p. 82)*
    - [11.2. Systemic disorders](#112-systemic-disorders) *(p. 83)*
    - [11.3. Metabolic disorders](#113-metabolic-disorders) *(p. 83)*
    - [11.4. Chronic kidney failure](#114-chronic-kidney-failure) *(p. 83)*
    - [11.5. Pulmonary tumour thrombotic microangiopathy](#115-pulmonary-tumour-thrombotic-microangiopathy) *(p. 83)*
    - [11.6. Fibrosing mediastinitis](#116-fibrosing-mediastinitis) *(p. 83)*
  - [12. Definition of a pulmonary hypertension centre](#12-definition-of-a-pulmonary-hypertension-centre) *(p. 84)*
    - [12.1. Facilities and skills required for a pulmonary hypertension centre](#121-facilities-and-skills-required-for-a-pulmonary) *(p. 85)*
    - [12.2. European Reference Network](#122-european-reference-network) *(p. 85)*
    - [12.3. Patient associations and patient empowerment](#123-patient-associations-and-patient-empowerment) *(p. 85)*
  - [13. Key messages](#13-key-messages) *(p. 86)*
  - [14. Gaps in evidence](#14-gaps-in-evidence) *(p. 86)*
    - [14.1. Pulmonary arterial hypertension (group 1)](#141-pulmonary-arterial-hypertension-(group-1)) *(p. 86)*
    - [14.2. Pulmonary hypertension associated with left heart disease (group 2)](#142-pulmonary-hypertension-associated-with-left-he) *(p. 86)*
    - [14.3. Pulmonary hypertension associated with lung diseases and/or hypoxia (group 3)](#143-pulmonary-hypertension-associated-with-lung-di) *(p. 87)*
    - [14.4. Chronic thrombo-embolic pulmonary hypertension (group 4)](#144-chronic-thrombo-embolic-pulmonary-hypertension) *(p. 87)*
    - [14.5. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5)](#145-pulmonary-hypertension-with-unclear-and/or-mul) *(p. 87)*
  - [15. ‘What to do’ and ‘What not to do’ messages from the Guidelines](#15-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 87)*
  - [16. Quality indicators](#16-quality-indicators) *(p. 93)*
  - [17. Supplementary data](#17-supplementary-data) *(p. 94)*
  - [18. Data availability statement](#18-data-availability-statement) *(p. 94)*
  - [19. Author information](#19-author-information) *(p. 94)*
  - [20. Appendix](#20-appendix) *(p. 94)*
    - [ESC/ERS Scientific Document Group](#esc/ers-scientific-document-group) *(p. 94)*
  - [21. References](#21-references) *(p. 95)*
  - [21. References](#21-references) *(p. 95)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology
(ESC) and the European Respiratory Society (ERS).
Endorsed by the International Society for Heart and Lung
Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG).
Authors/Task Force Members: Marc Humbert
(France), Gabor Kovacs (Austria),
Marius M. Hoeper (Germany), Roberto Badagliacca (Italy), Rolf M.F. Berger
(Netherlands), Margarita Brida (Croatia), Jørn Carlsen (Denmark),
Andrew J.S. Coats (United Kingdom), Pilar Escribano-Subias (Spain),
Pisana Ferrari (Italy), Diogenes S. Ferreira (Brazil), Hossein Ardeschir Ghofrani
(Germany), George Giannakoulas (Greece), David G. Kiely (United Kingdom),
Eckhard Mayer (Germany), Gergely Meszaros (Hungary), Blin Nagavci (Germany),
Karen M. Olsson (Germany), Joanna Pepke-Zaba (United Kingdom),
Jennifer K. Quint (United Kingdom), Göran Rådegran (Sweden),
Gerald Simonneau (France), Olivier Sitbon (France), Thomy Tonia (Switzerland),
Mark Toshner (United Kingdom), Jean-Luc Vachiery (Belgium),
Anton Vonk Noordegraaf (Netherlands), Marion Delcroix
*† (ERS Chairperson)
(Belgium), Stephan Rosenkranz
*† (ESC Chairperson) (Germany), and ESC/ERS
Scientiﬁc Document Group
* Corresponding authors: Stephan Rosenkranz, Clinic III for Internal Medicine (Department of Cardiology, Pulmonology and Intensive Care Medicine), and Cologne Cardiovascular
Research Center (CCRC), Heart Center at the University Hospital Cologne, Kerpener Str. 62, 50937 Köln, Germany. Tel.: +49-221-478-32356. Email: stephan.rosenkranz@ukkoeln.de; and
Marion Delcroix, Clinical Department of Respiratory Diseases, Centre of Pulmonary Vascular Diseases, University Hospitals of Leuven, Herestraat 49, 3000 Leuven, Belgium. Tel.: +32 16
346813. Email: marion.delcroix@uzleuven.be
† The two chairpersons contributed equally to the document and are joint corresponding authors.
Author/Task Force Member afﬁliations are listed in author information.
1 Representing the Association for European Paediatric and Congenital Cardiology (AEPC)
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), and Heart Failure Association (HFA).
Councils: Council on Cardiovascular Genomics.
Working Groups: Adult Congenital Heart Disease, Pulmonary Circulation and Right Ventricular Function, Thrombosis.
Patient Forum
The content of these European Society of Cardiology (ESC)/European Respiratory Society (ERS) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC/ERS Guidelines may be translated or reproduced in any form without written permission from the ESC and the ERS. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal, and the party authorized to handle such permissions on behalf of the ESC (journals.
permissions@oup.com).
https://doi.org/10.1093/eurheartj/ehac237
ESC/ERS GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Markus Schwerzmann (ESC Review Coordinator) (Switzerland), Anh-Tuan Dinh-Xuan
(ERS Review Coordinator) (France), Andy Bush (United Kingdom), Magdy Abdelhamid (Egypt), Victor Aboyans
(France), Eloisa Arbustini (Italy), Riccardo Asteggiano (Italy), Joan-Albert Barberà (Spain), Maurice Beghetti
(Switzerland), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia), Robin Condliffe (United Kingdom),
Frances de Man (Netherlands), Volkmar Falk (Germany), Laurent Fauchier (France), Sean Gaine (Ireland),
Nazzareno Galié (Italy), Wendy Gin-Sing (United Kingdom), John Granton (Canada), Ekkehard Grünig
(Germany), Paul M. Hassoun (United States of America), Merel Hellemons (Netherlands), Tiny Jaarsma
(Sweden), Barbro Kjellström (Sweden), Frederikus A. Klok (Netherlands), Aleksandra Konradi (Russian
Federation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Irene Lang (Austria),
Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory Y.H. Lip (United Kingdom), Maja-Lisa Løchen
(Norway), Alexander G. Mathioudakis (United Kingdom), Richard Mindham (United Kingdom),
Shahin Moledina1 (United Kingdom), Robert Naeije (Belgium), Jens Cosedis Nielsen (Denmark),
Horst Olschewski (Austria), Isabelle Opitz (Switzerland), Steffen E. Petersen (United Kingdom),
Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Abilio Reis (Portugal), Arsen D. Ristić (Serbia),
Nicolas Roche (France), Rita Rodrigues (Portugal), Christine Selton-Suty (France), Rogerio Souza (Brazil),
Andrew J. Swift (United Kingdom), Rhian M. Touyz (Canada/United Kingdom), Silvia Ulrich (Switzerland),
Martin R. Wilkins (United Kingdom), and Stephen John Wort (United Kingdom)
All experts involved in the development of these guidelines have submitted declarations of interest. These have been compiled in a report and simultaneously published in a supplementary document to the guidelines. The report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary data that includes background information and detailed discussion of the data that have provided the basis of the guidelines.
Keywords
Guidelines • Pulmonary hypertension • Pulmonary arterial hypertension • Chronic thrombo-embolic pulmonary hypertension • Left heart disease • Congenital heart disease • Lung disease • Connective tissue disease • Endothelin receptor antagonists • Phosphodiesterase type 5 inhibitors • Soluble guanylate cyclase stimulators • Prostacyclin analogues • Prostacyclin receptor agonists • Pulmonary endarterectomy • Balloon pulmonary angioplasty • Lung transplantation
Table of contents
1. Preamble .............................................................................................................
3624
2. Introduction ......................................................................................................
3625
2.1. What is new ............................................................................................
3625
2.2. Methods ....................................................................................................
3635
3. Deﬁnitions and classiﬁcations ....................................................................
3636
3.1. Deﬁnitions ................................................................................................
3636
3.2. Classiﬁcations ..........................................................................................
3637
4. Epidemiology and risk factors ....................................................................
3638
4.1. Group 1, pulmonary arterial hypertension ................................
3638
4.2. Group 2, pulmonary hypertension associated with left heart disease .................................................................................................................
3640
4.3. Group 3, pulmonary hypertension associated with lung diseases and/or hypoxia ..............................................................................
3640
4.4. Group 4, pulmonary hypertension associated with chronic pulmonary artery obstruction ..................................................................
3640
4.5. Group 5, pulmonary hypertension with unclear and/or multifactorial mechanisms ..........................................................................
3640
5. Pulmonary hypertension diagnosis ..........................................................
3640
5.1. Diagnosis ...................................................................................................
3640
5.1.1. Clinical presentation ..................................................................... 3640
5.1.2. Electrocardiogram ......................................................................... 3640
5.1.3. Chest radiography ......................................................................... 3641
5.1.4. Pulmonary function tests and arterial blood gases ......... 3641
5.1.5. Echocardiography .......................................................................... 3642
Disclaimer: The ESC/ERS Guidelines represent the views of the ESC and the ERS and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their publication. The ESC and the ERS are not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC/ERS Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, particularly in relation to good use of health care or therapeutic strategies. Health professionals are encouraged to take the ESC/ERS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC/ERS Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. The ESC/ERS Guidelines do not exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
This article has been co-published with permission in the European Heart Journal and European Respiratory Journal. © the European Society of Cardiology and the European Respiratory
Society 2022. All rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article. For permissions please e-mail: journals.permissions@oup.com.
ESC/ERS Guidelines
3619


<!-- PAGE 3 -->

### Page 3

5.1.6. Ventilation/perfusion lung scan ................................................ 3643
5.1.7. Non-contrast and contrast-enhanced chest computed tomography examinations, and digital subtraction angiography ................................................................................................... 3644
5.1.8. Cardiac magnetic resonance imaging .................................... 3645
5.1.9. Blood tests and immunology .................................................... 3646
5.1.10. Abdominal ultrasound ............................................................... 3646
5.1.11. Cardiopulmonary exercise testing ....................................... 3646
5.1.12. Right heart catheterization, vasoreactivity, exercise, and
ﬂuid challenge .............................................................................................. 3646
5.1.12.1. Right heart catheterization ............................................. 3646
5.1.12.2. Vasoreactivity testing ........................................................ 3647
5.1.12.3. Exercise right heart catheterization ........................... 3647
5.1.12.4. Fluid challenge ...................................................................... 3647
5.1.13. Genetic counselling and testing ............................................ 3648
5.2. Diagnostic algorithm ............................................................................
3648
5.2.1 Step 1 (suspicion) ........................................................................... 3648
5.2.2. Step 2 (detection) ......................................................................... 3648
5.2.3. Step 3 (conﬁrmation) ................................................................... 3650
5.3. Screening and early detection ..........................................................
3652
5.3.1. Systemic sclerosis .......................................................................... 3653
5.3.2. BMPR2 mutation carriers ........................................................... 3653
5.3.3. Portal hypertension ...................................................................... 3653
5.3.4. Pulmonary embolism ................................................................... 3653
6. Pulmonary arterial hypertension (group 1) .........................................
3655
6.1. Clinical characteristics .........................................................................
3655
6.2. Severity and risk assessment ............................................................
3655
6.2.1. Clinical parameters ....................................................................... 3655
6.2.2. Imaging ................................................................................................ 3656
6.2.2.1. Echocardiography .................................................................. 3656
6.2.2.2. Cardiac magnetic resonance imaging ........................... 3656
6.2.3. Haemodynamics ............................................................................. 3656
6.2.4. Exercise capacity ............................................................................ 3657
6.2.5. Biochemical markers .................................................................... 3658
6.2.6. Patient-reported outcome measures ................................... 3658
6.2.7. Comprehensive prognostic evaluation, risk assessment,
and treatment goals .................................................................................. 3659
6.3. Therapy .....................................................................................................
3660
6.3.1. General measures .......................................................................... 3660
6.3.1.1. Physical activity and supervised rehabilitation .......... 3660
6.3.1.2. Anticoagulation ...................................................................... 3660
6.3.1.3. Diuretics .................................................................................... 3661
6.3.1.4. Oxygen ...................................................................................... 3661
6.3.1.5. Cardiovascular drugs ........................................................... 3661
6.3.1.6. Anaemia and iron status .................................................... 3661
6.3.1.7. Vaccination ............................................................................... 3661
6.3.1.8. Psychosocial support ........................................................... 3661
6.3.1.9. Adherence to treatments .................................................. 3661
6.3.2. Special circumstances ................................................................... 3662
6.3.2.1. Pregnancy and birth control ............................................. 3662
6.3.2.1.1. Pregnancy ......................................................................... 3662
6.3.2.1.2. Contraception ................................................................ 3662
6.3.2.2. Surgical procedures .............................................................. 3662
6.3.2.3. Travel and altitude ................................................................ 3662
6.3.3. Pulmonary arterial hypertension therapies ........................ 3663
6.3.3.1. Calcium channel blockers .................................................. 3663
6.3.3.2. Endothelin receptor antagonists .................................... 3664
6.3.3.2.1. Ambrisentan ................................................................... 3665
6.3.3.2.2. Bosentan ........................................................................... 3665
6.3.3.2.3. Macitentan ....................................................................... 3666
6.3.3.3. Phosphodiesterase 5 inhibitors and guanylate cyclase stimulators ............................................................................................... 3666
6.3.3.3.1. Sildenaﬁl ............................................................................ 3667
6.3.3.3.2. Tadalaﬁl ............................................................................. 3667
6.3.3.3.3. Riociguat ........................................................................... 3667
6.3.3.4. Prostacyclin analogues and prostacyclin receptor agonists ...................................................................................................... 3667
6.3.3.4.1. Epoprostenol .................................................................. 3667
6.3.3.4.2. Iloprost .............................................................................. 3667
6.3.3.4.3. Treprostinil ...................................................................... 3667
6.3.3.4.4. Beraprost ......................................................................... 3667
6.3.3.4.5. Selexipag ........................................................................... 3667
6.3.4. Treatment strategies for patients with idiopathic,
heritable, drug-associated, or connective tissue diseaseassociated pulmonary arterial hypertension .................................. 3667
6.3.4.1. Initial treatment decision in patients without cardiopulmonary comorbidities ...................................................... 3668
6.3.4.2. Treatment decisions during follow-up in patients without cardiopulmonary comorbidities .................................... 3669
6.3.4.3. Pulmonary arterial hypertension with cardiopulmonary comorbidities ...................................................... 3670
6.3.5. Drug interactions ........................................................................... 3671
6.3.6. Interventional therapy ................................................................. 3671
6.3.6.1. Balloon atrial septostomy and Potts shunt ................ 3671
6.3.6.2. Pulmonary artery denervation ........................................ 3671
6.3.7. Advanced right ventricular failure .......................................... 3672
6.3.7.1. Intensive care unit management ..................................... 3672
6.3.7.2. Mechanical circulatory support ....................................... 3672
6.3.8. Lung and heart–lung transplantation ..................................... 3672
6.3.9. Evidence-based treatment algorithm .................................... 3673
6.3.10. Diagnosis and treatment of pulmonary arterial hypertension complications ................................................................... 3673
6.3.10.1. Arrhythmias .......................................................................... 3673
6.3.10.2. Haemoptysis ......................................................................... 3673
6.3.10.3. Mechanical complications ................................................ 3673
6.3.11. End-of-life care and ethical issues ........................................ 3674
6.3.12. New drugs in advanced clinical development (phase 3
studies) ........................................................................................................... 3674
7. Speciﬁc pulmonary arterial hypertension subsets ............................
3674
7.1. Pulmonary arterial hypertension associated with drugs and toxins ...................................................................................................................
3674
7.2. Pulmonary arterial hypertension associated with connective tissue disease ....................................................................................................
3675
7.2.1. Epidemiology and diagnosis ....................................................... 3675
7.2.2. Therapy .............................................................................................. 3675
7.3. Pulmonary arterial hypertension associated with human immunodeﬁciency virus infection ............................................................
3676
7.3.1. Diagnosis ........................................................................................... 3676
7.3.2. Therapy .............................................................................................. 3676
7.4. Pulmonary arterial hypertension associated with portal hypertension ....................................................................................................
3677
7.4.1. Diagnosis ........................................................................................... 3677
7.4.2. Therapy .............................................................................................. 3677
7.4.2.1. Liver transplantation ............................................................ 3677
7.5. Pulmonary arterial hypertension associated with adult congenital heart disease ..............................................................................
3678
7.5.1. Diagnosis and risk assessment ................................................. 3678
7.5.2. Therapy .............................................................................................. 3679
7.6. Pulmonary arterial hypertension associated with schistosomiasis ................................................................................................
3680
3620
ESC/ERS Guidelines


<!-- PAGE 4 -->

### Page 4

7.7. Pulmonary arterial hypertension with signs of venous/
capillary involvement ....................................................................................
3680
7.7.1. Diagnosis ........................................................................................... 3681
7.7.2. Therapy .............................................................................................. 3681
7.8. Paediatric pulmonary hypertension ...............................................
3681
7.8.1. Epidemiology and classiﬁcation ................................................ 3681
7.8.2. Diagnosis and risk assessment ................................................. 3683
7.8.3. Therapy .............................................................................................. 3683
8. Pulmonary hypertension associated with left heart disease
(group 2) ..................................................................................................................
3685
8.1. Deﬁnition, prognosis, and pathophysiology ...............................
3685
8.2. Diagnosis ...................................................................................................
3687
8.2.1. Diagnosis and control of the underlying left heart disease ................................................................................................ 3687
8.2.2. Evaluation of pulmonary hypertension and patient phenotyping .................................................................................................. 3687
8.2.3. Invasive assessment of haemodynamics ............................... 3687
8.3. Therapy .....................................................................................................
3688
8.3.1. Pulmonary hypertension associated with left-sided heart failure ............................................................................................................... 3688
8.3.1.1. Heart failure with reduced ejection fraction ............. 3688
8.3.1.2. Heart failure with preserved ejection fraction ......... 3688
8.3.1.3. Interatrial shunt devices ..................................................... 3689
8.3.1.4. Remote pulmonary arterial pressure monitoring in heart failure ............................................................................................. 3689
8.3.2. Pulmonary hypertension associated with valvular heart disease ............................................................................................................. 3689
8.3.2.1. Mitral valve disease ............................................................... 3689
8.3.2.2. Aortic stenosis ....................................................................... 3689
8.3.2.3. Tricuspid regurgitation ........................................................ 3689
8.3.3. Recommendations on the use of drugs approved for
PAH in PH-LHD ......................................................................................... 3689
9. Pulmonary hypertension associated with lung diseases and/or hypoxia (group 3) ................................................................................................
3690
9.1. Diagnosis ...................................................................................................
3692
9.2. Therapy .....................................................................................................
3692
9.2.1. Pulmonary hypertension associated with chronic obstructive pulmonary disease or emphysema ............................ 3692
9.2.2. Pulmonary hypertension associated with interstitial lung disease ............................................................................................................. 3692
9.2.3. Recommendations on the use of drugs approved for
PAH in PH associated with lung disease .......................................... 3693
10. Chronic thrombo-embolic pulmonary hypertension (group 4)
3693
10.1. Diagnosis ................................................................................................
3694
10.2. Therapy ...................................................................................................
3695
10.2.1. Surgical treatment ....................................................................... 3695
10.2.2. Medical therapy ............................................................................ 3695
10.2.3. Interventional treatment .......................................................... 3696
10.2.4. Multimodal treatment ............................................................... 3697
10.2.5. Follow-up ........................................................................................ 3698
10.3. Chronic thrombo-embolic pulmonary hypertension team and experience criteria ................................................................................
3698
11. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5) .......................................................................................
3699
11.1. Haematological disorders ................................................................
3699
11.2. Systemic disorders .............................................................................
3700
11.3. Metabolic disorders ...........................................................................
3700
11.4. Chronic kidney failure ......................................................................
3700
11.5. Pulmonary tumour thrombotic microangiopathy ................
3700
11.6. Fibrosing mediastinitis .......................................................................
3700
12. Deﬁnition of a pulmonary hypertension centre .............................
3701
12.1. Facilities and skills required for a pulmonary hypertension centre ..................................................................................................................
3702
12.2. European Reference Network .....................................................
3702
12.3. Patient associations and patient empowerment ...................
3702
13. Key messages .................................................................................................
3703
14. Gaps in evidence ...........................................................................................
3703
14.1. Pulmonary arterial hypertension (group 1) .............................
3703
14.2. Pulmonary hypertension associated with left heart disease
(group 2) ............................................................................................................
3703
14.3. Pulmonary hypertension associated with lung diseases and/
or hypoxia (group 3) ....................................................................................
3704
14.4. Chronic thrombo-embolic pulmonary hypertension
(group 4) ............................................................................................................
3704
14.5. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5) .................................................................................
3704
15. ‘What to do’ and ‘What not to do’ messages from the Guidelines .......................................................................................................
3704
16. Quality indicators .........................................................................................
3710
17. Supplementary data .....................................................................................
3711
18. Data availability statement .......................................................................
3711
19. Author information .....................................................................................
3711
20. Appendix ..........................................................................................................
3711
21. References .......................................................................................................
3712
Tables of Recommendations
Recommendation Table 1 — Recommendations for right heart catheterization and vasoreactivity testing ............................................
3648
Recommendation Table 2 — Recommendations for diagnostic strategy ................................................................................................................
3652
Recommendation Table 3 — Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension .......................
3654
Recommendation Table 4 — Recommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension .....................................................................................
3660
Recommendation Table 5 — Recommendations for general measures and special circumstances .......................................................
3662
Recommendation Table 6 — Recommendations for women of childbearing potential ....................................................................................
3663
Recommendation Table 7 — Recommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension ............................
3664
Recommendation Table 8 — Recommendations for the treatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present without cardiopulmonary comorbiditiesa ...................................................
3668
Recommendation Table 9 — Recommendations for initial oral drug combination therapy for patients with idiopathic, heritable,
or drug-associated pulmonary arterial hypertension without cardiopulmonary comorbidities ................................................................
3669
Recommendation Table 10 — Recommendations for sequential drug combination therapy for patients with idiopathic, heritable,
or drug-associated pulmonary arterial hypertension ......................
3670
Recommendation Table 11 — Recommendations for the treatment of non-vasoreactive patients with idiopathic, heritable,
or drug-associated pulmonary arterial hypertension who present with cardiopulmonary comorbiditiesa ....................................................
3671
ESC/ERS Guidelines
3621


<!-- PAGE 5 -->

### Page 5

Recommendation Table 12 — Recommendations for intensive care management for pulmonary arterial hypertension ..................... 3672
Recommendation Table 13 — Recommendations for lung transplantation .................................................................................................
3673
Recommendation Table 14 — Recommendations for pulmonary arterial hypertension associated with drugs or toxins ...................
3674
Recommendation Table 15 — Recommendations for pulmonary arterial hypertension associated with connective tissue disease
3675
Recommendation Table 16 — Recommendations for pulmonary arterial hypertension associated with human immunodeﬁciency virus infection ...................................................................................................
3676
Recommendation Table 17 — Recommendations for pulmonary arterial hypertension associated with portal hypertension ..........
3677
Recommendation Table 18 — Recommendations for shunt closure in patients with pulmonary–systemic ﬂow ratio .1.5:1
based on calculated pulmonary vascular resistance .........................
3680
Recommendation Table 19 — Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease
3680
Recommendation Table 20 — Recommendations for pulmonary arterial hypertension with signs of venous/capillary involvement
3681
Recommendation Table 21 — Recommendations for paediatric pulmonary hypertension ..............................................................................
3685
Recommendation Table 22 — Recommendations for pulmonary hypertension associated with left heart disease ................................
3690
Recommendation Table 23 — Recommendations for pulmonary hypertension associated with lung disease and/or hypoxia ..........
3693
Recommendation Table 24 — Recommendations for chronic thrombo-embolic pulmonary hypertension and chronic thromboembolic pulmonary disease without pulmonary hypertension ........
3698
Recommendation Table 25 — Recommendations for pulmonary hypertension centres .....................................................................................
3702
List of tables
Table 1 Strength of the recommendations according to GRADE
3635
Table 2 Quality of evidence grades and their deﬁnitions ..............
3635
Table 3 Classes of recommendations ....................................................
3636
Table 4 Levels of evidence ..........................................................................
3636
Table 5 Haemodynamic deﬁnitions of pulmonary hypertension
3637
Table 6 Clinical classiﬁcation of pulmonary hypertension ............
3638
Table 7 Drugs and toxins associated with pulmonary arterial hypertension .....................................................................................................
3640
Table 8 Electrocardiogram abnormalities in patients with pulmonary hypertension ..............................................................................
3643
Table 9 Radiographic signs of pulmonary hypertension and concomitant abnormalities .........................................................................
3643
Table 10 Additional echocardiographic signs suggestive of pulmonary hypertension ..............................................................................
3645
Table 11 Haemodynamic measures obtained during right heart catheterization ..................................................................................................
3646
Table 12 Route of administration, half-life, dosages, and duration of administration of the recommended test compounds for vasoreactivity testing in pulmonary arterial hypertension .............
3647
Table 13 Phenotypic features associated with pulmonary arterial hypertension mutations ...............................................................................
3649
Table 14 Characteristic diagnostic features of patients with different forms of pulmonary hypertension ........................................
3651
Table 15 World Health Organization classiﬁcation of functional status of patients with pulmonary hypertension ...............................
3656
Table 16 Comprehensive risk assessment in pulmonary arterial hypertension (three-strata model) ..........................................................
3657
Table 17 Suggested assessment and timing for the follow-up of patients with pulmonary arterial hypertension ..................................
3658
Table 18 Variables used to calculate the simpliﬁed four-strata risk-assessment tool .......................................................................................
3659
Table 19 Dosing of pulmonary arterial hypertension medication in adults ...............................................................................................................
3664
Table 20 Criteria for lung transplantation and listing in patients with pulmonary arterial hypertension ...................................................
3672
Table 21 Clinical classiﬁcation of pulmonary arterial hypertension associated with congenital heart disease ..............................................
3678
Table 22 Use of pulmonary arterial hypertension therapies in children ................................................................................................................
3684
Table 23 Patient phenotyping and likelihood for left heart disease as cause of pulmonary hypertension ......................................................
3688
Table 24 Pulmonary hypertension with unclear and/or multifactorial mechanisms ...........................................................................
3699
List of ﬁgures
Figure 1 Central illustration ........................................................................
3639
Figure 2 Symptoms in patients with pulmonary hypertension ...
3641
Figure 3 Clinical signs in patients with pulmonary hypertension
3642
Figure 4 Transthoracic echocardiographic parameters in the assessment of pulmonary hypertension ................................................
3644
Figure 5 Echocardiographic probability of pulmonary hypertension and recommendations for further assessment ......
3645
Figure 6 Diagnostic algorithm of patients with unexplained dyspnoea and/or suspected pulmonary hypertension ....................
3650
Figure 7 Pathophysiology and current therapeutic targets of pulmonary arterial hypertension (group 1) .........................................
3655
Figure 8 Vasoreactivity testing algorithm of patients with presumed diagnosis of idiopathic, heritable, or drug-associated pulmonary arterial hypertension ..............................................................
3665
Figure 9 Evidence-based pulmonary arterial hypertension treatment algorithm for patients with idiopathic, heritable,
drug-associated, and connective tissue disease-associated pulmonary arterial hypertension ..............................................................
3666
Figure 10 Neonatal and paediatric vs. adult pulmonary hypertension .....................................................................................................
3682
Figure 11 Pathophysiology of pulmonary hypertension associated with left heart disease (group 2) ..............................................................
3686
Figure 12 Pathophysiology of pulmonary hypertension associated with lung disease (group 3) ........................................................................
3691
Figure 13 Diagnostic strategy in chronic thrombo-embolic pulmonary hypertension ..............................................................................
3694
Figure 14 Management strategy in chronic thrombo-embolic pulmonary hypertension ..............................................................................
3696
Figure 15 Overlap in treatments/multimodality approaches in chronic thrombo-embolic pulmonary hypertension .......................
3697
Figure 16 Pulmonary hypertension centre schematic .....................
3701
Abbreviations and acronyms
6MWD
6-minute walking distance
6MWT
6-minute walking test
ABG
Arterial blood gas analysis
ACEi
Angiotensin-converting enzyme inhibitor
3622
ESC/ERS Guidelines


<!-- PAGE 6 -->

### Page 6

ALAT
Alanine aminotransferase
ARB
Angiotensin receptor blocker
ARNI
Angiotensin receptor–neprilysin inhibitor
ASAT
Aspartate aminotransferase
ASIG
Australian Scleroderma Interest Group
BNP
Brain natriuretic peptide
BPA
Balloon pulmonary angioplasty
BPD
Bronchopulmonary dysplasia
CAMPHOR
Cambridge Pulmonary Hypertension Outcome
Review
CCB
Calcium channel blocker
CDH
Congenital diaphragmatic hernia cGMP
Cyclic guanosine monophosphate
CHD
Congenital heart disease
CI
Cardiac index; Conﬁdence interval cMRI
Cardiac magnetic resonance imaging
CO
Cardiac output
COMPERA
Comparative, Prospective Registry of Newly
Initiated Therapies for PH
COPD
Chronic obstructive pulmonary disease
CpcPH
Combined post- and pre-capillary pulmonary hypertension
CPET
Cardiopulmonary exercise testing
CPFE
Combined pulmonary ﬁbrosis and emphysema
CT
Computed tomography
CTD
Connective tissue disease
CTEPD
Chronic thrombo-embolic pulmonary disease
CTEPH
Chronic thrombo-embolic pulmonary hypertension
CTPA
Computed tomography pulmonary angiography
DECT
Dual-energy computed tomography
DLCO
Lung diffusion capacity for carbon monoxide
DPAH
Drug- or toxin-associated pulmonary arterial hypertension dPAP
Diastolic pulmonary arterial pressure
DPG
Diastolic pressure gradient
DSA
Digital subtraction angiography
ECG
Electrocardiogram
ECMO
Extracorporeal membrane oxygenation
EHJ
EMA
European Medicines Agency
EOV
Exercise oscillatory ventilation
ERA
Endothelin receptor antagonist
ERJ
European Respiratory Journal
ERN
European Reference Network
ERN-LUNG
European Reference Network on rare respiratory diseases
ERS
European Respiratory Society
ESC
European Society of Cardiology
EtD
Evidence to Decision
FPHR
French Pulmonary Hypertension Registry
FVC
Forced vital capacity
GRADE
Grading of Recommendations, Assessment,
Development, and Evaluations
HAART
Highly active antiretroviral therapy
Hb
Haemoglobin
HF
Heart failure
HFpEF
Heart failure with preserved ejection fraction
HIV
Human immunodeﬁciency virus
HPAH
Heritable pulmonary arterial hypertension
HPS
Hepatopulmonary syndrome
HR
Hazard ratio
HR-QoL
Health-related quality of life
ICU
Intensive care unit
IgG4
Immunogolobulin G4
ILD
Interstitial lung disease
IPAH
Idiopathic pulmonary arterial hypertension
IpcPH
Isolated post-capillary pulmonary hypertension
IP receptor
Prostacyclin I2 receptor
ISWT
Incremental shuttle walking test i.v.
Intravenous
LA
Left atrium/left atrial
LAS
Lung allocation score
LHD
Left heart disease
LTx
Lung transplantation
LV
Left ventricle/left ventricular
LVAD
Left ventricular assist device mPAP
Mean pulmonary arterial pressure
MR
Magnetic resonance
MRI
Magnetic resonance imaging
NOAC
Novel oral anticoagulant
NT-proBNP
N-terminal pro-brain natriuretic peptide
OR
Odds ratio
PA
Pulmonary artery
PAC
Pulmonary arterial compliance
PaCO2
Partial pressure of arterial carbon dioxide
PADN
Pulmonary artery denervation
PAH
Pulmonary arterial hypertension
PAH-CTD
Pulmonary arterial hypertension associated with connective tissue disease
PAH-SSc
Pulmonary arterial hypertension associated with systemic sclerosis
PAH-SYMPACT
Pulmonary Arterial Hypertension-Symptoms and Impact
PaO2
Partial pressure of arterial oxygen
PAP
Pulmonary arterial pressure
PAVM
Pulmonary arteriovenous malformation
PAWP
Pulmonary arterial wedge pressure
PCH
Pulmonary capillary haemangiomatosis
PDE5i
Phosphodiesterase 5 inhibitor
PE
Pulmonary embolism
PEA
Pulmonary endarterectomy
PET
Positron emission tomography
PETCO2
End-tidal partial pressure of carbon dioxide
PFT
Pulmonary function test
PH
Pulmonary hypertension
PH-LHD
Pulmonary hypertension associated with left heart disease
PICO
Population, Intervention, Comparator, Outcome
PoPH
Porto-pulmonary hypertension
PPHN
Persistent pulmonary hypertension of the newborn
PROM
Patient-reported outcome measure
PVD
Pulmonary vascular disease
ESC/ERS Guidelines
3623


<!-- PAGE 7 -->

### Page 7

PVOD
Pulmonary veno-occlusive disease
PVR
Pulmonary vascular resistance
PVRI
Pulmonary vascular resistance index
QI
Quality indicator
Qp/Qs
Pulmonary blood ﬂow/systemic blood ﬂow
RA
Right atrium/right atrial
RAP
Right atrial pressure
RCT
Randomized controlled trial
REVEAL
Registry to Evaluate Early and Long-Term PAH
Disease Management
RHC
Right heart catheterization
RR
Relative risk
RV
Right ventricle/right ventricular
RVEF
Right ventricular ejection fraction
RV-FAC
Right ventricular fractional area change
RVOT AT
Right ventricular outﬂow tract acceleration time
SaO2
Arterial oxygen saturation s.c.
Subcutaneous
SCD
Sickle cell disease sGC
Soluble guanylate cyclase
SGLT-2i
Sodium–glucose cotransporter-2 inhibitor
SLE
Systemic lupus erythematosus
SPAHR
Swedish Pulmonary Arterial Hypertension Registry sPAP
Systolic pulmonary arterial pressure
SPECT
Single-photon emission computed tomography
SSc
Systemic sclerosis
SV
Stroke volume
SVI
Stroke volume index
SvO2
Mixed venous oxygen saturation
TAPSE
Tricuspid annular plane systolic excursion
TGF-β
Transforming growth factor-β
TPR
Total pulmonary resistance
TR
Tricuspid regurgitation
TRPG
Tricuspid regurgitation pressure gradient
TRV
Tricuspid regurgitation velocity
TSH
Thyroid-stimulating hormone
V/Q
Ventilation perfusion
VE/VCO2
Ventilatory equivalent for carbon dioxide
VKA
Vitamin K antagonist
VO2
Oxygen uptake
VO2/HR
Oxygen pulse
VTE
Venous thrombo-embolism
WHO-FC
World Health Organization functional class
WSPH
World Symposium on Pulmonary Hypertension
WU
Wood units
1. Preamble
Guidelines summarize and evaluate available evidence, with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision-making of health professionals in their daily practice. However, guidelines are not a substitute for the patient’s relationship with their practitioner. The ﬁnal decisions concerning an individual patient must be made by the responsible health professional(s), based on what they consider to be the most appropriate in the circumstances. These decisions are made in consultation with the patient and caregiver as appropriate.
Guidelines are intended for use by health professionals. To ensure that all physicians have access to the most recent recommendations, both the
European Society of Cardiology (ESC) and European Respiratory Society
(ERS) make their guidelines freely available in their own journals. The ESC
and ERS warn non-medical readers that the technical language may be misinterpreted and decline any responsibility in this respect.
Many Guidelines have been issued in recent years by the ESC and
ERS. Because of their impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The ERS and ESC guidance and procedure to formulate and issue clinical practice recommendations can be found on the societies’ relevant website or journal (https://www.escardio.org/Guidelines and https://openres.
ersjournals.com/content/8/1/00655-2021).
The
ESC
and
ERS
Guidelines represent the ofﬁcial position of the ESC and ERS on a given topic and are regularly updated.
The panel of experts of these speciﬁc guidelines comprised an equal number of ERS and ESC members, including representatives from relevant subspecialty groups involved in the medical care of patients with this pathology.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conﬂicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/
Guidelines). They have been compiled in a report and co-published in a supplementary document of the guidelines. This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arose during the writing period were notiﬁed to the ESC and updated. The Task
Force received its entire ﬁnancial support from the ESC and ERS without any involvement from the health care industry.
The ESC Clinical Practice Guidelines (CPG) Committee and the ERS
Guidelines Director reporting to the ERS Science Council supervise and co-ordinate the preparation of new guidelines. These Guidelines underwent extensive review by the ESC CPG Committee, the ERS
Guidelines Working Group, and external experts. The guidelines were developed after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of drafting. After appropriate revisions, the guidelines were signed off by all the experts in the Task Force. The ﬁnalized document was signed off by the ESC CPG
Committee and endorsed by the ERS Executive Committee before being simultaneously published in the European Heart Journal (EHJ)
and the European Respiratory Journal (ERJ). The decision to publish the guidelines in both journals was made to ensure adequate dissemination of the recommendations in both the cardiology and respiratory ﬁelds.
The task of developing the ESC/ERS Guidelines also included creating educational tools and implementation programmes for the recommendations, including condensed pocket guidelines versions, summary slides, a lay summary, and an electronic version for digital applications
(smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access the full-text version of the guidelines, which is freely available via the ESC and ERS websites,
and hosted on the EHJ and ERJ websites. The National Cardiac
Societies of the ESC are encouraged to endorse, adopt, translate,
3624
ESC/ERS Guidelines


<!-- PAGE 8 -->

### Page 8

and implement all ESC Guidelines. Pulmonary national societies are also encouraged to share these guidelines with their members and develop a summary or editorials in their own language, if appropriate.
Implementation programmes are needed because it has been shown that the outcome of disease may be favourably inﬂuenced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the ESC/ERS Guidelines fully into account when exercising their clinical judgement, as well as in determining and implementing preventive, diagnostic, or therapeutic medical strategies. However, the ESC/ERS Guidelines do not override,
in any way, the individual responsibility of health professionals to make appropriate and accurate decisions in considering each patient’s health condition and in consulting with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription and, where appropriate, to respect the ethical rules of their profession in each country.
Off-label use of medication may be presented in these guidelines if a sufﬁcient level of evidence shows that it can be considered medically appropriate to a given condition and if patients could beneﬁt from the recommended therapy. However, the ﬁnal decisions concerning an individual patient must be made by the responsible health professional, giving special consideration to:
• The speciﬁc situation of the patient. In this respect, it is speciﬁed that, unless otherwise provided for by national regulations, offlabel use of medication should be limited to situations where it is in the patient’s interest to do so, with regards to the quality,
safety, and efﬁcacy of care, and only after the patient has been fully informed and provided consent.
• Country-speciﬁc health regulations, indications by governmental drug regulatory agencies, and the ethical rules to which health professionals are subject, where applicable.
2. Introduction
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and may be associated with a variety of cardiovascular and respiratory diseases. The complexity of managing PH requires a multifaceted, holistic, and multidisciplinary approach, with active involvement of patients with PH in partnership with clinicians. Streamlining the care of patients with PH in daily clinical practice is a challenging but essential requirement for effectively managing PH. In recent years, substantial progress has been made in detecting and managing PH, and new evidence has been timeously integrated in this fourth edition of the ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Reﬂecting the multidisciplinary input into managing patients with PH and interpreting new evidence,
the Task Force included cardiologists and pneumologists, a thoracic surgeon, methodologists, and patients. These comprehensive clinical practice guidelines cover the whole spectrum of PH, with an emphasis on diagnosing and treating pulmonary arterial hypertension (PAH) and chronic thrombo-embolic pulmonary hypertension (CTEPH).
2.1. What is new
One of the most important proposals from the 6th World
Symposium on Pulmonary Hypertension (WSPH) was to reconsider the haemodynamic deﬁnition of PH.1 After careful evaluation, the new deﬁnitions of PH have been endorsed and expanded in these guidelines, including a revised cut-off level for pulmonary vascular resistance (PVR) and a deﬁnition of exercise PH.
The classiﬁcation of PH has been updated, including repositioning of vasoreactive patients with idiopathic pulmonary arterial hypertension (IPAH) and a revision of group 5 PH, including repositioning of
PH in lymphangioleiomyomatosis in group 3.
Concerning the diagnosis of PH, a new algorithm has been developed aiming at earlier detection of PH in the community. In addition,
expedited referral is recommended for high-risk or complex patients. Screening strategies are also proposed.
The risk-stratiﬁcation table has been expanded to include additional echocardiographic and cardiac magnetic resonance imaging (cMRI)
prognostic indicators. The recommendations for initial drug therapies have been simpliﬁed, building on this revised, three-strata, multiparametric risk model to replace functional classiﬁcation. At follow-up, a four-strata risk-assessment tool is now proposed based on reﬁned cut-off levels for World Health Organization functional class
(WHO-FC), 6-minute walking distance (6MWD), and N-terminal pro-brain natriuretic peptide (NT-proBNP), categorizing patients as low, intermediate–low, intermediate–high, or high risk.
The PAH treatment algorithm has been modiﬁed, highlighting the importance of cardiopulmonary comorbidities, risk assessment both at diagnosis and follow-up, and the importance of combination therapies.
Treatment strategies during follow-up have been based on the fourstrata model intended to facilitate more granular decision-making.
The recommendations for managing PH associated with left heart disease (PH-LHD) and lung disease have been updated, including a new haemodynamic deﬁnition of severe PH in patients with lung disease.
In group 4 PH, the term chronic thrombo-embolic pulmonary disease (CTEPD) with or without PH has been introduced, acknowledging the presence of similar symptoms, perfusion defects, and organized ﬁbrotic obstructions in patients with or without PH at rest. Interventional treatment by balloon pulmonary angioplasty
(BPA) in combination with medical therapy has been upgraded in the therapeutic algorithm of CTEPH.
New standards for PH centres have been presented and, for the
ﬁrst time, patient representatives were actively involved in developing these guidelines.
Questions with direct consequences for clinical practitioners regarding each PH classiﬁcation subgroup were selected and addressed, namely guidance on: initial treatment strategy for group 1 PH (Population,
Intervention, Control, Outcome [PICO] I); use of oral phosphodiesterase 5 inhibitors (PDE5is) for the treatment of group 2 PH (PICO II); use of oral PDE5is for the treatment of group 3 PH (PICO III); and use of PH
drugs prior to BPA for the treatment of group 4 PH (PICO IV). These questions were considered to be important because: most contemporary PH registries describe variable use of initial oral monotherapy and combination therapy; large case series show widespread use of
PDE5is in group 2 PH, despite a class III recommendation in the 2015
ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension; large case series show widespread use of PDE5is in group
3 PH, despite a class III recommendation in the 2015 ESC/ERS
Guidelines for the diagnosis and treatment of pulmonary hypertension;
and there is no clear guidance for therapy with PH drugs in patients with inoperable CTEPH prior to BPA.
ESC/ERS Guidelines
3625


<!-- PAGE 9 -->

### Page 9

Selected revised recommendations (R) and new recommendations (N)
New or revised
Recommendation in 2015 version
Classa
Recommendation in 2022 version
Classa
Right heart catheterization and vasoreactivity testing – Recommendation Table 1
N
It is recommended that RHC comprises a complete set of haemodynamics and is performed following standardized protocols
I
R
Adenosine should be considered for performing vasoreactivity testing as an alternative
Inhaled iloprost may be considered for performing vasoreactivity testing as an alternative
IIa
Inhaled nitric oxide, inhaled iloprost, or i.v. epoprostenol are recommended for performing vasoreactivity testing
I
Diagnostic strategy – Recommendation Table 2
N
It is recommended to assign an echocardiographic probability of PH, based on an abnormal TRV and the presence of other echocardiographic signs suggestive of
PH (see Table 10)
I
N
It is recommended to maintain the current threshold for
TRV (.2.8 m/s) for echocardiographic probability of PH
according to the updated haemodynamic deﬁnition
I
N
Based on the probability of PH by echocardiography,
further testing should be considered in the clinical context (i.e. symptoms and risk factors or associated conditions for PAH/CTEPH)
IIa
N
In symptomatic patients with intermediate echocardiographic probability of PH, CPET may be considered to further determine the likelihood of PH
IIb
Screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension –
Recommendation Table 3
N
In patients with SSc, an annual evaluation of the risk of having PAH is recommended
I
R
Resting echocardiography is recommended as a screening test in asymptomatic patients with SSc, followed by annual screening with echocardiography, DLCO, and biomarkers
I
In adult patients with SSc of .3 years’ disease duration,
an FVC ≥40%, and a DLCO ,60%, the DETECT
algorithm is recommended to identify asymptomatic patients with PAH
I
N
In patients with SSc, where breathlessness remains unexplained following non-invasive assessment, RHC is recommended to exclude PAH
I
N
Assessing the risk of having PAH, based on an evaluation of breathlessness, in combination with echocardiogram or PFTs and BNP/NT-proBNP, should be considered in patients with SSc
IIa
N
Policies to evaluate the risk of having PAH should be considered in hospitals managing patients with SSc
IIa
R
RHC is recommended in all cases of suspected PAH
associated with CTD
I
In symptomatic patients with SSc, exercise echocardiography or CPET, or CMR may be considered to aid decisions to perform RHC
IIb
N
In patients with CTD with overlap features of SSc, an annual evaluation of the risk of PAH may be considered
IIb
R
In PE survivors with exercise dyspnoea, CTEPH should be considered
IIa
In patients with persistent or new-onset dyspnoea or exercise limitation following PE, further diagnostic evaluation to assess for CTEPH/CTEPD is recommended
I
Continued
3626
ESC/ERS Guidelines


<!-- PAGE 10 -->

### Page 10

N
For symptomatic patients with mismatched perfusion lung defects beyond 3 months of anticoagulation for acute PE, referral to a PH/CTEPH centre is recommended after considering the results of echocardiography, BNP/NT-proBNP, and/or CPET
I
N
Counselling regarding the risk of PAH, and annual screening is recommended for individuals who test positive for PAH-causing mutations and in ﬁrst-degree relatives of patients with HPAH
I
N
In patients referred for liver transplantation,
echocardiography is recommended as a screening test for
PH
I
N
Further tests (echocardiography, BNP/NT-proBNP,
PFTs, and/or CPET) should be considered in symptomatic patients with CTD, portal hypertension, or HIV to screen for PAH
IIa
Evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension – Recommendation Table 4
N
For risk stratiﬁcation at the time of diagnosis, the use of a three-strata model (low, intermediate, and high risk) is recommended, taking into account all available data including haemodynamics
I
N
For risk stratiﬁcation during follow-up, the use of a four-strata model (low, intermediate–low, intermediate–
high, and high risk) based on WHO-FC, 6MWD, and
BNP/NT-proBNP is recommended, with additional variables taken into account as necessary
I
R
Achievement/maintenance of an intermediate-risk proﬁle should be considered an inadequate treatment response for most patients with PAH
IIa
In some PAH aetiologies and in patients with comorbidities, optimization of therapy should be considered on an individual basis while acknowledging that a low-risk proﬁle is not always achievable
IIa
General measures and special circumstances – Recommendation Table 5
R
Supervised exercise training should be considered in physically deconditioned PAH patients under medical therapy
IIa
Supervised exercise training is recommended in patients with PAH under medical therapy
I
R
Immunization of PAH patients against inﬂuenza and pneumococcal infection is recommended
I
Immunization of patients with PAH against SARS-CoV-2,
inﬂuenza, and Streptococcus pneumoniae is recommended
I
R
Correction of anaemia and/or iron status may be considered in PAH patients
IIb
In the presence of iron-deﬁciency anaemia, correction of iron status is recommended in patients with PAH
I
N
In the absence of anaemia, iron repletion may be considered in patients with PAH with iron deﬁciency
IIb
R
Oral anticoagulant treatment may be considered in patients with IPAH, HPAH, and PAH due to use of anorexigens
IIb
Anticoagulation is not generally recommended in patients with PAH but may be considered on an individual basis
IIb
R
The use of angiotensin-converting enzyme inhibitors,
angiotensin-2 receptor antagonists, beta-blockers, and ivabradine is not recommended in patients with PAH
unless required by comorbidities (i.e. high blood pressure,
coronary artery disease, or left HF)
III
The use of ACEis, ARBs, ARNIs, SGLT-2is, beta-blockers,
or ivabradine is not recommended in patients with PAH
unless required by comorbidities (i.e. high blood pressure,
coronary artery disease, left HF, or arrhythmias)
III
R
In-ﬂight O2 administration should be considered for patients in WHO-FC III and IV and those with arterial blood O2 pressure consistently ,8 kPa (60 mmHg)
IIa
In-ﬂight O2 administration is recommended for patients using oxygen or whose arterial blood oxygen pressure is
,8 kPa (60 mmHg) at sea level
I
R
In elective surgery, epidural rather than general anaesthesia should be preferred whenever possible
IIa
For interventions requiring anaesthesia, multidisciplinary consultation at a PH centre to assess risk and beneﬁt should be considered
IIa
Continued
ESC/ERS Guidelines
3627


<!-- PAGE 11 -->

### Page 11

Women of childbearing potential – Recommendation Table 6
R
It is recommended that PAH patients avoid pregnancy
I
It is recommended that women of childbearing potential with PAH are counselled at the time of diagnosis about the risks and uncertainties associated with becoming pregnant; this should include advice against becoming pregnant, and referral for psychological support where needed
I
N
It is recommended that women of childbearing potential with PAH be provided with clear contraceptive advice,
considering the individual needs of the woman but recognizing that the implications of contraceptive failure are signiﬁcant in PAH
I
N
It is recommended that women with PAH who consider pregnancy or who become pregnant receive prompt counselling in an experienced PH centre to facilitate genetic counselling and shared decision-making, and to provide psychological support to the patients and their families where needed
I
N
For women with PAH having termination of pregnancy, it is recommended that this be performed in PH centres,
with psychological support provided to the patient and her family
I
N
For women with PAH who desire to have children, where available, adoption and surrogacy with pre-conception genetic counselling may be considered
IIb
N
As teratogenic potential has been reported in preclinical models for endothelin receptor antagonists and riociguat,
these drugs are not recommended during pregnancy
III
Treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension –
Recommendation Table 7
R
Continuation of high doses of CCBs is recommended in patients with IPAH, HPAH, and DPAH in WHO-FC I or II
with marked haemodynamic improvement (near normalization)
I
Continuing high doses of CCBs is recommended in patients with IPAH, HPAH, or DPAH in WHO-FC I or II
with marked haemodynamic improvement (mPAP
,30 mmHg and PVR ,4 WU)
I
N
In patients with a positive vasoreactivity test but insufﬁcient long-term response to CCBs who require additional PAH therapy, continuation of CCB therapy should be considered
IIa
Treatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present without cardiopulmonary comorbiditiesb – Recommendation Table 8
N
In patients with IPAH/HPAH/DPAH who present at high risk of death, initial combination therapy with a PDE5i, an
ERA, and i.v./s.c. prostacyclin analogues should be consideredc
IIa
N
In patients with IPAH/HPAH/DPAH who present at intermediate–low risk of death while receiving ERA/
PDE5i therapy, the addition of selexipag should be considered
IIa
N
In patients with IPAH/HPAH/DPAH who present at intermediate–high or high risk of death while receiving
ERA/PDE5i therapy, the addition of i.v./s.c. prostacyclin analogues and referral for lung transplantation (LTx)
evaluation should be considered
IIa
Continued
3628
ESC/ERS Guidelines


<!-- PAGE 12 -->

### Page 12

N
In patients with IPAH/HPAH/DPAH who present at intermediate–low risk of death while receiving ERA/
PDE5i therapy, switching from PDE5i to riociguat may be considered
IIb
Initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension without cardiopulmonary comorbidities – Recommendation Table 9
R
Ambrisentan + tadalaﬁl
I
Initial combination therapy with ambrisentan and tadalaﬁl is recommended
I
N
Initial combination therapy with macitentan and tadalaﬁl is recommended
I
R
Other ERA + PDE-5i
IIa
Initial combination therapy with other ERAs and PDE5is should be considered
IIa
N
Initial combination therapy with macitentan, tadalaﬁl, and selexipag is not recommended
III
Sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension –
Recommendation Table 10
N
It is recommended to base treatment escalations on risk assessment and general treatment strategies (see treatment algorithm)
I
R
Macitentan added to sildenaﬁl
I
The addition of macitentan to PDE5is or oral/inhaled prostacyclin analogues is recommended to reduce the risk of morbidity/mortality events
I
N
The addition of oral treprostinil to ERA or PDE5i/
riociguat monotherapy is recommended to reduce the risk of morbidity/mortality events
I
R
Bosentan added to sildenaﬁl
IIb
The addition of bosentan to sildenaﬁl is not recommended to reduce the risk of morbidity/mortality events
III
R
Riociguat added to bosentan
I
The addition of riociguat to bosentan should be considered to improve exercise capacity
IIa
Treatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present with cardiopulmonary comorbiditiesb – Recommendation Table 11
N
In patients with IPAH/HPAH/DPAH and cardiopulmonary comorbidities, initial monotherapy with a PDE5i or an ERA should be considered
IIa
N
In patients with IPAH/HPAH/DPAH with cardiopulmonary comorbidities who present at intermediate or high risk of death while receiving PDE5i or ERA monotherapy, additional PAH medication may be considered on an individual basis
IIb
Efﬁcacy of intensive care management for pulmonary arterial hypertension – Recommendation Table 12
N
When managing patients with right HF in the ICU, it is recommended to involve physicians with expertise, treat causative factors, and use supportive measures including inotropes and vasopressors, ﬂuid management, and PAH
drugs as appropriate
I
N
Mechanical circulatory support may be an option for selected patients as a bridge to transplantation or to recovery, and interhospital transfer should be considered if such resources are unavailable on site
IIa
Continued
ESC/ERS Guidelines
3629


<!-- PAGE 13 -->

### Page 13

Lung transplantation – Recommendation Table 13
R
Lung transplantation is recommended soon after inadequate clinical response on maximal medical therapy
I
It is recommended that potentially eligible candidates are referred for LTx evaluation when they have an inadequate response to oral combination therapy,
indicated by an intermediate–high or high risk or by a
REVEAL risk score .7
I
N
It is recommended to list patients for LTx who present with a high risk of death or with a REVEAL risk score ≥10
despite receiving optimized medical therapy, including s.c.
or i.v. prostacyclin analogues
I
Pulmonary arterial hypertension associated with drugs or toxins – Recommendation Table 14
N
It is recommended to make a diagnosis of drug- or toxin-associated PAH in patients who had relevant exposure and in whom other causes of PH have been excluded
I
N
In patients with suspected drug- or toxin-associated PAH,
it is recommended to discontinue the causative agent immediately whenever possible
I
N
Immediate PAH therapy should be considered in patients who present with intermediate/high-risk PAH at diagnosis
IIa
N
Patients with low-risk PAH should be re-evaluated 3–4
months after discontinuing the suspected drug or toxin,
and PAH therapy may be considered when the haemodynamics have not normalized
IIb
Pulmonary arterial hypertension associated with connective tissue disease – Recommendation Table 15
N
In patients with PAH associated with CTD, treatment of the underlying condition according to current guidelines is recommended
I
Pulmonary arterial hypertension associated with human immunodeﬁciency virus infection – Recommendation Table 16
N
In patients with PAH associated with HIV infection,
antiretroviral treatment according to current guidelines is recommended
I
N
In patients with PAH associated with HIV infection, initial monotherapy should be considered, followed by sequential combination if necessary, taking into consideration comorbidities and drug–drug interactions
IIa
Pulmonary arterial hypertension associated with portal hypertension – Recommendation Table 17
R
Echocardiographic assessment for signs of PH is recommended in symptomatic patients with liver disease or portal hypertension and in all candidates for liver transplantation
I
Echocardiography is recommended in patients with liver disease or portal hypertension with signs or symptoms suggestive of PH, and as a screening tool in patients evaluated for liver transplantation or transjugular portosystemic shunt
I
R
It is recommended that the treatment algorithm for patients with other forms of PAH should be applied to patients with PAH associated with portal hypertension,
taking into account the severity of liver disease
I
In patients with PAH associated with portal hypertension,
initial monotherapy should be considered, followed by sequential combination if necessary, taking into consideration the underlying liver disease and indication for liver transplantation
IIa
R
Liver transplantation may be considered in selected patients responding well to PAH therapy
IIb
Liver transplantation should be considered on an individual basis in patients with PAH associated with portal hypertension, as long as PVR is normal or near normal with PAH therapy
IIa
Continued
3630
ESC/ERS Guidelines


<!-- PAGE 14 -->

### Page 14

N
Drugs approved for PAH are not recommended for patients with portal hypertension and unclassiﬁed PH (i.e.
elevated mPAP, high CO, and a normal PVR)
III
Shunt closure in patients with pulmonary–systemic ﬂow ratio .1.5:1 based on calculated pulmonary vascular resistance–
Recommendation Table 18
N
In patients with ASD, VSD, or PDA and a PVR ,3 WU,
shunt closure is recommended
I
N
In patients with ASD, VSD, or PDA and a PVR of 3–5
WU, shunt closure should be considered
IIa
N
In patients with ASD and a PVR .5 WU that declines to
,5 WU with PAH treatment, shunt closure may be considered
IIb
N
In patients with VSD or PDA and a PVR .5 WU, shunt closure may be considered after careful evaluation in specialized centres
IIb
N
In patients with ASD and a PVR .5 WU despite PAH
treatment, shunt closure is not recommended
III
Pulmonary arterial hypertension associated with adult congenital heart disease – Recommendation Table 19
N
Risk assessment is recommended for patients with persistent PAH after defect closure
I
N
Risk assessment should be considered in patients with
Eisenmenger syndrome
IIa
R
Bosentan is recommended in WHO-FC III patients with
Eisenmenger syndrome
I
Bosentan is recommended in symptomatic patients with
Eisenmenger syndrome to improve exercise capacity
I
R
The use of supplemental iron treatment may be considered in patients with low ferritin plasma levels
IIb
Supplemental iron treatment should be considered in patients with iron deﬁciency
IIa
R
Combination drug therapy may be considered in patients with Eisenmenger syndrome
IIb
In patients with PAH after corrected adult CHD, initial oral combination therapy with drugs approved for PAH
should be considered for patients at low and intermediate risk, while initial combination therapy including i.v./s.c.
prostacyclin analogues should be considered for patients at high risk
IIa
R
Combination drug therapy may be considered in patients with Eisenmenger syndrome
IIb
In patients with adult CHD, including Eisenmenger syndrome, sequential combination therapy should be considered if patients do not meet treatment goals
IIa
N
In women with Eisenmenger syndrome, pregnancy is not recommended
III
R
If symptoms of hyperviscosity are present, phlebotomy with isovolumic replacement should be considered, usually when the haematocrit is .65%
IIa
In patients with Eisenmenger syndrome, routine phlebotomy to lower elevated haematocrit is not recommended
III
Pulmonary arterial hypertension with signs of venous/capillary involvement – Recommendation Table 20
R
A combination of clinical ﬁndings, physical examination,
bronchoscopy, and radiological ﬁndings is recommended to diagnose PVOD/PCH
I
A combination of clinical and radiological ﬁndings, ABG,
PFTs, and genetic testing is recommended to diagnose
PAH with signs of venous and/or capillary involvement
(PVOD/PCH)
I
N
In patients with PVOD/PCH, the use of drugs approved for PAH may be considered with careful monitoring of clinical symptoms and gas exchange
IIb
N
Lung biopsy is not recommended to conﬁrm a diagnosis of PVOD/PCH
III
Paediatric pulmonary hypertension – Recommendation Table 21
N
It is recommended to perform the diagnostic work-up,
including RHC and acute vasoreactivity testing, and treat children with PH at centres with speciﬁc expertise in paediatric PH
I
Continued
ESC/ERS Guidelines
3631


<!-- PAGE 15 -->

### Page 15

R
A PH diagnostic algorithm work-up is recommended for diagnosis and deﬁnition of the speciﬁc aetiology group in paediatric PH patients
I
In children with PH, a comprehensive work-up for conﬁrming diagnosis and speciﬁc aetiology is recommended (similar to that in adults, but adapted for age)
I
N
For conﬁrming PH diagnosis, RHC is recommended,
preferably before initiating any PAH therapy
I
N
In children with IPAH/HPAH, acute vasoreactivity testing is recommended to detect those who may beneﬁt from calcium channel blocker therapy
I
N
It is recommended to deﬁne a positive response to acute vasoreactivity testing in children similar to adults by a reduction of mPAP ≥10 mmHg to reach an absolute value of mPAP ≤40 mmHg, with an increased or unchanged CO
I
R
A PAH-speciﬁc therapeutic algorithm is recommended in paediatric PH patients
I
In children with PAH, a therapeutic strategy based on risk stratiﬁcation and treatment response is recommended,
extrapolated from that in adults but adapted for age
I
R
Speciﬁc paediatric determinants of risk should be considered
IIa
It is recommended to monitor the treatment response in children with PAH by serially assessing a panel of data derived from clinical assessment, echocardiographic evaluation, biochemical markers, and exercise tolerance tests
I
N
Achieving and maintaining a low-risk proﬁle should be considered as an adequate treatment response for children with PAH
IIa
N
It is recommended to screen infants with bronchopulmonary dysplasia for PH
I
N
In infants with (or at risk of) bronchopulmonary dysplasia and PH, treating lung disease, including hypoxia,
aspiration, and structural airway disease, and optimizing respiratory support is recommended before initiating
PAH therapy
I
N
In neonates and infants, a diagnostic and therapeutic approach to PH distinct from that in older children and adults should be considered, given the frequent association with developmental vascular and parenchymal lung disease
IIa
Pulmonary hypertension associated with left heart disease – Recommendation Table 22
N
RHC is recommended for suspected PH in patients with
LHD, if it aids management decisions
I
N
RHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair
I
R
Patients with PH-LHD and a severe pre-capillary component as indicated by a high DPG and/or high PVR
should be referred to an expert PH centre for a complete diagnostic work-up and an individual treatment decision
IIa
For patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV
dysfunction, referral to a PH centre for a complete diagnostic work-up is recommended
I
N
In patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is recommended
I
N
When patients with PH and multiple risk factors for LHD,
who have a normal PAWP at rest but an abnormal response to exercise or ﬂuid challenge, are treated with
PAH drugs, close monitoring is recommended
I
Continued
3632
ESC/ERS Guidelines


<!-- PAGE 16 -->

### Page 16

N
In patients with PH at RHC, a borderline PAWP (13–
15 mmHg) and features of HFpEF, additional testing with exercise or ﬂuid challenge may be considered to uncover post-capillary PH
IIb
Pulmonary hypertension associated with lung disease and/or hypoxia – Recommendation Table 23
R
Echocardiography is recommended for the non-invasive diagnostic assessment of suspected PH in patients with lung disease
I
If PH is suspected in patients with lung disease, it is recommended that echocardiographyd be performed and the results interpreted in conjunction with ABG,
PFTs including DLCO, and CT imaging
I
R
Optimal treatment of the underlying lung disease, including long-term O2 therapy in patients with chronic hypoxaemia, is recommended in patients with PH due to lung diseases
I
In patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where indicated, hypoxaemia,
sleep-disordered breathing, and/or alveolar hypoventilation
I
R
Referral to an expert centre is recommended in patients with echocardiographic signs of severe PH and/or severe right ventricular dysfunction
I
In patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH,
referral to a PH centre is recommendede
I
N
In patients with lung disease and severe PH, an individualized approach to treatment is recommended
I
N
It is recommended to refer eligible patients with lung disease and PH for LTx evaluation
I
R
RHC is not recommended for suspected PH in patients with lung disease, unless therapeutic consequences are to be expected (e.g. LTx, alternative diagnoses such as PAH
or CTEPH, and potential enrolment in a clinical trial)
III
In patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions
I
N
Inhaled treprostinil may be considered in patients with
PH associated with ILD
IIb
N
The use of ambrisentan is not recommended in patients with PH associated with IPF
III
N
The use of riociguat is not recommended in patients with
PH associated with IIP
III
Chronic thrombo-embolic pulmonary hypertension and chronic thrombo-embolic pulmonary disease without pulmonary hypertension – Recommendation Table 24
R
Lifelong anticoagulation is recommended in all patients with CTEPH
I
Lifelong therapeutic doses of anticoagulation are recommended in all patients with CTEPH
I
N
Antiphospholipid syndrome testing is recommended in patients with CTEPH
I
N
In patients with CTEPH and antiphospholipid syndrome,
anticoagulation with VKAs is recommended
I
R
It is recommended that all patients with CTEPH receive assessment of operability and decisions regarding other treatment strategies made by a multidisciplinary team of experts
I
It is recommended that all patients with CTEPH are reviewed by a CTEPH team for the assessment of multimodality management
I
R
Surgical PEA in deep hypothermia circulatory arrest is recommended for patients with CTEPH
I
PEA is recommended as the treatment of choice for patients with CTEPH and ﬁbrotic obstructions within pulmonary arteries accessible by surgery
I
R
Interventional BPA may be considered in patients who are technically inoperable or carry an unfavourable risk:beneﬁt ratio for PEA
IIb
BPA is recommended in patients who are technically inoperable or have residual PH after PEA and distal obstructions amenable to BPA
I
R
Riociguat is recommended in symptomatic patients who have been classiﬁed as having persistent/recurrent CTEPH
after surgical treatment or inoperable CTEPH by a CTEPH
team including at least one experienced PEA surgeon
I
Riociguat is recommended for symptomatic patients with inoperable CTEPH or persistent/recurrent PH after PEA
I
Continued
ESC/ERS Guidelines
3633


<!-- PAGE 17 -->

### Page 17

N
Long-term follow-up is recommended after PEA and
BPA, as well as for patients with CTEPH established on medical therapy
I
N
A multimodality approach should be considered for patients with persistent PH after PEA and for patients with inoperable CTEPH
IIa
N
In patients with CTEPD without PH, long-term anticoagulant therapy should be considered on an individual basisf
IIa
N
PEA or BPA should be considered in selected symptomatic patients with CTEPD without PH
IIa
N
Treprostinil s.c. may be considered in patients in
WHO-FC III–IV who have inoperable CTEPH or persistent/recurrent PH after PEA
IIb
R
Off-label use of drugs approved for PAH may be considered in symptomatic patients who have been classiﬁed as having inoperable CTEPH by a CTEPH team including at least one experienced PEA surgeon
IIb
Off-label use of drugs approved for PAH may be considered in symptomatic patients who have inoperable
CTEPH
IIb
N
In patients with inoperable CTEPH, a combination of sGC stimulator/PDE5i, ERA, or parenteral prostacyclin analogues may be considered
IIb
N
BPA may be considered for technically operable patients with a high proportion of distal disease and an unfavourable risk:beneﬁt ratio for PEA
IIb
Pulmonary hypertension centres – Recommendation Table 25
N
It is recommended that PH centres maintain a patient registry
I
N
It is recommended that PH centres collaborate with patient associations
I
N
Accreditation of the PH centres should be considered
(e.g. https://ec.europa.eu/health/ern/assessment_en)
IIa
R
It should be considered that a referral centre follow at least 50 patients with PAH or CTEPH and should receive at least two new referrals per month with documented
PAH or CTEPH
IIa
PH centres should follow-up a sufﬁcient number of patients to maintain expertise (at least 50 patients with
PAH or CTEPH and at least two new referrals per month with documented PAH or CTEPH) and consider establishing collaborations with high-volume centres
IIa
© ESC/ERS 2022
6MWD, 6-minute walking distance; ABG, arterial blood gas analysis; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–
neprilysin inhibitor; ASD, atrial septal defect; BNP, brain natriuretic peptide; BPA, balloon pulmonary angioplasty; CCB, calcium channel blocker; CHD, congenital heart disease; CI,
cardiac index; CMR, cardiac magnetic resonance; CO, cardiac output; CpcPH, combined post- and pre-capillary pulmonary hypertension; CPET, cardiopulmonary exercise testing;
CT, computed tomography; CTD, connective tissue disease; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension;
DLCO, Lung diffusion capacity for carbon monoxide; DPAH, drug-associated pulmonary arterial hypertension; DPG, diastolic pressure gradient; ERA, endothelin receptor antagonist; FVC, forced vital capacity; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HIV, human immunodeﬁciency virus; HPAH, heritable pulmonary arterial hypertension; ICU, intensive care unit; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; IPF, idiopathic pulmonary ﬁbrosis; i.v., intravenous; LHD, left heart disease; LTx, lung transplantation; mPAP, mean pulmonary arterial pressure; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; PAP, pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PCH, pulmonary capillary haemangiomatosis; PDA,
patent ductus arteriosus; PDE5i, phosphodiesterase 5 inhibitor; PE, pulmonary embolism; PEA, pulmonary endarterectomy; PFTs, pulmonary function tests; PH, pulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVOD, pulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; RAP, mean right atrial pressure; RHC, right heart catheterization; RV, right ventricle; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; s.c., subcutaneous; sGC, soluble guanylate cyclase; SGLT-2i, sodium–glucose cotransporter-2 inhibitor; SSc, systemic sclerosis; SVI, stroke volume index; TRV, tricuspid regurgitation velocity; VKA, vitamin K antagonist; VSD,
ventricular septal defect; VTE, venous thrombo-embolism; WHO-FC, World Health Organization functional class; WU, Wood units.
aClass of recommendation.
bCardiopulmonary comorbidities are predominantly encountered in elderly patients and include risk factors for HFpEF, such as obesity, diabetes, coronary heart disease, a history of hypertension, and/or a low DLCO.
cInitial triple-combination therapy including i.v./s.c. prostacyclin analogues may also be considered in patients presenting at intermediate risk but severe haemodynamic impairment (e.g.
RAP ≥20 mmHg, CI ,2.0 L/min/m2, SVI ,31 mL/m2, and/or PVR ≥12 WU).
dAssessments should ideally be made when the patient is clinically stable, as exacerbations can signiﬁcantly raise PAP.
eThis recommendation does not apply to patients with end-stage lung disease who are not considered candidates for LTx.
fLong-term anticoagulant therapy is recommended when the risk of PE recurrence is intermediate or high, or when there is no history of VTE.
3634
ESC/ERS Guidelines


<!-- PAGE 18 -->

### Page 18

2.2. Methods
Three main methodological approaches were used in these guidelines, depending on the type of questions addressed:
(i) Four questions that were considered highly important were formulated in the PICO format, and assessed with full systematic reviews and application of the Grading of Recommendations,
Assessment, Development, and Evaluations (GRADE) approach2 and the Evidence to Decision (EtD) framework3 (see
Supplementary
Data,
Section
2.1
for full methodology description and supportive material). The resulting recommendations were rated as strong or conditional, based on four potential levels of evidence (high, moderate, low, or very low;
Tables 1 and 2). All Task Force members approved the recommendations. In addition, these recommendations were also presented and voted following the usual ESC approach.
(ii) Eight questions that were considered of key importance (key narrative questions) were assessed with systematic literature searches and application of the EtD framework.6 The evidence grading was performed following the usual ESC
approach.
(iii) The remaining topics of interest were assessed using the process commonly followed in ESC Guidelines. Structured literature searches were undertaken and grading tables, as outlined in
Tables 3 and 4, were created to describe level of conﬁdence in
New recommendations developed with GRADE Evidence to Decision framework
GRADE
Recommendations
Quality of evidence
Strength of recommendation
Classa
Levelb
In patients with IPAH/HPAH/DPAH who present at low or intermediate risk of death, initial combination therapy with a PDE5i and an ERA is recommended
Low
Conditional
I
B
The use of PDE5i in patients with HFpEF and isolated post-capillary PH is not recommended
Low
Conditional
III
C
PDE5i may be considered in patients with severe PH associated with ILD (individual decision-making in PH centres)
Very low
Conditional
IIb
C
The use of PDE5i in patients with ILD and non-severe PH is not recommended
Very low
Conditional
III
C
In patients with CTEPH who are candidates for BPA, medical therapy should be considered prior to the intervention
Very low
Conditional
IIa
B
© ESC/ERS 2022
BPA, balloon pulmonary angioplasty; CTEPH, chronic thrombo-embolic pulmonary hypertension; DPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; HPAH, heritable pulmonary arterial hypertension; HFpEF, heart failure with preserved ejection fraction; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; PH, pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
Table 1
Strength of the recommendations according to GRADE
Recommendation strength
Rationale
Strong recommendation for
The panel is certain that the desirable outweigh the undesirable effects
Conditional recommendation for
The panel is less conﬁdent that the desirable outweigh the undesirable effects
Conditional recommendation against
The panel is less conﬁdent that the undesirable outweigh the desirable effects
Strong recommendation against
The panel is certain that the undesirable outweigh the desirable effects
No recommendation
The conﬁdence in the results might be very low to make a recommendation, or the trade-offs between desirable and undesirable effects are ﬁnely balanced, or no data are available.
© ESC/ERS 2022
Adapted from the ERS Handbook for Clinical Practice Guidelines.4
Table
2
Quality of evidence grades and their deﬁnitions5
Quality
Deﬁnition
High
We are very conﬁdent that the true effect lies close to that of the estimate of the effect
Moderate
We are moderately conﬁdent in the effect estimate: the true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different
Low
Our conﬁdence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low
We have very little conﬁdence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
© ESC/ERS 2022
ESC/ERS Guidelines
3635


<!-- PAGE 19 -->

### Page 19

the recommendation provided and the quality of evidence supporting the recommendation. The Task Force discussed each draft recommendation during web-based conference calls dedicated to speciﬁc sections, followed by consensus modiﬁcations and an online vote on each recommendation. Only recommendations that were supported by at least 75% of the Task Force members were included in the guidelines. The recommendation tables were colour-coded for ease of interpretation.
3. Deﬁnitions and classiﬁcations
3.1. Deﬁnitions
The deﬁnitions for PH are based on haemodynamic assessment by right heart catheterization (RHC). Although haemodynamics represent the central element of characterizing PH, the ﬁnal diagnosis and classiﬁcation should reﬂect the whole clinical context and consider the results of all investigations.
Table 3
Classes of recommendations
©ESC/ERS 2022
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.
efficacy of the given treatment or procedure.
favour of usefulness/efficacy.
Usefulness/efficacy is less well useful/effective, and in some cases
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not may be harmful. 
Is not recommended
     Class IIb established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in
Should be considered
Class II 
© ESC/ERS 2022
Table 4
Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC/ERS 2022
© ESC/ERS 2022
3636
ESC/ERS Guidelines


<!-- PAGE 20 -->

### Page 20

Pulmonary hypertension is deﬁned by a mean pulmonary arterial pressure (mPAP) .20 mmHg at rest (Table 5). This is supported by studies assessing the upper limit of normal pulmonary arterial pressure (PAP) in healthy subjects,7–9 and by studies investigating the prognostic relevance of increased PAP (key narrative question
1, Supplementary Data, Section 3.1).10–12
It is essential to include PVR and pulmonary arterial wedge pressure (PAWP) in the deﬁnition of pre-capillary PH, in order to discriminate elevated PAP due to pulmonary vascular disease (PVD)
from that due to left heart disease (LHD), elevated pulmonary blood
ﬂow, or increased intrathoracic pressure (Table 5). Based on the available data, the upper limit of normal PVR and the lowest prognostically relevant threshold of PVR is ≏2 Wood units (WU).7,8,13,14
Pulmonary vascular resistance depends on body surface area and age, with elderly healthy subjects having higher values. The available data on the best threshold for PAWP discriminating pre- and postcapillary PH are contradictory. Although the upper limit of normal
PAWP is considered to be 12 mmHg,15 previous ESC/ERS
Guidelines for the diagnosis and treatment of PH, as well as the recent consensus recommendation of the ESC Heart Failure
Association,16 suggest a higher threshold for the invasive diagnosis of heart failure (HF) with preserved ejection fraction (HFpEF)
(PAWP ≥15 mmHg). In addition, almost all therapeutic studies of
PAH have used the PAWP ≤15 mmHg threshold. Therefore, it is recommended keeping PAWP ≤15 mmHg as the threshold for precapillary PH, while acknowledging that any PAWP threshold is arbitrary and that the patient phenotype, risk factors, and echocardiographic ﬁndings, including left atrial (LA) volume, need to be considered when distinguishing pre- from post-capillary PH.
Patients with PAH are haemodynamically characterized by precapillary PH in the absence of other causes of pre-capillary PH,
such as CTEPH and PH associated with lung diseases. All PH groups may comprise both pre- and post-capillary components contributing to PAP elevation. In particular, older patients may present with several conditions predisposing them to PH. The primary classiﬁcation should be based on the presumed predominant cause of the pulmonary pressure increase.
Post-capillary
PH
is haemodynamically deﬁned as mPAP
.20 mmHg and PAWP .15 mmHg. Pulmonary vascular resistance is used to differentiate between patients with post-capillary PH who have a signiﬁcant pre-capillary component (PVR .2 WU—combined post- and pre-capillary PH [CpcPH]) and those who do not
(PVR ≤2 WU—isolated post-capillary PH [IpcPH]).
There are patients with elevated mPAP (.20 mmHg) but low
PVR (≤2 WU) and low PAWP (≤15 mmHg). These patients are frequently characterized by elevated pulmonary blood ﬂow and, although they have PH, they do not fulﬁl the criteria of pre- or post-capillary PH. This haemodynamic condition may be described by the term ‘unclassiﬁed PH’. Patients with unclassiﬁed PH may present with congenital heart disease (CHD), liver disease, airway disease, lung disease, or hyperthyroidism explaining their mPAP
elevation. Clinical follow-up of these patients is generally recommended. In the case of elevated pulmonary blood ﬂow, its aetiology should be explored.
As the groups of PH according to clinical classiﬁcation represent different clinical conditions, there may be additional clinically relevant haemodynamic thresholds (e.g. for PVR) for the individual PH groups besides the general thresholds of the haemodynamic deﬁnition of
PH, which are discussed in the corresponding sections.
Exercise PH, deﬁned by an mPAP/cardiac output (CO) slope
.3 mmHg/L/min between rest and exercise,17 has been reintroduced. The mPAP/CO slope is strongly age dependent and its upper limit of normal ranges from 1.6–3.3 mmHg/L/min in the supine position.17 An mPAP/CO slope .3 mmHg/L/min is not physiological in subjects aged ,60 years and may rarely be present in healthy subjects aged .60 years.17 A pathological increase in pulmonary pressure during exercise is associated with impaired prognosis in patients with exercise dyspnoea18 and in several cardiovascular conditions.19–22 Although an increased mPAP/CO slope deﬁnes an abnormal haemodynamic response to exercise, it does not allow for differentiation between pre- and post-capillary causes. The PAWP/
CO slope with a threshold .2 mmHg/L/min may best differentiate between pre- and post-capillary causes of exercise PH.23,24
3.2. Classiﬁcations
The basic structure of the classiﬁcation from the 2015 ESC/ERS
Guidelines for the diagnosis and treatment of PH25,26 and the
Proceedings of the 6th WSPH1 has been kept (Table 6). The general purpose of the clinical classiﬁcation of PH remains to categorize clinical conditions associated with PH, based on similar pathophysiological mechanisms,
clinical presentation,
haemodynamic characteristics, and therapeutic management (Figure 1). The main changes are as follows:
(i) The subgroups ‘non-responders at vasoreactivity testing’ and
‘acute responders at vasoreactivity testing’ have been added to IPAH as compared with the 2015 ESC/ERS Guidelines for the diagnosis and treatment of PH.25,26 In addition to patients with IPAH, some patients with heritable PAH (HPAH) or
Table 5
Haemodynamic deﬁnitions of pulmonary hypertension
Deﬁnition
Haemodynamic characteristics
PH
mPAP .20 mmHg
Pre-capillary PH
mPAP .20 mmHg
PAWP ≤15 mmHg
PVR .2 WU
IpcPH
mPAP .20 mmHg
PAWP .15 mmHg
PVR ≤2 WU
CpcPH
mPAP .20 mmHg
PAWP .15 mmHg
PVR .2 WU
Exercise PH
mPAP/CO slope between rest and exercise
.3 mmHg/L/min
© ESC/ERS 2022
CO, cardiac output; CpcPH, combined post- and pre-capillary pulmonary hypertension;
IpcPH, isolated post-capillary pulmonary hypertension; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PH, pulmonary hypertension;
PVR, pulmonary vascular resistance; WU, Wood units.
Some patients present with elevated mPAP (.20 mmHg) but low PVR (≤2 WU) and low PAWP (≤15 mmHg); this haemodynamic condition may be described by the term
‘unclassiﬁed PH’ (see text for further details).
ESC/ERS Guidelines
3637


<!-- PAGE 21 -->

### Page 21

drug- or toxin-associated PAH (DPAH) might be acute responders.
(ii) The groups ‘PAH with features of venous/capillary (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis
[PVOD/PCH]) involvement’ and ‘persistent PH of the newborn (PPHN)’ have been included in group 1 (PAH) as compared with the 2015 ESC/ERS Guidelines for the diagnosis and treatment of PH and in line with the Proceedings of the
6th WSPH.1
(iii) Instead of the general term ‘sleep-disordered breathing’, the term ‘hypoventilation syndromes’ should be used within group
3 to describe conditions with increased risk of PH. Sole nocturnal obstructive sleep apnoea is generally not a cause of PH, but
PH is frequent in patients with hypoventilation syndromes causing daytime hypercapnia.
4. Epidemiology and risk factors
Pulmonary hypertension is a major global health issue. All age groups are affected. Present estimates suggest a PH prevalence of ≏1% of the global population. Due to the presence of cardiac and pulmonary causes of PH, prevalence is higher in individuals aged .65 years.29
Globally, LHD is the leading cause of PH.29 Lung disease, especially chronic obstructive pulmonary disease (COPD), is the second most common cause.29 In the UK, the observed PH prevalence has doubled in the last 10 years and is currently 125 cases/million inhabitants.30 Irrespective of the underlying condition, developing PH
is associated with worsening symptoms and increased mortality.29
In developing countries, CHD, some infectious diseases (schistosomiasis, human immunodeﬁciency virus [HIV]), and high altitude represent important but under-studied causes of PH.29
4.1. Group 1, pulmonary arterial hypertension
Recent registry data from economically developed countries indicate a PAH incidence and prevalence of ≏6 and 48–55 cases/million adults, respectively.31 It has been thought to predominantly affect younger individuals, mostly females;32,33 this is currently true for
HPAH, which affects twice as many females as males. However, recent data from the USA and Europe suggest that PAH is now frequently diagnosed in older patients (i.e. those aged ≥65 years,
who often present with cardiovascular comorbidities, resulting in a more equal distribution between sexes).32 In most PAH registries,
IPAH was the most common subtype (50–60% of all cases), followed by PAH associated with connective tissue disease (CTD), CHD, and portal hypertension (porto-pulmonary hypertension [PoPH]).32
A number of drugs and toxins are associated with the development of PAH.1,34–45 The association between exposure to drugs and toxins and PAH is classiﬁed as deﬁnite or possible, as proposed at the 6th WSPH (Table 7).1 There is a deﬁnite association with drugs, with available data based on outbreaks, epidemiological casecontrol studies, or large multicentre series. A possible association is suggested by multiple case series or cases with drugs with similar mechanisms of action.1
Table
6
Clinical classiﬁcation of pulmonary hypertension
GROUP 1 Pulmonary arterial hypertension (PAH)
1.1 Idiopathic
1.1.1 Non-responders at vasoreactivity testing
1.1.2 Acute responders at vasoreactivity testing
1.2 Heritablea
1.3 Associated with drugs and toxinsa
1.4 Associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.5 PAH with features of venous/capillary (PVOD/PCH) involvement
1.6 Persistent PH of the newborn
GROUP 2 PH associated with left heart disease
2.1 Heart failure:
2.1.1 with preserved ejection fraction
2.1.2 with reduced or mildly reduced ejection fractionb
2.2 Valvular heart disease
2.3 Congenital/acquired cardiovascular conditions leading to post-capillary PH
GROUP 3 PH associated with lung diseases and/or hypoxia
3.1 Obstructive lung disease or emphysema
3.2 Restrictive lung disease
3.3 Lung disease with mixed restrictive/obstructive pattern
3.4 Hypoventilation syndromes
3.5 Hypoxia without lung disease (e.g. high altitude)
3.6 Developmental lung disorders
GROUP 4 PH associated with pulmonary artery obstructions
4.1 Chronic thrombo-embolic PH
4.2 Other pulmonary artery obstructionsc
GROUP 5 PH with unclear and/or multifactorial mechanisms
5.1 Haematological disordersd
5.2 Systemic disorderse
5.3 Metabolic disordersf
5.4 Chronic renal failure with or without haemodialysis
5.5 Pulmonary tumour thrombotic microangiopathy
5.6 Fibrosing mediastinitis
© ESC/ERS 2022
HF, heart failure; HIV, human immunodeﬁciency virus; PAH, pulmonary arterial hypertension;
PCH,
pulmonary capillary haemangiomatosis;
PH,
pulmonary hypertension; PVOD, pulmonary veno-occlusive disease.
aPatients with heritable PAH or PAH associated with drugs and toxins might be acute responders.
bLeft ventricular ejection fraction for HF with reduced ejection fraction: ≤40%; for HF
with mildly reduced ejection fraction: 41–49%.
cOther causes of pulmonary artery obstructions include: sarcomas (high or intermediate grade or angiosarcoma), other malignant tumours (e.g. renal carcinoma,
uterine carcinoma, germ-cell tumours of the testis), non-malignant tumours (e.g.
uterine leiomyoma), arteritis without connective tissue disease, congenital pulmonary arterial stenoses, and hydatidosis.
dIncluding inherited and acquired chronic haemolytic anaemia and chronic myeloproliferative disorders.
eIncluding sarcoidosis, pulmonary Langerhans’s cell histiocytosis, and neuroﬁbromatosis type 1.
fIncluding glycogen storage diseases and Gaucher disease.
3638
ESC/ERS Guidelines


<!-- PAGE 22 -->

### Page 22

1%
1%
Global population
Rare
Pulmonary arterial hypertension (PAH)
PH associated with left heart disease
PH associated with lung disease
PH associated with pulmonary artery obstructions
PH with unclear and/or multifactorial mechanisms
Very common
Common
Rare
Rare
Medical therapy 
Idiopathic/heritable
Associated 
conditions
CpcPH
IpcPH
Non-severe PH
Severe PH
CTEPH
Other pulmonary 
obstructions
Haematological disorders
Systemic disorders
PAH drugs
CCB in 
responders
Potentially: PAH
drugs (trials)
Lung transplantation 
IpcPH:
Treatment of LHDa
CpcPH:
Treatment of LHDa
PH-lung disease:
Optimized care of underlying lung 
disease
Severe PH:
Potentially: PAH 
drugs (trials)
Surgical therapy:
PEA
Interventional:
BPA
Medical therapy:
PH drugs
Optimized treatment of underlying disease
Pulmonary congestion in post-capillary PH
Pulmonary vascular disease /
obstruction in pre-capillary PH
Mortality Hazard Ratio mPAP (mmHg)
Mortality Hazard Ratio
PVR (Wood units)
Right heart failure
Prevalence
Potentially: PAH
drugs (trials)
6
5
4
3
1
2
10
20
30
40
50
60
5
4
3
1
2
0
2
3
4
5
6
0
1
CLINICAL CLASSIFICATION
PULMONARY HYPERTENSION
PREVALENCE
THERAPEUTIC STRATEGIES
Figure 1 Central illustration. BPA, balloon pulmonary angioplasty; CCB, calcium channel blocker; CTEPH, chronic thrombo-embolic pulmonary hypertension; CpCPH, combined post- and pre-capillary pulmonary hypertension; IpcPH, isolated post-capillary pulmonary hypertension; LHD, left heart disease; PAH, pulmonary arterial hypertension; PEA, pulmonary endarterectomy; PH, pulmonary hypertension. aTreatment of heart failure according to the
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.27 Treatment of left-sided valvular heart disease according to the 2021
ESC/EACTS Guidelines for the management of valvular heart disease.28
ESC/ERS Guidelines
3639


<!-- PAGE 23 -->

### Page 23

4.2. Group 2, pulmonary hypertension associated with left heart disease
In 2013, the Global Burden of Disease Study reported 61.7 million cases of HF worldwide, which represented almost a doubling since
1990.46 In Europe and the USA, .80% of patients with HF are aged ≥65 years. Post-capillary PH, either isolated or combined with a pre-capillary component, is a frequent complication mainly in HFpEF, affecting at least 50% of these patients.47,48 The prevalence of PH increases with severity of left-sided valvular diseases, and PH
can be found in 60–70% of patients with severe and symptomatic mitral valve disease49 and in up to 50% of those with symptomatic aortic stenosis.50
4.3. Group 3, pulmonary hypertension associated with lung diseases and/or hypoxia
Mild PH is common in advanced parenchymal and interstitial lung disease. Studies have reported that ≏1–5% of patients with advanced
COPD with chronic respiratory failure or candidates for lung volume reduction surgery or lung transplantation (LTx) have an mPAP .35–
40 mmHg.51,52
In idiopathic pulmonary
ﬁbrosis,
an mPAP
≥25 mmHg has been reported in 8–15% of patients upon initial work-up, with greater prevalence in advanced (30–50%) and endstage (.60%) disease.52 Hypoxia is a public health problem for the estimated 120 million people living at altitudes .2500 m. Altitude dwellers are at risk of developing PH and chronic mountain sickness.
However, it remains unclear to what extent PH and right HF are public health problems in high-altitude communities; this should be addressed with updated methodology and large-scale population studies.53
4.4. Group 4, pulmonary hypertension associated with chronic pulmonary artery obstruction
The number of patients diagnosed with CTEPH is increasing, probably due to a deeper understanding of the disease and more active screening for this condition in patients who remain dyspnoeic after pulmonary embolism (PE) or who have risk factors for developing CTEPH.
Registry data indicate a CTEPH incidence and prevalence of 2–6 and
26–38 cases/million adults, respectively.31,54,55 Patients with chronic thrombo-embolic pulmonary disease (CTEPD) without PH still represent a small proportion of the patients referred to CTEPH centres.56
4.5. Group 5, pulmonary hypertension with unclear and/or multifactorial mechanisms
Group 5 PH consists of a complex group of disorders that are associated with PH.57 The cause is often multifactorial and can be secondary to increased pre- and post-capillary pressure, as well as direct effects on pulmonary vasculature. The incidence and prevalence of PH in most of these disorders are unknown. However, high-quality registries have recently enabled estimation of PH prevalence in adult patients with sarcoidosis.58,59 Studies suggest that PH can be common and its presence is often associated with increased morbidity and mortality.58,59
5. Pulmonary hypertension diagnosis
5.1. Diagnosis
The diagnostic approach to PH is mainly focused on two tasks. The primary goal is to raise early suspicion of PH and ensure fast-track referral to PH centres in patients with a high likelihood of PAH,
CTEPH, or other forms of severe PH. The second objective is to identify underlying diseases, especially LHD (group 2 PH) and lung disease (group 3 PH), as well as comorbidities, to ensure proper classiﬁcation, risk assessment, and treatment.
5.1.1. Clinical presentation
Symptoms of PH are mainly linked to right ventricle (RV) dysfunction, and typically associated with exercise in the earlier course of the disease.25,26 The cardinal symptom is dyspnoea on progressively minor exertion. Other common symptoms are related to the stages and severity of the disease, and are listed in Figure 2.60–62 Potential clinical signs and physical ﬁndings are summarized in Figure 3.60,61
Importantly, the physical examination may also be the key to identifying the underlying cause of PH (see Figure 3).
5.1.2. Electrocardiogram
Electrocardiogram (ECG) abnormalities (Table 8) may raise suspicion of PH, deliver prognostic information, and detect arrhythmias and signs of LHD. In adults with clinical suspicion of PH (e.g. unexplained dyspnoea on exertion), right axis deviation has a high predictive value for PH.63 A normal ECG does not exclude the presence of PH, but a normal ECG in combination with normal biomarkers (BNP/
NT-proBNP) is associated with a low likelihood of PH in patients referred for suspected PH or at risk of PH (i.e. after acute PE).64,65
Table 7
Drugs and toxins associated with pulmonary arterial hypertension
Deﬁnite association
Possible association
Aminorex
Benﬂuorex
Dasatinib
Dexfenﬂuramine
Fenﬂuramine
Methamphetamines
Toxic rapeseed oil
Alkylating agents (cyclophosphamide,
mitomycin C)a
Amphetamines
Bosutinib
Cocaine
Diazoxide
Direct-acting antiviral agents against hepatitis
C virus (sofosbuvir)
Indirubin (Chinese herb Qing-Dai)
Interferon alpha and beta
Leﬂunomide
L-tryptophan
Phenylpropanolamine
Ponatinib
Selective proteasome inhibitors (carﬁlzomib)
Solvents (trichloroethylene)a
St John’s Wort
© ESC/ERS 2022
aPulmonary veno-occlusive disease.
3640
ESC/ERS Guidelines


<!-- PAGE 24 -->

### Page 24

5.1.3. Chest radiography
Chest radiography presents abnormal ﬁndings in most patients with
PH; however, a normal chest X-ray does not exclude PH.68
Radiographic signs of PH include a characteristic conﬁguration of the cardiac silhouette due to right heart (right atrium [RA]/RV)
and PA enlargement, sometimes with pruning of the peripheral vessels. In addition, signs of the underlying cause of PH, such as LHD or lung disease, may be found (Table 9).25,26,60,69,70
5.1.4. Pulmonary function tests and arterial blood gases
Pulmonary function tests (PFTs) and analysis of arterial blood gas
(ABG) or arterialized capillary blood are necessary to distinguish between PH groups, assess comorbidities and the need for supplementary oxygen, and determine disease severity. The initial work-up of patients with suspected PH should comprise forced spirometry,
body plethysmography, lung diffusion capacity for carbon monoxide
(DLCO), and ABG.
In patients with PAH, PFTs are usually normal or may show mild restrictive, obstructive, or combined abnormalities.71,72 More severe
PFT abnormalities are occasionally found in patients with PAH associated with CHD,73 and those with group 3 PH. The DLCO may be normal in patients with PAH, although it is usually mildly reduced.71 A
severely reduced DLCO (,45% of the predicted value) in the presence of otherwise normal PFTs can be found in PAH associated with systemic sclerosis (SSc), PVOD, in PH group 3—associated with emphysema, interstitial lung disease (ILD), or combined pulmonary ﬁbrosis and emphysema—and in some PAH phenotypes.74 A low
DLCO is associated with a poor prognosis in several forms of
PH.75–78
Patients with PAH usually have normal or slightly reduced partial pressure of arterial oxygen (PaO2). Severe reduction of PaO2 might raise suspicion for patent foramen ovale, hepatic disease, other abnormalities with right-to-left shunt
(e.g.
septal defect),
or low-DLCO-associated conditions.
Partial pressure of arterial carbon dioxide (PaCO2) is typically lower than normal due to alveolar hyperventilation.79 Low PaCO2
Symptoms
Dyspnoea on exertion (WHO-FC)
Fatigue and rapid exhaustion
Dyspnoea when bending forward (bendopnoea)
Palpitations
Haemoptysis
Exercise-induced abdominal distension and nausea
Weight gain due to fluid retention
Syncope (during or shortly after physical exertion)
Rare symptoms due to pulmonary artery dilationa
Exertional chest pain:
dynamic compression of the left main coronary artery
Early
Late
Hoarseness (dysphonia):
compression of the left laryngeal recurrent nerve
(cardiovocal or Ortner´s syndrome)
Shortness of breath, wheezing, cough, lower respiratory tract infection, atelectasis:
compression of the bronchi
Figure 2 Symptoms in patients with pulmonary hypertension. WHO-FC, World Health Organization functional class. aThoracic compression syndromes are found in a minority of patients with PAH with pronounced dilation of the pulmonary artery, and may occur at any disease stage and even in patients with otherwise mild functional impairment.
ESC/ERS Guidelines
3641


<!-- PAGE 25 -->

### Page 25

at diagnosis and follow-up is common in PAH and associated with unfavourable outcomes.80 Elevated PaCO2 is very unusual in PAH
and reﬂects alveolar hypoventilation, which in itself may be a cause of PH. Overnight oximetry or polysomnography should be performed if there is suspicion of sleep-disordered breathing or hypoventilation.81
5.1.5. Echocardiography
Independent of the underlying aetiology, PH leads to RV pressure overload and dysfunction, which can be detected by echocardiography.82–84 When performed accurately, echocardiography provides comprehensive information on right and left heart morphology, RV
and LV function, and valvular abnormalities, and gives estimates of haemodynamic parameters. Echocardiography is also a valuable tool with which to detect the cause of suspected or conﬁrmed
PH, particularly with respect to PH associated with LHD or CHD.
Yet, echocardiography alone is insufﬁcient to conﬁrm a diagnosis of PH, which requires RHC.
Given the heterogeneous nature of PH and the peculiar geometry of the RV, there is no single echocardiographic parameter that reliably informs about PH status and underlying aetiology.
Therefore, a comprehensive echocardiographic evaluation for suspected PH includes estimating the systolic pulmonary arterial pressure (sPAP) and detecting additional signs suggestive of PH,
aiming at assigning an echocardiographic level of probability of
PH. Echocardiographic ﬁndings of PH, including estimating pressure and signs of RV overload and/or dysfunction, are summarized in Figure 4.
Signs of PH
Central, peripheral, or mixed cyanosis
Accentuated pulmonary component of the second heart sound
RV third heart sound
Systolic murmur of tricuspid regurgitation
Diastolic murmur of pulmonary regurgitation
Signs pointing towards underlying cause of PH
Digital clubbing: Cyanotic CHD, fibrotic lung disease, bronchiectasis, PVOD, or liver disease
Differential clubbing/cyanosis:
PDA/Eisenmenger’s syndrome
Auscultatory findings (crackles or wheezing,
murmurs): lung or heart disease
Sequelae of DVT, venous insufficiency: CTEPH
Telangiectasia: HHT or SSc 
Sclerodactyly, Raynaud’s phenomenon, digital ulceration, GORD: SSc
Signs of RV backward failure
Signs of RV forward failure
Distended and pulsating jugular veins
Abdominal distension
Hepatomegaly
Ascites
Peripheral oedema
Peripheral cyanosis (blue lips and tips)
Dizziness
Pallor
Cool extremities 
Prolonged capillary refill the on tation lung disease ezing,
CTEPH
digital
Sig
S
Dis
Ab
He
Asc
Per
Per
Diz
Pal
Co
Pro
Figure 3 Clinical signs in patients with pulmonary hypertension. CHD, congenital heart disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; DVT, deep venous thrombosis; GORD, gastro-oesophageal reﬂux disease; HHT, hereditary haemorrhagic telangiectasia; PDA, patent ductus arteriosus; PH, pulmonary hypertension; PVOD, pulmonary veno-occlusive disease; RV, right ventricle; SSc, systemic sclerosis.
3642
ESC/ERS Guidelines


<!-- PAGE 26 -->

### Page 26

Estimates of sPAP are based on the peak tricuspid regurgitation velocity (TRV) and the TRV-derived tricuspid regurgitation pressure gradient (TRPG)—after excluding pulmonary stenosis—taking into account non-invasive estimates of RA pressure (RAP). Considering the inaccuracies in estimating RAP and the ampliﬁcation of measurement errors by using derived variables,85–87 these guidelines recommend using the peak TRV (and not the estimated sPAP) as the key variable for assigning the echocardiographic probability of
PH. A peak TRV .2.8 m/s may suggest PH; however, the presence or absence of PH cannot be reliably determined by TRV alone.88
Lowering the TRV threshold in view of the revised haemodynamic deﬁnition of PH is not supported by available data (key narrative question 2, Supplementary Data, Section 5.1).89–92 Tricuspid regurgitation (TR) velocity may underestimate (e.g. in patients with severe
TR)28 or overestimate (e.g. in patients with high CO in liver disease or sickle cell disease [SCD],93,94 misinterpretation of tricuspid valve closure artefact for the TR jet, or incorrect assignment of a peak TRV
in the case of maximum velocity boundary artefacts) pressure gradients. Hence, additional variables related to RV morphology and function are used to deﬁne the echocardiographic probability of PH
(Table 10),82–84,95 which may then be determined as low, intermediate, or high. When interpreted in a clinical context, this probability can be used to decide the need for further investigation, including cardiac catheterization in individual patients (Figure 5).
Echocardiographic measures of RV function include the tricuspid annular plane systolic excursion (TAPSE), RV fractional area change
(RV-FAC), RV free-wall strain, and tricuspid annulus velocity (S′
wave) derived from tissue Doppler imaging, and potentially RV ejection fraction
(RVEF)
derived from
3D
echocardiography.
Furthermore, the TAPSE/sPAP ratio—representing a non-invasive measure of RV–PA coupling96—may aid in diagnosing PH.90,97,98
The pattern of RV outﬂow tract (RVOT) blood ﬂow (mid-systolic
‘notching’) may suggest pre-capillary PH.99,100
To separate between group 2 PH and other forms of PH, and to assess the likelihood of left ventricle (LV) diastolic dysfunction, LA
size and signs of LV hypertrophy should always be measured, and
Doppler echocardiographic signs (e.g. E/A ratio, E/E′) should be assessed even if the reliability of the latter is considered low.16 To identify CHD, 2D Doppler and contrast examinations are helpful, but transoesophageal contrast echocardiography or other imaging techniques (e.g. computer tomography [CT] angiography, cMRI) are needed in some cases to detect or exclude sinus venosus atrial septal defects, patent ductus arteriosus, and/or anomalous pulmonary venous return.101 The clinical value of exercise Doppler echocardiography in identifying exercise PH remains uncertain because of the lack of validated criteria and prospective conﬁrmatory data. In most cases, increases in sPAP during exercise are caused by diastolic
LV dysfunction.16
5.1.6. Ventilation/perfusion lung scan
A ventilation/perfusion (V/Q) lung scan (planar or single-photon emission computed tomography [SPECT]) is recommended in the diagnostic work-up of patients with suspected or newly diagnosed
PH, to rule out or detect signs of CTEPH.102,103 The V/Q SPECT
is superior to planar imaging and is the methodology of choice; however, SPECT has been widely evaluated in assessing PE, but not to the same degree in CTEPH.68 In the absence of parenchymal lung disease, a normal perfusion scan excludes CTEPH with a negative predicted value of 98%.104,105 In most patients with PAH, V/Q
scintigraphy is normal or shows a speckled pattern but no typical perfusion defects characteristic of PE or CTEPH, whereas matched
V/Q defects may be found in patients with lung disease (i.e. group
3 PH). Non-matched perfusion defects similar to those seen in
Table 9
Radiographic signs of pulmonary hypertension and concomitant abnormalities
Signs of PH and concomitant abnormalities
Signs of left heart disease/
pulmonary congestion
Signs of lung disease
Right heart enlargement
Central air space opaciﬁcation
Flattening of diaphragm (COPD/
emphysema)
PA enlargement
(including aneurysmal dilatation)
Interlobular septal thickening ‘Kerley B’
lines
Hyperlucency
(COPD/
emphysema)
Pruning of the peripheral vessels
Pleural effusions
Lung volume loss
(ﬁbrotic lung disease)
‘Water-bottle’ shape of cardiac silhouettea
Left atrial enlargement
(including splayed carina)
Left ventricular dilation
Reticular opaciﬁcation
(ﬁbrotic lung disease)
© ESC/ERS 2022
COPD, chronic obstructive pulmonary disease; PA, pulmonary artery; PH, pulmonary hypertension.
aMay be present in patients with PH with advanced right ventricular failure and moderate pericardial effusion.
Table 8
Electrocardiogram abnormalities in patients with pulmonary hypertension
Typical ECG abnormalities in PH66
• P pulmonale (P .0.25 mV in lead II)
• Right or sagittal axis deviation (QRS axis .90° or indeterminable)
• RV hypertrophy (R/S .1, with R .0.5 mV in V1; R in V1 + S in lead V5
. 1 mV)
• Right bundle branch block—complete or incomplete (qR or rSR
patterns in V1)
• RV strain patterna (ST depression/T-wave inversion in the right pre-cordial V1–4 and inferior II, III, aVF leads)
• Prolonged QTc interval (unspeciﬁc)b
© ESC/ERS 2022
ECG, electrocardiogram; PH, pulmonary hypertension; QTc, corrected QT interval;
RV, right ventricular.
aPresent in advanced PH.
bPatients with pulmonary arterial hypertension can present with a prolonged QTc interval (although non-speciﬁc), which may reﬂect RV dysfunction and delayed myocardial repolarization, and is an independent predictor of mortality.67
ESC/ERS Guidelines
3643


<!-- PAGE 27 -->

### Page 27

CTEPH may be present in 7–10% of patients with PVOD/PCH or
PAH.106,107 Deposition of the perfusion agent in extrapulmonary organs may hint to cardiac or pulmonary right-to-left shunting and has been reported in CHD, hepato-pulmonary syndrome, and pulmonary arteriovenous malformations (PAVMs).68
5.1.7. Non-contrast and contrast-enhanced chest computed tomography examinations, and digital subtraction angiography
Computed tomography (CT) imaging may provide important information for patients with unexplained dyspnoea or suspected/conﬁrmed PH. The CT signs suggesting the presence of PH include an enlarged PA diameter, a PA-to-aorta ratio .0.9, and enlarged right heart chambers.68 A combination of three parameters (PA diameter
≥30 mm, RVOT wall thickness ≥6 mm, and septal deviation ≥140°
[or RV:LV ratio ≥1]) is highly predictive of PH.108 Non-contrast chest CT can help determine the cause of PH when there are features of parenchymal lung disease, and may also point towards the presence of PVOD/PCH by showing centrilobular ground-glass opacities (which may also be found in PAH), septal lines, and lymphadenopathy.68
Computed tomography pulmonary angiography (CTPA) is mainly used to detect direct or indirect signs of CTEPH, such as ﬁlling defects (including thrombus adhering to the vascular wall), webs or bands in the PAs, PA retraction/dilatation, mosaic perfusion, and enlarged bronchial arteries. Importantly, the diagnostic accuracy of
CTPA for CTEPH is limited (at the patient level, sensitivity and speciﬁcity are 76% and 96%, respectively),109 but was reported to be higher when modern, high-quality multi-detector CT scanners were used and when interpreted by experienced readers.109,110
Computed tomography pulmonary angiography may also be used to detect other cardiovascular abnormalities, including intracardiac shunts, abnormal pulmonary venous return, patent ductus arteriosus, and PAVMs.
RV
Ao
LA
LV
Enlarged right ventricle;
parasternal long-axis view
A
RV
RA
LV
Dilated RV with basal RV/LV 
ratio >1.0;
four-chamber view
B
RV
LV
Flattened interventricular septum
(arrows) leading to ‘D-shaped’ LV;
decreased LV eccentricity index;
parasternal short-axis view
C
RA
IVC
Distended inferior vena cava 
with diminished inspiratory collapsibility; subcostal view 
D
RVOT acceleration time of pulmonary ejection <105 ms mid-systolic ‘notch’ indicative of pre-capillary PH
E
Reduced right ventricular fractional area change (<35%);
four-chamber view
F
RV
RA
RVOT AT <105 ms
‘notch’
Diastole
Systole
RV
RA
LV
TAPSE 
<18 mm
M-Mode
Decreased tricuspid annular plane systolic excursion (TAPSE)
measured with M-Mode (<18 mm)
G
Decreased peak systolic (S’)
velocity of tricuspid annulus 
(<9.5 cm/s) measured with tissue Doppler
H
Enlarged right atrial area 
(>18 cm2);
four-chamber view
I
E’
S’
S’ <9.5 cm/s
RV
RA
A’
RV
Increased systolic peak tricuspid regurgitation velocity (peak TRV);
measured with continuous wave Doppler
J
Estimation of systolic pulmonary artery pressure (sPAP);
sPAP = TR pressure gradient + 
estimated RAP
K
Presence of pericardial effusion;
four-chamber view;
parasternal short-axis view;
other views (e.g. subcostal view)
L
RV
RA
Estimated RAP
RV
RA
IVC
IVC
Collapsea eRAP
<2.1 cm >50%
3 (0-5)
Peak TRV
>2.8 m/s
>2.1 cm >50%
8 (5-10)
>2.1 cm <50% 15 (10-20)
RV
LV
Peak TRV
>2.8 m/s
End-systolic
RA >18 cm2
Figure 4 Transthoracic echocardiographic parameters in the assessment of pulmonary hypertension. Ao, aorta; IVC, inferior vena cava; LA, left atrium;
LV, left ventricle; PH, pulmonary hypertension; RA, right atrium; RAP, right atrial pressure; RV, right ventricle; RVOT AT, right ventricular outﬂow tract acceleration time; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; TRV, tricuspid regurgitation velocity. aRefers to collapse on inspiration.
3644
ESC/ERS Guidelines


<!-- PAGE 28 -->

### Page 28

In patients presenting with a clinical picture of acute PE, chest CT
may be helpful in detecting signs of hitherto undetected CTEPH,
which may include the presence of the above CTEPH signs, and
RV hypertrophy as a sign for chronicity.111,112 Detecting ‘acute on chronic’ PE is important, as it may impact the management of patients with presumed acute PE.
Dual-energy CT (DECT) angiography and iodine subtraction mapping may provide additional diagnostic information by creating iodine maps,113 which reﬂect lung perfusion, thereby possibly increasing the diagnostic accuracy for CTEPH.114 Although increasingly used, the diagnostic value of DECT in the work-up of patients with PH has not been established.
Digital subtraction angiography (DSA) is mainly used to conﬁrm the diagnosis of CTEPH and to assess treatment options (i.e. operability or accessibility for BPA). Most centres use conventional two- or three-planar DSA. However, C-arm CT imaging may provide a higher spatial resolution, potentially identifying more target vessels for BPA and providing procedural guidance.115,116
5.1.8. Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging accurately and reproducibly assesses atrial and ventricular size, morphology, and function.
Additional information on RV/LV myocardial strain can be obtained by applying tagging or by post-processing feature tracking. In addition, cMRI can be used to measure blood ﬂow in the PA, aorta,
and vena cava, allowing for quantifying stroke volume (SV),
Table 10
Additional echocardiographic signs suggestive of pulmonary hypertension
A: The ventricles
B: Pulmonary artery
C: Inferior vena cava and RA
RV/LV basal diameter/
area ratio .1.0
RVOT AT
,105 ms and/or mid-systolic notching
IVC diameter
.21 mm with decreased inspiratory collapse (,50% with a sniff or ,20% with quiet inspiration)
Flattening of the interventricular septum (LVEI .1.1 in systole and/or diastole)
Early diastolic pulmonary regurgitation velocity .2.2 m/s
RA area (end-systole)
.18 cm2
TAPSE/sPAP ratio
,0.55 mm/mmHg
PA diameter .AR
diameter
PA diameter
.25 mm
© ESC/ERS 2022
AR, aortic root; IVC, inferior vena cava; LV, left ventricle; LVEI, left ventricle eccentricity index; PA, pulmonary artery; RA, right atrium; RV, right ventricle; RVOT AT, right ventricular outﬂow tract acceleration time; sPAP, systolic pulmonary arterial pressure;
TAPSE,
tricuspid annular plane systolic excursion;
TRV,
tricuspid regurgitation velocity.
aSigns contributing to assessing the probability of PH in addition to TRV (see Figure 5).
Signs from at least two categories (A/B/C) must be present to alter the level of echocardiographic probability of PH.
Peak tricuspid regurgitation velocity (m/s)
Presence of other echo PH signsb (see Table 10)
T
N
N
≤2.8a
2.9–3.4
PH PRO
R BABILITY
INTERMEDIATE
A
PH PRO
R BABILITY
HIGH
PH PRO
R BABILITY
LOW
>3.4
Y
Y
Yes/No
Y
Risk factors or associated conditions o
for 
f
PAH or CTEPH
P
N
N
Echo foll f
ow-up
(Class IIa)
Further interventionc/
RHC (if indicatedd)
(Class I) 
Alternative diagnosis
(Class IIa)
Y
Y
Yes/No
Y
Figure 5 Echocardiographic probability of pulmonary hypertension and recommendations for further assessment. CPET, cardiopulmonary exercise testing; CTEPH, chronic thrombo-embolic pulmonary hypertension; echo, echocardiography; LHD, left heart disease; N, no; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; RHC, right heart catheterization; TRV, tricuspid regurgitation velocity; Y, yes. aOr unmeasurable. The
TRV threshold of 2.8 m/s was not changed according to the updated haemodynamic deﬁnition of PH. bSigns from at least two categories in Table 10
(A/B/C) must be present to alter the level of echocardiographic probability of PH. cFurther testing may be necessary (e.g. imaging, CPET). dRHC should be performed if useful information/a therapeutic consequence is anticipated (e.g. suspected PAH or CTEPH), and may not be indicated in patients without risk factors or associated conditions for PAH or CTEPH (e.g. when mild PH and predominant LHD or lung disease are present).
ESC/ERS Guidelines
3645


<!-- PAGE 29 -->

### Page 29

intracardiac shunt, and retrograde ﬂow. By combining contrast magnetic resonance (MR) angiography and pulmonary perfusion imaging with late gadolinium-enhancement imaging of the myocardium, a complete picture of the heart and pulmonary vasculature can be obtained (see Supplementary Data, Table S2 for cMRI indices and normal values). A limitation is that there is no established method with which to estimate PAP. Even though the cost and availability of the technique precludes its use in the early diagnosis of PAH, it is sensitive in detecting early signs of PH and diagnosing CHD.117
5.1.9. Blood tests and immunology
The initial diagnostic assessment of patients with newly diagnosed
PH/PAH aims to identify comorbidities and possible causes or complications of PH. Laboratory tests that should be obtained at the time of PH diagnosis include: blood counts (including haemoglobin [Hb]);
serum electrolytes (sodium, potassium); kidney function (creatinine,
calculation of estimated glomerular ﬁltration rate, and urea); uric acid; liver parameters (alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase, γ-glutamyl transpeptidase, bilirubin); iron status (serum iron, transferrin saturation, and ferritin);
and BNP or NT-proBNP. In addition, serological studies should include testing for hepatitis viruses and HIV. Basic immunology laboratory work-up is recommended, including screening tests for anti-nuclear antibodies, anti-centromere antibodies, and anti-Ro.
Screening for biological markers of antiphospholipid syndrome is recommended in patients with CTEPH. Additional thrombophilia screening is not generally recommended, unless therapeutic consequences are to be expected.118 Pulmonary arterial hypertension and other forms of severe PH can be associated with thyroid function disorders; hence, laboratory screening should include at least thyroid-stimulating hormone.
5.1.10. Abdominal ultrasound
An abdominal ultrasound examination should be part of the comprehensive diagnostic work-up of patients with newly diagnosed PH,
particularly if liver disease is suspected. A major objective is to search for liver disease and/or portal hypertension, or portocaval shunt
(Abernethy malformation). During the course of the disease, patients with PH may develop secondary organ dysfunction mainly affecting the liver and kidneys.119 In these patients, abdominal ultrasound is needed for differential diagnostic reasons and to assess the extent of organ damage.
5.1.11. Cardiopulmonary exercise testing
Cardiopulmonary exercise testing (CPET) is a useful tool to assess the underlying pathophysiologic mechanisms leading to exercise intolerance. Patients with PAH show a typical pattern, with a low endtidal partial pressure of carbon dioxide (PETCO2), high ventilatory equivalent for carbon dioxide (VE/VCO2), low oxygen pulse (VO2/
HR), and low peak oxygen uptake (VO2).120 These ﬁndings should prompt consideration of PVD. In patients with LHD or COPD,
such a pattern may indicate an additional pulmonary vascular limitation.121,122 In populations at risk of PAH, such as those with SSc, a normal peak VO2 seems to exclude the diagnosis of PAH.123
5.1.12. Right heart catheterization, vasoreactivity,
exercise, and ﬂuid challenge
5.1.12.1. Right heart catheterization
Right heart catheterization is the gold standard for diagnosing and classifying PH. Performing RHC requires expertise and meticulous methodology following standardized protocols. In addition to diagnosing and classifying PH, clinical indications include haemodynamic assessment of heart or LTx candidates124 and evaluating congenital cardiac shunts. Interpreting invasive haemodynamics should be done in the context of the clinical picture and other diagnostic investigations. When performed in PH centres, the frequencies of serious adverse events (1.1%) and procedure-related mortality (0.055%) are low.125 A known thrombus or tumour in the RV or RA, recently implanted (,1 month) pacemaker, mechanical right heart valve,
TriClip, and an acute infection are contraindications to RHC; the risk:beneﬁt ratio should be individually assessed before each examination and discussed with the patient. The most feared complication of RHC is perforation of a PA.
The adequate preparation of patients for RHC is of major relevance. Pre-existing medical conditions should be optimally controlled at the time of the examination (particularly blood pressure and volume control). In the supine position, the mid-thoracic level is recommended as the zero reference level, which is at the level of the LA in most patients.126
For a complete assessment of cardiopulmonary haemodynamics,
all measures listed in Table 11 must be measured or calculated.
Table 11
Haemodynamic measures obtained during right heart catheterization
Measured variables
Normal value
Right atrial pressure, mean (RAP)
2–6 mmHg
Pulmonary artery pressure, systolic (sPAP)
15–30 mmHg
Pulmonary artery pressure, diastolic (dPAP)
4–12 mmHg
Pulmonary artery pressure, mean (mPAP)
8–20 mmHg
Pulmonary arterial wedge pressure, mean (PAWP)
≤15 mmHg
Cardiac output (CO)
4–8 L/min
Mixed venous oxygen saturation (SvO2)a
65–80%
Arterial oxygen saturation (SaO2)
95–100%
Systemic blood pressure
120/80 mmHg
Calculated parameters
Pulmonary vascular resistance (PVR)b
0.3–2.0 WU
Pulmonary vascular resistance index (PVRI)
3–3.5 WU·m2
Total pulmonary resistance (TPR)c
,3 WU
Cardiac index (CI)
2.5–4.0 L/min·m2
Stroke volume (SV)
60–100 mL
Stroke volume index (SVI)
33–47 mL/m2
Pulmonary arterial compliance (PAC)d
.2.3 mL/mmHg
© ESC/ERS 2022
WU, Wood units.
aDerived from blood sample taken from the pulmonary artery; compartmental oximetry to exclude an intracardiac shunt is recommended when SvO2 .75%.
bPVR, (mPAP−PAWP)/CO.
cTPR, mPAP/CO.
dPAC, SV/(sPAP−dPAP).
3646
ESC/ERS Guidelines


<!-- PAGE 30 -->

### Page 30

Incomplete assessments must be avoided, as this may lead to misdiagnosis. As a minimum, mixed venous oxygen saturation (SvO2)
and arterial oxygen saturation (SaO2) should be determined. A stepwise assessment of oxygen saturation should be performed in patients with SvO2 .75% and whenever a left-to-right shunt is suspected. Cardiac output (CO) should be assessed by the direct
Fick method or thermodilution (mean values of at least three measurements). The indirect Fick method is considered to be less reliable than thermodilution;127 however, thermodilution should not be used in the presence of shunts.
Pulmonary vascular resistance
([mPAP−PAWP]/CO) should be calculated for each patient. All pressure measurements, including PAWP, should be performed at end expiration (without breath-holding manoeuvre). In patients with large intrathoracic pressure changes during the respiratory cycle (i.e. COPD, obesity, during exercise), it is appropriate to average over at least three to four respiratory cycles. If no reliable PAWP
curve can be obtained, or if the PAWP values are implausible, additional measurement of LV end-diastolic pressure should be considered to avoid misclassiﬁcation. Saturations taken with the catheter in the wedged position can conﬁrm an accurate PAWP.128
5.1.12.2. Vasoreactivity testing
The purpose of vasoreactivity testing in PAH is to identify acute vasoresponders who may be candidates for treatment with high-dose calcium channel blockers (CCBs). Pulmonary vasoreactivity testing is only recommended in patients with IPAH, HPAH, or DPAH.
Inhaled nitric oxide129 or inhaled iloprost130,131 are the recommended test compounds for vasoreactivity testing (Table 12). There is similar evidence for intravenous (i.v.) epoprostenol, but due to incremental dose increases and repetitive measurements, testing takes much longer and is therefore less feasible.129 Adenosine i.v. is no longer recommended due to frequent side effects.132 A positive acute response is deﬁned as a reduction in mPAP by ≥10 mmHg to reach an absolute value ≤40 mmHg, with increased or unchanged CO.129 In patients with PH-LHD, vasoreactivity testing is restricted to evaluating heart transplantation candidacy (see Section 8.1), and in patients with PH
in the context of CHD with initial systemic-to-pulmonary shunting, vasoreactivity testing can be performed to evaluate the possibility of defect closure (see Section 7.5).101
5.1.12.3. Exercise right heart catheterization
Right heart catheterization is the gold standard method to assess cardiopulmonary haemodynamics during exercise and to deﬁne exercise PH.133 The main reason to perform exercise RHC is to investigate patients with unexplained dyspnoea and normal resting haemodynamics in order to detect early PVD or left heart dysfunction. In addition, exercise haemodynamics may reveal important prognostic and functional information in patients at risk of PAH
and CTEPH.22,134,135 To maximize the amount of information, exercise RHC may be combined with CPET. According to the available data and experience, exercise RHC is not associated with an additional risk of complications compared with resting RHC and
CPET.133
Incremental exercise tests (step or ramp protocol) with repeated haemodynamic measurements provide the most clinical information on pulmonary circulation. The minimally required haemodynamic variables measured at each exercise level include mPAP, sPAP, diastolic PAP (dPAP), PAWP, CO, heart rate, and systemic blood pressure. In addition, RAP, SvO2, and SaO2 should at least be measured at rest and peak exercise. Total pulmonary resistance (TPR), PVR, and cardiac index (CI) should be calculated at each exercise level, as well as arteriovenous difference in oxygen at peak exercise. The mPAP/
CO and PAWP/CO slopes should also be calculated.136,137 In patients with early PVD, PVR may be normal or mildly elevated at rest, but may change during exercise with a steep increase in mPAP, reﬂected by an mPAP/CO slope .3 mmHg/L/min, while the PAWP/CO slope usually remains ,2 mmHg/L/min. Patients with left heart dysfunction, such as those with HFpEF23 and/or dynamic mitral regurgitation,138 and a normal PAWP at rest, usually show a steep increase in mPAP and PAWP (and mPAP/CO,
PAWP/CO slope) during exercise.
According to recent studies, a PAWP/CO slope .2 mmHg/L/min may be helpful in recognizing an abnormal PAWP increase and,
therefore, a cardiac exercise limitation, especially in patients with
PAWP
12–15 mmHg at rest.23,24,139
A
PAWP
cut-off of
.25 mmHg during supine exercise has been recommended for diagnosing HFpEF.16 In patients with lung disease, increased intrathoracic pressure may contribute to mPAP elevation; this is exaggerated during exercise and can be recognized by a concomitant increase in
RAP.140 Some exercise haemodynamics are age dependent, with healthy elderly subjects presenting with steeper mPAP/CO and
PAWP/CO slopes than healthy young individuals.9,141
5.1.12.4. Fluid challenge
Fluid challenge may reveal LV diastolic dysfunction in patients with
PAWP ≤15 mmHg, but a clinical phenotype suggestive of LHD.
Table 12
Route of administration, half-life, dosages, and duration of administration of the recommended test compounds for vasoreactivity testing in pulmonary arterial hypertension
Compound
Route
Half-life
Dosage
Duration
Nitric oxide129
inh
15–30 s
10–20 p.p.m.
5–10 mina
Iloprost130,131
inh
30 min
5–10 µgb
10–15 minc
Epoprostenol129
i.v.
3 min
2–12 ng/kg/min
10 mind
© ESC/ERS 2022
Inh, inhaled; i.v., intravenous.
aMeasurement as a single step within the dose range.
bAt mouth piece.
cMeasurement as a single step, temporize full effect.
dIncremental increase in 2 ng/kg/min intervals, duration of 10 min at each step.
ESC/ERS Guidelines
3647


<!-- PAGE 31 -->

### Page 31

Most available data are derived from studies aiming to uncover
HFpEF (increase in PAWP) rather than identify group 2 PH (increase in PAP; see Section 8.1). It is generally accepted that rapid infusion
(over 5–10 min) of ≏500 mL (7–10 mL/kg) of saline would be sufﬁcient to detect an abnormal increase in PAWP to ≥18 mmHg (suggestive of HFpEF),142 although validation and long-term evaluation of these data are needed.143 There are insufﬁcient data on the haemodynamic response to ﬂuid challenge in patients with PAH. Recent data suggest that passive leg raise during RHC may also help to uncover occult HFpEF.144
5.1.13. Genetic counselling and testing
Mutations in PAH genes have been identiﬁed in familial PAH, IPAH,
PVOD/PCH, and anorexigen-associated PAH (Table 13).148 The screening recommendations herein speciﬁcally relate to patients with an a priori diagnosis of PAH and not ‘at-risk’ populations being screened for PAH (see Section 5.3). All patients with these conditions should be informed about the possibility of a genetic condition and that family members could carry a mutation that increases the risk of PAH, allowing for screening and early diagnosis.33,148 Even if genetic testing is not performed, family members should be made aware of early signs and symptoms, to ensure that a timely and appropriate diagnosis is made.148
Genetic counselling by appropriately trained PAH providers or geneticists should be performed prior to genetic testing, to address the complex questions related to penetrance, genetically at-risk family members, reproduction, genetic discrimination, and psychosocial issues. Careful genetic counselling with genetic counsellors or medical geneticists is critical prior to genetic testing for asymptomatic family members.148
If the familial mutation is known and an unaffected family member tests negative for that mutation, the risk of PAH for that person is the same as for the general population.148
Many of the less common mutations outlined have a potential additional set of syndromic features. These are summarized in Table 13
where speciﬁc clinical history, examination, and investigations are suggested. In particular, clinicians should undertake a thorough history and examination, as syndromic PAH diagnoses may be missed if not interrogated. For example, in one of the largest studies to date, TBX4, ALK1, and ENG mutations were represented in the top six most common genetic ﬁndings in adults with previously diagnosed
IPAH.149 These ﬁndings have been conﬁrmed and extended in international genetics consortia in 4241 patients with PAH.150 It is therefore apparent that there is either phenotypic heterogeneity of these syndromes or missed diagnostic features. As more genes associated with PAH are discovered, it will become increasingly difﬁcult to individually test for each. Next-generation sequencing has enabled the development of gene panels to simultaneously interrogate several genes.151 It is, however, important to check the genes included in the panel at the time of testing, since the composition changes as genetic discoveries advance.
5.2. Diagnostic algorithm
A multistep, pragmatic approach to diagnosis should be considered in patients with unexplained dyspnoea or symptoms/signs raising suspicion of PH. This strategy is depicted in detail in Figure 6 and
Table 14. The diagnostic algorithm does not address screening for speciﬁc groups at risk of PH.
5.2.1 Step 1 (suspicion)
Patients with PH are likely to be seen by ﬁrst-line physicians, mainly general practitioners, for non-speciﬁc symptoms. Initial evaluation should include a comprehensive medical (including familial) history,
thorough physical examination (including measurement of blood pressure, heart rate, and pulse oximetry), blood test to determine
BNP/NT-proBNP, and resting ECG. This ﬁrst step may raise a suspicion of a cardiac or respiratory disorder causing the symptoms.
5.2.2. Step 2 (detection)
The second step includes classical, non-invasive lung and cardiac testing. Among those tests, echocardiography is an important step in the
Recommendation Table 1 — Recommendations for right heart catheterization and vasoreactivity testing
Recommendations
Classa
Levelb
Right heart catheterization
It is recommended that RHC is performed to conﬁrm the diagnosis of PH (especially PAH or
CTEPH) and to support treatment decisions25,26
I
B
In patients with suspected or known PH, it is recommended that RHC is performed in experienced centres125
I
C
It is recommended that RHC comprises a complete set of haemodynamics and is performed following standardized protocols25,26,145
I
C
Vasoreactivity testing
Vasoreactivity testing is recommended in patients with I/H/DPAH to detect those who can be treated with high doses of a CCB129,146
I
B
It is recommended that vasoreactivity testing is performed at PH centres
I
C
It is recommended to consider a positive response to vasoreactivity testing by a reduction in mPAP
≥10 mmHg to reach an absolute value of mPAP
≤40 mmHg with an increased or unchanged
COc129
I
C
Inhaled nitric oxide, inhaled iloprost, or i.v.
epoprostenol are recommended for performing vasoreactivity testing129–132
I
C
Vasoreactivity testing, for identifying candidates for CCB therapy, is not recommended in patients with PAH other than I/H/DPAH, and in PH groups
2, 3, 4, and 5124,129
III
C
© ESC/ERS 2022
CCB, calcium channel blocker; CO, cardiac output; CTEPH, chronic thrombo-embolic pulmonary hypertension; I/H/DPAH, idiopathic, heritable, drug-associated pulmonary arterial hypertension; i.v., intravenous; mPAP, mean pulmonary arterial pressure;
PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; RHC, right heart catheterization.
aClass of recommendation.
bLevel of evidence.
cTesting should also be performed in patients with a baseline mPAP ≤40 mmHg, in whom the same responder criteria apply.
3648
ESC/ERS Guidelines


<!-- PAGE 32 -->

### Page 32

Table 13
Phenotypic features associated with pulmonary arterial hypertension mutations
Gene
Pulmonary hypertension phenotypic association
Putative molecular mechanism
Inheritance pattern
Potential distinguishing clinical and examination features
Investigations
Populations
Reference
BMPR2
Heritable and idiopathic PAH
Haploinsufﬁciency
Autosomal dominant
No speciﬁc or diagnostic clinical features described
No discriminative investigations described
Paediatric and adult
152
ATP13A3
Unknown
Autosomal dominant
Adult
149
AQP1
Unknown
Autosomal dominant
Adult
149
ABCC8
Haploinsufﬁciency
Autosomal dominant
Adult
153
KCNK3
Haploinsufﬁciency
Autosomal dominant
Adult
154
SMAD9
Haploinsufﬁciency
Autosomal dominant
Adult
155
Sox17
Heritable and idiopathic PAH
Congenital heart disease
Unknown
Autosomal dominant
Paediatric and adult
149
CAV1
Heritable and idiopathic PAH
Lipodystrophy
Gain of function;
dominant negative
Autosomal dominant
Deﬁciency of subcutaneous adipose tissue
Fasting triglyceride and leptin levels
Paediatric and adult
156
TBX4
Heritable and idiopathic PAH
Small patella syndrome
(ischiopatellar dysplasia)
Parenchymal lung disease
Bronchopulmonary dysplasia
Persistent pulmonary hypertension of the neonate
Unknown
Autosomal dominant
Patellar aplasia
Skeletal abnormalities,
particularly pelvis, knees, and feet
Skeletal X-rays: pelvis, knees, and feet
CT chest: diffuse parenchymal lung disease
Paediatric and (less commonly) adult
149,157
EIF2AK4
Pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis
Loss of function
Autosomal recessive
Distal phalangeal clubbing
Reduced DLCO
CT chest: interlobular septal thickening and mediastinal lymphadenopathy, and centrilobular ground-glass nodular opacities
Adult
158
KDR
Heritable and idiopathic PAH
Loss of function
Autosomal dominant
No speciﬁc or diagnostic clinical features described
Possible reduced DLCO
Older-onset adult
159
ENG
Heritable and idiopathic PAH
Hereditary haemorrhagic telangiectasia
Unknown
Autosomal dominant
Telangiectasia
Abnormal blood vessel formation
Visceral arteriovenous malformations
Bleeding diathesis
Iron-deﬁciency anaemia
Presence on imaging of pulmonary, hepatic,
cerebral, or spinal arteriovenous malformations
Invasive endoscopic assessment of gastrointestinal telangiectasia
Adult and paediatric
160
ACVRL1
Haploinsufﬁciency
Autosomal dominant
Adult and paediatric
160
GDF2
Haploinsufﬁciency
Autosomal dominant
Adult and paediatric
149
© ESC/ERS 2022
CT, computed tomography; DLCO, Lung diffusion capacity for carbon monoxide; PAH, pulmonary arterial hypertension.
ESC/ERS Guidelines
3649


<!-- PAGE 33 -->

### Page 33

diagnostic algorithm (Figure 6), as it assigns a level of probability of
PH, irrespective of the cause. In addition, it is an important step in identifying other cardiac disorders. Based on this initial assessment,
if causes other than PH are identiﬁed and/or in case of low probability of PH, patients should be managed accordingly.
5.2.3. Step 3 (conﬁrmation)
Patients should be referred to a PH centre for further evaluation in the following situations: (1) when an intermediate/high probability of
PH is established; (2) in the presence of risk factors for PAH, or a history of PE. A comprehensive work-up should be performed, with the goal of establishing the differential diagnoses and distinguishing between the various causes of PH according to the current clinical classiﬁcation. The PH centre is responsible for performing an invasive assessment according to the clinical scenario.
At any time, warning signs must be recognized, as they are associated with worse outcomes and warrant immediate intervention.
Such warning signs include: rapidly evolving or severe symptoms
Diagnostic algorithm of patients with unexplained exertional dyspnoea and/or suspected PH
Suspected cause
PH probability
Causes other than
PH identified
Medical history
Physical exam
ECG
BNP/NT-p
T roBNP
O2 saturation
Gene
G
ral practitioner
N
PFT
ABG
Chest X-ray a
Chest CTc
CPET
Lung assessmentb
Echocardiography
(see Figures 4–5,
Table 10)
T
CPET
Heartr  assessmentb
Y
Lung disease
Low
PH or cardiac disease
Intermediate/High
Fast-track refef rral at any time in case of i
warning signs g
a,
or when e PAH
P
or CTEPH
T
e are suspected s
Refer to PH cent f
re
(Class I)
Comprehensive PH
work-up (Table 14
T
and ReCo Table 2)
T
Invasive assessment as needed
(ReCo Table 2)
T
Rapid cross-refef rral as needed
Further diagnostic work-up
Risk factors for 
f
PAH
P
d or CTEPHe
Manage accordingly
Figure 6 Diagnostic algorithm of patients with unexplained dyspnoea and/or suspected pulmonary hypertension. ABG, arterial blood gas analysis; BNP,
brain natriuretic peptide; CPET, cardiopulmonary exercise testing; CT, computed tomography; CTEPH, chronic thrombo-embolic pulmonary hypertension; ECG, electrocardiogram; HIV, human immunodeﬁciency virus; N, no; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; PE, pulmonary embolism; PFT, pulmonary function tests; PH, pulmonary hypertension; ReCo, recommendation; Y, yes. aWarning signs include rapid progression of symptoms, severely reduced exercise capacity, pre-syncope or syncope on mild exertion, signs of right heart failure.
bLung and heart assessment by specialist as per local practice. cAs indicated; CT pulmonary angiography recommended if PH suspected. dIncludes connective tissue disease (especially systemic sclerosis), portal hypertension, HIV infection, and family history of PAH. eHistory of PE, permanent intravascular devices, inﬂammatory bowel diseases, essential thrombocythaemia, splenectomy, high-dose thyroid hormone replacement, and malignancy.
3650
ESC/ERS Guidelines


<!-- PAGE 34 -->

### Page 34

Table 14
Characteristic diagnostic features of patients with different forms of pulmonary hypertension
Diagnostic tool
Characteristic
ﬁndings/
features
Group 1 (PAH)
Group 2 (PH
associated with left heart disease)
Group 3 (PH
associated with lung disease)
Group 4 (PH
associated with pulmonary artery obstructions)
5.1.1 Clinical presentation
Clinical features
Variable age, but young,
female patients may be predominantly affected.a161 Clinical presentation depends on associated conditions and phenotype
See Section 5.1.1
Mostly elderly patients,
female predominance in case of HFpEF.161
History and clinical
ﬁndings suggestive of
LHD
Mostly elderly patients,
male predominance.161
History and clinical
ﬁndings suggestive of lung disease. Smoking history common
Variable age, but elderly male and female equally affected.
History of VTE (CTEPH
may occur in the absence of a VTE
history).
Risk factors for CTEPH
See Section 10.1
Oxygen requirement for hypoxaemia
Uncommon, except for conditions with low
DLCO or right-to-left shunting
Uncommon
Common, often profound hypoxaemia in severe PH
Uncommon; common in severe cases with predominantly distal pulmonary artery occlusions
5.1.3 Chest radiography
RA/RV/PA size ↑
Pruning of peripheral vessels
LA/LV size ↑
Cardiomegaly
Occasional signs of congestion (interstitial oedema/Kerley lines,
alveolar oedema,
pleural effusion)
Signs of parenchymal lung disease
RA/RV/PA size ↑
Number and size of peripheral vessels ↓
Occasional signs of pulmonary infarction
5.1.4 Pulmonary function tests and
ABG
Spirometry/PFT
impairment
Normal or mildly impaired
Normal or mildly impaired
Abnormal as determined by the underlying lung disease
Normal or mildly impaired
DLCO
Normal or mild-to-moderately reduced (low DLCO in
SSc-PAH, PVOD, and some IPAH phenotypes)
Normal or mild-to-moderately reduced, especially in
HFpEF
Often very low (,45%
predicted)
Normal or mild-to-moderately reduced
Arterial blood gas
PaO2
PaCO2
Normal or reduced
Reduced
Normal or reduced
Usually normal
Reduced
Reduced, normal, or increased
Normal or reduced
Normal or reduced
5.1.5
Echocardiography
Signs of PH (increased sPAP, enlarged RA/RV)
Congenital heart defects may be present
See Section 5.1.5
Signs of LHD (HFrEF,
HFpEF, valvular) and PH
(increased sPAP,
enlarged RA/RV)
See Section 8
Signs of PH (increased sPAP, enlarged RA/RV)
See Section 5.1.5
Signs of PH (increased sPAP, enlarged RA/RV)
See Section 5.1.5
5.1.6 Lung scintigraphy
Planar –
SPECT V/Q
Normal or matched
Normal or matched
Normal or matched
Mismatched perfusion defect
5.1.7 Chest CT
Signs of PH or PVOD
See Section 5.1.7
Signs of LHD
Pulmonary oedema
Signs of PH
Signs of parenchymal lung disease
Signs of PH
Intravascular ﬁlling defects, mosaic perfusion, enlarged bronchial arteries
Signs of PH
5.1.11
Cardiopulmonary exercise testing
High VE/VCO2 slope
Low PETCO2, decreasing during exercise
No EOV
Mildly elevated VE/
VCO2 slope
Normal PETCO2,
increasing during
Mildly elevated VE/
VCO2 slope
Normal PETCO2,
High VE/VCO2 slope
Low PETCO2,
decreasing during
Continued
ESC/ERS Guidelines
3651


<!-- PAGE 35 -->

### Page 35

(WHO-FC III/IV), clinical signs of RV failure, syncope, signs of low CO
state, poorly tolerated arrhythmias, and compromised or deteriorated haemodynamic status (hypotension, tachycardia). Such cases must be immediately managed as inpatients for initial work-up at a nearby hospital or PH centre. The presence of RV dysfunction by echocardiography, elevated levels of cardiac biomarkers, and/or haemodynamic instability must prompt referral to a PH centre for immediate assessment.
This diagnostic process emphasizes the importance of sufﬁcient awareness and collaboration between ﬁrst-line, specialized medicine and PH centres. Effective and rapid collaboration between each partner permits earlier diagnosis and management, and improves outcomes.
5.3. Screening and early detection
Despite the advent of PAH therapies that prevent clinical worsening166–168 and effective interventions for CTEPH,102 the time from symptom onset to PH diagnosis remains at .2 years,169,170 with most patients presenting with advanced disease. Decreasing the time to diagnosis may reduce emotional uncertainty in patients,171
reduce the use of health care resources, and enable treatment at an earlier stage when therapies may be more effective.172
A proposed multifaceted approach172 to facilitate an earlier diagnosis includes: (1) screening asymptomatic, high-risk groups (with exercise
EOV
increasing during exercise exercise
No EOV
5.1.12 Right heart catheterization
Pre-capillary PH
Post-capillary PH
Pre-capillary PH
Pre- (or post-) capillary
PH
© ESC/ERS 2022
ABG, arterial blood gas analysis; CT, computed tomography; CTEPH, chronic thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon monoxide; EOV,
exercise oscillatory ventilation; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IPAH, idiopathic pulmonary arterial hypertension;
LA, left atrium; LHD, left heart disease; LV, left ventricle; PA, pulmonary artery; PaCO2, partial pressure of arterial carbon dioxide; PAH, pulmonary arterial hypertension; PaO2, partial pressure of arterial oxygen; PETCO2, end-tidal partial pressure of carbon dioxide; PFT, pulmonary function test; PH, pulmonary hypertension; PVOD, pulmonary veno-occlusive disease;
RA, right atrium; RV, right ventricle; sPAP, systolic pulmonary arterial pressure; SPECT, single-photon emission computed tomography; SSc-PAH, systemic sclerosis-associated pulmonary arterial hypertension; VE/VCO2, ventilatory equivalent for carbon dioxide; V/Q, ventilation perfusion scintigraphy; VTE, venous thrombo-embolism.
↓, reduced; ↑, increased.
aHowever, it may affect individuals of all ages and sexes; diagnosis in males should not be delayed.
Recommendation Table 2 — Recommendations for diagnostic strategy
Recommendation
Classa
Levelb
Echocardiography
Echocardiography is recommended as the
ﬁrst-line, non-invasive, diagnostic investigation in suspected PH82,84,91
I
B
It is recommended to assign an echocardiographic probability of PH, based on an abnormal TRV and the presence of other echocardiographic signs suggestive of PH (see Table 10)91,92,162
I
B
It is recommended to maintain the current threshold for TRV (.2.8 m/s) for echocardiographic probability of PH according to the updated haemodynamic deﬁnition88
I
C
Based on the probability of PH by echocardiography, further testing should be considered in the clinical context (i.e. symptoms and risk factors or associated conditions for PAH/
CTEPH)92
IIa
B
In symptomatic patients with intermediate echocardiographic probability of PH, CPET may be considered to further determine the likelihood of PH123,163
IIb
C
Continued
Imaging
Ventilation/perfusion or perfusion lung scan is recommended in patients with unexplained PH to assess for CTEPH105
I
C
CT pulmonary angiography is recommended in the work-up of patients with suspected
CTEPH104
I
C
Routine biochemistry, haematology, immunology,
HIV testing, and thyroid function tests are recommended in all patients with PAH, to identify associated conditions
I
C
Abdominal ultrasound is recommended for the screening of portal hypertension164
I
C
Chest CT should be considered in all patients with PH
IIa
C
Digital subtraction angiography should be considered in the work-up of patients with
CTEPH
IIa
C
Other diagnostic tests
Pulmonary function tests with DLCO are recommended in the initial evaluation of patients with PH78
I
C
Open or thoracoscopic lung biopsy is not recommended in patients with PAH
III
C
© ESC/ERS 2022
CPET, cardiopulmonary exercise testing; CT, computed tomography; CTEPH, chronic thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon monoxide; HIV, human immunodeﬁciency virus; PAH, pulmonary arterial hypertension;
PH, pulmonary hypertension; TRV, tricuspid regurgitation velocity.
aClass of recommendation.
bLevel of evidence.
3652
ESC/ERS Guidelines


<!-- PAGE 36 -->

### Page 36

high prevalence or where the diagnosis signiﬁcantly impacts the proposed intervention), including individuals with SSc (prevalence: 5–
19%),173,174 BMPR2 mutation carriers (14–42%),33 ﬁrst-degree relatives of patients with HPAH,148 and patients undergoing assessment for liver transplantation (2–9%);175 (2) early detection of symptomatic patients in at-risk groups with conditions such as portal hypertension,176 HIV infection (0.5%),177 and non-SSc CTD, where the lower prevalence rates do not support asymptomatic screening; and (3) applying population-based strategies by deploying early detection approaches in PE follow-up clinics,178,179 breathlessness clinics,172 or in at-risk patients identiﬁed from their health care behaviour and/
or previous investigations.180
Screening can be deﬁned as the systematic application of a test or tests to identify at-risk, asymptomatic individuals. Screening approaches can also be extended to individuals who would not otherwise have sought medical attention on account of their symptoms, to facilitate early detection. Tools used to screen for PH have primarily been assessed, but not exclusively, in SSc,172,174 and include blood biomarkers (NT-proBNP), ECG, echocardiography (primarily using estimates of sPAP at rest, but also exercise studies),182 PFTs
(DLCO and forced vital capacity [FVC]/DLCO ratio), and exercise testing including CPET (which has been used in combination with screening algorithms to reduce the need for RHC).123,163
5.3.1. Systemic sclerosis
In SSc, the prevalence of PAH is 5–19%,174 with an annual incidence of developing PAH of 0.7–1.5%.183–185 Evidence for the clinical value of detecting PAH early in SSc was provided by a screening programme,186 which showed less severe haemodynamic impairment and better survival in screened patients compared with a contemporaneous, non-screened cohort,187 providing a strong rationale for screening for PAH in patients with SSc.
The diagnostic accuracy of echocardiography or other tests alone in detecting PAH is suboptimal.173 Several screening algorithms have been studied using a combination of clinicalfeatures, echocardiography, PFTs,
and NT-proBNP to select patients with SSc for RHC (DETECT;173
Australian Scleroderma Interest Group [ASIG]188). Such combined approaches have improved diagnostic accuracy compared with the use of echocardiography, NT-proBNP, or PFTs alone, and are able to prevent unnecessary RHC and identify patients with mPAP 21–24 mmHg.189
Therefore, a multimodal approach is warranted when screening patients with SSc for PAH; the echocardiographic assessment should follow the strategy described in Section 5.1.5.
Beyond initial screening, the frequency with which screening should be undertaken in asymptomatic subjects with SSc is unclear.
A study from the Australian Scleroderma Study Cohort, where annual screening was recommended (some patients were screened up to 10 times), noted that most patients were diagnosed with
PAH at their ﬁrst screening; however, those diagnosed on subsequent screening had a lower mPAP, PVR, and WHO-FC, and better survival than those diagnosed at ﬁrst screening.190 Based on current evidence, annual screening for PAH in patients with SSc is sufﬁcient.
Given the ﬁnancial and emotional cost associated with regular screening, stratifying subjects with SSc into those at highest and lowest risk of PAH would be desirable. Risk factors for PAH include: (1)
clinical and demographic factors (i.e. breathlessness, longer disease duration, sicca symptoms, digital ulceration, older age, and male sex);
and
(2)
the results of investigations
(e.g.
positive anti-centromere antibody proﬁle, mild ILD, low DLCO, elevated
FVC/DLCO ratio, or elevated NT-proBNP).174,191 A recent meta-analysis showed that reduced digital capillary density, as assessed by video-capillaroscopy, or progression to a severe active/
late pattern of vascular involvement is also a risk factor for
PAH.192 In addition to identifying patients at increased risk of PAH,
a simple prediction model integrating symptoms, DLCO, and
NT-proBNP identiﬁed subjects at very low probability of PAH
who could potentially avoid further speciﬁc testing for PH.183
Furthermore, CPET may help to identify patients with SSc with a low risk of having PAH and thus to avoid unnecessary RHC.123
The recommendations on screening for PAH in SSc have been established based on key narrative question 3 (Supplementary Data,
Section 5.2).
5.3.2. BMPR2 mutation carriers
In the evolving list of genes known to be associated with PAH, experience is largely restricted to BMPR2 mutation carriers who carry a lifetime risk of developing PAH of ≏20%, with penetrance higher in female carriers (42%) compared with male carriers (14%).33,148,193 There is currently no accepted screening strategy for evaluating PAH in
BMPR2 mutation carriers. At present, based on expert consensus,
asymptomatic relatives who screen positive for PAH-causing mutations are often offered yearly screening echocardiography.25,26 The
DELPHI-2 study, which prospectively screened carriers and relatives,
recently demonstrated a 9.1% pick up over 47+ 27 months of
PAH, with 2/55 diagnosed at baseline and 3/55 at follow-up; this equates to an incidence of 2.3%/year.33 The screening schedule included ECG, NT-proBNP, DLCO, echocardiography, CPET, and optional RHC; however, none of the cases would have been picked up by echocardiography alone. Screening programmes should adopt a multimodal approach, although the optimal strategy and screening period remains undeﬁned and will require multinational, multicentre study.
5.3.3. Portal hypertension
An estimated 1–2% of patients with liver disease and portal hypertension develop PoPH,176,194 which is of particular relevance in patients considered for transjugular portosystemic shunting or liver transplantation. In such patients, echocardiography is recommended to screen for PAH, even in the absence of symptoms. By using echocardiography,
sPAP can be measured in ≏80% of patients with portal hypertension,
which aids decisions to perform RHC. In patients assessed for liver transplantation, one study showed that an sPAP of .50 mmHg had
97% sensitivity and 77% speciﬁcity for detecting moderate-to-severe
PAH.195 Other investigators have recommended RHC when sPAP is
.38 mmHg.196 When screening for PoPH, it is advised to assess the echocardiographic probability of PH (see Section 5.1.5). In agreement with the International Liver Transplant Society, for patients awaiting liver transplantation, it is recommended to reassess for PAH annually,
although the optimal interval remains unclear.175
5.3.4. Pulmonary embolism
Chronic thrombo-embolic pulmonary hypertension is an uncommon and under-diagnosed complication of acute PE.112 The reported cumulative incidence of CTEPH after acute, symptomatic PE ranges
0.1–11.8%, depending on the collective investigated.112,178,197–199 A
ESC/ERS Guidelines
3653


<!-- PAGE 37 -->

### Page 37

systematic review and meta-analysis reported a CTEPH incidence of
0.6% in all patients with acute PE, 3.2% in survivors, and 2.8% in survivors without major comorbidities.178 A multicentre, observational, screening study reported a CTEPH incidence of 3.7/1000
patient-years and a 2 year cumulative incidence of 0.79% following acute PE.200 A recent prospective observational study (FOCUS,
Follow-up After Acute Pulmonary Embolism) showed a cumulative
2 year incidence of 2.3% and 16.0% for CTEPH and post-PE impairment, respectively, which were both associated with a higher risk of rehospitalization and death.201 Due to insufﬁcient awareness, some patients may have a delayed diagnosis of CTEPH because they may initially be misclassiﬁed as acute PE.112 In this context, the current guidelines do not recommend routine follow-up of patients with PE
by imaging methods of the pulmonary vascular tree, but suggest evaluating the index imaging test used to diagnose acute PE for signs of
CTEPH. Echocardiography is the preferred ﬁrst-line diagnostic test in patients with suspected CTEPH.103
Up to 50% of patients have persistent perfusion defects after an acute PE; however, the clinical relevance is unclear.202–204 All patients in whom symptoms can be attributed to post-thrombotic deposits within PAs are considered to have CTEPD, with or without PH.54
While persistent dyspnoea is common after acute PE,205 the prevalence of CTEPD without PH is unknown and requires further study
(see Section 10.1). A study exploring screening for CTEPH following acute PE identiﬁed, using echocardiography, a low yield of additional
CTEPH diagnoses in asymptomatic patients.206 Current PE guidelines recommend that further diagnostic evaluation may be considered in asymptomatic patients with risk factors for CTEPH at 3–6
months’ follow-up.103,207 Approaches to early detection of CTEPH
following acute PE are based on identifying patients at increased risk.208 In patients with persistent or new-onset dyspnoea after PE,
non-invasive approaches use echocardiography to assess for PH
and cross-sectional imaging to assess for persistent perfusion defects.
Limited data exist on strategies using DECT, CT lung subtraction iodine mapping, or 3D MR perfusion imaging. Scoring systems, including the Leiden CTEPH rule-out criteria206,209 can be used to inform diagnostic strategies. Cardiopulmonary exercise testing may identify characteristic features of exercise limitation due to PVD, or suggest an alternative diagnosis. The optimal timing for assessing symptoms to aid early detection of CTEPH may be 3–6 months after acute
PE, coinciding with the routine evaluation of anticoagulant treatment,
but earlier assessment may be necessary in highly symptomatic or deteriorating patients.54,103
Recommendation Table 3 — Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension
Recommendations
Classa
Levelb
Systemic sclerosis
In patients with SSc, an annual evaluation of the risk of having PAH is recommended183,186
I
B
Continued
In adult patients with SSc with .3 years’
disease duration, an FVC ≥40%, and a DLCO
,60%, the DETECT algorithm is recommended to identify asymptomatic patients with PAH173,186
I
B
In patients with SSc, where breathlessness remains unexplained following non-invasive assessment,
RHC is recommended to exclude PAH185–187
I
C
Assessing the risk of having PAH based on an evaluation of breathlessness, in combination with echocardiogram or PFTs and BNP/NT-proBNP,
should be considered in patients with
SSc172,173,186,188,190
IIa
B
Policies to evaluate the risk of having PAH
should be considered in hospitals managing patients with SSc
IIa
C
In symptomatic patients with SSc, exercise echocardiography or CPET, or CMR may be considered to aid decisions to perform RHC
IIb
C
In patients with CTD with overlap features of SSc,
an annual evaluation of the risk of PAH may be considered
IIb
C
CTEPH/CTEPD
In patients with persistent or new-onset dyspnoea or exercise limitation following PE, further diagnostic evaluation to assess for CTEPH/
CTEPD is recommended103
I
C
For symptomatic patients with mismatched perfusion lung defects beyond 3 months of anticoagulation for acute PE, referral to a PH/
CTEPH centre is recommended after considering the results of echocardiography, BNP/
NT-proBNP, and/or CPET203,206
I
C
Other
Counselling regarding the risk of PAH and annual screening are recommended in individuals who test positive for PAH-causing mutations and in
ﬁrst-degree relatives of patients with HPAH33
I
B
In patients referred for liver transplantation,
echocardiography is recommended as a screening test for PH
I
C
Further tests (echocardiography, BNP/
NT-proBNP, PFTs, and/or CPET) should be considered in symptomatic patients with CTD,
portal hypertension, or HIV to screen for PAH172
IIa
B
© ESC/ERS 2022
BNP,
brain natriuretic peptide;
CMR,
cardiac magnetic resonance;
CPET,
cardiopulmonary exercise testing; CTD, connective tissue disease; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon monoxide; FVC, forced vital capacity; HIV, human immunodeﬁciency virus; HPAH, heritable pulmonary arterial hypertension;
NT-proBNP,
N-terminal pro-brain natriuretic peptide;
PAH,
pulmonary arterial hypertension; PE, pulmonary embolism; PFT, pulmonary function test; PH, pulmonary hypertension; RHC, right heart catheterization; SSc, systemic sclerosis.
aClass of recommendation.
bLevel of evidence.
3654
ESC/ERS Guidelines


<!-- PAGE 38 -->

### Page 38

### 6 Pulmonary arterial hypertension (group 1)

6.1. Clinical characteristics
The symptoms of PAH are non-speciﬁc and mainly related to progressive RV dysfunction (see Section 5.1.1) as a consequence of progressive pulmonary vasculopathy (Figure 7). The presentation of PAH
may be modiﬁed by diseases that are associated with PAH, as well as comorbidities. More detailed descriptions of the individual PAH subsets are reported in Section 7.
6.2. Severity and risk assessment
6.2.1. Clinical parameters
Clinical assessment is a key part of evaluating patients with PAH, as it provides valuable information for determining disease severity, improvement, deterioration, or stability. At follow-up, changes in
WHO-FC (Table 15), episodes of chest pain, arrhythmias, haemoptysis, syncope, and signs of right HF provide important information.
Physical examination should assess heart rate, rhythm, blood pressure, cyanosis, enlarged jugular veins, oedema, ascites, and pleural effusions. The WHO-FC is one of the strongest predictors of survival,
Intimal proliferation, fibrosis
Pulmonary vasculopathy
Right heart failure
Medial hypertrophy
Vascular remodelling
Plexiform lesion
Thrombosis
Vasoconstriction
Pulmonary artery
Vascular obstruction
Right ventricular remodelling /
dysfunction
Current therapeutic targets
Medial hyperplasia
Intimal proliferation
Plexiform lesions
NO-sGC-cGMP pathway
Endothelin pathway
Prostacyclin pathway
L-arginine
Nitric oxide
(Vasodilatation and antiproliferation)
sGC
PDE5
GTP
cGMP
GMP
Arachidonic acid
Prostacyclin
(Vasodilatation and antiproliferation)
cAMP
IP receptor
Pro-endothelin-1
Endothelin-1
(Vasoconstriction and proliferation)
Endothelin receptor A
Endothelin receptor B
P
P
MP
G
MP
Figure 7 Pathophysiology and current therapeutic targets of pulmonary arterial hypertension (group 1). cAMP, cyclic adenosine monophosphate; (c)
GMP, (cyclic) guanosine monophosphate; GTP, guanosine-5′-triphosphate; IP receptor, prostacyclin I2 receptor; NO, nitric oxide; PDE5, phosphodiesterase 5; sGC, soluble guanylate cyclase.
ESC/ERS Guidelines
3655


<!-- PAGE 39 -->

### Page 39

both at diagnosis and follow-up,210–212 and worsening WHO-FC is one of the most alarming indicators of disease progression, which should trigger further investigations to identify the cause(s) of clinical deterioration.210,213,214
6.2.2. Imaging
Imaging of the heart plays an essential role in the follow-up of patients with PAH. Several echocardiographic and cMRI parameters have been proposed to monitor RV function during the course of
PAH. Table S2 provides a list of imaging parameters and relative cutoff values associated with increased and decreased risk of adverse events.
6.2.2.1. Echocardiography
Echocardiography is a widely available imaging modality and is readily performed at the patient’s bedside. It is crucial that a high-quality echocardiographic assessment by PH specialists is undertaken to reduce intraobserver and interobserver variability. Of note, estimated sPAP at rest is not prognostic and irrelevant to therapeutic decisionmaking.212,215,216 An increase in sPAP does not necessarily reﬂect disease progression and a decrease in sPAP does not necessarily reﬂect improvement.
Despite the complex geometry of the right heart, echocardiographic surrogates of the true right heart dimensions, which include a description of RV and RA areas, and the LV eccentricity index, provide useful clinical information in PAH.217,218 Right ventricular dysfunction can be evaluated measuring fractional area change, TAPSE, tissue Doppler, and 2D speckle tracking myocardial strain recording of RV free-wall motion, all of which represent isovolumetric and ejection-phase indices of load-induced RV
pump failure.219–224 The rationale for the reported measurements is strong, as RV systolic function metrics assess the adaptation of RV contractility to increased afterload, and increased right heart dimension and inferior vena cava dilation reﬂect failure of this mechanism, hence maladaptation.225 Pericardial effusion and tricuspid regurgitation (TR) grading further explore
RV overload and are of prognostic relevance in these patients.218,226–228 All of these variables are physiologically interdependent and their combination provides additional prognostic information over single measurements.223
Echocardiography also enables combined parameters to be measured, such as the TAPSE/sPAP ratio, which is tightly linked to RV–
PA coupling and predicts outcome.96,97 Echocardiographic measurements of RV and RA sizes combined with LV eccentricity index are crucial for assessing RV reverse remodelling as an emerging marker of treatment efﬁcacy.220,229 Three-dimensional echocardiography may achieve better estimation than standard 2D assessment, but underestimations of volumes and ejection fraction have been reported,
and technical issues are, as yet, unresolved.230
6.2.2.2. Cardiac magnetic resonance imaging
The role of cMRI in evaluating patients with PAH has been addressed in several studies, and RV volumes, RVEF, and SV are essential prognostic determinants in PAH.225,231–236 In patients with PAH, initial cMRI measurements added prognostic value to current risk scores.231,232 In addition, risk assessment at 1 year of follow-up based on cMRI was at least equal to risk assessment based on RHC.237 The cMRI risk-assessment variables based on the current literature are included in Table 16.117,225,231–235,237 The stroke volume index (SVI)
cut-off levels are based on the consensus of the literature;238 a change of 10 mL in SV (LV end-diastolic volume−LV end-systolic volume) during follow-up is considered clinically signiﬁcant.239 The value of cMRI in the follow-up of patients has been shown in several studies, and cMRI enables treatment effects to be monitored and treatment strategies adapted in time to prevent clinical failure.240–242
6.2.3. Haemodynamics
Cardiopulmonary haemodynamics assessed by RHC provide important prognostic information, both at the time of diagnosis and at follow-up.129,212,213,216,238,243–245,247,248 Currently available riskstratiﬁcation tools include haemodynamic variables for prognostication: RAP and PVR in REVEAL risk scores,213,249,250 and RAP, CI, and
SvO2 in the ESC/ERS risk-stratiﬁcation table.25,26 The mPAP provides little prognostic information, except in acute vasodilator responders.129 A recent study from France, which combined clinical and haemodynamic parameters, found that WHO-FC, 6MWD,
RAP, and SVI (but not SV and SvO2) were independent predictors of outcome.238
To reﬁne the risk-stratiﬁcation table (Table 16), SVI criteria are now added with the cut-off values of .38 mL/m2 and ,31 mL/m2
to determine low-risk and high-risk status, respectively.238
The optimal timing of follow-up RHC has not been determined.
While some centres regularly perform invasive follow-up assessments, others perform them as clinically indicated, and there is no evidence that any of these strategies is associated with better outcomes (Table 17).
Table 15
World Health Organization classiﬁcation of functional status of patients with pulmonary hypertension
Class
Descriptiona
WHO-FC I
Patients with PH but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnoea or fatigue, chest pain, or near syncope
WHO-FC II
Patients with PH resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnoea or fatigue, chest pain, or near syncope
WHO-FC III
Patients with PH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnoea or fatigue,
chest pain, or near syncope
WHO-FC IV
Patients with PH with an inability to carry out any physical activity without symptoms. These patients manifest signs of right HF. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity
© ESC/ERS 2022
PH, pulmonary hypertension; WHO-FC, World Health Organization functional class.
aFunctional classiﬁcation of PH modiﬁed after the New York Heart Association functional classiﬁcation according to the World Health Organization 1998.147
3656
ESC/ERS Guidelines


<!-- PAGE 40 -->

### Page 40

6.2.4. Exercise capacity
The 6-minute walking test (6MWT) is the most widely used measure of exercise capacity in PH centres. The 6MWT is easy to perform,
inexpensive, and widely accepted by patients, health professionals,
and medicines agencies as an important and validated variable in
PH. As with all PH assessments, 6MWT results must always be interpreted in the clinical context. The 6MWD is inﬂuenced by factors such as sex, age, height, weight, comorbidities, need for oxygen,
learning curve, and motivation. Test results are usually given in absolute distance (metres) rather than the percentage of predicted values. Change in 6MWD is one of the most commonly used parameters in PAH clinical trials as a primary endpoint, key secondary endpoint, or component of clinical worsening.251 A recent investigation showed that the best absolute-threshold values for 1 year mortality and 1 year survival, respectively, were 165 m and 440 m,
respectively.252 Improvements in 6MWD have had less predictive value than deterioration on key clinical outcomes (mortality and survival).250,252,253 These results are consistent with observations from clinical trials and registries;254,255 however, there is no single threshold that would apply to all patients.256 Some studies have also suggested that adding SaO2 measured by pulse oximetry and heart rate responses may improve prognostic relevance.246,257 Hypoxaemia observed during the 6MWT is associated with worse survival, but these
ﬁndings still await conﬁrmation in large multicentre studies.
The incremental shuttle walking test (ISWT) is an alternative maximal test for assessing patients with PAH. The ISWT has a potential advantage over the 6MWT in that it does not have a ceiling effect;
furthermore, it keeps the simplicity of a simple-to-perform ﬁeld test, in contrast to CPET. However, the ISWT experience in PAH
is currently limited.258
Cardiopulmonary exercise testing is a non-invasive method for assessing functional capacity and exercise limitation. It is usually
Table 16
Comprehensive risk assessment in pulmonary arterial hypertension (three-strata model)
Determinants of prognosis (estimated
1-year mortality)
Low risk
(,5%)
Intermediate risk
(5–20%)
High risk
(.20%)
Clinical observations and modiﬁable variables
Signs of right HF
Absent
Absent
Present
Progression of symptoms and clinical manifestations
No
Slow
Rapid
Syncope
No
Occasional syncopea
Repeated syncopeb
WHO-FC
I, II
III
IV
6MWDc
.440 m
165–440 m
,165 m
CPET
Peak VO2 .15 mL/min/kg
(.65% pred.)
VE/VCO2 slope ,36
Peak VO2 11–15 mL/min/kg
(35–65% pred.)
VE/VCO2 slope 36–44
Peak VO2 ,11 mL/min/kg
(,35% pred.)
VE/VCO2 slope .44
Biomarkers: BNP or NT-proBNPd
BNP ,50 ng/L
NT-proBNP ,300 ng/L
BNP 50–800 ng/L
NT-proBNP 300–1100 ng/L
BNP .800 ng/L
NT-proBNP .1100 ng/L
Echocardiography
RA area ,18 cm2
TAPSE/sPAP .0.32 mm/mmHg
No pericardial effusion
RA area 18–26 cm2
TAPSE/sPAP 0.19–0.32 mm/
mmHg
Minimal pericardial effusion
RA area .26 cm2
TAPSE/sPAP ,0.19 mm/mmHg
Moderate or large pericardial effusion cMRIe
RVEF .54%
SVI .40 mL/m2
RVESVI ,42 mL/m2
RVEF 37–54%
SVI 26–40 mL/m2
RVESVI
42–54 mL/m2
RVEF ,37%
SVI ,26 mL/m2
RVESVI .54 mL/m2
Haemodynamics
RAP ,8 mmHg
CI ≥2.5 L/min/m2
SVI .38 mL/m2
SvO2 .65%
RAP 8–14 mmHg
CI 2.0–2.4 L/min/m2
SVI 31–38 mL/m2
SvO2 60–65%
RAP .14 mmHg
CI ,2.0 L/min/m2
SVI ,31 mL/m2
SvO2 ,60%
© ESC/ERS 2022
6MWD, 6-minute walking distance; BNP, brain natriuretic peptide; CI, cardiac index; cMRI, cardiac magnetic resonance imaging; CPET, cardiopulmonary exercise testing; HF, heart failure;
NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; pred., predicted; RA, right atrium; RAP, right atrial pressure; sPAP, systolic pulmonary arterial pressure; SvO2, mixed venous oxygen saturation; RVESVI, right ventricular end-systolic volume index; RVEF, right ventricular ejection fraction; SVI, stroke volume index;
TAPSE, tricuspid annular plane systolic excursion; VE/VCO2, ventilatory equivalents for carbon dioxide; VO2, oxygen uptake; WHO-FC, World Health Organization functional class.
aOccasional syncope during heavy exercise or occasional orthostatic syncope in a stable patient.
bRepeated episodes of syncope even with little or regular physical activity.
cObserve that 6MWD is dependent upon age, height, and burden of comorbidities.
dTo harmonize with the four-strata model shown in Table 18, the BNP and NT-proBNP cut-off levels have been updated from the 2015 version based on data from the REVEAL registry,
acknowledging that the European validation studies have used the original cut-off levels.274,292,293,295,296,302
ecMRI parameters adapted from Section 6.2.2.2.
ESC/ERS Guidelines
3657


<!-- PAGE 41 -->

### Page 41

performed as a maximal exercise test, and is safe even in patients with severe exercise limitation.259,260 Most PH centres use an incremental ramp protocol, although the test has not yet been standardized for this patient population. Robust prognostic evidence for peak VO2 and VE/VCO2 has been found in three studies, all powered for multivariable analysis.261–263 When associated with SVI, peak
VO2 provided useful information to further stratify patients with
PAH at intermediate risk.264 However, the added value of CPET
on top of common clinical and haemodynamic variables remains largely unexplored.
6.2.5. Biochemical markers
Considerable efforts have been made to identify additional biomarkers of PVD, addressing prognosis,265–272 diagnosis, and differentiation of PH subtypes,270,273–276 as well as PAH treatment response.266 Emerging proteins related to PAH and vascular remodelling include bone morphogenetic proteins 9 and 10 and translationally controlled tumour protein.270,277,278 Proteome-wide screening in IPAH and HPAH identiﬁed a multimarker panel with prognostic information in addition to the REVEAL risk score.271 Another study found that early development of SSc-associated PAH (PAH-SSc) was predicted by high circulating levels of C-X-C motif chemokine 4 in patients with SSc.276 However, none of these biomarkers have been introduced in clinical practice.
Thus, BNP and NT-proBNP remain the only biomarkers routinely used in clinical practice at PH centres, correlating with myocardial stress and providing prognostic information.279 Brain natriuretic peptide and NT-proBNP are not speciﬁc for PH, as they can be elevated in other forms of heart disease, exhibiting great variability. The previously proposed cut-off levels of BNP (,50, 50–300, and
.300 ng/L) and NT-proBNP (,300, 300–1400, and .1400 ng/L)
for low, intermediate, and high risk, respectively, in the ESC/ERS
risk-assessment model at baseline and during follow-up are prognostic for long-term outcomes and can be used to predict response to treatment.266 Reﬁned cut-off values for BNP (,50, 50–199, 200–
800, and .800 ng/L) and NT-pro-BNP (,300, 300–649, 650–
1100, and .1100 ng/L) for low, intermediate–low, intermediate–
high, and high risk, respectively, have recently been introduced as part of a four-strata risk-assessment strategy (see Section 6.2.7).280
6.2.6. Patient-reported outcome measures
A patient-reported outcome measure (PROM) is a term for health outcomes that are ‘self-reported’ by the patient. It is the patient’s experience of living with PH and its impact on them and their caregivers, including symptomatic, intellectual, psychosocial, spiritual,
and goal-orientated dimensions of the disease and its treatment.
Despite treatment advances improving survival, patients with PAH
present with a range of non-speciﬁc yet debilitating symptoms, which affect health-related quality of life (HR-QoL).281,282
Patient-reported outcome measures remain an underused outcome measure. Tools validated in patients with PAH should be used to assess HR-QoL282,283 in individual patients. There has been a reliance on generic PROMs, which have been studied in patients with PAH but may lack sensitivity to detect changes in
PAH.284,285 To address this, a number of PH-speciﬁc HR-QoL instruments have been developed and validated (e.g.
Cambridge
Pulmonary
Hypertension
Outcome
Review
[CAMPHOR],286
emPHasis-10,282,287 Living with Pulmonary Hypertension,288 and
Pulmonary
Arterial
Hypertension-Symptoms and
Impact
[PAH-SYMPACT]).289
These disease-speciﬁc
PROMs track
Table 17
Suggested assessment and timing for the follow-up of patients with pulmonary arterial hypertension
At baseline
3–6 months after changes in therapya
Every 3–6 months in stable patientsa
In case of clinical worsening
Medical assessment (including
WHO-FC)
6MWT
Blood test (including
NT-proBNP)b,c
ECG
Echocardiography or cMRI
ABG or pulse oximetryd
Disease-speciﬁc HR-QoL
CPET
RHC
© ESC/ERS 2022
6MWT, 6-minute walking test; ABG, arterial blood gas analysis; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; BNP, brain natriuretic peptide; cMRI, cardiac magnetic resonance imaging; CPET, cardiopulmonary exercise testing; ECG, electrocardiogram; HR-QoL, health-related quality of life; INR, international normalized ratio; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; RHC, right heart catheterization; TSH, thyroid-stimulating hormone; WHO-FC, World Health Organization functional class.
Green: is indicated; yellow: should be considered; orange: may be considered.
aIntervals to be adjusted according to patient needs, PAH aetiology, risk category, demographics, and comorbidities.
bBasic laboratory tests include blood count, INR (in patients receiving vitamin K antagonists), serum creatinine, sodium, potassium, ASAT/ALAT, bilirubin, and BNP/NT-proBNP.
cExtended laboratory tests (e.g. TSH, troponin, uric acid, iron status, etc.) according to clinical circumstances.
dABG should be performed at baseline but may be replaced by pulse oximetry in stable patients at follow-up.
3658
ESC/ERS Guidelines


<!-- PAGE 42 -->

### Page 42

functional status, clinical deterioration, and prognosis in PAH, and are more sensitive to the differences in the risk status than generic
PROMs.290,291 In addition, HR-QoL scores provide independent prognostic information.287
6.2.7. Comprehensive prognostic evaluation, risk assessment, and treatment goals
In the 2015 ESC/ERS Guidelines for the diagnosis and treatment of
PH, risk assessment was based on a multiparametric approach using a three-strata model to classify patients at low, intermediate, or high risk of death. Originally, these strata were based on estimated 1 year mortality rates of ,5%, 5–10%, and .10%, respectively.25,26 Since then, registry data have shown that observed 1 year mortality rates in the intermediate- and high-risk groups were sometimes higher than predicted (i.e. up to 20% in the intermediate-risk group and
.20% in the high-risk group). These numbers have been updated accordingly in the revised three-strata risk model (Table 16).292–294
Several abbreviated approaches of the 2015 ESC/ERS riskstratiﬁcation tool have been introduced and independently validated using the Swedish Pulmonary Arterial Hypertension Registry
(SPAHR),292 the Comparative, Prospective Registry of Newly
Initiated Therapies for PH (COMPERA),293 and the French PH
Registry (FPHR).295 Other risk-stratiﬁcation tools have been developed from the US REVEAL, including the REVEAL 2.0 risk score calculator, and an abridged version (REVEAL Lite 2).249,296 In all these studies, WHO-FC, 6MWD, and BNP/NT-proBNP emerged as the variables with the highest predictive value.
The main limitation of the
2015
ESC/ERS
three-strata,
risk-assessment tool is that 60–70% of the patients are classiﬁed as intermediate risk.292–295,297–303 An initial attempt to substratify the intermediate-risk group has been proposed, using a modiﬁed mean score in the SPAHR equation (with low–intermediate, 1.5–1.99
and high–intermediate, 2.0–2.49 as cut-offs), where the high–intermediate group was associated with worse survival.302 There have also been attempts to further improve risk stratiﬁcation by exploring the additional value of new biomarkers,304 or by measuring RV structure and function by echocardiography and cMRI.231,305,306 Other strategies have included incorporating renal function307 or combining 6MWD with TAPSE/sPAP ratio;96,97 however, all of these strategies have to be further validated.
Two recent registry studies have evaluated a four-strata,
risk-assessment tool based on reﬁned cut-off levels for WHO-FC,
6MWD, and NT-proBNP (Table 18).280,308 Patients were categorized as low, intermediate–low, intermediate–high, or high risk. Together,
these studies included .4000 patients with PAH and showed that the four-strata model performed at least as well as the three-strata model in predicting mortality. The four-strata model predicted survival in patients with IPAH, HPAH, DPAH, and PAH associated with CTD (including the SSc subgroup), and in patients with PoPH.
The observed 1-year mortality rates in the four risk strata were 0–
3%, 2–7%, 9–19%, and .20%, respectively. Compared with the three-strata model, the four-strata model was more sensitive to changes in risk from baseline to follow-up, and these changes were associated with changes in the long-term mortality risk. The main advantage of the four-strata model over the three-strata model is better discrimination within the intermediate-risk group, which helps guide therapeutic decision-making (see Section 6.3.4). For these reasons,
the four-strata model is included in the updated treatment algorithm
(see Figure 9). However, the three-strata model is maintained for initial assessment, which should be comprehensive and include echocardiographic and haemodynamic variables, for which cut-off values for the four-strata model have yet to be established.
Several studies have identiﬁed WHO-FC, 6MWD, and BNP/
NT-proBNP as the strongest prognostic predictors.293,295,296 With the abbreviated risk-assessment tools, missing values become an important limitation. REVEAL Lite 2 provides accurate prediction when one key variable (WHO-FC, 6MWD, or BNP/NT-proBNP) is unavailable, but is no longer accurate when two of these variables are missing.293,296 The original three-strata SPAHR/COMPERA risk tool was developed with at least two variables available, while the four-strata model was developed and validated in patients for whom all three variables were available. It is therefore recommended to use at least these three variables for risk stratiﬁcation. However,
two components may be used when variables are missing, especially when a functional criterion (WHO-FC or 6MWD) is combined with
BNP or NT-proBNP.296
Collectively,
the available studies support a
risk-based,
goal-orientated treatment approach in patients with PAH, where achieving and/or maintaining a low-risk status is favourable and recommended (key narrative question 4, Supplementary Data,
Section 6.1).298,300,303,309,310 For risk stratiﬁcation at diagnosis, use of the three-strata model is recommended taking into account as many factors as possible (Table 16), with a strong emphasis on disease type, WHO-FC, 6MWD, BNP/NT-proBNP, and haemodynamics.
Table 18
Variables used to calculate the simpliﬁed four-strata risk-assessment tool
Determinants of prognosis
Low risk
Intermediate–low risk
Intermediate–high risk
High risk
Points assigned
1
2
3
4
WHO-FC
I or IIa
-
III
IV
6MWD, m
.440
320–440
165–319
,165
BNP or
NT-proBNP,a ng/L
,50
,300
50–199
300–649
200–800
650–1100
.800
.1100
© ESC/ERS 2022
6MWD, 6-minute walking distance; BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide; WHO-FC, World Health Organization functional class.
Risk is calculated by dividing the sum of all grades by the number of variables and rounding to the next integer.
aWHO-FC I and II are assigned 1 point as both are associated with good long-term survival.
ESC/ERS Guidelines
3659


<!-- PAGE 43 -->

### Page 43

At follow-up, the four-strata model (Table 18) is recommended as a basic risk-stratiﬁcation tool, but additional variables should be considered as needed, especially right heart imaging and haemodynamics. At any stage, individual factors such as age,
sex, disease type, comorbidities, and kidney function should also be considered.
6.3. Therapy
According to the revised haemodynamic deﬁnition, PAH may be diagnosed in patients with mPAP .20 mmHg and PVR .2 WU. Yet,
the efﬁcacy of drugs approved for PAH has only been demonstrated in patients with mPAP ≥25 mmHg and PVR .3 WU (see
Supplementary Data, Table S1). No data are available for the efﬁcacy of drugs approved for PAH in patients whose mPAP is ,25 mmHg and whose PVR is ,3 WU. Hence, for such patients, the efﬁcacy of drugs approved for PAH has not been established. The same is true for patients with exercise PH, who, by deﬁnition, do not fulﬁl the diagnostic criteria for PAH. Patients at high risk of developing
PAH, for instance patients with SSc or family members of patients with HPAH, should be referred to a PH centre for individual decision-making.
6.3.1. General measures
Managing patients with PAH requires a comprehensive treatment strategy and multidisciplinary care. In addition to applying PAH drugs,
general measures and care in special situations represent integral components of optimized patient care. In this context, the systemic consequences of PH and right-sided HF, often contributing to disease burden, should be appropriately managed.119
6.3.1.1. Physical activity and supervised rehabilitation
The 2015 ESC/ERS Guidelines for the diagnosis and treatment of PH
suggested that patients with PAH should be encouraged to be active within symptom limits.25,26 Since then, additional studies have shown the beneﬁcial impact of exercise training on exercise capacity
(6MWD) and quality of life.312–316 A large, randomized controlled trial (RCT) in 11 centres across 10 European countries, including
116 patients with PAH/CTEPH on PAH drugs, showed a signiﬁcant improvement in 6MWD of 34.1 + 8.3 m, quality of life, WHO-FC,
and peak VO2 compared with standard of care.315 Since most of the studies included patients who were stable on medical treatment,
patients with PAH should be treated with the best standard of pharmacological treatment and be in a stable clinical condition before embarking on a supervised rehabilitation programme. Establishing specialized rehabilitation programmes for patients with PH would further enhance patient access to this intervention.317
6.3.1.2. Anticoagulation
There are several reasons to consider anticoagulation in patients with
PAH. Histopathological specimens from PAH patients’ lungs have shown in situ thrombosis of pulmonary vessels. Patients with CHD
or PA aneurysms may develop thrombosis of the central PAs.
Abnormalities in the coagulation and ﬁbrinolytic system indicating a pro-coagulant state have been reported in patients with PAH.318
Data from RCTs on anticoagulation in PAH are lacking, and registry data have yielded conﬂicting results. The largest registry analysis so far suggested a potential survival beneﬁt associated with anticoagulation in patients with IPAH,319 but this ﬁnding was not conﬁrmed by others.320 Two recent meta-analyses also concluded that using anticoagulants may improve survival in patients with IPAH;321,322
however, none of the included studies were methodologically robust. Despite the lack of evidence, registry data obtained between
2007 and 2016 showed that anticoagulation was used in 43% of patients with IPAH.293 In PAH associated with SSc, registry data and meta-analyses uniformly indicated that anticoagulation may be harmful.320–322 In CHD, there are also no RCTs on anticoagulation. There is also no consensus about the use of anticoagulants in patients who have permanent i.v. lines for therapy with prostacyclin analogues; this is left to local centre practice.
As anticoagulation is associated with an increased bleeding risk,
and in the absence of robust data, no general recommendation has been made for or against the use of anticoagulants in patients with
PAH.; therefore, individual decision-making is required.
Recommendation Table 4 — Recommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension
Recommendations
Classa
Levelb
It is recommended to evaluate disease severity in patients with PAH with a panel of data derived from clinical assessment, exercise tests,
biochemical markers, echocardiography, and haemodynamic evaluations212,213,216,249,292,293,295,296,302,307
I
B
Achieving and maintaining a low-risk proﬁle on optimized medical therapy is recommended as a treatment goal in patients with
PAH210,212,213,216,298,300,303,309,310
I
B
For risk stratiﬁcation at the time of diagnosis, the use of a three-strata model (low, intermediate,
and high risk) is recommended, taking into account all available data, including haemodynamics292,293,295
I
B
For risk stratiﬁcation during follow-up, the use of a four-strata model (low, intermediate–low,
intermediate–high, and high risk) based on
WHO-FC, 6MWD, and BNP/NT-proBNP is recommended, with additional variables taken into account as necessary280,308
I
B
In some PAH aetiologies and patients with comorbidities, optimization of therapy should be considered on an individual basis, while acknowledging that a low-risk proﬁle is not always achievable293,294,299,311
IIa
B
© ESC/ERS 2022
6MWD, 6-minute walking distance; BNP, brain natriuretic peptide; NT-proBNP,
N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension;
WHO-FC, World Health Organization functional class.
aClass of recommendation.
bLevel of evidence.
3660
ESC/ERS Guidelines


<!-- PAGE 44 -->

### Page 44

6.3.1.3. Diuretics
Right HF is associated with systemic ﬂuid retention, reduced renal blood ﬂow, and activation of the renin–angiotensin–aldosterone system. Increased right-sided ﬁlling pressures are transmitted to the renal veins, increasing interstitial and tubular hydrostatic pressure within the encapsulated kidney, which decreases net glomerular ﬁltration rate and oxygen delivery.119
Avoiding ﬂuid retention is one of the key objectives in managing patients with PH. Once these patients develop signs of right-sided HF and oedema, restricting ﬂuid intake and using diuretics is recommended.
The three main classes of diuretics—loop diuretics, thiazides, and mineralocorticoid receptor antagonists—are used as monotherapy or in combination, as determined by the patient’s clinical need and kidney function. Patients requiring diuretic therapy should be advised to regularly monitor their body weight and to seek medical advice in case of weight gain. Close collaboration between patients, PH centres, especially PH nurses, and primary care physicians plays a vital role. Kidney function and serum electrolytes should be regularly monitored, and intravascular volume depletion must be avoided as it may cause a further decline in CO and systemic blood pressure. Physicians should bear in mind that ﬂuid retention and oedema may not necessarily signal right-sided HF, but may also be a side effect of PAH therapy.323
6.3.1.4. Oxygen
Although oxygen administration reduces PVR and improves exercise tolerance in patients with PAH, there are no data to suggest that longterm oxygen therapy has sustained beneﬁts on the course of the disease. Most patients with PAH, except those with CHD and pulmonary-to-systemic shunts, have minor degrees of arterial hypoxaemia at rest, unless they have a patent foramen ovale. Data show that nocturnal oxygen therapy does not modify the natural history of advanced Eisenmenger syndrome.324 In the absence of robust data on the use of oxygen in patients with PAH, guidance is based on evidence in patients with COPD;325 when PaO2 is ,8 kPa (60 mmHg; alternatively, SaO2 ,92%) on at least two occasions, patients are advised to take oxygen to achieve a PaO2 .8 kPa. Ambulatory oxygen may be considered when there is evidence of symptomatic beneﬁt and correctable desaturation on exercise.326,327 Nocturnal oxygen therapy should be considered in case of sleep-related desaturation.328
6.3.1.5. Cardiovascular drugs
No data from rigorous clinical trials are available on the usefulness and safety of drugs that are effective in systemic hypertension or leftsided HF, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers (ARBs), angiotensin receptor–neprilysin inhibitors
(ARNIs),
sodium–glucose cotransporter-2
inhibitors
(SGLT-2is), beta-blockers, or ivabradine in patients with PAH. In this group of patients, these drugs may lead to potentially dangerous drops in blood pressure, heart rate, or both. Likewise, the efﬁcacy of digoxin/digitoxin has not been documented in PAH, although these drugs may be administered to slow ventricular rate in patients with
PAH who develop atrial tachyarrhythmias.
6.3.1.6. Anaemia and iron status
Iron deﬁciency is common in patients with PAH and is deﬁned by serum ferritin ,100 µg/L, or serum ferritin 100–299 µg/L and transferrin saturation ,20%.329 The underlying pathological mechanisms are complex.330–333 In patients with PAH, iron deﬁciency is associated with impaired myocardial function, aggravated symptoms, and increased mortality risk.333,334 Based on these data, regular monitoring of iron status (serum iron, ferritin, transferrin saturation,
soluble transferrin receptors) is recommended in patients with PAH.
In patients with severe iron deﬁciency anaemia (Hb ,7–8 g/dL),
i.v. supplementation is recommended.335–337 Oral iron formulations containing ferrous (Fe2+) sulfate, ferrous gluconate, and ferrous fumarate are often poorly tolerated, and drug efﬁcacy may be impaired in patients with PAH.330,331 Ferric maltol is a new, orally available formulation of ferric (Fe3+) iron and maltol. One small, open-label study suggested good tolerability and efﬁcacy in patients with severe PH
with mild-to-moderate iron deﬁciency and anaemia.338 In contrast,
two small, 12 week, randomized, cross-over trials studying iron supplementation in PAH patients without anaemia provided no signiﬁcant clinical beneﬁt.339 Randomized controlled trials comparing oral and i.v. iron supplementation in patients with PAH are lacking.
6.3.1.7. Vaccination
As a general health care measure, it is recommended that patients with PAH be vaccinated at least against inﬂuenza, Streptococcus pneumoniae, and SARS-CoV-2.
6.3.1.8. Psychosocial support
Receiving a diagnosis of PH—often after a substantial delay—and experiencing the physical limitations have a substantial impact on psychological, emotional, and social aspects of patients and their families. Symptoms of depression and anxiety, as well as adjustment disorders, have a high prevalence in patients with PAH. Pulmonary arterial hypertension also has grave repercussions on ability to work and income.281,340–344
Empathic and hopeful communication is essential for physicians caring for patients with PAH. Awareness and knowledge about the disease and its treatment options empower patients to engage in shared decision-making. Adequate diagnostic screening tools are the key to identifying patients in need of referral for psychological/
psychiatric support, including psychopharmacological medication,345
or social assistance. Patient support groups may play an important role, and patients should be advised to join such groups. Given the life-limiting character of PAH, advanced care planning with referral to specialist palliative care services should be supported at the right time.346
6.3.1.9. Adherence to treatments
Adhering to medical therapy is key to successfully managing PAH. In general, factors that affect adherence are patient related (e.g. demographics, cognitive impairment, polypharmacy, adverse reactions/
side effects, psychological health, health literacy, patient understanding of the treatment rationale, and comorbidities), physician related
(expertise, awareness of guidelines, and multidisciplinary team approach), and health care system related (work setting, access to treatments, and cost).347
Recent studies have indicated that adherence to drug therapy in patients with PAH may be suboptimal.348,349 Given the complexity of PAH treatment, potential side effects, and risks associated with treatment interruptions,
adherence should be periodically
ESC/ERS Guidelines
3661


<!-- PAGE 45 -->

### Page 45

monitored by a member of the multidisciplinary team, to identify non-adherence and any changes to the treatment regimen spontaneously triggered by patients or non-expert physicians. To promote adherence, it is important to ensure that patients are involved in care decisions and appropriately informed about treatment options and rationale, expectations, side effects, and potential consequences of non-adherence. Patients should be advised that any changes in treatment should be made in cooperation with the PH centre.
6.3.2. Special circumstances
6.3.2.1. Pregnancy and birth control
6.3.2.1.1. Pregnancy. Historically, pregnancy in women with PAH
and other forms of severe PH has been associated with maternal mortality rates of up to 56% and neonatal mortality rates of up to
13%.350 With improved treatment of PAH and new approaches to managing women during pregnancy and the peri-partum period, maternal mortality has declined but remains high, ranging 11–25%.351–355
For these reasons, previous ESC/ERS Guidelines for the diagnosis and treatment of PH have recommended that patients with PAH should avoid pregnancy.25,26 However, there are reports of favourable pregnancy outcomes in women with PH, including, but not limited to, women with IPAH who respond to CCB therapy.353,354,356,357
Nonetheless, pregnancy remains associated with unforeseeable risks,
and may accelerate PH progression.358 Women with PH can deteriorate at any time during or after pregnancy. Therefore, physicians have a responsibility to inform patients about the risks of pregnancy,
so that women and their families can make informed decisions.
Women with poorly controlled disease, indicated by an intermediate- or high-risk proﬁle and signs of RV dysfunction, are at high risk of adverse outcomes; in the event of pregnancy, they should be carefully counselled and early termination should be advised. For patients with well-controlled disease, a low-risk proﬁle,
and normal or near-normal resting haemodynamics who consider becoming pregnant, individual counselling and shared decisionmaking are recommended. In such cases, alternatives such as adoption and surrogacy may also be explored. Pre-conception genetic counselling should also be considered in HPAH.
Women with PH who become pregnant or present during pregnancy with newly diagnosed PAH should be treated, whenever possible, in centres with a multidisciplinary team experienced in managing PH in pregnancy. If pregnancy is continued, PAH therapy may have to be adjusted. It is recommended to stop endothelin receptor antagonists (ERAs), riociguat, and selexipag because of potential or unknown teratogenicity.359 Despite limited evidence, CCBs,
PDE5is, and inhaled/i.v./subcutaneous (s.c.) prostacyclin analogues are considered safe during pregnancy.356,360
Pregnancy in PH is a very sensitive topic and requires empathic communication. Psychological support should be offered whenever needed.
6.3.2.1.2. Contraception. Women with PH of childbearing potential should be provided with clear contraceptive advice, considering the individual needs of the woman but recognizing that the implications of contraceptive failure are signiﬁcant in PH. With appropriate use, many forms of contraception, including oral contraceptives, are highly effective. In patients treated with bosentan, reduced efﬁcacy of hormonal contraceptives should be carefully considered.361 Using hormonal implants or an intrauterine device are alternative options with low failure rates. Surgical sterilization may be considered but is associated with peri-operative risks. Emergency post-coital hormonal contraception is safe in PH.
6.3.2.2. Surgical procedures
Surgical procedures in patients with PH are associated with an elevated risk of right HF and death. In a prospective, multinational registry including 114 patients with PAH who underwent non-cardiac and non-obstetric surgery, the peri-operative mortality rate was 2% in elective procedures and 15% in emergency procedures.362 The mortality risk was associated with the severity of PH. The decision to perform surgery should be made by a multidisciplinary team involving a
PH physician, and must be based on an individual risk:beneﬁt assessment considering various factors, including indication, urgency, PH
severity, and patient preferences. Risk scores to predict the perioperative mortality risk have been developed but require further validation.363 General recommendations cannot be made. The same is true regarding the preferred mode of anaesthesia. Pre-operative optimization of PAH therapy should be attempted whenever possible
(see also the 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery).364
6.3.2.3. Travel and altitude
Hypobaric hypoxia may induce arterial hypoxaemia, additional hypoxic pulmonary vasoconstriction, and increased RV load in
PAH.365,366 Cabin aircraft pressures are equivalent to altitudes up to 2438 m,367 at which the PaO2 decreases to that of an inspired
O2 fraction of 15.1% at sea level.365 However, evidence suggests that short-term (less than 1 day) normobaric hypoxia is generally well tolerated in clinically stable patients with PAH.365,368–372
In-ﬂight oxygen administration is advised for patients using oxygen at sea level and for those with PaO2 ,8 kPa (60 mmHg) or SaO2
,92%.25,26,325,369,372 An oxygen ﬂow rate of 2 L/min will raise inspired oxygen pressure to values as at sea level, and patients already using oxygen at sea level should increase their oxygen ﬂow rate.25,26,373
As the effects of moderate to long-term (hours–days) hypoxia exposure in PAH remain largely unexplored,374,375 patients should avoid altitudes .1500 m without supplemental oxygen.25,26,369
However, patients with PAH who are not hypoxaemic at sea level have tolerated day trips to 2500 m reasonably well.376 Patients should travel with written information about their disease, including a medication list, bring extra doses of their medication, and be informed about local PH centres near their travel destination.25,26
Recommendation Table 5 — Recommendations for general measures and special circumstances
Recommendations
Classa
Levelb
General measures
Supervised exercise training is recommended in patients with PAH under medical therapy314,315,317
I
A
Continued
3662
ESC/ERS Guidelines


<!-- PAGE 46 -->

### Page 46

6.3.3. Pulmonary arterial hypertension therapies
6.3.3.1. Calcium channel blockers
Patients with PAH who respond favourably to acute vasoreactivity testing (Figure 8) may respond favourably to treatment with
CCBs.129,146 Less than 10% of patients with IPAH, HPAH, or DPAH
are responders, while an acute vasodilator response does not predict a favourable long-term response to CCBs in patients with other forms of PAH.129,146,378 The CCBs that have predominantly been used in
PAH are nifedipine, diltiazem, and amlodipine.129,146 Amlodipine and felodipine are increasingly being used in clinical practice due to their long half-life and good tolerability. The daily doses that have shown efﬁcacy in PAH are relatively high and they must be reached progressively (Table 19). The most common adverse events are systemic hypotension and peripheral oedema.
Patients who meet the criteria for a positive acute vasodilator response and treated with CCBs should be closely followed for safety and efﬁcacy, with a complete reassessment after 3–6 months of therapy, including RHC. Additional acute vasoreactivity testing should be performed at re-evaluation to detect persistent vasodilator response, supporting possible increases in CCB dosage. Patients with a satisfactory chronic response present with WHO-FC I/II and marked haemodynamic improvement (ideally, mPAP ,30 mmHg and PVR ,4 WU) while on CCB therapy. In the absence of a satisfactory response, additional PAH therapy should be instituted. In some cases, a combination of CCBs with approved PAH drugs is required because of clinical deterioration with CCB withdrawal
Psychosocial support is recommended in patients with PAH
I
C
Immunization of patients with PAH against
SARS-CoV-2, inﬂuenza, and Streptococcus pneumoniae is recommended
I
C
Diuretic treatment is recommended in patients with PAH with signs of RV failure and ﬂuid retention
I
C
Long-term oxygen therapy is recommended in patients with PAH whose arterial blood oxygen pressure is ,8 kPa (60 mmHg)c
I
C
In the presence of iron-deﬁciency anaemia,
correction of iron status is recommended in patients with PAH
I
C
In the absence of anaemia, iron repletion may be considered in patients with PAH with iron deﬁciency
IIb
C
Anticoagulation is not generally recommended in patients with PAH but may be considered on an individual basis
IIb
C
The use of ACEis, ARBs, ARNIs, SGLT-2is,
beta-blockers, or ivabradine is not recommended in patients with PAH unless required by comorbidities (i.e. high blood pressure, coronary artery disease, left HF, or arrhythmias)
III
C
Special circumstances
In-ﬂight oxygen administration is recommended for patients using oxygen or whose arterial blood oxygen pressure is ,8 kPa (60 mmHg) at sea level
I
C
For interventions requiring anaesthesia,
multidisciplinary consultation at a PH centre to assess risk and beneﬁt should be considered
IIa
C
© ESC/ERS 2022
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
ARNI, angiotensin receptor–neprilysin inhibitor; HF, heart failure; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; RV, right ventricle; SARS-CoV-2,
severe acute respiratory syndrome coronavirus-2;
SGLT-2i,
sodium–glucose cotransporter-2 inhibitor.
aClass of recommendation.
bLevel of evidence.
cMeasured on at least two occasions.
Recommendation Table 6 — Recommendations for women of childbearing potential
Recommendations
Classa
Levelb
It is recommended that women of childbearing potential with PAH are counselled at the time of diagnosis about the risks and uncertainties associated with becoming pregnant; this should include advice against becoming pregnant, and referral for psychological support where needed
I
C
Continued
It is recommended to provide women of childbearing potential with PAH with clear contraceptive advice, considering the individual needs of the woman but recognizing that the implications of contraceptive failure are signiﬁcant in PAH
I
C
It is recommended that women with PAH who consider pregnancy or who become pregnant receive prompt counselling in an experienced PH
centre, to facilitate genetic counselling and shared decision-making, and to provide psychological support to the patients and their families where needed
I
C
For women with PAH having a termination of pregnancy, it is recommended that this be performed in PH centres, with psychological support provided to the patients and their families
I
C
For women with PAH who desire to have children,
where available, adoption and surrogacy with preconception genetic counselling may be considered
IIb
C
As teratogenic potential has been reported in pre-clinical models for endothelin receptor antagonists and riociguat, these drugs are not recommended during pregnancy359,377
III
B
© ESC/ERS 2022
PAH, pulmonary arterial hypertension; PH, pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
ESC/ERS Guidelines
3663


<!-- PAGE 47 -->

### Page 47

attempts. Patients who have not undergone a vasoreactivity study or those with a negative test should not be started on CCBs because of potentially severe side effects (e.g. severe hypotension, syncope, and
RV failure), unless prescribed at standard doses for other indications.379
6.3.3.2. Endothelin receptor antagonists
Binding of endothelin-1 to endothelin receptors A and B on PA
smooth-muscle cells promotes vasoconstriction and proliferation
(Figure 7).380 Endothelin B receptors are mostly expressed on
Recommendation Table 7 — Recommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension
Recommendations
Classa
Levelb
High doses of CCBs are recommended in patients with IPAH, HPAH, or DPAH who are responders to acute vasoreactivity testing
I
C
Close follow-up with complete reassessment after 3–4 months of therapy (including RHC) is recommended in patients with IPAH, HPAH, or
DPAH treated with high doses of CCBs
I
C
Continuing high doses of CCBs is recommended in patients with IPAH, HPAH, or DPAH in
WHO-FC I or II with marked haemodynamic improvement (mPAP ,30 mmHg and PVR ,4
WU)
I
C
Initiating PAH therapy is recommended in patients who remain in WHO-FC III or IV or those without marked haemodynamic improvement after high doses of CCBs
I
C
In patients with a positive vasoreactivity test but insufﬁcient long-term response to CCBs who require additional PAH therapy, continuation of
CCB therapy should be considered
IIa
C
CCBs are not recommended in patients without a vasoreactivity study or non-responders, unless prescribed for other indications (e.g. Raynaud’s phenomenon)
III
C
© ESC/ERS 2022
CCB, calcium channel blocker; DPAH, drug-associated pulmonary arterial hypertension;
HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; RHC, right heart catheterization;
WHO-FC, World Health Organization functional class; WU, Wood units.
aClass of recommendation.
bLevel of evidence.
Table 19
Dosing of pulmonary arterial hypertension medication in adults
Starting dose
Target dose
Calcium channel blockers
Amlodipine
5 mg o.d.
15–30 mg o.d.a
Diltiazem
60 mg b.i.d.b
120–360 mg b.i.d.b
Felodipine
5 mg o.d.
15–30 mg o.d.a
Continued
Nifedipine
10 mg t.i.d.
20–60 mg b.i.d. or t.i.d.
Endothelin receptor antagonists (oral administration)
Ambrisentan
5 mg o.d.
10 mg o.d.
Bosentan
62.5 mg b.i.d.
125 mg b.i.d.
Macitentan
10 mg o.d.
10 mg o.d.
Phosphodiesterase 5 inhibitors (oral administration)
Sildenaﬁl
20 mg t.i.d.
20 mg t.i.d.c
Tadalaﬁl
20 or 40 mg o.d.
40 mg o.d.
Prostacyclin analogues (oral administration)
Beraprost sodium
20 µg t.i.d.
Maximum tolerated dose up to
40 µg t.i.d.
Beraprost extended release
60 µg b.i.d.
Maximum tolerated dose up to
180 µg b.i.d.
Treprostinil
0.25 mg b.i.d.
or
0.125 mg t.i.d.
Maximum tolerated dose
Prostacyclin receptor agonist (oral administration)
Selexipag
200 µg b.i.d.
Maximum tolerated dose up to
1600 µg b.i.d.
Soluble guanylate cyclase stimulator (oral administration)
Riociguatd
1 mg t.i.d.
2.5 mg t.i.d.
Prostacyclin analogues (inhaled administration)
Iloproste
2.5 µg 6–9
times per day
5.0 µg 6–9 times per day
Treprostinile
18 µg 4 times per day
54–72 µg 4 times per day
Prostacyclin analogues (i.v. or s.c. administration)
Epoprostenol i.v.
2 ng/kg/min
Determined by tolerability and effectiveness; typical dose range at 1 year is 16–30 ng/kg/min,
with wide individual variability
Treprostinil s.c. or i.v.
1.25 ng/kg/
min
Determined by tolerability and effectiveness; typical dose range at 1 year is 25–60 ng/kg/min,
with wide individual variability
© ESC/ERS 2022
b.i.d., twice daily; i.v., intravenous; o.d., once daily; s.c., subcutaneous; t.i.d., three times daily.
Dosages are those commonly used in clinical practice. This does not exclude the use of alternative dosages.
aThe daily dosages of amlodipine and felodipine can be administered in a single dose or divided into two doses.
bThere are different release formulations of diltiazem, some of which should be administered o.d. or t.i.d.
cSildenaﬁl is approved at a dose of 20 mg t.i.d. but doses used in practice vary widely and are sometimes higher.
dIn patients at risk of systemic hypotension, riociguat may be started at 0.5 mg t.i.d.
eDoses provided are for nebulizers and may differ with the use of other formulations and other inhalation devices.
3664
ESC/ERS Guidelines


<!-- PAGE 48 -->

### Page 48

pulmonary endothelial cells, promoting vasodilation through accelerated production of prostacyclin and nitric oxide, and clearance of endothelin-1.380 Nevertheless, selective blocking of endothelin A receptors alone or non-selective blocking of both A and B receptors has shown similar effectiveness in PAH.380 Endothelial receptor antagonists have teratogenic effects and should not be used during pregnancy.381
6.3.3.2.1. Ambrisentan. Ambrisentan is an oral ERA that preferentially blocks the endothelin A receptors. The approved dosages in adults are 5 mg and 10 mg o.d. In patients with PAH, it has demonstrated efﬁcacy for symptoms, exercise capacity, haemodynamics,
and time to clinical worsening.382 An increased incidence of peripheral oedema was reported with ambrisentan use, while there was no increased incidence of abnormal liver function.
6.3.3.2.2. Bosentan. Bosentan is an oral, dual ERA that improves exercise capacity, WHO-FC, haemodynamics, and time to clinical worsening in patients with PAH.383 The approved target dose in adults is 125 mg b.i.d. Dose-dependent increases in liver transaminases can occur in ≏10% of treated patients (reversible after dose reduction or discontinuation).384 Thus, liver function testing should be performed monthly in patients receiving bosentan.384 Due to pharmacokinetic interactions, bosentan may render hormonal contraceptives unreliable and lower serum levels of warfarin, sildenaﬁl,
and tadalaﬁl.361,385–387
Y
Vaso
V
reactivity testing algorithm in patients with presumed diagnosis of I/H/D-PAH and t
P
reatment of responders
Refer to PH cent f
re
Reassess after 3–6 months
Continue therapy and p
reassess every 6–12 months
Right heart catheterization with pulmonary vasoreactivity testinga
(Class I)
Initiate therapy with calcium channel bloc p
kers k
and titrate to optimized individual doseb
(Class I)
≥10 mmHg mPAP d
P
rop from baseline to ≤40 mmHg with increased or unchanged cardiac output
Y
WHO-FC I/II, BNP <50 ng/L or NT-p
T
roBNP <300 ng/L,
normal or near-normal resting haemodynamicsc
Treat according to Figure 9
N
N
Figure 8 Vasoreactivity testing algorithm of patients with presumed diagnosis of idiopathic, heritable, or drug-associated pulmonary arterial hypertension. BNP, brain natriuretic peptide; I/H/D-PAH, idiopathic, heritable, drug-associated pulmonary arterial hypertension; mPAP, mean pulmonary arterial pressure; N, no; NT-proBNP, N-terminal pro-brain natriuretic peptide; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; WHO-FC,
World Health Organization functional class; WU, Wood units; Y, yes. aInhaled nitric oxide and inhaled iloprost are recommended; intravenous epoprostenol can be used if inhaled nitric oxide or inhaled iloprost are unavailable. bSee text for details. cmPAP ≤30 mmHg and PVR ≤4 WU.
ESC/ERS Guidelines
3665


<!-- PAGE 49 -->

### Page 49

6.3.3.2.3. Macitentan. Macitentan is an oral, dual ERA that has been found to increase exercise capacity and reduce a composite endpoint of clinical worsening in patients with PAH.167 While no liver toxicity has been shown, a reduction in Hb to ≤8 g/dL was observed in 4.3% of patients receiving 10 mg of macitentan.167
6.3.3.3. Phosphodiesterase 5 inhibitors and guanylate cyclase stimulators
Stimulating soluble guanylate cyclase (sGC) by nitric oxide results in production of the intracellular second messenger cyclic guanosine monophosphate (cGMP) (Figure 7). This pathway is controlled by a
Risk (3 strata)
(Table 16)
T
Initial ERA
R
+ PDE5i therapy p
(Class I)
Initial ERA + PDE5i and i.v.v/s.c. P
. CAb
(Class IIa)
Initial oral monotherapy p
with PDE5i or ERA
R
(Class IIa)
Add i.v.v o
. r s r .c. P
. CA and/or evaluate a
fof r lung transplantati a on
(Class IIa)
Regular fof llow-up assessment and individualized therapy p
Regular fof llow-up assessment
(Tab
T le 17)
Low or intermediate
High
Risk (4 strata) 
(Table 18)
T
Continue initial therapy p
(Class I)
Low
Intermediate-low
Intermediate-high or high
OR
Add PRA
R
(Class IIa)
Switch from
PDE5i to sGCs
(Class IIb)
Tr
T eatment of patients with I/H/D-PAH or 
P
PAH-CTD
P
Diagnosis confirmed at PH centre, vaso
,
reactivity testing negative
General measures throughout the course of the disease
(ReCo Table 5)
T
(Class I)
Patient without cardiopulmonary comorbiditiesa
Patient with cardiopulmonary comorbiditiesa
All risk categories
Figure 9 Evidence-based pulmonary arterial hypertension treatment algorithm for patients with idiopathic, heritable, drug-associated, and connective tissue disease-associated pulmonary arterial hypertension. DLCO, Lung diffusion capacity for carbon monoxide; ERA, endothelin receptor antagonist; I/
H/D-PAH, idiopathic, heritable, or drug-associated pulmonary arterial hypertension; i.v., intravenous; PAH-CTD, PAH associated with connective tissue disease; PCA, prostacyclin analogue; PDE5i, phosphodiesterase 5 inhibitor; PH, pulmonary hypertension; PRA, prostacyclin receptor agonist; ReCo, recommendation; s.c., subcutaneous; sGCs, soluble guanylate cyclase stimulator. aCardiopulmonary comorbidities are conditions associated with an increased risk of left ventricular diastolic dysfunction, and include obesity, hypertension, diabetes mellitus, and coronary heart disease; pulmonary comorbidities may include signs of mild parenchymal lung disease and are often associated with a low DLCO (,45% of the predicted value).
bIntravenous epoprostenol or i.v./s.c. treprostinil.
3666
ESC/ERS Guidelines


<!-- PAGE 50 -->

### Page 50

negative feedback loop through degradation of cGMP via different phosphodiesterases, among which subtype 5 (PDE5) is abundantly expressed in the pulmonary vasculature.388 Phosphodiesterase 5 inhibitors and sGC stimulators must not be combined with each other and with nitrates, as this can result in systemic hypotension.389
6.3.3.3.1. Sildenaﬁl. Sildenaﬁl is an orally active, potent, and selective inhibitor of PDE5. Several RCTs of patients with PAH treated with sildenaﬁl (with or without background therapy) have conﬁrmed favourable results on exercise capacity, symptoms, and/or haemodynamics.390–392 The approved dose of sildenaﬁl is 20 mg t.i.d.
Most side effects of sildenaﬁl are mild to moderate and mainly related to vasodilation (headache, ﬂushing, and epistaxis).
6.3.3.3.2. Tadalaﬁl. Tadalaﬁl is a once-daily administered PDE5i. An
RCT of 406 patients with PAH (53% on background bosentan therapy) treated with tadalaﬁl at doses up to 40 mg o.d. showed favourable results on exercise capacity, symptoms, haemodynamics, and time to clinical worsening.393 The side effect proﬁle was similar to that of sildenaﬁl.
6.3.3.3.3. Riociguat. While PDE5is augment the nitric oxide–cGMP
pathway by slowing cGMP degradation, sGC stimulators enhance cGMP production by directly stimulating the enzyme, both in the presence and absence of endogenous nitric oxide.394 An RCT of
443 patients with PAH (44% and 6% on background therapy with
ERAs or prostacyclin analogues, respectively) treated with riociguat up to 2.5 mg t.i.d. showed favourable results on exercise capacity,
haemodynamics, WHO-FC, and time to clinical worsening.395 The side effect proﬁle was similar to that of PDE5is.
6.3.3.4. Prostacyclin analogues and prostacyclin receptor agonists
The prostacyclin metabolic pathway (Figure 7) is dysregulated in patients with PAH, with less prostacyclin synthase expressed in PAs and reduced prostacyclin urinary metabolites.396 Prostacyclin analogues and prostacyclin receptor agonists induce potent vasodilation,
inhibit platelet aggregation, and also have both cytoprotective and anti-proliferative activities.397 The most common adverse events observed with these compounds are related to systemic vasodilation and include headache, ﬂushing, jaw pain, and diarrhoea.
6.3.3.4.1. Epoprostenol. Epoprostenol has a short half-life (3–
5 min) and needs continuous i.v. administration via an infusion pump and a permanent tunnelled catheter. A thermo-stable formulation is available to maintain stability up to 48 h.398 Its efﬁcacy has been demonstrated in three unblinded RCTs in patients with IPAH
(WHO-FC
III
and
IV)399,400
and
SSc-associated
PAH.401
Epoprostenol improved symptoms, exercise capacity, haemodynamics, and mortality.399 Long-term, persistent efﬁcacy has also been shown in IPAH,212,245 as well as in other associated PAH conditions.402–404 Serious adverse events related to the delivery system include pump malfunction, local site infection, catheter obstruction,
and sepsis. Recommendations for preventing central venous catheter bloodstream infections have been proposed.405,406
6.3.3.4.2. Iloprost. Iloprost is a prostacyclin analogue approved for inhaled administration. Inhaled iloprost has been evaluated in one
RCT, in which six to nine repetitive iloprost inhalations were compared with placebo in treatment-naïve patients with PAH or
CTEPH.407 The study showed an increase in exercise capacity and improvement in symptoms, PVR, and clinical events in the iloprost group compared with the placebo group.
6.3.3.4.3. Treprostinil. Treprostinil is available for s.c., i.v., inhaled,
and oral administration. Treprostinil s.c. improved exercise capacity,
haemodynamics, and symptoms in PAH.408 Infusion-site pain was the most common adverse effect, which led to treatment discontinuation in 8% of cases.408 Based on its chemical stability, i.v. treprostinil may also be administered via implantable pumps, improving convenience and likely decreasing the occurrence of line infections.409,410
Inhaled treprostinil improved the 6MWD, NT-proBNP, and quality of life measures in patients with PAH on background therapy with either bosentan or sildenaﬁl.411 Inhaled treprostinil is not approved in Europe.
Oral treprostinil has been evaluated in two RCTs of patients with
PAH on background therapy with bosentan and/or sildenaﬁl. In both trials, the primary endpoint—6MWD—did not reach statistical signiﬁcance.412,413 An additional RCT in treatment-naïve patients with
PAH showed improved 6MWD.414 An event-driven RCT that enrolled 690 patients with PAH demonstrated that oral treprostinil reduced the risk of clinical worsening events in patients who were receiving oral monotherapy with ERAs or PDE5is.415 Oral treprostinil is not approved in Europe.
6.3.3.4.4. Beraprost. Beraprost is a chemically stable and orally active prostacyclin analogue. Two RCTs have shown a modest, shortterm improvement in exercise capacity in patients with PAH;416,417
however, there were no haemodynamic improvements or long-term outcome beneﬁts. Beraprost is not approved in Europe.
6.3.3.4.5. Selexipag. Selexipag is an orally available, selective, prostacyclin receptor agonist that is chemically distinct from prostacyclin,
with different pharmacology. In a pilot RCT in patients with PAH (receiving stable ERA and/or PDE5i therapy), selexipag reduced PVR
after 17 weeks.418 An event-driven, phase 3 RCT that enrolled
1156 patients419 showed that selexipag alone or on top of mono or double therapy with an ERA and/or a PDE5i reduced the relative risk of composite morbidity/mortality events by 40%. The most common side effects were headache, diarrhoea, nausea, and jaw pain.
6.3.4. Treatment strategies for patients with idiopathic, heritable, drug-associated, or connective tissue disease-associated pulmonary arterial hypertension
Pulmonary arterial hypertension is a rare and life-threatening disease and should be managed, where possible, at PH centres in close collaboration with the patient’s local physicians.
This section describes drug treatment and is focused on nonvasoreactive patients with IPAH/HPAH/DPAH and on patients with PAH associated with connective tissue disease (PAH-CTD).
Information on the dosing of PAH medication is summarized in
Table 19. For other forms of PAH, treatment strategies have to be modiﬁed (see Section 7). The approach to vasoreactive patients with IPAH/HPAH/DPAH is described in Section 6.3.3.1.
ESC/ERS Guidelines
3667


<!-- PAGE 51 -->

### Page 51

In addition to targeted drug treatment, the comprehensive management of patients with PAH includes general measures that may include supplementary oxygen, diuretics to optimize volume status,
psychosocial support, and standardized exercise training (Section
6.3.1).315 Prior to the treatment decisions, patients and their next of kin should be provided with appropriate and timely information about the risks and beneﬁts of the treatment options so they can make the ﬁnal, informed, and joint decision about the treatment with the medical team. Treatment decisions in patients with IPAH/
HPAH/DPAH or PAH-CTD should be stratiﬁed according to the presence or absence of cardiopulmonary comorbidities (Section
6.3.4.3) and according to disease severity assessed by risk stratiﬁcation (Section 6.2.7).
6.3.4.1. Initial treatment decision in patients without cardiopulmonary comorbidities
The initial treatment of patients with PAH should be based on a comprehensive, multiparameter risk assessment, considering disease type and severity, comorbidities, access to therapies, economic aspects, and patient preference.
The following considerations predominantly apply to patients with
IPAH/HPAH/DPAH or PAH-CTD without cardiopulmonary comorbidities, as patients with comorbidities were under-represented in the clinical studies addressing treatment strategies and combination therapy in patients with PAH. Treatment considerations for patients with PAH and cardiopulmonary comorbidities are summarized in Section 6.3.4.3.
For patients presenting at low or intermediate risk, initial combination therapy with an ERA and a PDE5i is recommended. This approach was assessed in the AMBITION study, which compared initial combination therapy using ambrisentan at a target dose of
10 mg o.d. and tadalaﬁl at a target dose of 40 mg o.d. with initial monotherapy with either drug.166 AMBITION predominantly included patients with IPAH/HPAH/DPAH or PAH-CTD. The primary endpoint was the time to ﬁrst clinical failure event (a composite of death, hospitalization for worsening PAH, disease progression, or unsatisfactory long-term clinical response). The hazard ratio (HR)
for the primary endpoint in the combination-therapy group vs. the pooled monotherapy group was 0.50 (95% conﬁdence interval
[CI], 0.35–0.72; P , 0.001) and there were signiﬁcant improvements in 6MWD and NT-proBNP with initial combination therapy. At the end of the study, 10% of the patients assigned to initial combination therapy had died compared with 14% of the patients assigned to initial monotherapy (HR 0.67; 95% CI, 0.42–1.08).420
In the TRITON study, treatment-naïve patients with PAH were assigned to initial dual-combination therapy with macitentan and tadalaﬁl, or initial triple-combination therapy with macitentan
10 mg o.d., tadalaﬁl at a target dose of 40 mg o.d., and selexipag up to 1600 µg o.d.421 TRITON predominantly included patients with IPAH/HPAH/DPAH or PAH-CTD. At week 26, PVR was reduced by 52% and 54%, with double- or triple-combination therapy, respectively, and 6MWD had increased by 55 m and 56 m,
respectively. The geometric means of the NT-proBNP ratio from baseline to week 26 were 0.25 and 0.26, respectively.
Hence, TRITON did not show a beneﬁt of oral triple- vs. oral double-combination therapy but conﬁrmed that substantial improvements in haemodynamics and exercise capacity can be obtained with initial ERA/PDE5i combination therapy. Further studies are needed to determine whether oral triple-combination therapy impacts long-term outcomes.
Based on the evidence generated by these and other studies,303,422–424 initial dual-combination therapy with an ERA and a
PDE5i is recommended for newly diagnosed patients who present at low or intermediate risk. Initial oral triple-combination therapy is not recommended, given the current lack of evidence supporting this strategy. In patients presenting at high risk, initial triplecombination therapy including an i.v./s.c. prostacyclin analogue should be considered.426,427 While it is acknowledged that the evidence for this approach is limited to case series, there is consensus that this strategy has the highest likelihood of success, especially in view of registry data from France showing that initial triplecombination therapy including an i.v./s.c. prostacyclin analogue was associated with better long-term survival than monotherapy or dualcombination therapy.428 Initial triple-combination therapy including an i.v./s.c. prostacyclin analogue should also be considered in patients at intermediate risk presenting with severe haemodynamic impairment (e.g. RAP ≥20 mmHg, CI ,2.0 L/min/m2, SVI ,31 mL/m2,
and/or PVR ≥12 WU).238,426
The recommendations for initial oral double-combination therapy are based on PICO question I (Supplementary Data, Section 6.2).
Although the quality of evidence is low, initial oral combination therapy with an ERA and a PDE5i achieves important targets in symptom improvement (functional class), exercise capacity, cardiac biomarkers, and reduction of hospitalizations.
Recommendation Table 8 — Recommendations for the treatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present without cardiopulmonary comorbiditiesa
Recommendation Table 8A
Recommendations
Classb
Levelc
Recommendations for initial therapy
In patients with IPAH/HPAH/DPAH who present at high risk of death, initial combination therapy with a PDE5i, an ERA, and i.v./s.c. prostacyclin analogues should be consideredd
IIa
C
Recommendations for treatment decisions during follow-up
In patients with IPAH/HPAH/DPAH who present at intermediate–low risk of death while receiving
ERA/PDE5i therapy, the addition of selexipag should be considered419
IIa
B
In patients with IPAH/HPAH/DPAH who present at intermediate–high or high risk of death while receiving ERA/PDE5i therapy, the addition of i.v./
s.c. prostacyclin analogues and referral for LTx evaluation should be considered
IIa
C
In patients with IPAH/HPAH/DPAH who present at intermediate–low risk of death while receiving
ERA/PDE5i therapy, switching from PDE5i to riociguat may be considered429
IIb
B
© ESC/ERS 2022
3668
ESC/ERS Guidelines


<!-- PAGE 52 -->

### Page 52

6.3.4.2. Treatment decisions during follow-up in patients without cardiopulmonary comorbidities
Patients with PAH require regular follow-up, including risk stratiﬁcation and an assessment of patient concordance with therapy.
Patients who achieve a low-risk status have a much superior long-term survival compared with patients with intermediateor high-risk status.292,295,296 Achieving and maintaining a lowrisk proﬁle is therefore a key objective in managing patients with PAH.
Several clinical trials have assessed the safety and efﬁcacy of sequential combination therapy in patients with PAH. SERAPHIN enrolled 742 patients with PAH, mostly with IPAH/HPAH/DPAH and
PAH-CTD, of whom 63.7% were receiving other PAH medication at the time of enrolment, mostly sildenaﬁl.167 In the subgroup of patients with background PAH therapy, macitentan at a daily dose of
10 mg reduced the risk of clinical worsening events compared with placebo (HR 0.62; 95% CI, 0.43–0.89).167
GRIPHON assessed the safety and efﬁcacy of selexipag.419 This study enrolled 1156 patients with PAH, also mostly with IPAH/
HPAH/DPAH or PAH-CTD, who were treatment naïve or receiving background therapy with an ERA, PDE5i, or a combination of both. Selexipag at a dose of up to 1600 µg b.i.d. was associated with a reduced risk of clinical worsening events independent of the background medication. In patients receiving ERA/PDE5i combination therapy (n = 376), the risk of clinical worsening events was lower with selexipag than with placebo (HR 0.63; 95% CI, 0.44–
0.90).431
The effects of combination therapy on long-term survival in patients with PAH remain unclear. A 2016 meta-analysis demonstrated that combination therapy (initial and sequential) was associated with a signiﬁcant risk reduction for clinical worsening (relative risk [RR]
0.65; 95% CI, 0.58–0.72; P , 0.0001);432 however, all-cause mortality was not improved (RR 0.86; 95% CI, 0.72–1.03; P = 0.09) and a substantial proportion of patients had clinical worsening events or died despite receiving combination therapy. In addition, registry data showed that the use of combination therapy increased since 2015
but there was no clear improvement in overall survival rates.428,433,434 These data were corroborated by a study showing that less than half of patients receiving initial combination therapy with an ERA and a PDE5i achieved and maintained a low-risk proﬁle.422
Switching from PDE5is to riociguat has also been investigated as a treatment-escalation strategy.429,435 REPLACE was a randomized, controlled, open-label study that enrolled patients on a
PDE5i-based therapy who were in WHO-FC III and had a
6MWD of 165–440 m.429 The study predominantly included patients with IPAH/HPAH/DPAH or PAH-CTD who were randomized to continue their PDE5i or to switch from a PDE5i to riociguat up to 2.5 mg t.i.d. The study met its primary endpoint,
termed ‘clinical improvement’, which was a composite of prespeciﬁed improvements in 6MWD, WHO-FC, and NT-proBNP
at week 24. Clinical improvement at week 24 was demonstrated in 41% of the patients who switched to riociguat and in 20% of the patients who maintained their PDE5i (odds ratio [OR] 2.78;
95% CI, 1.53–5.06; P = 0.0007). In addition, fewer patients in the riociguat group experienced a clinical worsening event (OR 0.10;
95% CI, 0.01–0.73; P = 0.0047).
Based on the evidence summarized above, the following recommendations for treatment decisions during follow-up are:
Recommendation Table 8B
GRADE
Recommendations
Quality of evidence
Strength of recommendation
Classa
Levelb
Recommendations for initial therapy
In patients with IPAH/
HPAH/DPAH who present at low or intermediate risk of death, initial combination therapy with a PDE5i and an
ERA is recommended166
Low
Conditional
I
B
© ESC/ERS 2022
CI, cardiac index; DLCO, Lung diffusion capacity for carbon monoxide; DPAH,
drug-associated pulmonary arterial hypertension;
ERA,
endothelin receptor antagonist; HFpEF, heart failure with preserved ejection fraction; HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension;
i.v., intravenous; LTx, lung transplantation; PAH, pulmonary arterial hypertension;
PDE5i, phosphodiesterase 5 inhibitor; PVR, pulmonary vascular resistance; RAP, right atrial pressure; s.c., subcutaneous; SVI, stroke volume index; WU, Wood units.
aCardiopulmonary comorbidities are predominantly encountered in elderly patients and include risk factors for HFpEF such as obesity, diabetes, coronary heart disease, a history of hypertension, and/or a low DLCO.
bClass of recommendation.
cLevel of evidence.
dInitial triple-combination therapy including i.v./s.c. prostacyclin analogues may also be considered in patients presenting at intermediate risk but severe haemodynamic impairment (e.g. RAP ≥20 mmHg, CI ,2.0 L/min/m2, SVI ,31 mL/m2, and/or PVR
≥12 WU).
Recommendation Table 9 — Recommendations for initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension without cardiopulmonary comorbidities
Recommendations
Classa
Levelb
Initial combination therapy with ambrisentan and tadalaﬁl is recommended166,420,423
I
B
Initial combination therapy with macitentan and tadalaﬁl is recommended421,430
I
B
Initial combination therapy with other ERAs and
PDE5is should be considered430
IIa
B
Initial combination therapy with macitentan,
tadalaﬁl, and selexipag is not recommended421
III
B
© ESC/ERS 2022
ERA, endothelin receptor antagonist; PDE5i, phosphodiesterase 5 inhibitor.
aClass of recommendation.
bLevel of evidence.
ESC/ERS Guidelines
3669


<!-- PAGE 53 -->

### Page 53

(i) In patients who achieve a low-risk status with their initial PAH
therapy, continuation of treatment is recommended.
(ii) In patients who are at intermediate–low risk despite receiving
ERA/PDE5i therapy, adding selexipag should be considered to reduce the risk of clinical worsening. In these patients, switching from PDE5i to riociguat may also be considered.
(iii) In patients who are at intermediate–high or high risk while receiving oral therapies, the addition of i.v. epoprostenol or i.v./
s.c. treprostinil and referral for LTx evaluation should be considered.309,436 If adding i.v./s.c. prostacyclin analogues is unfeasible,
adding selexipag or switching from PDE5i to riociguat may be considered.
6.3.4.3. Pulmonary arterial hypertension with cardiopulmonary comorbidities
Over the past decade, the demographics and characteristics of patients with IPAH have changed, especially in industrialized countries.447 In several contemporary registries, the average age of patients diagnosed with IPAH is ≏60 years or older.161,295,299,447,448
Many elderly patients have cardiopulmonary comorbidities, making the distinction from group 2 and group 3 PH challenging.
Among elderly patients diagnosed with IPAH, two main disease phenotypes have emerged. One phenotype (herein called the left heart phenotype) consists of elderly, mostly female patients with risk factors for HFpEF (e.g. hypertension, obesity, diabetes,
or coronary heart disease) but pre-capillary PH rather than postcapillary PH;449,450 ≏30% of these patients have a history of atrial
ﬁbrillation.161 The other phenotype (called the cardiopulmonary phenotype) consists of elderly, predominantly male patients who have a low DLCO (,45% of the predicted value), are often hypoxaemic, have a signiﬁcant smoking history, and have risk factors for LHD.77,78,161,451 In a cluster analysis of 841 newly diagnosed patients with IPAH from the COMPERA registry,
12.6% had a classic phenotype of young, mostly female patients without cardiopulmonary comorbidities, while 35.8% presented with a left heart phenotype and 51.6% with a cardiopulmonary phenotype.161
Recommendation Table 10 — Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension
Recommendations
Classa
Levelb
General recommendation for sequential combination therapy
It is recommended to base treatment escalations on risk assessment and general treatment strategies (see Figure 9)
I
C
Evidence from studies with a composite morbidity/mortality endpoint as the primary outcome measure
The addition of macitentan to PDE5is or oral/
inhaled prostacyclin analogues is recommended to reduce the risk of morbidity/mortality events167,168,437
I
B
The addition of selexipag to ERAsc and/or PDE5is is recommended to reduce the risk of morbidity/
mortality events418,419
I
B
The addition of oral treprostinil to ERA or PDE5i/
riociguat monotherapy is recommended to reduce the risk of morbidity/mortality events412,413,415
I
B
The addition of bosentan to sildenaﬁl is not recommended to reduce the risk of morbidity/
mortality events419a
III
B
Evidence from studies with change in 6MWD as the primary outcome measure
The addition of sildenaﬁl to epoprostenol is recommended to improve exercise capacity392,438
I
B
The addition of inhaled treprostinil to sildenaﬁl or bosentan monotherapy should be considered to improve exercise capacity411,439
IIa
B
The addition of riociguat to bosentan should be considered to improve exercise capacity395,440
IIa
B
Continued
The addition of tadalaﬁl to bosentan may be considered to improve exercise capacity393
IIb
C
The addition of inhaled iloprost to bosentan may be considered to improve exercise capacity441,442
IIb
B
The addition of ambrisentan to sildenaﬁl may be considered to improve exercise capacity443
IIb
C
The addition of bosentan to sildenaﬁl may be considered to improve exercise capacity419,444
IIb
C
The addition of sildenaﬁl to bosentan may be considered to improve exercise capacity444–446
IIb
C
Other sequential double- or triple-combination therapies may be considered to improve exercise capacity and/or alleviate PH symptoms
IIb
C
Evidence from studies with safety of combination therapy as the primary outcome measure
Combining riociguat and PDE5is is not recommendedd 389
III
B
© ESC/ERS 2022
6MWD, 6-minute walking distance; ERA, endothelin receptor antagonist; PDE5i,
phosphodiesterase 5 inhibitor; PH, pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
cERAs used in the GRIPHON study were bosentan and ambrisentan.
dThe PATENT plus study investigated the combination of sildenaﬁl and riociguat;
however, combining riociguat with any PDE5i is contraindicated.
3670
ESC/ERS Guidelines


<!-- PAGE 54 -->

### Page 54

There are no evidence-based rules for determining a
patient’s phenotype. The AMBITION study used the presence of more than three risk factors for LHD together with certain haemodynamic criteria to exclude patients from the primary analysis.166 However, the COMPERA cluster analysis mentioned above found that the presence of a single risk factor may change the phenotype.161 Pending further data, it is the overall proﬁle that should be used to determine a patient’s phenotype.
Compared with patients without cardiopulmonary comorbidities,
patients with cardiopulmonary comorbidities respond less well to
PAH medication, are more likely to discontinue this medication due to efﬁcacy failure or lack of tolerability, are less likely to reach a low-risk status, and have a higher mortality risk. While the age-adjusted mortality of patients with the left heart phenotype seems to be similar to that of patients with classical PAH, patients with a cardiopulmonary phenotype and a low DLCO have a particularly high mortality risk.77,78,161,450,451
As patients with cardiopulmonary comorbidities were underrepresented in or excluded from PAH trials, no evidence-based treatment recommendations can be made for this patient population. Registry data suggest that most physicians use PDE5is as primary treatment for these patients.
Endothelin receptor antagonists or PDE5i/ERA combinations are occasionally used,
but the drug discontinuation rate is higher than in patients with classical PAH.447,450 A subgroup analysis from AMBITION, which assessed the response to PAH therapy in 105 patients who were excluded from the primary analysis set because of a left heart phenotype, found that these patients—compared with patients in the primary analysis set—had less clinical improvement and a higher likelihood of drug discontinuations due to safety and tolerability with both monotherapy and initial combination therapy.449
Data from the ASPIRE registry demonstrated that patients with
IPAH and a cardiopulmonary phenotype had less improvement in exercise capacity and PROMs compared with patients with classical IPAH.451
In patients with a left heart phenotype, ERA therapy is associated with an elevated risk of ﬂuid retention.449 Moreover,
in patients with a cardiopulmonary phenotype, PAH medication may cause a decline in the peripheral oxygen saturation.452
There is little published experience on the use of prostacyclin analogues or prostacyclin receptor agonists in this patient population.453
The lack of solid evidence for treating elderly patients with PAH
and cardiopulmonary comorbidities makes treatment recommendations challenging, and patients should be counselled accordingly.
In the absence of evidence on treatment strategies in these patients,
risk stratiﬁcation is of limited usefulness in guiding therapeutic decision-making. Initial monotherapy (see Supplementary Data,
Table S3) is recommended for most of these patients, with
PDE5is being the most widely used compounds according to registry data.161 Further treatment decisions should be made on an individual basis in collaboration with the PH centre and local physicians.
The treatment algorithm for patients with PAH is shown in
Figure 9 and the accompanying section describing the treatment algorithm.
6.3.5. Drug interactions
Among PAH drugs, clinically relevant pharmacokinetic interactions are observed between bosentan and sildenaﬁl (reduced sildenaﬁl plasma concentration385), bosentan and hormonal contraceptives
(reduced contraception efﬁcacy361), and bosentan and vitamin K antagonists (VKAs) (potential need for VKA dose adjustment386).
Additional pharmacokinetic interactions of potential clinical relevance are listed in Supplementary Data, Table S4.
6.3.6. Interventional therapy
6.3.6.1. Balloon atrial septostomy and Potts shunt
Balloon atrial septostomy,454,455 by creating an interatrial shunt, and
Potts shunt,456–459 by connecting the left PA and descending aorta,
aim to decompress the right heart and increase systemic blood
ﬂow, thereby improving systemic oxygen transport despite arterial oxygen desaturation. As these procedures are complex and associated with high risk, including substantial procedure-related mortality, they are rarely performed in patients with PAH and may only be considered in centres with experience in the techniques.
6.3.6.2. Pulmonary artery denervation
The rationale for performing a PA denervation (PADN) is based on the increased sympathetic overdrive characterizing PAH, which is associated with poor outcome.460,461 Although the contribution of this mechanism to developing PAH is not completely understood, it is associated with vasoconstriction and vascular remodelling through a baroreﬂex mediated by stretch receptors located at the bifurcation of the PAs.462,463 Applying radiofrequency at the latter acutely and
Recommendation Table 11 — Recommendations for the treatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present with cardiopulmonary comorbiditiesa
Recommendations
Classb
Levelc
Recommendations for initial therapy
In patients with IPAH/HPAH/DPAH and cardiopulmonary comorbidities, initial monotherapy with a PDE5i or an ERA should be considered
IIa
C
Recommendations for treatment decisions during follow-up
In patients with IPAH/HPAH/DPAH with cardiopulmonary comorbidities who present at intermediate or high risk of death while receiving
PDE5i or ERA monotherapy, additional PAH
medication may be considered on an individual basis
IIb
C
© ESC/ERS 2022
DPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; PDE5i,
phosphodiesterase 5 inhibitor.
aCardiopulmonary comorbidities are predominantly encountered in elderly patients and include risk factors for HFpEF such as obesity, diabetes, coronary heart disease, a history of hypertension, and/or a low DLCO.
bClass of recommendation.
cLevel of evidence.
ESC/ERS Guidelines
3671


<!-- PAGE 55 -->

### Page 55

chronically improves haemodynamic variables.464 However, there is little evidence yet from multicentre RCTs demonstrating a beneﬁt of PADN in patients already receiving recommended medical therapy.
A small multicentre study tested the feasibility of PADN using an intravascular ultrasound catheter in patients receiving dual or triple therapy for PAH;465 the procedure was safe and associated with a reduction in
PVR, and increases in 6MWD and daily activity. Although potentially promising, PADN should be considered experimental.
6.3.7. Advanced right ventricular failure
6.3.7.1. Intensive care unit management
Patients with PH may require intensive care treatment for right HF,
comorbidities (including major surgery), or both. The mortality risk is high in such patients,466,467 and specialized centres should be involved whenever possible. In addition to basic intensive care unit
(ICU) standards, RV function in these patients should be carefully monitored. Non-speciﬁc clinical signs of right HF with low CO include pale skin with peripheral cyanosis, hypotension, tachycardia,
declining urine output, and increasing lactate levels. Non-invasive monitoring should include biomarkers (NT-proBNP and troponin)
and echocardiography. Minimum invasive monitoring consists of an upper body central venous catheter to measure central venous pressure and central venous oxygen saturation, the latter reﬂecting CO.
Right heart catheterization or other forms of advanced haemodynamic assessment should be considered in patients with advanced right HF or in complex situations.468
Treating right HF should focus on treatable triggers such as infection, arrhythmia, anaemia, and other comorbidities. Fluid management is of utmost importance in these patients, most of whom require a negative ﬂuid balance to reduce RV pre-load, thereby improving RV geometry and function.468 Patients with a low CO may beneﬁt from treatment with inotropes; dobutamine and milrinone are the most frequently used substances in this setting. Maintaining the mean systemic blood pressure .60 mmHg is a key objective when treating right HF, and patients with persistent hypotension may require vasopressors such as norepinephrine or vasopressin.
Intubation and invasive mechanical ventilation should be avoided whenever possible in patients with advanced RV failure because of a high risk of further haemodynamic deterioration and death.
Pulmonary arterial hypertension medication should be considered on an individual basis, taking into account underlying disease, comorbidities, and existing medication. In patients with newly diagnosed PAH presenting with low CO, combination therapy including i.v./s.c. prostacyclin analogues should be considered.426
6.3.7.2. Mechanical circulatory support
In specialist centres, various forms of mechanical circulatory support are available for managing RV failure, with veno-arterial extracorporeal membrane oxygenation (ECMO) being the most widely used approach. Mechanical circulatory support has become an established bridging tool to transplantation in patients with irreversible right HF,
but is occasionally used as a bridge to recovery in patients with treatable causes and potentially reversible RV failure.468 No general recommendations can be made regarding the indication for mechanical circulatory support, which needs to be individualized, considering patient factors and local resources.469,470 Long-term mechanical support analogous to left ventricular assist devices (LVADs) is not yet available for patients with PH and end-stage right HF.
6.3.8. Lung and heart–lung transplantation
Lung transplantation remains an important treatment option for patients with PAH refractory to optimized medical therapy. In patients with PAH, referral to an LTx centre should be considered early
(Table 20):
Recommendation Table 12 — Recommendations for intensive care management for pulmonary arterial hypertension
Recommendations
Classa
Levelb
When managing patients with right HF in the ICU,
it is recommended to involve physicians with expertise, treat causative factors, and use supportive measures, including inotropes and vasopressors, ﬂuid management, and PAH drugs,
as appropriate
I
C
Mechanical circulatory support may be an option for selected patients as a bridge to transplantation or recovery, and interhospital transfer should be considered if such resources are unavailable on site
IIa
C
© ESC/ERS 2022
HF, heart failure; ICU, intensive care unit; PAH, pulmonary arterial hypertension.
aClass of recommendation.
bLevel of evidence.
Table 20
Criteria for lung transplantation and listing in patients with pulmonary arterial hypertension
Referral
Potentially eligible patients for whom LTx might be an option in case of treatment failure
ESC/ERS intermediate–high or high risk or REVEAL risk score .7 on appropriate PAH medication
Progressive disease or recent hospitalization for worsening PAH
Need for i.v. or s.c. prostacyclin therapy
Known or suspected high-risk variants, such as PVOD or PCH, systemic sclerosis, or large and progressive pulmonary artery aneurysms
Signs of secondary liver or kidney dysfunction due to PAH or other potentially life-threatening complications, such as recurrent haemoptysis
Listing
Patient has been fully evaluated and prepared for transplantation
ESC/ERS high risk or REVEAL risk score .10 on appropriate PAH
medication, usually including i.v. or s.c. prostacyclin analogues
Progressive hypoxaemia, especially in patients with PVOD or PCH
Progressive, but not end-stage liver of kidney dysfunction due to PAH, or life-threatening haemoptysis
© ESC/ERS 2022
ERS, European Respiratory Society; ESC, European Society of Cardiology; i.v.,
intravenous; LTx, lung transplantation; PAH, pulmonary arterial hypertension; PCH,
pulmonary capillary haemangiomatosis; PVOD, pulmonary veno-occlusive disease;
s.c., subcutaneous.
3672
ESC/ERS Guidelines


<!-- PAGE 56 -->

### Page 56

(1) when they present with an inadequate response to treatment despite optimized combination therapy; (2) when they present with an intermediate–high or high risk of death (i.e. 1-year mortality
.10% when estimated with established risk-stratiﬁcation tools)471
(see Section 6.2.7), which exceeds the current mortality rate after
LTx;472 (3) when patients have a disease variant that poorly responds to medical therapy, such as PVOD or PCH.
Both heart–lung and bilateral LTx have been performed for PAH.
Currently, most patients receive bilateral LTx, while combined heart–lung transplantation is reserved for patients who have additional non-correctable cardiac conditions.473 With the introduction of the lung allocation score (LAS), waiting list mortality has decreased and the odds of receiving a donor organ have increased.474 In some countries, an ‘exceptional LAS’ can be obtained for patients with severe PH. Some other countries not using the LAS have successfully implemented high-priority programmes for these patients.475 The patient and their next of kin should be fully engaged in the transplant assessment process and informed of the risks and beneﬁts, and the
ﬁnal decision should be jointly made between the patient and medical team (see Section 6.3.1.8). For patients with PAH who survive the early post-transplant period, long-term outcomes are good. A study found that for primary transplant patients with IPAH who survived to 1 year, conditional median survival was 10.0 years.476
6.3.9. Evidence-based treatment algorithm
A treatment algorithm for patients with IPAH/HPAH/DPAH or
PAH-CTD is shown in Figure 9. The evidence supporting this algorithm has mainly been generated in patients with IPAH/HPAH/
DPAH or PAH-CTD who present without cardiopulmonary comorbidities. Patients with HIV-associated PAH, PoPH, and PAH associated with congenital heart disease were not enrolled or under-represented in most PAH therapy trials. Treatment recommendations for these patients are provided in Section 7.
6.3.10. Diagnosis and treatment of pulmonary arterial hypertension complications
6.3.10.1. Arrhythmias
The most common types of arrhythmias observed in PAH are supraventricular, mainly atrial ﬁbrillation and atrial ﬂutter, while the frequency of ventricular arrhythmias and bradyarrhythmias appears to be considerably lower.477–479 Of note, age is an independent risk factor for atrial arrhythmias. In prospective studies, the incidence of atrial arrhythmias was 3–25% over an observation time of 5 years in cohorts primarily containing patients with IPAH.479–481
In the absence of speciﬁc evidence for PAH, managing anticoagulation in patients with PAH and atrial arrhythmia should follow the recommendations for patients with other cardiac conditions.477
Patients with PAH are especially sensitive to haemodynamic stress during atrial arrhythmias due to tachycardia and loss of atrioventricular synchrony. Maintaining sinus rhythm is an important treatment objective in these patients. New-onset arrhythmias frequently lead to clinical deterioration and are associated with increased mortality.481
Observational studies have shown that a variety of rhythm control strategies are feasible, including pharmacological cardioversion with anti-arrhythmic drugs, electrical cardioversion, and invasive catheter ablation procedures. To achieve or maintain a stable sinus rhythm,
prophylaxis with anti-arrhythmic drugs without negative inotropic effects, such as oral amiodarone, should be considered, even if speciﬁc data regarding their efﬁcacy are lacking. Low-dose beta-blockers and/or digoxin may be used on an individual patient basis.
Catheter ablation is the preferred approach in managing atrial ﬂutter and some other atrial tachycardias, although catheter ablation in patients with PAH is often more technically challenging than in patients with a structurally normal right heart chamber.482 The safety and efﬁcacy of ablation techniques for atrial ﬁbrillation speciﬁcally in the PAH population are uncertain, and it is possible that, due to remodelling of the RA, non-pulmonary vein triggers may play a more important role than in patients without PAH.483
6.3.10.2. Haemoptysis
Haemoptysis, ranging from mild to life-threatening, may occur in all forms of PH but is particularly common in HPAH and PAH associated with CHD. Pulmonary bleeding frequently originates from enlarged bronchial arteries;484–486 hence, the diagnostic evaluation of patients with
PAH
and haemoptysis should include a
contrast-enhanced CT scan with an arterial phase. Even if the source of bleeding cannot be determined, embolization of enlarged bronchial arteries is recommended in patients who present with moderate-to-severe haemoptysis or recurrent episodes of mild haemoptysis. Lung transplant should be considered in patients with recurrent and severe haemoptysis despite optimized treatment.
6.3.10.3. Mechanical complications
Mechanical complications in patients with PAH usually arise from progressive dilatation of the PA and include PA aneurysms, rupture,
and dissection, and compression of adjacent structures such as the left main coronary artery, pulmonary veins, main bronchi, and recurrent laryngeal nerves.487–492
Pulmonary artery aneurysm was independently related to an increased risk of sudden cardiac death in one study.492 Symptoms and signs are non-speciﬁc; in most cases, patients are asymptomatic and these complications are incidentally diagnosed. Pulmonary artery aneurysms are usually detected during echocardiography and best visualized by contrast-enhanced CT or MRI. Treatment options for asymptomatic
PA aneurysm or PA dissection are not well deﬁned. LTx has to be considered on an individual basis.490,493
Recommendation Table 13 — Recommendations for lung transplantation
Recommendations
Classa
Levelb
It is recommended that potentially eligible candidates are referred for LTx evaluation when they have an inadequate response to oral combination therapy, indicated by an intermediate–
high or high risk or by a REVEAL risk score .7
I
C
It is recommended to list patients for LTx who present with a high risk of death or with a REVEAL
risk score ≥10 despite receiving optimized medical therapy including s.c. or i.v. prostacyclin analogues
I
C
© ESC/ERS 2022
i.v., intravenous; LTx, lung transplantation; s.c., subcutaneous.
aClass of recommendation.
bLevel of evidence.
ESC/ERS Guidelines
3673


<!-- PAGE 57 -->

### Page 57

For patients with left main coronary artery compression syndrome, percutaneous coronary stenting is an effective and safe treatment.62 For patients with asymptomatic left main coronary artery compression or non-severe compromise of its anatomy, evaluation with intravascular ultrasound or coronary pressure wire may help to avoid unnecessary interventions.494
6.3.11. End-of-life care and ethical issues
The clinical course of PAH may be characterized by progressive deterioration and occasional episodes of acute decompensation. Life expectancy is difﬁcult to predict, as patients may either die slowly because of progressive right HF or experience sudden death.
Patient-orientated care is essential in managing PAH. Information about disease severity and possible prognosis should be provided at initial diagnosis but empathic and hopeful communication, as well as yielding hope, is essential, in line with Section 6.3.1.8. At the right time, open and sensitive communication will enable advanced planning and discussion of a patient’s fears, concerns, and wishes, and will ultimately contribute to making the ﬁnal, well-informed, and joint decision about treatment with the medical team.
Patients approaching end of life require frequent assessment of their full needs by a multidisciplinary team. In advanced stages, recognizing that cardiopulmonary resuscitation in severe PAH has a poor outcome may enable a do not resuscitate order; this may facilitate patients being in their preferred place of care at end of life.
Attention should be given to controlling distressing symptoms and prescribing appropriate drugs while withdrawing medication that is no longer needed,
which may include
PAH
medication.
Well-informed psychological, social, and spiritual support is also vital.
Specialist palliative care should be consulted for patients whose needs are beyond the expertise of the PH team.346
6.3.12. New drugs in advanced clinical development
(phase 3 studies)
Pulmonary arterial hypertension remains an incurable condition with a high mortality rate, despite use of PAH drugs mainly targeting imbalance of vasoactive factors. Novel agents, which are currently in phase 3 development, are ralinepag and sotatercept. Ralinepag is an orally available prostacyclin receptor agonist, which, in a phase
2 RCT that included 61 patients with PAH, improved PVR compared with placebo after 22 weeks of therapy.495 Sotatercept—a fusion protein comprising the extracellular domain of the human activin receptor type IIA linked to the Fc domain of human immunoglobulin
G1—acts as a ligand trap for members of the transforming growth factor (TGF)-β superfamily, thus restoring balance between growthpromoting and growth-inhibiting pathways.496 In a phase 2 RCT that included 106 patients with PAH treated over 24 weeks, s.c. sotatercept reduced PVR in patients receiving background PAH therapy;496
improvements were also observed in 6MWD and NT-proBNP.496
7. Speciﬁc pulmonary arterial hypertension subsets
7.1. Pulmonary arterial hypertension associated with drugs and toxins
Several drugs and toxins are associated with developing PAH or
PVOD/PCH. Historically, certain appetite suppressants and toxic rapeseed oil were the most prominent examples, whereas methamphetamines, interferons, and some tyrosine kinase inhibitors are more common causes nowadays (Table 7). Pulmonary arterial hypertension is a rare complication in patients exposed to these drugs, and many of these drugs have also been linked to other pulmonary complications such as parenchymal lung disease or pleural effusions.
These pulmonary complications may occur concurrently.
Methamphetamine-associated PAH has mainly been reported from the USA, where some centres have found that 20–29% of their otherwise idiopathic cases of PAH were associated with methamphetamine use.497,498 Compared with patients with IPAH, those with methamphetamine-associated PAH had more severe haemodynamic impairment and a higher mortality risk.498 Alpha and beta interferons have also been associated with developing PAH.499 The same is true of some tyrosine kinase inhibitors, especially dasatinib,
but also bosutinib and ponatinib.40,500
Drug- or toxin-induced PAH should always be considered in patients presenting with unexplained exertional dyspnoea or other warning signs. The diagnostic approach should be the same as in other forms of PH, and the diagnosis is usually made by excluding other forms of PH in patients who have been exposed to drugs associated with developing PAH.
Treatment of DPAH follows the same basic principles as treating other forms of PAH. Importantly, partial or full reversal of PAH has been reported after discontinuing the causative agent, at least for interferons and dasatinib.499,500 Hence, multidisciplinary management of the patient should include discontinuing the presumed causative agents once PAH is diagnosed (also see the 2022 ESC Guidelines on Cardio-Oncology).501 In patients with mild PH and a low-risk proﬁle, discontinuing the trigger alone may be sufﬁcient, and it is recommended that these patients be observed over 3–4 months before considering PAH therapy. Pulmonary arterial hypertension therapy should be initiated in patients who do not normalize their haemodynamics after withdrawing or in patients presenting with more advanced PAH at diagnosis. Unlike in other forms of PAH, de-escalation of PAH therapy is often possible during the course of the disease.500
Physicians should bear in mind that DPAH may have features of
PVOD/PCH, especially in patients treated with alkylating agents such as mitomycin C or cyclophosphamide. Health professional awareness is essential in identifying cases of DPAH and reporting adverse effects of pharmaceutical products.
Recommendation Table 14 — Recommendations for pulmonary arterial hypertension associated with drugs or toxins
Recommendations
Classa
Levelb
It is recommended to make a diagnosis of drug- or toxin-associated PAH in patients who had relevant exposure and in whom other causes of
PH have been excluded
I
C
In patients with suspected drug- or toxin-associated PAH, it is recommended to immediately discontinue the causative agent whenever possible
I
C
Continued
3674
ESC/ERS Guidelines


<!-- PAGE 58 -->

### Page 58

7.2. Pulmonary arterial hypertension associated with connective tissue disease
Pulmonary arterial hypertension is a well-known pulmonary vascular complication of
SSc,173,502–504
systemic lupus erythematosus
(SLE),505–507 mixed CTD,506 and, rarely, dermatomyositis508 and
Sjögren’s syndrome.509 Conversely, the relationship between rheumatoid arthritis and PAH is not established.510 After IPAH, PAH-CTD is the second most prevalent type of PAH in western countries.511
Systemic sclerosis, particularly in its limited variant, represents the main cause of PAH-CTD in Europe and the USA (SLE being more common in Asia).173,502,506 The prevalence of pre-capillary PH in large cohorts of patients with SSc is 5–19%.173,502 In these patients, PH may occur in association with ILD504,512 or as a result of PAH,173,502–504,506
sometimes with features of venous/capillary involvement.504,513
Moreover, group 2 PH-LHD is also common due to myocardial SSc involvement.504,514 Of note, patients with SLE may also present with PAH, LHD, ILD, and CTEPH (mostly in the setting of antiphospholipid syndrome). It is therefore essential to carefully determine which mechanism is operative in a given patient, since this will dictate treatment in the context of a multifaceted disease.
Cluster analysis performed in patients with SSc has shown that pre-capillary PH can be characterized into distinct clusters that differ in prognosis.503 One cluster, characterized by the presence of extensive ILD, and another by severely impaired haemodynamics carried a dismal prognosis, while the two others showed either the absence of
ILD or the presence of limited ILD, with mild-to-moderate risk PAH
and a relatively favourable overall prognosis.503
7.2.1. Epidemiology and diagnosis
There is a strong female predominance in PAH-CTD (female/male ratio 4:1), and mean age at diagnosis is commonly .50 years, especially in SSc.173,502–511,513,515,516 In the setting of a CTD, patients may present with concomitant disorders such as ILD, and have shorter survival compared with patients with IPAH.503 The unadjusted risk of death for PAH-SSc compared with IPAH is 2.9, and the predictors of outcome are broadly similar to those for IPAH.516,517 Symptoms and clinical presentation are also similar to IPAH, and some patients thought to have IPAH can be identiﬁed as having an associated CTD
by careful clinical examination and immunological screening tests.
Chest CT is recommended for evaluating the presence of associated
ILD or PVOD/PCH.504,513,515 An isolated reduction of DLCO is common in PAH-CTD.173,502–504
Resting echocardiography combined with other tests is recommended as a screening test in asymptomatic patients with SSc, followed by annual assessments. Screening/early detection is discussed in Section 5.3.1. In other CTDs, PH screening in the absence of suggestive symptoms is not recommended, while echocardiography should be performed in the presence of symptoms. As in other forms of PAH, RHC is recommended in all cases of suspected PAH-CTD to conﬁrm diagnosis, determine severity, and rule out LHD.504
7.2.2. Therapy
Drugs for PAH should be prescribed in PAH-CTD according to the same treatment algorithm as in IPAH (Figure 9). Patients with
PAH-CTD have been included in most of the major RCTs for regulatory approval of PAH therapy.518 Some aspects of PAH-CTD
treatment differ according to the associated
CTD.506
Immunosuppressive therapy combining glucocorticosteroids and cyclophosphamide may result in clinical improvement in patients with SLE- or mixed CTD-associated PAH,506 while it is not recommended in PAH-SSc.519 Patients with SSc and other CTDs may have
ILD and/or HFpEF, which needs to be considered when initiating
PAH therapy.504,515 In SSc, the long-term risk/beneﬁt ratio of oral anticoagulation is unfavourable because of an increased risk of bleeding,
while VKAs are recommended in PAH-CTD with a thrombophilic predisposition (e.g. antiphospholipid syndrome).319
Subgroup analyses of patients with PAH-SSc enrolled in RCTs performed with monotherapy or combination therapy of ERAs, PDE5is,
sGC stimulators, prostacyclin receptor agonists, epoprostenol, and prostacyclin analogues have shown positive effects vs.
placebo.301,401,519,520 In some of these trials, the magnitude of the response in the PAH-CTD subgroup was lower than in the IPAH
subgroup.519,520 Continuous i.v. epoprostenol therapy improved exercise capacity, symptoms, and haemodynamics in a 3-month RCT in
PAH-SSc.401 However, a retrospective analysis showed a better effect of i.v. epoprostenol on survival in IPAH compared with
PAH-SSc.521 The choice of PAH therapy in the context of SSc and its systemic manifestations may consider other vascular damage such as digital ulcers.522
Connective tissue disease should not be considered as an a priori contraindication for LTx.523 This has been extensively studied in SSc,
where a multidisciplinary approach optimizing SSc management before, during, and after surgery is recommended.523 Indications and contraindications for transplantation have to be adapted to the speciﬁcities of CTD, with a special focus on digestive (gastrooesophageal reﬂux disease and intestinal disease), cardiac, renal,
and cutaneous involvement.523
Immediate PAH therapy should be considered in patients who present with intermediate-/high-risk
PAH at diagnosis
IIa
C
Patients with low-risk PAH should be re-evaluated
3–4 months after discontinuing the suspected drug or toxin, and PAH therapy may be considered when the haemodynamics have not normalized
IIb
C
© ESC/ERS 2022
PAH, pulmonary arterial hypertension; PH, pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 15 — Recommendations for pulmonary arterial hypertension associated with connective tissue disease
Recommendations
Classa
Levelb
In patients with PAH associated with CTD,
treatment of the underlying condition according to current guidelines is recommended166,167,419,524
I
A
Continued
ESC/ERS Guidelines
3675


<!-- PAGE 59 -->

### Page 59

7.3. Pulmonary arterial hypertension associated with human immunodeﬁciency virus infection
The use of highly active antiretroviral therapy (HAART), and advances in managing opportunistic infections have contributed to increased life expectancy in patients with HIV.525,526 Consequently,
the spectrum of complications has shifted towards other long-term conditions, including PAH. Clinical and histopathological ﬁndings in
PAH associated with HIV infection (PAH-HIV) share many similarities with IPAH.1,527 With the availability of HAART given in combination with PAH therapies, the prognosis of PAH-HIV has markedly improved in recent years.526,528 In addition, the incidence of
PAH-HIV has declined in parallel with the increasing availability of
HAART.528 Taken together, these effects on survival and incidence have resulted in a stable PAH prevalence in patients with HIV over recent decades. A French population study indicated that the prevalence of PAH in individuals with HIV infection was 0.46%, which is very similar to the prevalence before the HAART era.177
The pathogenesis of PAH-HIV remains unclear. There is no evidence of a direct role of HIV in the pathogenesis of PAH and, although present in inﬂammatory cells in the lungs, the virus itself has never been found in pulmonary vascular lesions of patients with PAH-HIV.529 This suggests that an indirect action of viral infection on inﬂammation and growth factors may act as a trigger in a predisposed patient.
7.3.1. Diagnosis
Pulmonary arterial hypertension associated with HIV shares a clinical presentation with IPAH. Before the availability of HAART most patients were in WHO-FC III or IV at diagnosis. Nowadays, patients are diagnosed with much less severe symptoms and haemodynamics.
Patients may present with other risk factors for PAH such as liver disease (chronic viral hepatitis B or C) or exposure to drugs or toxins.
Patients with PAH-HIV are more likely to be male and i.v. drug abusers.403,526 There is no correlation between the severity of PAH and the stage of HIV infection or the degree of immunodeﬁciency.403,530
Because of its low prevalence, asymptomatic patients with HIV
should not be screened for PAH. However, echocardiography should be performed in patients with unexplained dyspnoea to detect HIV-related cardiovascular complications such as myocarditis,
cardiomyopathy, or PAH. Right heart catheterization is mandatory to conﬁrm the diagnosis of PAH-HIV and to rule out LHD.527
Pulmonary arterial hypertension is an independent risk factor for death in patients with HIV. In the 1990s, before the availability of
HAART, patients with PAH-HIV had poor outcomes, with a 3 year survival of ,50%.403 The overall survival has now improved and patients with PAH-HIV have a better prognosis than most patients with other forms of PAH.526
7.3.2. Therapy
Current recommendations for the treatment of PAH-HIV are largely based on data from IPAH.25,26
Treatment of PAH-HIV with HAART has improved functional status and survival in some retrospective studies.525,526,531 The use of
HAART in PAH-HIV is therefore recommended, irrespective of viral load and CD4+ cell count.
Anticoagulation is not recommended because of an increased risk of bleeding and drug interactions.319,527 Patients with PAH-HIV are usually non-responders to acute vasoreactivity testing and therefore should not receive CCBs.378
The prospective, open-label, BREATHE-4 study showed that bosentan markedly improved WHO-FC, exercise capacity, quality of life,
and haemodynamics after
16
weeks in patients with
PAH-HIV.532 In a long-term, retrospective series, bosentan therapy was associated with haemodynamic normalization in 10/59 patients.533 Bosentan potentially interacts with antiretroviral drugs,
and close monitoring is required when combined with HAART.
Very few patients with PAH-HIV have been included in RCTs with ambrisentan and macitentan, and no deﬁnite conclusion can be drawn from those studies.
Positive effects of sildenaﬁl and tadalaﬁl in PAH-HIV have been established in case studies.534,535 Interactions have been reported between PDE5is and protease inhibitors, resulting in major increases in PDE5i concentrations; these drugs should be introduced at low dosages with careful monitoring of potential side effects, including hypotension.536,537 There are no data on the use of the sGC stimulator riociguat in PAH-HIV.
Treatment with i.v. epoprostenol resulted in signiﬁcant improvement in WHO-FC, exercise capacity, haemodynamics, and survival in selected patients with PAH-HIV.403,538 There are very few data on the use of i.v. or s.c. treprostinil or inhaled iloprost in
PAH-HIV.539,540
There are no clinical trial data on the use of combination therapy for PAH-HIV. Given the lack of supporting evidence and potential safety concerns when PAH drugs are co-administered with antiretroviral drugs, initial monotherapy with PAH medication is recommended, followed by an individualized use of combination therapy in patients who do not reach a low-risk proﬁle.
In patients with PAH associated with CTD, the same treatment algorithm as for patients with
IPAH is recommended
I
C
© ESC/ERS 2022
PAH-CTD, pulmonary arterial hypertension associated with connective tissue disease;
IPAH, idiopathic pulmonary arterial hypertension.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 16 — Recommendations for pulmonary arterial hypertension associated with human immunodeﬁciency virus infection
Recommendations
Classa
Levelb
In patients with PAH associated with HIV
infection, antiretroviral treatment according to current guidelines is recommended541,542
I
A
In patients with PAH associated with HIV
infection, initial monotherapy should be considered, followed by sequential combination if necessary, taking into consideration comorbidities and drug–drug interactions
IIa
C
© ESC/ERS 2022
HIV, Human immunodeﬁciency virus; PAH, pulmonary arterial hypertension.
aClass of recommendation.
bLevel of evidence.
3676
ESC/ERS Guidelines


<!-- PAGE 60 -->

### Page 60

7.4. Pulmonary arterial hypertension associated with portal hypertension
Pulmonary arterial hypertension associated with portal hypertension, commonly referred to as PoPH, develops in 2–6% of patients with portal hypertension, with or without liver disease. In PAH registries, PoPH represents 5–15% of the patients.543–545 Rarely, some patients with PoPH have portosystemic shunts in the absence of portal hypertension (congenital extrahepatic cavoportal shunts).546
However, PoPH is distinct from hepatopulmonary syndrome
(HPS), which is characterized by intrapulmonary vascular dilatations and hypoxaemia. Of note, HPS and PoPH can occur sequentially or concurrently in patients with portal hypertension.547
7.4.1. Diagnosis
The diagnosis of PoPH is based on the presence of otherwise unexplained pre-capillary PH in patients with portal hypertension or a portosystemic shunt. The diagnostic approach is the same as in other patients with suspected or newly detected PH. Transthoracic echocardiography is usually the ﬁrst non-invasive assessment in patients with suspected PH, and echocardiography is also recommended as a screening tool in patients evaluated for liver transplantation. As patients with liver disease often have an elevated CO, TRV tends to overestimate
PAP in these patients. Hence, RHC with comprehensive haemodynamic assessment is essential to conﬁrm the diagnosis of PH and to distinguish
PAH (with elevated PVR) from unclassiﬁed PH (with a normal PVR).
7.4.2. Therapy
Patients with unclassiﬁed PH (i.e. mPAP .20 mmHg, elevated CO,
and PVR ≤2.0 WU) should be regularly followed-up but should not be treated with drugs approved for PAH.
In patients with an established diagnosis of PoPH, treatment should follow the same general principles as in other patients with
PAH, taking into account the severity of underlying liver disease,
the indication for liver transplantation, and the potential effects of
PAH medication on gas exchange, which may deteriorate with vasodilators in patients with PoPH.548,549 All drugs approved for PAH can principally be used to treat patients with PoPH, bearing in mind that these patients are usually excluded from registration studies.
Nevertheless, various case series support the use of approved
PAH medication in patients with PoPH. The largest series published so far reported on 574 patients with PoPH treated with various PAH
drugs, mostly PDE5is or ERAs, alone and in combination.545 Most patients (56.8%) were in Child–Pugh class A at the time of PAH diagnosis. At the ﬁrst follow-up, which took place 4.5 months after starting treatment, improvements were seen in haemodynamics,
WHO-FC, 6MWD, and BNP/NT-proBNP; survival at 5 years was
51%. In patients presenting with mild liver disease, the main causes of death were PAH progression and malignancy, whereas complications of liver disease were the most common causes of death in patients with advanced liver disease. The 5 year survival of patients who underwent liver transplantation (n = 63) was 81%.
The only RCT dedicated to the treatment of PoPH was PORTICO,
a 12 week study that randomized 85 patients to macitentan (n = 43)
or placebo (n = 42).168 PORTICO met its primary endpoint, demonstrating a signiﬁcant reduction in PVR from baseline (ratio of geometric mean 0.65; 95% CI, 0.59–0.72; P , 0.0001). There were, however,
no differences between the two treatment groups in secondary outcome measures, including WHO-FC, 6MWD, and NT-proBNP.
7.4.2.1. Liver transplantation
Porto-pulmonary hypertension is not per se an indication for liver transplantation. Pulmonary arterial hypertension poses a major threat to patients who undergo liver transplantation when indicated for the severity of liver disease. In a historical series from the Mayo Clinic, severe PAH with mPAP ≥50 mmHg was associated with a 100% perioperative mortality rate. In patients with mPAP 35–50 mmHg and
PVR .3.0 WU, mortality was still 50%.550 In liver transplantation candidates with PAH, targeted medical therapy successfully improves haemodynamics and establishes eligibility for transplantation.545,551–
554 However, haemodynamic criteria for successful liver transplantation have not been ﬁrmly established. The International Liver
Transplant Society proposed haemodynamic targets of mPAP
,35 mmHg and PVR ,5 WU, or mPAP ≥35 mmHg and PVR ,3
WU in patients receiving PAH therapy, while acknowledging that these criteria need to be further validated.175 An mPAP ≥45 mmHg is regarded as an absolute contraindication to liver transplantation.175
In patients with PoPH who successfully underwent liver transplantation, de-escalation or discontinuation of PAH medication is often feasible, but this has to be performed on an individual basis.551,554
Recommendation Table 17 — Recommendations for pulmonary arterial hypertension associated with portal hypertension
Recommendations
Classa
Levelb
Echocardiography is recommended in patients with liver disease or portal hypertension with signs or symptoms suggestive of PH, and as a screening tool in patients evaluated for liver transplantation or transjugular portosystemic shunt
I
C
It is recommended that patients with PAH
associated with portal hypertension are referred to centres with expertise in managing both conditions
I
C
In patients with PAH associated with portal hypertension, initial monotherapy should be considered, followed by sequential combination if necessary, taking into consideration the underlying liver disease and indication for liver transplantation
IIa
C
Liver transplantation should be considered on an individual basis in patients with PAH associated with portal hypertension, as long as PVR is normal or near normal with PAH therapy
IIa
C
Drugs approved for PAH are not recommended for patients with portal hypertension and unclassiﬁed PH (i.e. elevated mPAP, high CO, and a normal PVR)
III
C
© ESC/ERS 2022
mPAP, mean pulmonary arterial pressure; CO, cardiac output; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PVR, pulmonary vascular resistance.
aClass of recommendation.
bLevel of evidence.
ESC/ERS Guidelines
3677


<!-- PAGE 61 -->

### Page 61

7.5. Pulmonary arterial hypertension associated with adult congenital heart disease
The presence of PH in adults with CHD has a negative impact on the natural course of CHD, and worsens clinical status and overall outcome.555 Pulmonary arterial hypertension associated with adult CHD
is included in group 1 of the PH clinical classiﬁcation (Table 6) and represents a heterogeneous patient population. Post-capillary PH in adult
CHD (e.g. systolic or diastolic, systemic, ventricular dysfunction in combination with shunt lesions or complex adult CHD, and systemic atrioventricular valve dysfunction) should be excluded to determine further management. A speciﬁc clinical classiﬁcation (Table 21) is provided to better characterize PAH associated with adult CHD. Some complex
CHDs are associated with congenital abnormalities of the pulmonary vascular tree leading to segmental PH. In segmental PH, one or more,
but not all, segments of the lung(s) are hypertensive and each hypertensive area may present with PH of different severity, while other parts of the lung vasculature may be hypoplastic. Pulmonary atresia with ventricular septal defect and systemic-to-pulmonary collaterals is the most frequent condition, but other complex CHDs may also lead to segmental PH.
Approximately 3–7% of patients with adult CHD will eventually develop PAH; it is more frequently encountered in females, and the incidence depends on the underlying lesion and increases with age and age at defect closure.556 The estimated prevalence of PAH
in patients after correcting a simple cardiac defect is 3%.557 The epidemiology of PAH associated with adult CHD is expected to change due to advances in diagnostic and therapeutic paediatric cardiology,
resulting in fewer patients with simple adult CHD and more patients with complex lesions and/or closed defects who develop PAH in adulthood.558
The clinical presentation of Eisenmenger syndrome, an advanced form of adult CHD-associated PAH, is characterized by the multiorgan effects of chronic hypoxaemia, including cyanosis, and haematological changes, including secondary erythrocytosis and thrombocytopenia;
the main symptoms are dyspnoea, fatigue, and syncope. Eisenmenger syndrome may also present with haemoptysis, chest pain, cerebrovascular accidents, brain abscesses, coagulation abnormalities, and sudden death. Patients with adult CHD and Down syndrome are at an increased risk of developing Eisenmenger syndrome.
7.5.1. Diagnosis and risk assessment
The diagnostic work-up of PAH associated with adult CHD should be based on the presence of symptoms and includes medical history, physical examination, PFTs, ABG, imaging (especially echocardiography), and exercise and laboratory testing. Of note, standard echocardiographic criteria for detecting PH may not be applicable in complex adult CHD.559 Right heart catheterization with compartmental oximetry for calculating pulmonary blood ﬂow/systemic blood ﬂow (Qp/Qs) is required to conﬁrm PAH diagnosis and guide therapeutic interventions. Thermodilution should be avoided in the presence of intracardiac shunts, and direct Fick is the most accurate method. Pulmonary vascular resistance may be overestimated due to erythrocytosis.560 Interpreting invasive haemodynamics (see Section 5.1.12) should be made in the context of multiparametric assessment of exercise capacity, laboratory testing, and imaging.
Predictors of worse outcomes in adult CHD-associated PAH are
WHO-FC III–IV, exercise intolerance assessed by 6MWD or peak
VO2, history of hospitalization for right HF, biomarkers (NT-proBNP
.500 pg/mL, C-reactive protein .10 mg/mL, high serum creatinine,
and low albumin levels), iron deﬁciency, and echocardiographic indices of RV dysfunction.559,561 When compared with patients with IPAH, patients with Eisenmenger syndrome may have a relatively stable longterm clinical course. The right ventricle is unloaded by the right-to-left shunt, sustaining CO at the expense of hypoxaemia and cyanosis.
However, due to immortal time bias, prognosis of Eisenmenger syndrome is not as favourable as previously thought.562
As in other forms of PAH, risk assessment is important to guide therapy, and speciﬁc risk factors have been described in Eisenmenger syndrome. A large multicentre study showed that mortality in adults with Eisenmenger syndrome was predicted by the presence of pretricuspid shunt, advancing age, low rest oxygen saturation, absence of sinus rhythm, and presence of pericardial effusion.563
Table 21
Clinical classiﬁcation of pulmonary arterial hypertension associated with congenital heart disease
(1) Eisenmenger syndrome
Includes all large intra- and extracardiac defects that begin as systemic-to-pulmonary shunts and progress to severely elevated
PVR and to reverse (pulmonary-to-systemic) or bidirectional shunting. Cyanosis, secondary erythrocytosis, and multiple organ involvement are usually present. Closing the defects is contraindicated.
(2) PAH associated with prevalent systemic-to-pulmonary shunts
• Correctablea
• Non-correctable
Include moderate-to-large defects. PVR is mildly to moderately increased and systemic-to-pulmonary shunting is still prevalent,
whereas cyanosis at rest is not a feature.
(3) PAH with small/coincidentalb defects
Markedly elevated PVR in the presence of cardiac defects considered haemodynamically non-signiﬁcant (usually ventricular septal defects
,1 cm and atrial septal defects ,2 cm of effective diameter assessed by echocardiography), which themselves do not account for the development of elevated PVR. The clinical picture is very similar to IPAH. Closing the defects is contraindicated.
(4) PAH after defect correction
Congenital heart disease is repaired, but PAH either persists immediately after correction or recurs/develops months or years after correction in the absence of signiﬁcant, post-operative,
haemodynamic lesions.
© ESC/ERS 2022
IPAH,
idiopathic pulmonary arterial hypertension;
PAH,
pulmonary arterial hypertension; PVR, pulmonary vascular resistance.
aWith surgery or intravascular percutaneous procedure, see also the Recommendation
Table 18 for shunt closure.
bThe size applies to adult patients. However, also in adults, the simple diameter may be insufﬁcient for deﬁning the haemodynamic relevance of the defect, and also the pressure gradient, the shunt size and direction, and the pulmonary-to-systemic ﬂows ratio should be considered.
3678
ESC/ERS Guidelines


<!-- PAGE 62 -->

### Page 62

7.5.2. Therapy
Outcomes in adult CHD-associated PAH have improved with the availability of new PAH therapies, advances in surgical and perioperative management, and a team-based, multidisciplinary approach in PH centres. These patients should be managed by specialized health professionals.
Patient education,
behavioural modiﬁcations, and social and psychological support are all important aspects of management.
Shunt closure (surgical or interventional) may only be considered in patients with prevalent systemic-to-pulmonary shunting without signiﬁcantly increased PVR. Criteria for defect closure based on Qp/Qs ratio and (baseline and/or after targeted PAH
treatment)
PVR
have been proposed by the
2020
ESC
Guidelines for the management of adult congenital heart disease.101 Decisions on shunt closure should not be made on haemodynamic numbers alone, and a multiparametric strategy should be followed. For instance, shunt closure is not indicated in the case of desaturation during exercise in the 6MWT or
CPET, or when there is secondary erythrocytosis suggesting dynamic reversal of shunt. There is no evidence for a long-term beneﬁt of a treat-and-repair approach in patients with adult
CHD-associated PAH with prevalent systemic-to-pulmonary shunts; therefore, there is a need for future prospective studies.564 Defect closure is contraindicated in all patients with
Eisenmenger syndrome, and may also adversely affect patients with small/coincidental defects that behave similarly to IPAH.565
There are no prospective data available on the usefulness of vasoreactivity testing, balloon closure testing, or lung biopsy for assessing operability and normalization of PVR after closure.566
Patients with adult CHD-associated PAH may present with clinical deterioration in different circumstances, such as arrhythmia, during non-cardiac surgery requiring general anaesthesia, dehydration or bleeding, thrombo-embolism, and lung infections. Surgeries should be limited to those deemed essential, and performed in specialized centres with anaesthetists experienced in adult CHD and PAH.
Endocarditis should be suspected in patients with sepsis, whereas a cerebral abscess should be excluded in those with neurological symptoms or new headache, especially in those with low oxygen saturations and complex anatomies. It is recommended to avoid strenuous exercise, but mild and moderate activities seem to be beneﬁcial.567 Patients should receive all recommended vaccinations and endocarditis prophylaxis in the presence of cyanosis. Although pregnant patients with left-to-right shunts and stable, well-controlled
PAH have tolerated pregnancy well under specialized care, pregnancy is still associated with both high maternal mortality and foetal complications in Eisenmenger syndrome and should be discouraged in this setting;568,569 hence, effective contraception is highly recommended. Levonorgestrel-based, long-acting, reversible contraception implants or intrauterine devices have been recommended for these patients.570
Secondary erythrocytosis is beneﬁcial for adequate oxygen transport and delivery, and routine phlebotomy should be avoided whenever possible. Symptoms of hyperviscosity in the presence of haematocrit .65% should be approached with appropriate hydration. Iron deﬁciency should be corrected. When i.v. iron supplementation is administered, special care should be taken to avoid air emboli during administration.571 Supplemental oxygen therapy has not been shown to impact survival.
Oral anticoagulant treatment with VKAs may be considered in patients with large PA aneurysms with thrombus, atrial arrhythmias,
and previous thrombo-embolic events, but with low bleeding risk.
In patients with very high Hb levels (.20 mg/dL), standard international normalized ratio measures are less accurate,
and citrate-adjusted blood bottles must be used. Regarding using novel oral anticoagulants (NOACs), a large, nationwide, German, adult
CHD
database
(including
106
NOAC-treated patients with
Eisenmenger syndrome) showed that NOAC users had higher longterm risk of bleeding, major adverse cardiovascular events, and mortality compared with those on VKAs, suggesting that initiating
NOACs should be reserved for experienced adult CHD centres,
carefully weighing potential beneﬁts and risks.572,573
Compared with other group 1 subgroups, limited data exist on the use of drugs approved for PAH in patients with adult CHD-associated
PAH. Bosentan improved 6MWD and decreased PVR in patients with
Eisenmenger syndrome in WHO-FC III.574 Patients with more complex lesions were less likely to respond to PAH therapies compared with patients with simple lesions. An RCT investigating the efﬁcacy of macitentan found no effect on 6MWD in a mixed cohort of patients with Eisenmenger syndrome (6MWD improved in both treatment and placebo arms), although decreases in NT-proBNP and PVR
were noted in the macitentan arm.575
Experiences with other ERAs and PDE5is have shown favourable functional and haemodynamic results in Eisenmenger syndrome.576
In a small, single-centre, pilot study, adding nebulized iloprost to a background of oral PAH therapy failed to improve 6MWD in
Eisenmenger syndrome.577 In case symptoms persist or in clinical deterioration, a sequential and symptom-orientated treatment strategy is recommended in Eisenmenger syndrome, starting with an oral
ERA (or PDE5i) and escalating therapy. Should symptoms not adequately improve with oral therapies, i.v./s.c. options should be proactively considered.578 There is a theoretical risk of paradoxical embolism in right-to-left shunt lesions with the presence of a central venous catheter for i.v. therapy; therefore, s.c. prostacyclin analogue infusion may be considered.
The effect of PAH therapies in patients with prevalent systemic-to-pulmonary shunts is less well established. Patients with small/coincidental defects should be treated with PAH medication.557 This is also the case for patients with PAH after defect correction who have increased mortality compared with those with
Eisenmenger syndrome.579 These patients were included in major
RCTs with PAH therapies and should be evaluated based on comprehensive risk assessment (Table 16).580 The effect of PAH therapies in patients with segmental PH remains a matter of debate.101,581
While some series have reported promising results, there have been cases where therapies were not tolerated.581 Similarly, using PAH
therapies in Fontan circulation has yielded conﬂicting results, and results of further studies are awaited.582–584
Heart–lung transplantation or LTx with heart surgery is an option in highly selected cases not responsive to medical treatment; however, it is limited by organ availability and lesion complexity.
Mortality is high during the ﬁrst year after surgery, especially after heart–lung transplantation, but remains relatively low thereafter.585
ESC/ERS Guidelines
3679


<!-- PAGE 63 -->

### Page 63

7.6. Pulmonary arterial hypertension associated with schistosomiasis
Schistosomiasis is one of the most common chronic infectious diseases worldwide, affecting around 200 million people.586,587
Schistosomiasis-associated PAH is present in 5% of patients with the hepatosplenic form of the disease.586 It is thus a leading cause of PAH, especially in some regions of South America, Africa, and
Asia.
Compared with patients with
IPAH,
patients with schistosomiasis-associated PAH present with higher CO and lower
PVR, and have a better survival.587 Registry data suggest that survival in schistosomiasis-associated PAH has improved in recent years with the use of PAH drugs.588
7.7. Pulmonary arterial hypertension with signs of venous/capillary involvement
The common risk factors, identical genetic substrate, and indistinguishable clinical presentations of PCH and PVOD necessitate their consideration as a single disease belonging to the group 1 PH spectrum of diseases (PAH with signs of venous/capillary involvement).1,425,589 In PVOD/PCH, post-capillary lesions affecting septal veins and pre-septal venules consist of loose, ﬁbrous remodelling of the intima that may totally occlude the lumen.1,425,589,590 These changes are frequently associated with PCH consisting of capillary
Recommendation Table 18 — Recommendations for shunt closure in patients with pulmonary–systemic
ﬂow ratio .1.5:1 based on calculated pulmonary vascular resistance
Recommendations
Classa
Levelb
In patients with an ASD, VSD, or PDA and a PVR
,3 WU, shunt closure is recommended
I
C
In patients with an ASD, VSD, or PDA and a PVR
of 3–5 WU, shunt closure should be considered
IIa
C
In patients with an ASD and a PVR .5 WU that declines to ,5 WU with PAH treatment, shunt closure may be considered
IIb
C
In patients with a VSD or PDA and a PVR .5 WU,
shunt closure may be considered after careful evaluation in specialized centres
IIb
C
In patients with an ASD and a PVR .5 WU
despite PAH treatment, shunt closure is not recommended
III
C
© ESC/ERS 2022
ASD, atrial septal defect; PAH, pulmonary arterial hypertension; PDA, patent ductus arteriosus; PVR, pulmonary vascular resistance; VSD, ventricular septal defect; WU,
Wood units.
Decisions on shunt closure should not be made on haemodynamic numbers alone; a multiparametric strategy should be followed (see Section 7.5.2).
aClass of recommendation.
bLevel of evidence.
Recommendation Table 19 — Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease
Recommendations
Classa
Levelb
Risk assessment
Risk assessment is recommended for patients with persistent PAH after defect closure
I
C
Risk assessment should be considered in patients with Eisenmenger syndrome
IIa
C
Treatment
Bosentan is recommended in symptomatic patients with Eisenmenger syndrome to improve exercise capacity574
I
B
In patients with Eisenmenger syndrome, the use of supplemental oxygen therapy should be considered in cases where it consistently increases arterial oxygen saturation and reduces symptoms
IIa
C
Supplemental iron treatment should be considered in patients with iron deﬁciency
IIa
C
In patients with adult CHD, including Eisenmenger syndrome, other ERAs, PDE5is, riociguat,
prostacyclin analogues, and prostacyclin receptor agonists should be considered
IIa
C
Continued
In patients with PAH after corrected adult CHD,
initial oral combination therapy with drugs approved for PAH should be considered for patients at low and intermediate risk, while initial combination therapy including i.v./s.c. prostacyclin analogues should be considered for patients at high risk
IIa
Cc
In patients with adult CHD, including Eisenmenger syndrome, sequential combination therapy should be considered if patients do not meet treatment goals
IIa
C
In the absence of signiﬁcant haemoptysis, oral anticoagulant treatment may be considered in patients with Eisenmenger syndrome with pulmonary artery thrombosis
IIb
C
In women with Eisenmenger syndrome,
pregnancy is not recommended
III
C
In patients with Eisenmenger syndrome, routine phlebotomy to lower elevated haematocrit is not recommended
III
C
© ESC/ERS 2022
CHD, congenital heart disease; ERA, endothelin receptor antagonist; i.v., intravenous;
PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; s.c.,
subcutaneous.
aClass of recommendation.
bLevel of evidence.
cLevel of evidence differs from the 2020 ESC Guidelines for the management of adult congenital heart disease because the number of patients with adult CHD included in the AMBITION study was very low.
3680
ESC/ERS Guidelines


<!-- PAGE 64 -->

### Page 64

ectasia and proliferation, with doubling and tripling of the alveolar septal capillary layers that may be focally distributed within the alveolar interstitium.425,590
The proportion of patients with IPAH that fulﬁl the criteria for
PVOD/PCH is ≏10%, resulting in a lowest estimate of PVOD/PCH
incidence and prevalence of ,1 case/million.425 In contrast to
IPAH, there is a male predominance in PVOD/PCH and its prognosis is worse.425,589,591 Familial PVOD/PCH typically occurs in the young siblings of one generation, with unaffected and sometimes consanguineous parents, indicating that the disease segregates as a recessive trait.158,425,591 Biallelic mutations in the EIF2AK4 gene cause heritable PVOD/PCH.158 In addition, PVOD/PCH can complicate the course of associated conditions, such as SSc,425 or be associated with exposure to environmental triggers, such as alkylating agents (cyclophosphamide, mitomycin C)34 and solvents
(trichloroethylene).38
7.7.1. Diagnosis
Most patients complain of non-speciﬁc dyspnoea on exertion and fatigue.590 Physical examination may reveal digital clubbing and bibasal crackles on lung auscultation.590 Pulmonary arterial hypertension and PVOD/PCH share the same haemodynamic proﬁle as precapillary PH.590,591 The PAWP is not elevated because the pulmonary vascular changes occur in small venulae and capillaries, while the
LA ﬁlling pressure remains normal.590,591 A diagnosis of PVOD/PCH
is based on the results of tests suggesting venous post-capillary involvement, chronic interstitial pulmonary oedema, and capillary proliferation.1,590,591 These tests include PFTs (decreased DLCO,
frequently ,50% theoretical values), ABG (hypoxaemia), and non-contrast chest CT (subpleural thickened septal lines, centrilobular ground-glass opacities,
and mediastinal lymphadenopathy).1,425,589,591,592 Importantly, these patients are at risk of drug-induced pulmonary oedema with PAH therapy, a ﬁnding suggestive of PVOD/PCH.425,591 Detecting biallelic EIF2AK4 mutations is sufﬁcient to conﬁrm a
diagnosis of heritable
PVOD/
PCH.158,591,592 Lung biopsy is hazardous in PH and is not recommended for diagnosing PVOD/PCH.1,425
7.7.2. Therapy
There is no established medical therapy for PVOD/PCH.425
Compared with IPAH, PVOD/PCH has a poor prognosis and limited response to PAH therapy, with a risk of pulmonary oedema due to pulmonary venous obstruction.425,591 However, there are reports of incomplete and transient clinical improvement in individual patients with PVOD/PCH treated with PAH therapy, which should be used with great caution in this setting.425,591 Diuretics, oxygen therapy, and slow titration of PAH therapy can be used on an individual basis.425 Therefore, therapy for PVOD/PCH should be undertaken at centres with extensive experience in managing
PH, and patients should be fully informed about the risks.425
Anecdotal reports suggest a potential beneﬁt of immunomodulatory treatments, but this approach requires further study.593
The only curative therapy for PVOD/PCH is LTx, and eligible patients should be referred to a transplant centre for evaluation upon diagnosis.425,591 Pathological examination of the explanted lungs will conﬁrm the diagnosis.590
7.8. Paediatric pulmonary hypertension
Pulmonary hypertension may present at all ages, including in infants and children. Pulmonary hypertension in childhood shares many common features with PH in adulthood; however, there are also important differences, which concern epidemiology, aetiology, genetic background, age-dependent diagnostic and treatment approaches,
and disease monitoring. An important and conceptually distinctive feature of paediatric PH is injury to developing foetal, neonatal, or paediatric lung circulation.
7.8.1. Epidemiology and classiﬁcation
The reported annual incident rate for paediatric PH is 64/million children.594 The distribution of the various aetiologies of PH in childhood differs from PH in adulthood.594–596 Pulmonary arterial hypertension is the most frequent type of PH in children, with the vast majority (82%) of cases being infants with transient PAH (i.e.
PPHN or repairable cardiac shunt defects). Of the remaining children with PAH, most have either IPAH, HPAH, or irreversible
CHD-associated PAH. The reported incidences of IPAH/HPAH
and (non-transient) CHD-associated PAH are 0.7 and 2.2/million children, respectively, with a prevalence of 4.4 and 15.6/million children, respectively.594 Other conditions associated with PAH
(Table 6) do occur in children but are rare.
Another signiﬁcant proportion (34–49%) of children with nontransient PH are neonates and infants with PH associated with respiratory disease, especially developmental lung diseases, including bronchopulmonary dysplasia (BPD), congenital diaphragmatic hernia
(CDH), and congenital pulmonary vascular abnormalities.594–598
These children form a prominent and distinctive group in paediatric
PH and are currently classiﬁed as PH group 3 associated with
Recommendation Table 20 — Recommendations for pulmonary arterial hypertension with signs of venous/
capillary involvement
Recommendations
Classa
Levelb
A combination of clinical and radiological ﬁndings,
ABG, PFTs, and genetic testing is recommended to diagnose PAH with signs of venous and/or capillary involvement (PVOD/PCH)591
I
A
Identiﬁcation of biallelic EIF2AK4 mutations is recommended to conﬁrm a diagnosis of heritable
PVOD/PCH158,591
I
A
Referral of eligible patients with PVOD/PCH to a transplant centre for evaluation is recommended as soon as the diagnosis is established
I
C
In patients with PVOD/PCH, the use of drugs approved for PAH may be considered with careful monitoring of clinical symptoms and gas exchange
IIb
C
Lung biopsy is not recommended to conﬁrm a diagnosis of PVOD/PCH
III
C
© ESC/ERS 2022
ABG, arterial blood gas analysis; PAH, pulmonary arterial hypertension; PCH,
pulmonary capillary haemangiomatosis; PFT, pulmonary function test; PVOD,
pulmonary veno-occlusive disease.
aClass of recommendation.
bLevel of evidence.
ESC/ERS Guidelines
3681


<!-- PAGE 65 -->

### Page 65

developmental lung disease (Table 6; Table S7). A signiﬁcant and growing proportion of children with PH associated with respiratory disease is made up of pre-term infants with BPD. Also, newly recognized genetic developmental lung disorders—including alveolar capillary dysplasia, TBX4-mutation-related lung disorders, and surfactant abnormalities—are currently classiﬁed in this category (Figure 10).599
Another distinctive feature of PH in children is the high burden of genetic disorders. Childhood PH is often associated with chromosomal, genetic, and syndromic anomalies (11–52%). Like in adults,
gene mutations implicated in the pathogenesis of HPAH are found in 20–30% of sporadic cases, where paediatric HPAH seems to be characterized by an enrichment in
TBX4
and
ACVRL1
Comorbidities
Risk factors for outcome
Risk assessment tool
Risk assessment tool
Therapy
Treatment algorithm
Treatment algorithm
Evidence
Diabetes
Hypertension
Heart failure
Renal failure
Chromosomal abnormalities
Syndromic features
+/-
Cohort studies
+++
RCTs
Diagnosis
RHC+AVTa
Diagnostic algorithm
RHC+AVTa
Diagnostic algorithm
~
~
~
Child
Adult
A
Infant
PPHN
IPAH/HPAH
PAH-CHD
PAH-CTD
PoPH
PAH-HIV
IPAH/HPAH
PAH-CHD
1
Congenital PVS
Left heart failure
Congenital MS
Cardiomyopathy
2
Metabolic disorders
Haematologic diseases
Systemic diseases
5
Developmental lung diseases
Bronchopulmonary dysplasia
Congenital diaphragmatic hernia
Alveolar capillary dysplasia
Trisomy 21
chILD
Hypoventilation syndrome
COPD
ILD
3
Congenital PS
Congenital PS
CTEPH
4
Congenital malformations
Optimize respiratory support
Nutritional support
GORD treatment
Inhaled NO,
PAH drugs
Respiratory support
Suprasystemic PH
Necrotizing enterocolitis
Steroids
ASD/VSD
Echocardiography
RHC?
Extremely limited
Simple CHD
Complex CHD
PH classification
Figure 10 Neonatal and paediatric vs. adult pulmonary hypertension. ASD, atrial septal defect; AVT, acute vasoreactivity testing; CHD, congenital heart disease; COPD, chronic obstructive pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; GORD, gastro-oesophageal reﬂux disease; HPAH, heritable pulmonary arterial hypertension; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; MS, mitral stenosis; NO, nitric oxide; PAH, pulmonary arterial hypertension; PAH-CHD, PAH associated with congenital heart disease; PAH-CTD, PAH associated with connective tissue disease; PAH-HIV, PAH associated with HIV infection; PH, pulmonary hypertension; PoPH, porto-pulmonary hypertension; PPHN,
persistent pulmonary hypertension of the newborn; PS, pulmonary arterial stenosis; PVS, pulmonary vein stenosis; RCT, randomized controlled trial;
RHC, right heart catheterization; VSD, ventricular septal defect. aIn patients with idiopathic, heritable or drug-associated PAH. Pulmonary hypertension in neonates and infants signiﬁcantly differs in aetiology, pathophysiology, risk assessment, and treatment from older children and adults, while PH in older children has more similarities with PH in adults.
3682
ESC/ERS Guidelines


<!-- PAGE 66 -->

### Page 66

variations.600,601 Additionally, 17% of children with PAH have other disorders known to be associated with PAH, including trisomy 21.
Finally, 23% of children with PAH have copy number variations not previously associated with PH.600,602,603
Given the frequent association of paediatric PAH with chromosomal, genetic, and syndromic anomalies (for which the mechanistic basis for PAH is generally uncertain), genetic testing may be considered for deﬁning aetiology and comorbidities, stratifying risk, and identifying family members at risk; however, this should be after appropriate expert genetic counselling for the child and family (see
Section 5.1.13).
The clinical PH classiﬁcation (Table 6) is also followed for paediatric PH. To improve applicability of this classiﬁcation in infants and children with PH, it has been adapted to give room to PH associated with various congenital cardiovascular and pulmonary diseases or speciﬁc paediatric conditions (Tables S5–S8).599
7.8.2. Diagnosis and risk assessment
Historically, the deﬁnition of PH in children aged .3 months has been the same as in adults. The deﬁnition for PH has now been redeﬁned to mPAP .20 mmHg in adults as well as in children. The impact of an mPAP 21–24 mmHg on outcomes in children is unknown.
However, in the interest of consistency and to facilitate transition from paediatric to adult PH care, it is recommended that the updated deﬁnition for PH also be followed in children. No treatment recommendations currently exist for this group of children (mPAP 21–
24 mmHg).
Regarding the newly introduced criterion to include PVR .2 WU
to identify pre-capillary PH in adults, PVR had previously been included in the deﬁnition for PAH in children. In children, blood ﬂows are traditionally indexed assuming that systemic and pulmonary blood ﬂows change proportionally with body size, while the transpulmonary pressure gradient does not. Since blood ﬂow is the denominator in the equation for calculating PVR, the need for indexing of
PVR in children is emphasized, and the criterion of pulmonary vascular resistance index (PVRI) ≥3 WU·m2 in the deﬁnition for PAH in children remains unchanged.599
Since the aetiology of paediatric PH is very diverse, a methodical and comprehensive diagnostic approach is crucial to reach an accurate diagnosis and treatment plan. As in adults, IPAH is a diagnosis ‘per exclusion’. A diagnostic work-up, similar to that in adults but customized for paediatric PH, is recommended.599 Pre-term infants with
BPD should be screened for PH, since PH is prevalent in this population and seriously affects outcome.604
Also in children, RHC is the gold standard for deﬁnitively diagnosing and establishing the nature of PH, and provides important data for stratifying risk.604a,605 To identify those suitable for high-dose CCB
treatment, acute vasoreactivity testing is recommended in children with IPAH/HPAH. The criteria used in adults for a positive acute response have identiﬁed children who will show sustained beneﬁt from
CCB therapy; however, these criteria do not deﬁne reversibility of
PAH or operability in children with CHD. Since RHC in children with PH may be associated with major complications (in 1–3% of cases, especially in young infants and those in worse clinical condition),
risks and beneﬁts have to be balanced in the individual child.605 Heart catheterization in children with PAH should be exclusively performed in experienced paediatric PH centres. Indications for repeated RHC in children with PH are currently not well deﬁned.
Treatment of children with PAH is based on risk stratiﬁcation.599
Predictors of worse outcome in paediatric PAH are similar to those in adults, and include clinical evidence of RV failure, progression of symptoms, WHO-FC III–IV, certain echocardiographic parameters
(e.g. TAPSE), and elevated serum NT-proBNP. A 6MWD ,350 m has also been suggested as a predictor of worse outcome in paediatric PH, but its value in young children is less established. Further prognosticators identiﬁed in paediatric PAH are failure to thrive and haemodynamic variables, such as RAP .10 mmHg, the ratio of mean pulmonary-to-systemic blood pressure .0.75, and PVRI
.20 WU·m2.602,606,607 Paediatric risk-assessment tools based on these parameters have been retrospectively validated in observational paediatric registries.599,604a
7.8.3. Therapy
The ultimate goal of treatment should be to improve survival and facilitate normal childhood activities without limitations. In the absence of RCTs in paediatric PAH, recommended treatment algorithms are extrapolated from those in adults and enhanced with data from observational studies in children with PAH.599
Observational cohort studies support treatment algorithms designed for adults to be used for children (including the superiority of combination therapy over monotherapy).608 Drugs investigated in children, with or without formal approval by the European
Medicines Agency (EMA) for treating children with PAH, are shown in Table 22.
A paediatric treatment algorithm, derived from that for adults, is based on risk stratiﬁcation, recommending general measures, highdose CCB therapy for responders to acute vasoreactivity testing
(where close follow-up is mandatory, as some patients may fail longterm therapy), oral or inhaled combination therapy for children at low risk, and combination therapy with i.v./s.c. prostacyclin analogues for those at high risk.599
In the case of insufﬁcient response to recommended drug therapy,
or when drugs are unavailable, a Potts shunt (a surgical or interventional connection between the left PA and the descending aorta),
BAS, or LTx may be considered in children with severe PH (see
Sections 6.3.6.1 and 6.3.8).599 Reported clinical experience with
Potts shunts is limited to just over 100 patients, predominantly children, with a mortality of 12–25% and long-term clinical beneﬁt in a subset of children with long-term follow-up.456–459
Monitoring of treatment effect and disease course is pivotal in managing all patients with PAH (adults and in children). In children with PAH, clinical risk scores including WHO-FC, TAPSE, and serum
NT-proBNP are potential treatment targets for goal-orientated treatment.604a,609
Contemporary treatment algorithms for infants with PPHN have been proposed but are outside the scope of these guidelines.610
The recommendations discussed above apply to children with
PAH, whereas the speciﬁc group of infants with neonatal PVD, mostly classiﬁed as PH associated with developmental lung disease and with heterogeneous aetiology, require a distinct and customized approach (Figure 10).
In pre-term infants with BPD and PH, the underlying lung disease should primarily be treated. Frequently, these infants are additionally
ESC/ERS Guidelines
3683


<!-- PAGE 67 -->

### Page 67

Table 22
Use of pulmonary arterial hypertension therapies in children
Drug
Paediatric study data
European Medicines Agency approval for use in children with PAH
Ref.
Phosphodiesterase 5 inhibitors (oral)
Sildenaﬁl
RCT, open-label extension: tolerability, efﬁcacy
Yes, for ≥1 year of age
Recommended dosing:
,20 kg: 30 mg/day in 3 doses; ≥20 kg: 60 mg/
day in 3 doses
Avoid higher dosing in children (.3 mg/kg/day)
613,614
Tadalaﬁl
RCT, open-label: safety, tolerability, pharmacokinetics
No
Suggested dosing:
0.5–1 mg/kg/day in one dose
Max: 40 mg/day
Evaluated only in children aged .3 years
615,616
Endothelin receptor antagonists (oral)
Bosentan
Open-label, uncontrolled: safety, tolerability, pharmacokinetics,
efﬁcacy
Yes, for ≥1 year of age
Paediatric formulation
Recommended dosing:
4 mg/kg/day in 2 doses
Max: 250 mg/day
617–620
Ambrisentan
Open-label, uncontrolled: safety, tolerability, pharmacokinetics
Yes, for children aged .8 years
Recommended dosing:
2.5–10 mg/day in one dose
621,622
Macitentan
Insufﬁcient data in children
Open-label, ongoing: efﬁcacy, safety, pharmacokinetics in children aged 2–18 years
No
Prostacyclin analogues (i.v./s.c.)
Epoprostenol i.v.
Cohort studies, retrospective
No
Suggested dosing:
Starting dose: 1–2 ng/kg/min without a known maximum
In children, a stable dose is usually 40–80 ng/kg/min
Dose increases may be required
623–626
Treprostinil i.v./
s.c.
Cohort studies, retrospective: pharmacokinetics
No
Suggested dosing:
Starting dose: 2 ng/kg/min without a known maximum
In children, a stable dose is usually 50–100 ng/kg/min
Dose increases may be required
624,626,627
Other
Iloprost
(inhaled)
Insufﬁcient data in children
Small case series, retrospective
No
Selexipag (oral)
Insufﬁcient data in children
Randomized, placebo-controlled, add-on, ongoing: safety,
tolerability, pharmacokinetics in children aged 2–18 years
No
Riociguat (oral)
Insufﬁcient data in children
Open-label, ongoing: safety, tolerability, pharmacokinetics in children aged 6–18 years
No
© ESC/ERS 2022
i.v., intravenous; PAH, pulmonary arterial hypertension; RCT, randomized controlled trial; s.c., subcutaneous.
3684
ESC/ERS Guidelines


<!-- PAGE 68 -->

### Page 68

treated with therapies for PAH, including sildenaﬁl and bosentan;
however, these are not approved by the EMA for use in infants with group 3 PH and developmental lung diseases (BPD, CDH).
Their effects on outcomes in this population are unclear, and data enabling robust treatment recommendations are lacking. These children should be treated by multidisciplinary teams involving cardiologists, neonatologists, pulmonologists, and nutritionists. Pulmonary hypertension in these infants may disappear with lung healing, although long-term cardiovascular sequelae have been reported.611,612
8. Pulmonary hypertension associated with left heart disease
(group 2)
8.1. Deﬁnition, prognosis, and pathophysiology
Among patients with LHD, PH and RV dysfunction are frequently present and associated with high mortality.47 This includes patients with HF with reduced, mildly reduced, or preserved ejection fraction
(HFrEF, HFmrEF, or HFpEF), left-sided valvular heart disease, and congenital/acquired cardiovascular conditions leading to postcapillary PH.13,631–635 Arguably, PH-LHD represents the most prevalent form of PH, accounting for 65–80% of cases.47
Consistent with the general deﬁnitions of PH, PH-LHD (group 2
PH) is deﬁned by an mPAP .20 mmHg and a PAWP .15 mmHg.
Within this haemodynamic condition of post-capillary PH, IpcPH is deﬁned by PVR ≤2 WU and CpcPH by PVR .2 WU (Table 5).
The diastolic pressure gradient (DPG) (calculated as the difference between dPAP and PAWP) is no longer used to distinguish between
IpcPH and CpcPH because of conﬂicting data on prognostication in
LHD.142
Across the spectrum of LHD, increases in PAP and PVR are associated with an increased disease burden and a worse outcome.13,631,633,635 In a large patient cohort—predominantly with post-capillary PH—a PVR ≥2.2 WU was associated with adverse outcomes and considered abnormal.13 However, even within this subgroup of patients with LHD and CpcPH, the risk of mortality increases with progressive elevation in PVR. In patients with advanced
HFrEF and those with HFpEF or valvular heart disease, a PVR
.5 WU carries additional prognostic information and is considered clinically meaningful by physicians.142,450,631–639 Elevated PVR also appears to be associated with decreased survival in special situations,
such as in patients undergoing interventions for correcting valvular heart disease,634 heart transplantation,142,633 or LVAD implantation.142,637 Based on available data, a PVR .5 WU may indicate a severe pre-capillary component, the presence of which may prompt physicians to refer patients to PH centres for specialized care.
The prevalence of PH in patients with LHD is difﬁcult to assess and depends on the methodology of diagnostic testing (echocardiography or invasive haemodynamics), cut-off values used to deﬁne
PH, and populations studied. Observational studies suggest an estimated prevalence of PH of 40–72% in patients with HFrEF and
36–83% in those with HFpEF.48,639–643 When PVR is used to deﬁne
Recommendation Table 21 — Recommendations for paediatric pulmonary hypertension
Recommendations
Classa
Levelb
Children
It is recommended to perform the diagnostic work-up, including RHC and acute vasoreactivity testing, and treat children with PH at centres with speciﬁc expertise in paediatric PH
I
C
In children with PH, a comprehensive work-up for conﬁrming diagnosis and speciﬁc aetiology is recommended (similar to that in adults, but adapted for age)
I
C
For conﬁrming PH diagnosis, RHC is recommended,
preferably before initiating any PAH therapy
I
C
In children with IPAH/HPAH, acute vasoreactivity testing is recommended to detect those who may beneﬁt from CCB therapy
I
C
It is recommended to similarly deﬁne a positive response to acute vasoreactivity testing in children and adults by a reduction in mPAP ≥10 mmHg to reach an absolute value of mPAP ≤40 mmHg,
with an increased or unchanged CO
I
C
In children with PAH, a therapeutic strategy based on risk stratiﬁcation and treatment response is recommended, extrapolated from that in adults but adapted for age
I
C
It is recommended to monitor the treatment response in children with PAH by serially assessing a panel of data derived from clinical assessment,
echocardiographic evaluation, biochemical markers, and exercise tolerance tests
I
C
Achieving and maintaining a low-risk proﬁle should be considered as an adequate treatment response for children with PAH
IIa
C
Infants
It is recommended to screen infants with bronchopulmonary dysplasia for PH628,629
I
B
In infants with (or at risk of) bronchopulmonary dysplasia and PH, treating lung disease—including hypoxia, aspiration, and structural airway disease
—and optimizing respiratory support is recommended before initiating PAH therapy630
I
B
Continued
In neonates and infants, a diagnostic and therapeutic approach to PH distinct from that in older children and adults should be considered,
given the frequent association with developmental vascular and parenchymal lung disease
IIa
C
© ESC/ERS 2022
CCB, calcium channel blocker; CO, cardiac output; HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; RHC, right heart catheterization.
aClass of recommendation.
bLevel of evidence.
ESC/ERS Guidelines
3685


<!-- PAGE 69 -->

### Page 69

a pre-capillary component in patients with HF and post-capillary PH,
≏20–30% of patients are categorized as having CpcPH.47,644,645 In patients with valvular heart disease, echocardiographic studies have shown that PH is present in up to 65% of patients with symptomatic aortic stenosis,646–651 while virtually all patients with severe mitral valve stenosis develop PH,652 which can also be found in most patients with signiﬁcant degenerative or functional mitral regurgitation.
The pathophysiology of PH-LHD combines several mechanisms
(Figure 11): (1) an initial passive increase in LV ﬁlling pressures and backward transmission into the pulmonary circulation; (2) PA
Variable degree of pulmonary congestion, vasoconstriction, vascular remodelling
Left ventricular phenotype
Right ventricular phenotype
Pulmonary vascular disease
Pulmonary congestion
No PH
IpcPH
CpcPHa
HFrEF
Aortic valve
HFmrEF
LA pressure
Remodelling
Right heart strain
Congestion
HFpEF
Mitral valve
EF ≤40%
Stenosis/Regurgitation 
EF 41–49%
EF ≥50%
Heart failure/cardiomyopathy
Valvular heart disease
Controlled
LHD
LA dysfunction
Vasoconstriction
Arteriolar
RV dysfunction
Venous
RV–PA 
uncoupling
LA pressure (mmHg)
LA volume (ml)
20
15
5
10
20
40
60
80
100
120
Figure 11 Pathophysiology of pulmonary hypertension associated with left heart disease (group 2). CpcPH, combined post- and pre-capillary pulmonary hypertension; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IpcPH, isolated post-capillary pulmonary hypertension; LA, left atrial; LHD, left heart disease; RV, right ventricle/right ventricular; PA, pulmonary artery; PH, pulmonary hypertension. aCpcPH is deﬁned by post-capillary PH and PVR .2 WU; a PVR .5 WU may be considered a severe pre-capillary component.
3686
ESC/ERS Guidelines


<!-- PAGE 70 -->

### Page 70

endothelial dysfunction (including vasoconstriction); (3) vascular remodelling (which may occur in both venules and/or arterioles); (4)
RV dilatation/dysfunction and functional TR;653–656 and (5) altered
RV–PA coupling.655–657 The haemodynamic proﬁle of CpcPH vs.
IpcPH and elevated PVR reﬂects pulmonary vascular abnormalities,
which contribute to an increased RV afterload. Resulting dysfunction of the RV is frequent and associated with a worse prognosis in patients with PH-LHD. In HFpEF, where RV dysfunction may occur via distinct mechanisms (Figure S1), deterioration of RV, but not LV
systolic function, has been observed over time, and both prevalent and incident RV dysfunction are predictors of mortality.658
The occurrence of PH in patients with LHD may also be due to other causes, including undetected CTEPH or PAH. Further, respiratory comorbidities such as COPD and sleep apnoea are also common in patients with LHD and may contribute to PH and impact prognosis. Patients with HFpEF and PH associated with HFpEF75,76
may also present with a low DLCO, which is an independent predictor of outcome.75
8.2. Diagnosis
In patients with LHD, symptoms (e.g. exertional dyspnoea) and physical signs of PH (e.g. peripheral oedema) frequently overlap with those of the underlying left heart condition and are mostly nonspeciﬁc. However, while pulmonary congestion or pleural effusion indicate LHD as the underlying cause of PH, other features may suggest the presence of relevant PH (see Section 5.1.1).
Routine diagnostic tests including BNP/NT-proBNP, ECG, and echocardiography may show signs of underlying LHD, but may also indicate PH. While BNP/NT-proBNP cannot discriminate between left- or right-sided HF, ECG ﬁndings such as right axis deviation or
RV strain may suggest the presence of PH in patients with LHD.
Echocardiography can diagnose HFrEF and HFpEF; identify speciﬁc cardiac conditions, including those with restrictive ﬁlling pattern;
and diagnose additional valvular heart disease; it may also detect elevated sPAP and other features of PH (RA area, PA enlargement, RV/
LV ratio, LV eccentricity index, RV forming the apex), leading to an echocardiographic probability of PH (see Section 5.1.5). A stepwise,
composite echocardiographic score may discriminate pre- vs. postcapillary PH and predict PVD in patients with LHD.659,660
Additional information may be gathered from further testing, including biomarkers, imaging-derived markers of RV dysfunction, and
CPET-derived variables.142
Given the complexity and variability of cardiopulmonary haemodynamics in patients with LHD, the distinction between post- and pre-capillary PH and the diagnosis of PH-LHD vs. other forms of
PH can be challenging. Diagnostic clues in the evaluation of suspected
PH in LHD include: (1) diagnosis and control of the underlying LHD;
(2) evaluation for PH and patient phenotyping; and (3) invasive haemodynamic evaluation, when indicated.
8.2.1. Diagnosis and control of the underlying left heart disease
Patients with suspected PH-LHD will have an established diagnosis of
LHD, such as HFrEF/HFmrEF, HFpEF, valvular heart disease, and/or
CHD. The distinction between PH associated with HFpEF and other forms of PH (e.g. PAH, CTEPH) may be challenging, particularly given the increased burden of cardiovascular comorbidities in real-world
PAH populations.142,450,661 In this context, validated scores for diagnosing HFpEF (HFA-PEFF, H2FPEF)16,662,663 may be helpful for detecting it as an underlying condition in PH, and the presence or absence of risk factors for PAH or CTEPH should be determined.
Patients with signs of predominant RV strain and/or PH should be further evaluated. Patients should be assessed or reassessed when they are fully recompensated and in a clinically stable condition.
8.2.2. Evaluation of pulmonary hypertension and patient phenotyping
Patients with LHD and suspected PH should be evaluated following the diagnostic strategy for PH (see Section 5). This requires identifying clinical features and a multimodal approach using non-invasive diagnostic tests such as echocardiography, ECG, and BNP/
NT-proBNP levels. In the presence of mild PH and predominant
LHD, no further testing may be necessary. Otherwise, CTEPH and signiﬁcant lung disease should be ruled out by V/Q scan and PFTs,
and additional cardiac imaging including cMRI may be considered in selected cases. For phenotyping, a combination of variables may help to determine the likelihood of LHD, and HFpEF in particular,
vs. other causes of PH (Table 23). Pulmonary hypertension associated with left heart disease is likely in the presence of known cardiac disease, multiple cardiovascular comorbidities/risk factors, atrial
ﬁbrillation at diagnosis, and speciﬁc imaging ﬁndings (LV hypertrophy,
increased LA size, and reduced LA strain). Although exercise echocardiography has been proposed to uncover HFpEF, it is unable to diagnose or classify PH in this context. A combination of clinical ﬁndings and phenotyping is required to decide about the need for further invasive assessment.
8.2.3. Invasive assessment of haemodynamics
The decision to perform cardiac catheterization and to invasively assess cardiopulmonary haemodynamics should depend on the presence of an intermediate to high echocardiographic probability of
PH, and should be determined by the need to obtain relevant information for prognostication or management. In patients with a high likelihood of LHD as the main cause of PH, or with established underlying LHD and mild PH (Table 23), invasive assessment for
PH is usually not indicated. Indications for RHC in LHD include:
(1) suspected PAH or CTEPH; (2) suspected CpcPH with a severe pre-capillary component, where further information will aid phenotyping and treatment decisions (Figure S2); and (3) advanced HF and evaluation for heart transplantation. While several haemodynamic measures (mPAP, PVR, pulmonary arterial compliance [PAC], transpulmonary pressure gradient, and DPG) are associated with outcomes in PH-LHD,142,632,635 the most robust and consistent data are available for PVR. Invasive assessment should be conducted in experienced centres, when management of the underlying LHD has been optimized and patients are in a clinically stable condition.
With respect to respiratory variations of intrathoracic pressures,
all pressure readings should be taken at end-expiration.
Additional testing during RHC may be useful for distinguishing between PAH and HFpEF,18,23,664–669 and to uncover LHD in patients with a high likelihood of PH-LHD and normal resting PAWP;670–673
both exercise testing and ﬂuid challenge may be considered in special situations (see Section 5.1.12). Conditions associated with reduced
LV diastolic compliance or valvular heart disease may be associated
ESC/ERS Guidelines
3687


<!-- PAGE 71 -->

### Page 71

with a rapid increase in PAWP when challenged with increased systemic venous return.674 While the upper limit of normal remains controversial,142,143,665,667 a PAWP cut-off of .18 mmHg has been suggested to identify HFpEF as the underlying cause of PH, despite normal PAWP at baseline.143 While this may help to classify PH,
therapeutic consequences of such testing remain to be determined.
As differentiating between severe PH associated with HFpEF and
IPAH with cardiac comorbidities is challenging, patients with an unclear diagnosis, particularly those with a predominant pre-capillary component (e.g. PVR .5 WU), should be referred to a PH centre for individualized management.
8.3. Therapy
The primary strategy in managing PH-LHD is optimizing treatment of the underlying cardiac disease. Nevertheless, a pathophysiological sequence ranging from left-sided heart disease via pulmonary circulation to chronic right heart strain (at rest or exercise) is present in many patients.47 Since deterioration of RV function over time is associated with poor outcomes in HFpEF,658 preserving RV function should be considered an important treatment goal. Diuretics remain the cornerstone of medical therapy in the presence of ﬂuid retention due to PH-LHD.
There is limited and conﬂicting evidence for the use of drugs approved for PAH in patients with group 2 PH. Some medications may have variable and potentially detrimental effects in such patients and are therefore not indicated in PH-LHD. Management strategies for PH in various left heart aetiologies are described below.
8.3.1. Pulmonary hypertension associated with left-sided heart failure
8.3.1.1. Heart failure with reduced ejection fraction
Patients with HFrEF or HFmrEF require guideline-directed treatment including established medical and interventional therapies.27
In patients with advanced HFrEF, implanting an LVAD may signiﬁcantly reduce or even normalize mPAP,675 although this is not achieved in all patients,676 and an increased DPG emerged as a negative prognostic factor after LVAD implantation.677 With regards to
PAH drugs, bosentan was assessed in an RCT of patients with PH
associated with HFrEF,678 showing no efﬁcacy but an increase in adverse events compared with placebo, predominantly related to
ﬂuid retention.
Small studies have suggested that sildenaﬁl may improve haemodynamics and exercise capacity in PH and
HFrEF,679–681 but RCTs are lacking.
8.3.1.2. Heart failure with preserved ejection fraction
In patients with HFpEF, blood pressure, volume load, and risk factors should be controlled, which may lower ﬁlling pressures and PAP.27
Recently, the SGLT-2i empagliﬂozin improved outcomes in patients
Table 23
Patient phenotyping and likelihood for left heart disease as cause of pulmonary hypertension
Feature
PH-LHD unlikely
Intermediate probability
PH-LHD likely
Age
,60 years
60–70 years
.70 years
Obesity, hypertension, dyslipidaemia, glucose intolerance/
diabetes
No factors
1–2 factors
.2 factors
Presence of known LHD
No
Yes
Yes
Previous cardiac intervention
No
No
Yes
Atrial ﬁbrillation
No
Paroxysmal
Permanent/persistent
Structural LHD
No
No
Present
ECG
Normal or signs of RV
strain
Mild LVH
LBBB or LVH
Echocardiography
No LA dilation
E/e′ ,13
No LA dilation
Grade ,2 mitral ﬂow
LA dilation (LAVI .34 mL/
m2)
LVH
Grade .2 mitral ﬂow
CPET
High VE/VCO2 slope
No EOV
Elevated VE/VCO2 slope
EOV
Mildly elevated VE/VCO2
slope
EOV
cMRI
No left heart abnormalities
LVH
LA dilation (strain or LA/RA
.1)
© ESC/ERS 2022
cMRI, cardiac magnetic resonance imaging; CPET, cardiopulmonary exercise testing; E/e’, ratio between early mitral inﬂow velocity and mitral annular early diastolic velocity; ECG,
electrocardiogram; EOV, exercise oscillatory ventilation; LA, left atrial; LAVI, left atrial volume index; LBBB, left bundle branch block; LHD, left heart disease; LVH, left ventricular hypertrophy; PH, pulmonary hypertension; PH-LHD, left heart disease associated with pulmonary hypertension; RA, right atrium; RV, right ventricle; VE/VECO2, ventilatory equivalents for carbon dioxide.
Assigning the likelihood of LHD as a cause of PH. This assessment may help to decide which patients should undergo a full work-up, including invasive haemodynamic assessment (see
Figure 11 and Figure S2).
3688
ESC/ERS Guidelines


<!-- PAGE 72 -->

### Page 72

with an LV ejection fraction of 40–60%.682 Endothelin receptor antagonists have not proved successful in this population, as both bosentan683 and macitentan684 failed to show efﬁcacy but rather led to more adverse events (ﬂuid retention) vs. placebo in patients with
HFpEF-associated
PH
and
HF
with ejection fraction
.35%-associated CpcPH, respectively. Phosphodiesterase 5 inhibitors were assessed in two small RCTs in patients with HFpEF and
PH with distinct haemodynamic characteristics. In patients with a predominantly IpcPH proﬁle, sildenaﬁl had no effect on mPAP (primary endpoint) or other haemodynamic and clinical measures vs.
placebo.685 In patients with a predominantly CpcPH proﬁle, sildenaﬁl improved haemodynamics, RV function, and quality of life at 6 and 12
months vs. placebo.686 Furthermore, retrospective analyses and registry data suggested improvements in exercise capacity with
PDE5i therapy in patients with HFpEF-associated CpcPH and with a severe pre-capillary component (PVR mostly .5 WU).450,687
8.3.1.3. Interatrial shunt devices
Recent data suggest that speciﬁc interventions may be considered in selected cases of HFpEF, such as interatrial shunt devices to unload the left heart. While this was associated with short-term improvements in pulmonary vascular function,688 the long-term effect on the pulmonary circulation remains unknown. The recent REDUCE LAP-HF II trial failed to show a reduction in HF events after placement of an atrial shunt device in a population of HF patients with LVEF ≥40%,689 with worse outcomes in the presence of PVD.690 In addition, a sustained increase in PA blood ﬂow may be a matter of concern, as this may trigger vascular remodelling in patients with pre-existing PH.
8.3.1.4. Remote pulmonary arterial pressure monitoring in heart failure
The importance of decongestion in patients with HF is underscored by the use of implantable pressure sensors, remotely monitoring
PAP as a surrogate of left-sided ﬁlling pressure. Pulmonary arterial pressure-based adjustment of HF therapy substantially reduced HF
hospitalizations and improved outcomes in both patients with
HFpEF and HFrEF,691–694 with adjustment of diuretic therapy being the most prominent therapeutic consequence. Further strategies to optimize management depending on the haemodynamic phenotype in PH-LHD remain to be established. In HFrEF, novel medical therapies such as ARNIs and SGLT-2is reduced remotely monitored
PAP and diuretic use,695–698 potentially providing opportunities to further optimize PAP-guided HF therapy.
8.3.2. Pulmonary hypertension associated with valvular heart disease
Pulmonary hypertension frequently occurs as a consequence of valvular heart disease. While surgical or interventional approaches for valvular repair improve cardiopulmonary haemodynamics by reducing PAWP and PAP and improving forward SV,699 persistent PH
after correcting valvular heart disease is frequent and associated with adverse outcomes.634,700
8.3.2.1. Mitral valve disease
Both mitral stenosis and regurgitation regularly lead to post-capillary
PH. Functional (secondary) mitral regurgitation occurs in both HFrEF
and HFpEF, and is an important contributor to PH in LHD. Reducing mitral regurgitation according to the recommendations of the 2021
ESC/EACTS Guidelines for the management of valvular heart disease28 has a crucial role in improving haemodynamics in patients with HFrEF, as this reduces mPAP and PAWP and improves the
CI.699 Nevertheless, registry data have demonstrated that even moderately elevated sPAP negatively impacts post-procedural outcomes after catheter-based therapy.700
8.3.2.2. Aortic stenosis
In patients with aortic stenosis undergoing surgical or catheter-based aortic valve repair, pre-interventional PH is associated with a higher risk of in-hospital adverse events and adverse long-term outcomes.646–651 Although post-procedural improvement in PH correlates with symptom relief and favourable outcomes, persistence of
PH is common, and even moderate PH is associated with a higher all-cause mortality.646–651
Of note, medical therapy of PH post-valvular repair may be harmful. A randomized study of 231 patients with surgically corrected valvular heart disease and persistent PH showed that sildenaﬁl therapy vs. placebo was associated with worse outcome when compared with placebo;701 however, this study did not distinguish between different types of PH (pre-capillary, IpcPH, and CpcPH).
8.3.2.3. Tricuspid regurgitation
Severe TR is associated with volume overload, increased RV workload, and maladaptive remodelling, leading to symptomatic right HF
and impaired survival.702,703 While primary TR is relatively rare, functional TR may arise from annular dilation in the presence of both PH
and LHD. Transcatheter tricuspid valve interventions have recently emerged, aiming at reducing TR and RV volume overload. Of note,
correcting TR in patients with PAH or PH in (non-valvular) LHD
with signiﬁcantly elevated PVR and/or RV dysfunction must be considered with great caution, as this may be hazardous.704 Right ventricle–
PA coupling is an independent predictor of all-cause mortality in such patients.705 Patient selection appears crucial, and a comprehensive diagnostic approach integrating imaging modalities and invasive haemodynamic assessment is necessary in the evaluation process prior to tricuspid valve repair, particularly since echocardiography underestimates sPAP in the presence of severe TR.
8.3.3. Recommendations on the use of drugs approved for PAH in PH-LHD
The recommendations on the use of drugs approved for PAH in patients with PH-LHD have been established based on key narrative question 5 (Supplementary Data, Section 8.3).
The recommendations on the use of PDE5is in patients with
CpcPH associated with HFpEF are based on PICO question II
(Supplementary Data, Section 8.4). Two RCTs that enrolled patients with HFpEF and PH were identiﬁed, but no study that speciﬁcally enrolled patients with HFpEF and CpcPH. Harmful effects cannot be excluded, even if the available data from clinical studies, case series, and registries suggest that PDE5is may be safely administered to patients with HFpEF-associated CpcPH. As a result, a general recommendation for or against the use of PDE5is in patients with HFpEF and CpcPH cannot be made. However, it is clinically relevant to make a recommendation against their use for patients with HFpEF and IpcPH.
ESC/ERS Guidelines
3689


<!-- PAGE 73 -->

### Page 73

### 9 Pulmonary hypertension associated with lung diseases and/

or hypoxia (group 3)
Pulmonary hypertension is frequently observed in patients with
COPD and/or emphysema, ILD, combined pulmonary ﬁbrosis and emphysema (CPFE), and hypoventilation syndromes.52,165,707,708
Pulmonary hypertension is uncommon in obstructive sleep apnoea unless other conditions coexist, such as COPD or daytime hypoventilation.709 At high altitude (.2500 m) hypoxia-induced PH is thought to affect .5% of the population, the development of PH
being related to geography and genetic factors.710
A PH screening study performed on a large cohort of .100
patients with lymphangioleiomyomatosis conﬁrmed that PH is usually mild in that setting: from six patients (5.7%) presenting with pre-capillary PH, none had mPAP .30 mmHg and
PH was associated with PFT alteration, suggesting that the rise in mPAP is associated with parenchymal involvement.711
Thus, PH in lymphangioleiomyomatosis is now classiﬁed in group 3 PH.1
In patients with lung disease, PH is categorized as non-severe or severe, depending on haemodynamic ﬁndings (Figure 12). In the
2015 ESC/ERS Guidelines for the diagnosis and treatment of
PH, severe PH was deﬁned by mPAP .35 mmHg or mPAP
≥25 mmHg with CI ,2.5 L/min/m2.25,26 However, two recent studies have demonstrated that a PVR .5 WU is a better threshold for predicting worse prognosis in patients with PH associated with both COPD and ILD.712,713 Based on these data, the current guidelines used PVR to distinguish between non-severe PH (PVR
Recommendation Table 22 — Recommendations for pulmonary hypertension associated with left heart disease
Recommendation Table 22A
Recommendations
Classa
Levelb
In patients with LHD, optimizing treatment of the underlying condition is recommended before considering assessment of suspected
PH27,28
I
A
RHC is recommended for suspected PH in patients with LHD, if it aids management decisions
I
C
RHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair
I
C
For patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV dysfunction, referral to a PH centre for a complete diagnostic work-up is recommended29,47,142
I
C
In patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is recommended
I
C
When patients with PH and multiple risk factors for LHD, who have a normal PAWP at rest but an abnormal response to exercise or
ﬂuid challenge, are treated with PAH drugs, close monitoring is recommended
I
C
In patients with PH at RHC, a borderline PAWP (13–15 mmHg) and features of HFpEF, additional testing with exercise or ﬂuid challenge may be considered to uncover post-capillary PH133,143
IIb
C
Drugs approved for PAH are not recommended in PH-LHDc 631,678,683,684,701,706
III
A
© ESC/ERS 2022
Recommendation Table 22B
GRADE
Recommendations
Quality of evidence
Strength of recommendation
Classa
Levelb
No recommendation can be given for or against the use of PDE5is in patients with HFpEF and combined post- and pre-capillary PH
Low
None
–
–
The use of PDE5is in patients with HFpEF and isolated post-capillary PH is not recommended
Low
Conditional
III
C
© ESC/ERS 2022
CpcPH, combined post- and pre-capillary PH; ERA, endothelin receptor antagonist; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LHD, left heart disease; PAH, pulmonary arterial hypertension; PAWP, pulmonary arterial wedge pressure; PDE5is, phosphodiesterase 5 inhibitors; PH,
pulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right ventricular; WU, Wood units.
aClass of recommendation.
bLevel of evidence.
cSafety concerns have been identiﬁed when ERAs are used in patients with HF (HFpEF and HFrEF, with or without PH) and when sildenaﬁl is used in patients with persistent PH after correction of valvular heart disease.
3690
ESC/ERS Guidelines


<!-- PAGE 74 -->

### Page 74

≤5 WU) and severe PH (PVR .5 WU). Whereas non-severe PH
is common in advanced COPD and ILD deﬁned by spirometric criteria, severe PH is uncommon, occurring in 1–5% of cases of
COPD and ,10% of patients with advanced ILD, with limited data in obesity hypoventilation syndrome.714,715 Even non-severe
PH in lung disease negatively impacts symptoms and survival, and is associated with increased hospitalization.715–717 Patients with lung disease and severe PH have a worse outcome than those with non-severe PH, providing evidence that this distinction has clinical signiﬁcance.51,712,713,718,719 It is noteworthy that developing severe PH is largely independent of spirometry but usually accompanied by hypoxaemia, low PaCO2, and a signiﬁcant reduction in DLCO.51,714,718,719
Pulmonary hypertension presenting in patients with lung disease may be due to a number of causes, including undiagnosed CTEPH
or PAH.714,720 Cardiac comorbidities are also common in patients with lung disease and may contribute to PH. A number of distinct phenotypes of PH in patients with lung disease, including a pulmonary vascular phenotype, have been proposed.51,720 The pulmonary vascular phenotype is characterized by better preserved spirometry,
low DLCO, hypoxaemia, a range of parenchymal involvement on lung imaging, and a circulatory limitation to exercise.51,714,718–722
Recent studies have shown that the clinical characteristics, disease trajectory, response to treatment,451,718,719 and histological correlates723,724 of patients with severe PH and minor lung disease are different to those in patients with IPAH, including a poorer prognosis.
Remodelling of airways, lung parenchyma, and vessels
Prevalence
~70%
~20%
~5–10%
Mostly ventilatory exercise limitation
Mostly circulatory exercise limitation
Remodelling of pulmonary vessels
Remodelling of airways and parenchyma
Hypoxaemia at rest and/or during exercise
No PH
Non-severe PH
Severe PH
(PVR >5 WU)
COPD
ILD
CPFE
R
Emphysema
Fibrosis
Vascular pruning
CPFE
Figure 12 Pathophysiology of pulmonary hypertension associated with lung disease (group 3). COPD, chronic obstructive pulmonary disease; CPFE,
combined pulmonary ﬁbrosis and emphysema; ILD, interstitial lung disease; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; WU,
Wood units. Shown are underlying lung diseases (upper panel); contributing pathogenic pulmonary alterations of airways, parenchyma, and vessels
(middle panel); and the relation of airway/parenchymal remodelling and vascular remodelling to the degree of PH and its consequences for exercise limitation (ventilatory vs. circulatory, lower panel).
ESC/ERS Guidelines
3691


<!-- PAGE 75 -->

### Page 75

9.1. Diagnosis
In patients with lung disease, symptoms of PH, especially exertional dyspnoea, overlap with those of the underlying condition. Physical
ﬁndings may also be non-speciﬁc, for example: ankle swelling is common during episodes of ventilatory failure in COPD, where activation of the renin–angiotensin–aldosterone system may cause ﬂuid retention, usually in the setting of preserved RV function.
Non-invasive tests—such as ECG showing right axis deviation or
RV strain, elevated levels of BNP/NT-proBNP, CPET, or features on cross-sectional imaging—may suggest the diagnosis of PH in patients with lung disease.725,726 Echocardiography remains the most widely used non-invasive diagnostic tool for assessing PH; however, the accuracy of echocardiography in patients with advanced respiratory diseases is low, with a TRV unmeasurable in .50% of patients in some studies, and there is a tendency to overestimate PAP and misclassify patients with PH.86,87,727 More recent data suggest that a stepwise, composite, echocardiographic score can identify patients with severe PH, with and without an estimate of TRV, using other echocardiographic features including RA area, RV:LV ratio, and LV eccentricity index.728 Where PH is suspected, combining echocardiography with a contrast-enhanced CT may aid diagnostic assessment and disease classiﬁcation.108,729–731 Pulmonary artery enlargement, RV outﬂow hypertrophy, and increased RV:LV ratio may suggest a diagnosis of
PH.108 Ideally, assessments should be made or repeated when the patient is clinically stable, as exacerbations can signiﬁcantly raise PAP.
Key parts of evaluating suspected PH in lung disease include integrating: (1) the presence or absence of risk factors for PAH, CTEPH, or
LHD; (2) clinical features, including disease trajectory (e.g. rapid recent deterioration vs. gradual change over years, and oxygen requirements);
(3) PFTs, including DLCO and blood gas analysis; (4) NT-proBNP measurements, ECG, and echocardiography; and (5) cross-sectional imaging with contrast-enhanced CT, SPECT, or V/Q lung scan and, in selected cases, cMRI732 to assess the need for RHC. Cardiopulmonary exercise testing may be helpful in assessing ventilatory or cardiac limitation in patients with lung disease,121,733 although data are limited regarding its clinical use in identifying patients with PH in lung disease.
Indications for RHC in lung disease include assessment for surgical treatments (selected patients considered for LTx and lung volume reduction surgery), suspected PAH or CTEPH, and where further information will aid phenotyping of disease and consideration of therapeutic interventions (Figure S3).712,718,734 Such testing should ideally be conducted in PH centres when patients are clinically stable and treatment of underlying lung disease has been optimized. Consideration should be given to how pressure measurements are made, due to the impact of changing intrathoracic pressures on pulmonary haemodynamics during the respiratory cycle (see Section 5.1.12).735
9.2. Therapy
The therapeutic approach to group 3 PH starts with optimizing the treatment of the underlying lung disease, including supplementary oxygen and non-invasive ventilation, where indicated, as well as enrolment into pulmonary rehabilitation programmes.736 There is limited and conﬂicting evidence for the use of medication approved for PAH in patients with group 3 PH, and these drugs may have variable and sometimes detrimental effects on haemodynamics, exercise capacity, gas exchange,
and outcomes in this patient population.181,737–740
9.2.1. Pulmonary hypertension associated with chronic obstructive pulmonary disease or emphysema
Studies using drugs approved for PAH in patients with PH associated with COPD or emphysema have yielded conﬂicting results and are mostly limited by small sample size, short duration, and insufﬁcient haemodynamic characterization of PH.739,741,742 In a 16 week RCT
of 28 patients with COPD and severe PH conﬁrmed by RHC, sildenaﬁl therapy resulted in statistically signiﬁcant improvements in PVR
and quality of life.743 Registry data identiﬁed that ≏30% of patients with COPD and severe PH, predominantly treated with PDE5is,
had improved WHO-FC, 6MWD, and PVR vs. baseline, and those with a treatment response had improved transplant-free survival.51,718 However, in the absence of large randomized trials, the evidence is insufﬁcient to support the general use of medication approved for PAH in patients with COPD and PH. Patients with COPD
and suspected or conﬁrmed severe PH should be referred to PH
centres for individual decision-making.
9.2.2. Pulmonary hypertension associated with interstitial lung disease
Numerous phase 2 and phase 3 studies have investigated the use of
ERAs to treat ILD, all with negative results.740,744,745 In addition, the
PDE5i sildenaﬁl has been investigated in phase 3 trials of patients with
ILD, also with negative results.746,747 Few data from RCTs are available for patients with PH associated with ILD, and many of the studies performed for this indication748,749 suffered from the same limitations as the aforementioned studies in PH associated with COPD. In addition,
there were several adverse safety signals: ambrisentan was associated with an increased risk of clinical worsening in patients with ILD with and without PH,740,750 while riociguat was associated with an increased risk of clinical worsening events, including potential excess mortality, in patients with PH associated with idiopathic interstitial pneumonia.181
In contrast, promising results have been obtained with the use of inhaled treprostinil. A phase 3 RCT (INCREASE) examined inhaled treprostinil at a target dose of 72 µg given four times daily in 326 patients with PH associated with ILD.734,751 The PH diagnosis was conﬁrmed by RHC within 1 year prior to enrolment. At week 16, the placebo-corrected 6MWD improved by 31 m with inhaled treprostinil. There were also improvements in NT-proBNP and clinical worsening events, the latter driven by a lower proportion of patients whose 6MWD declined by .15% from baseline.
Given the signiﬁcant impact of even non-severe PH in patients with lung disease, eligible patients should be referred for LTx evaluation. In patients with ILD and PH, inhaled treprostinil may be considered based on the ﬁndings from the INCREASE study, but further data are needed, especially on long-term outcomes. The routine use of other medication approved for PAH is not recommended in patients with ILD and non-severe PH. For patients with severe PH
and/or severe RV dysfunction, or where there is uncertainty regarding the treatment of PH, referral to a PH centre is recommended for careful evaluation, to facilitate entry into RCTs, and consider PAH
therapies on an individual basis (Figure S3). Registry data show that some patients with group 3 PH are being treated with PAH medication, predominantly PDE5is,718,752,753 but it is unclear if and to what extent these patients beneﬁt from this treatment.
3692
ESC/ERS Guidelines


<!-- PAGE 76 -->

### Page 76

9.2.3. Recommendations on the use of drugs approved for PAH in PH associated with lung disease
The recommendations on the use of drugs approved for PAH in patients with PH associated with COPD and ILD have been established based on key narrative questions 6 and 7 (Supplementary Data,
Sections 9.1 and 9.2, respectively).
The recommendations on the use of PDE5is in patients with severe PH associated with ILD are based on PICO question III
(Supplementary Data, Section 9.3). There are no direct data from
RCTs on the safety, tolerability, and efﬁcacy of PDE5is in patients with PH associated with ILD. The indirect data included in the guidelines do not enable ﬁrm conclusions to be drawn. Given the lack of robust evidence, the Task Force members felt unable to provide a recommendation for or against the use of PDE5is in patients with ILD and severe PH, and recommend that these patients are referred to a PH centre for individualized decision-making.
10. Chronic thrombo-embolic pulmonary hypertension (group 4)
All patients whose symptoms can be attributed to post-thrombo-embolic ﬁbrotic obstructions within the PA are
Recommendation Table 23 — Recommendations for pulmonary hypertension associated with lung disease and/or hypoxia
Recommendation Table 23A
Recommendations
Classa
Levelb
If PH is suspected in patients with lung disease, it is recommended that echocardiographyc be performed and the results interpreted in conjunction with ABG, PFTs including DLCO, and CT imaging
I
C
In patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where indicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation
I
C
In patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH, referral to a PH
centre is recommendedd
I
C
In patients with lung disease and severe PH, an individualized approach to treatment is recommended
I
C
It is recommended to refer eligible patients with lung disease and PH for LTx evaluation
I
C
In patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions
I
C
Inhaled treprostinil may be considered in patients with PH associated with ILD734
IIb
B
The use of ambrisentan is not recommended in patients with PH associated with IPF740
III
B
The use of riociguat is not recommended in patients with PH associated with IIP181
III
B
The use of PAH medication is not recommended in patients with lung disease and non-severe PHe
III
C
© ESC/ERS 2022
Recommendation Table 23B
GRADE
Recommendations
Quality of evidence
Strength of recommendation
Classa
Levelb
PDE5is may be considered in patients with severe PH associated with ILD
(individual decision-making in PH centres)
Very low
Conditional
IIb
C
The use of PDE5is in patients with ILD and non-severe PH is not recommended
Very low
Conditional
III
C
© ESC/ERS 2022
ABG, arterial blood gas analysis; CT, computed tomography; DLCO, Lung diffusion capacity for carbon monoxide; IIP, idiopathic interstitial pneumonia; IPF, idiopathic pulmonary
ﬁbrosis; ILD, interstitial lung disease; LTx, lung transplantation; PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; PFT, pulmonary function test; PH,
pulmonary hypertension; RHC, right heart catheterization.
aClass of recommendation.
bLevel of evidence.
cAssessments should ideally be made when the patient is clinically stable, as exacerbations can signiﬁcantly raise pulmonary artery pressure.
dThis recommendation does not apply to patients with end-stage lung disease who are not considered candidates for LTx.
eThis does not include inhaled treprostinil, which may be considered in patients with PH associated with ILD, irrespective of PH severity.
ESC/ERS Guidelines
3693


<!-- PAGE 77 -->

### Page 77

considered to have CTEPD with or without PH; CTEPH remains the preferred term for patients with PH, as deﬁned in Section 3.1
(Table 5).54 Chronic thrombo-embolic pulmonary disease describes symptomatic patients with mismatched perfusion defects on V/Q
scan and with signs of chronic, organized, ﬁbrotic clots on CTPA or
DSA, such as ring-like stenoses, webs/slits, and chronic total occlusions
(pouch lesions or tapered lesions), after at least 3 months of therapeutic anticoagulation. Pulmonary hypertension in this setting is not only a consequence of PA obstruction by organized ﬁbrotic clots but can also be related to the associated microvasculopathy. In those patients without PH at rest, breathlessness could be due to exercise PH (see deﬁnition in Section 3.1, Table 5) and/or increased dead space ventilation.54 Excluding ventilatory limitation, deconditioning and psychogenic hyperventilation syndrome by CPET and LV myocardial or valvular disease by echocardiography is of upmost importance when making therapeutic decisions in patients with CTEPD without PH.
10.1. Diagnosis
Chronic thrombo-embolic pulmonary hypertension is a common and important cause of PH, with a distinct management strategy.
Thus, the possibility of CTEPH should be carefully considered in all patients with PH (Figure 13). In the context of acute PE, CTEPH
CTEPH diagnostic algorithm for symptomatic patients f
Patients with confirmed CTEPH
CTEPH suspected from history of PEa or risk factors for CTEPH
f
Tr
T eatment assessment by MDT at CTEPH centre
(Class I)
PH work-up
N
Y
Perfusion imaging
(V/Q scan or new modalityb)
Any mismatched perfusion defects f
Echocardiography
Intermediate or high probability of PH
Refer to CTEPH/PH centre
Comprehensive work-upd
(Table 14
T
, ReCo
,
Table 2)
T
Abnormal exercise tests
(CPETc, st
,
ress echocardiography)
suggestive for CTEPD
f
AND
CTPA + D
P
SA
when CTPA is inconclusi
P
ve
RHC
AND
Figure 13 Diagnostic strategy in chronic thrombo-embolic pulmonary hypertension. CPET, cardiopulmonary exercise test; CTEPD, chronic thromboembolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; CTPA, computed tomography pulmonary angiography; DECT,
dual-energy computed tomography; DSA, digital subtraction angiography; MDT, multidisciplinary team; MRI, magnetic resonance imaging; N, no; PE, pulmonary embolism; PETCO2, end-tidal partial pressure of carbon dioxide; PH, pulmonary hypertension; ReCo, recommendation; RHC, right heart catheterization; sPAP, systolic pulmonary arterial pressure; V/Q, ventilation/perfusion; VE/VCO2, ventilatory equivalents for carbon dioxide; VO2/HR, oxygen pulse; VO2, oxygen uptake; Y, yes. aCTEPH suspected from history of PE, including elevated sPAP on echocardiography and signs suggesting CTEPH on
CTPA performed at the time of the acute PE (Section 5.1.7). bAlternative perfusion imaging techniques—such as iodine subtraction mapping, DECT, and
MRI perfusion—are currently under evaluation. cTypical pattern, including low PETCO2, high VE/VCO2, low VO2/HR, and low peak VO2 (Section 5.1.11).
dComprehensive work-up after 3 months of therapeutic anticoagulation or sooner in unstable or rapidly deteriorating patients. Ideally, CTPA, DSA, and
RHC are performed in CTEPH centres, but they are sometimes performed in PH centres, depending on the country and organization.
3694
ESC/ERS Guidelines


<!-- PAGE 78 -->

### Page 78

should be considered: (1) if radiological signs (detailed in Section
5.1.7) suggest CTEPH on the CTPA performed to diagnose PE,112
and/or if estimated sPAP is .60 mmHg112 on echocardiogram; (2)
when dyspnoea or functional limitations persist in the clinical course post-PE;754 and (3) in asymptomatic patients with risk factors for
CTEPH or a high CTEPH prediction score.755 Clinical conditions such as permanent intravascular devices (pacemaker, long-term central lines, ventriculoatrial shunts), inﬂammatory bowel diseases, essential thrombocythaemia,
polycythaemia vera,
splenectomy,
antiphospholipid syndrome, high-dose thyroid hormone replacement, and malignancy are risk factors for CTEPH.54,103,756
Alternative causes of PA obstructions (also included in group 4 of the
PH classiﬁcation)—including PA sarcomas, other malignant tumours
(e.g. renal carcinoma, uterine carcinoma, and germ-cell tumours of the testis), non-malignant tumours (e.g. uterine leiomyoma), arteriitis without CTD, congenital or acquired PA stenoses, parasites (hydatid cyst), and foreign-body embolism—have to be considered in the differential diagnosis of CTEPD.757 They can be explored by speciﬁc additional imaging such as 18F-2-ﬂuoro-2-deoxy-D-glucose-positron emission tomography (PET) scan, which can provide additional information when PA sarcoma is suspected.758
Ventilation/perfusion scintigraphy207 remains the most effective tool in excluding CTEPD. Alternative perfusion imaging techniques
—such as iodine subtraction mapping, DECT, and MRI perfusion—
have numerous theoretical advantages over V/Q but are more technically challenging and expensive, have limited availability, and currently lack multicentre validation.
Computed tomography pulmonary angiography with bi-planar reconstruction is broadly used for diagnosing CTEPD and assessing operability, but a negative CTPA, even if high quality, does not exclude
CTEPD, as distal disease can be missed. Digital subtraction angiography is still used to assess treatment options when CTPA is inconclusive. Selective segmental angiography, cone-beam CT, and area detector CT allow for more accurate visualization of subsegmental vasculature and are useful for procedural guidance for BPA. The beneﬁts of the new technologies require validating in prospective trials before being recommended for routine clinical use; a large,
European, multicentre study is currently ongoing.759
10.2. Therapy
The CTEPH treatment algorithm includes a multimodal approach of combinations of pulmonary endarterectomy (PEA), BPA, and medical therapies to target the mixed anatomical lesions: proximal, distal,
and microvasculopathy, respectively (Figures 14 and 15).
General measures recommended for PAH also apply to CTEPH,
including supervised exercise training, which is effective and safe in inoperable CTEPH patients,760 as well as early after PEA.761
Lifelong therapeutic anticoagulation is recommended for patients with CTEPH, as recurrent pulmonary thrombo-embolism accompanied by insufﬁcient clot resolution are key pathophysiological features of this disease. There are no RCTs in CTEPH with any of the approved anticoagulants; however, despite this lack of evidence, VKAs are recommended by experts, and are most widely used as background therapy for patients with CTEPH. More recently, NOACs have more frequently been used as alternatives to VKAs, again, lacking evidence from RCTs. A
retrospective case series from the UK and a multicentre prospective registry (EXPERT) showed comparable bleeding rates for VKAs and
NOACs in CTEPH, but recurrent venous thrombo-embolism rates were higher in those receiving NOACs.762,763 In patients with antiphospholipid syndrome (10% of the CTEPH population), VKAs are recommended.103,764,765 Screening for antiphospholipid syndrome should be performed at CTEPH diagnosis. In the absence of any evidence in favour or against prolonged anticoagulation in patients with CTEPD without
PH, long-term anticoagulant therapy is based on individual decisionmaking. It is recommended when the risk of PE recurrence is intermediate or high, thereby following the 2019 ESC/ERS Guidelines for the diagnosis and management of acute pulmonary embolism (Table 11).103
10.2.1. Surgical treatment
Surgical PEA is the treatment of choice for patients with accessible
PA lesions.102 As surgery may normalize pulmonary haemodynamics
(65% decrease in PVR)766 and functional capacity, an expert multidisciplinary team including an experienced PEA surgeon (on-site or closely collaborating) is mandatory for evaluating operability and deciding ﬁnal treatment.102
Operability is based on team experience, accessibility of PA lesions, correlation between severity of PH and degree of PA obstructions, and comorbidities.767 The surgical technique is complex but well standardized with .30 years of experience. It consists of a complete bilateral endarterectomy of the PAs down to segmental and subsegmental levels in phases of deep hypothermic circulatory arrest
(Figure 15).767,768 In CTEPH centres, surgical outcomes are favourable, with peri-operative mortality rates ,2.5% due to improved management of cardiac and pulmonary complications and wellestablished use of ECMO.768 Post-operative PH is frequently observed (≏25%),766 but long-term outcomes after PEA surgery are excellent regarding survival (averaging 90% at 3 years) and quality of life,769–771 even in patients with distal PA obstructions.772 On the other hand, patients with proximal operable disease declining surgery have a poor long-term outcome, with a 5 year survival of
53%
compared with
83%
in patients undergoing
PEA.773
Therefore, PEA should be offered to all operable patients with a favourable risk:beneﬁt ratio, ideally during a personal consultation between the patient and the PEA surgeon.102
Selected symptomatic patients with CTEPD without PH can be successfully treated by PEA, with clinical and haemodynamic improvements at rest and exercise.135,774 Those patients would require careful discussion to balance risk and beneﬁt.
10.2.2. Medical therapy
To manage the microvascular component of CTEPH (Figure 15),
medical therapies have been used off-label based on uncontrolled studies and/or regional approvals. Meanwhile, three RCTs have successfully been conducted. The ﬁrst phase 3 RCT investigated the efﬁcacy of riociguat in patients with inoperable CTEPH or those with persistent/recurrent PH after PEA.775 Riociguat, after 16 weeks of therapy, improved 6MWD and reduced PVR by 31% compared with placebo, and is approved for this indication. Treprostinil s.c.
was investigated in a phase 3 RCT, which showed improved
6MWD at week 24 in patients with inoperable CTEPH or those with persistent/recurrent PH after PEA receiving a high dose compared with a low dose;776 s.c. treprostinil is approved for this indication. In a phase 2 study including only patients with inoperable
CTEPH, macitentan 10 mg improved PVR and 6MWD vs. placebo
ESC/ERS Guidelines
3695


<!-- PAGE 79 -->

### Page 79

at 16 and 24 weeks, respectively.777 A phase 3 RCT is ongoing to evaluate the safety and efﬁcacy of macitentan 75 mg in inoperable or persistent/recurrent CTEPH (NCT04271475).
Other medical therapies—PDE5is (e.g. sildenaﬁl) and ERAs (e.g.
bosentan)—have been used off-label, as their efﬁcacy in inoperable
CTEPH has not been proven by RCTs or registry data.769,778,779
However, oral combination therapy, including PDE5is and ERAs, is common practice in patients with CTEPH with severe haemodynamic compromise.780
10.2.3. Interventional treatment
Balloon pulmonary angioplasty (Figure 15) has become an established treatment for selected patients with inoperable CTEPH or persistent/recurrent PH after PEA, improving haemodynamics (PVR decrease 49–66%), right heart function, and exercise capacity.781–794
Long-term outcomes are promising, but evidence is still scarce.795
A staged interventional procedure with a limited number of dilated PA segments per session is preferred.102,788 The number of sessions needed and haemodynamic results are dependent on experience.781 While BPA is effective, it is associated with serious complications, which may be fatal. Procedural and post-interventional complications include vascular injury due to wire perforation, and lung injury with haemoptysis and/or hypoxia.102,781,796,797 As with all interventional procedures, a signiﬁcant learning curve has been shown, with reducing complication rates over time;781 therefore,
this procedure should be performed in high-volume CTEPH centres.
As the rates of interventional complications can be reduced by medical pre-treatment, patients with a PVR .4 WU should be treated before BPA (Figure 15).798
Selected symptomatic patients with CTEPD without PH and segmental/subsegmental lesions can successfully be treated by BPA,
with clinical and haemodynamic improvements at rest and exercise.799
Preliminary data on PADN point towards improved exercise capacity and pulmonary haemodynamics in patients with persistent PH
after PEA;800 further conﬁrmation is being awaited.
Patients with confirmed CTEPHa
Lifelong ther f
apeutic anticoagulation
(Class I)
Tr
T eatment assessment by MDTb
(Class I)
PEA as treatment of choicec
(Class I)
Long-term foll f
ow-up at a CTEPH/PH centrec
(Class I)
Medical therapy (ReCo p
Table 24)
T
(Class I)
BPA
P
d
(Class I)
Operable
Persistent/recurrent symptomatic PH
N
N
Y
Y
Figure 14 Management strategy in chronic thrombo-embolic pulmonary hypertension. BPA, balloon pulmonary angioplasty; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; MDT, multidisciplinary team; N, no; PAH, pulmonary arterial hypertension; PEA, pulmonary endarterectomy; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; ReCo, recommendation; WU,
Wood units; Y, yes. aSelected symptomatic patients with CTEPD without PH can also be treated by PEA and BPA. bMDT meeting can be virtual.
cTreatment assessment may differ, depending on the level of expertise in PEA and BPA. dFor inoperable patients with PVR .4 WU, medical therapy should be considered prior to BPA; there are limited data on BPA as ﬁrst-line therapy.
3696
ESC/ERS Guidelines


<!-- PAGE 80 -->

### Page 80

10.2.4. Multimodal treatment
Multimodal therapy including surgery, medication, and intervention is offered to selected patients with CTEPH (Figure 15).102
Using medical therapy in patients with high pre-operative PVR to improve pulmonary haemodynamics before PEA is common practice but still controversial, as it is felt to delay timely surgical referral and therefore deﬁnitive treatment.801–803
A signiﬁcant proportion of symptomatic patients may have persistent or recurrent PH following PEA, which may also beneﬁt from medical and/or interventional therapies (Figure 15).804–806 An mPAP ≥30 mmHg has been associated with initiation of medical therapies post-PEA, and an mPAP ≥38 mmHg and PVR ≥5 WU
with worse long-term survival.806
Some patients with CTEPH may have mixed anatomical lesions, with surgically accessible lesions in one lung and inoperable lesions in the other lung. Such patients might beneﬁt from a combined approach with BPA (prior to or at the same time as surgery) and PEA to decrease the surgical risk and improve the ﬁnal result.807
The recommendations on BPA and medical therapy in patients with inoperable CTEPH have been established based on key narrative question 8 (Supplementary Data, Section 10.1).
The recommendation on the use of medical therapy before interventional therapy in patients with CTEPH who are considered inoperable but candidates for BPA is based on PICO question IV
(Supplementary Data, Section 10.2). The included evidence suggests
A
B
C
D
E
PEA
Medical therapy
Microvasculopathy
Proximal PA fibrotic obstructions
Multimodal CTEPH treatment
Distal PA fibrotic obstructions
BPA
1
2
3
Figure 15 Overlap in treatments/multimodality approaches in chronic thrombo-embolic pulmonary hypertension. BPA, balloon pulmonary angioplasty; CTEPH, chronic thrombo-embolic pulmonary hypertension; PA, pulmonary artery; PEA, pulmonary endarterectomy. Top panels: (A) Proximal
PA ﬁbrotic obstructions (vessel diameter 10–40 mm). (B) Distal segmental and subsegmental PA ﬁbrotic obstruction potentially suitable for both
PEA and BPA interventions (vessel diameter 2–10 mm). (C) Distal subsegmental PA ﬁbrotic obstructions form a web-lesion in a subsegmental branch of the PA suitable for BPA interventions (vessel diameter 0.5–5 mm). (D) Distal subsegmental PA ﬁbrotic obstructions form web-like lesions, which might be accompanied by microvasculopathy (vessel diameter ,0.5 mm). (E) Microvasculopathy (vessel diameter ,0.05 mm) treated with medical therapy.
Bottom panels: (A) bottom left: PEA; vessel diameter (0.2–3 cm). The right PA is opened and the suction dissector is introduced between the artery wall and ﬁbrosis. Following the inside of the artery down to segmental and subsegmental levels, the ﬁbrotic material is subsequently freed from the wall and removed with forceps. (A) bottom right: PEA specimen with ‘tails’ to subsegmental branches of the PA; cross-section of partially organized and permeabilized thrombotic lesion of the large PA dissected during PEA. (B, C, D) The wire is introduced between the ﬁbrotic material (1), then the balloon is inﬂated, leading to a rupture of the web (2). Fibrotic material is connected to the vessel wall (3). (E) Small muscular PA displaying eccentric intimal ﬁbrosis involving intimal thickening and proliferation—target for medical therapies.
ESC/ERS Guidelines
3697


<!-- PAGE 81 -->

### Page 81

that pre-treatment improves pulmonary haemodynamics and safety of the procedure. This is conﬁrmed by the clinical experience of Task
Force members. However, due to the low certainty of the evidence,
the recommendation is conditional.
10.2.5. Follow-up
Regardless of the result of PEA/BPA, patients should be regularly followed-up, including invasive assessment with RHC 3–6 months after intervention, allowing for consideration of a multimodal treatment approach. After successful treatment, yearly non-invasive followup, including echocardiography and an evaluation of exercise capacity,
is indicated because recurrent PH has been described (Figure 14).806
Risk assessment with either the ESC/ERS or REVEAL risk score developed for PAH has been validated in medically treated patients with CTEPH,300,808,809 but it is unknown if its use has any therapeutic implication or affects outcome.
Therearenodataorconsensusonwhatisthetherapeutictargetafter
PEA/BPAormedicaltherapyinCTEPH.Mostexpertsacceptachievinga good functional class (WHO-FC I–II) and/or normalization or near normalization of haemodynamics at rest, obtained at RHC 3–6 months post-procedure (PEA or last BPA), and improvement in quality of life.
10.3. Chronic thrombo-embolic pulmonary hypertension team and experience criteria
To optimize patients’ outcomes, CTEPH centres should fulﬁl criteria for a PH centre (Section 12) and have a CTEPH multidisciplinary team consisting of a PEA surgeon, BPA interventionist, PH specialist, and thoracic radiologist, trained in high-volume PEA and/or BPA centres.
The team should meet regularly to review new referrals and posttreatment follow-up cases. Ideally, CTEPH centres should have
PEA activities (.50/year)810 and BPAs (.30 patients/year or
.100 procedures/year),781 as these ﬁgures have been associated with better outcome. The CTEPH centres should also manage medically treated patients. Based on regional requirements, these numbers may be adjusted for the country’s population, ideally concentrating care and expertise in high-volume centres.
Recommendation Table 24 — Recommendations for chronic thrombo-embolic pulmonary hypertension and chronic thrombo-embolic pulmonary disease without pulmonary hypertension
Recommendation Table 24A
Recommendations
Classa
Levelb
CTEPH
Lifelong, therapeutic doses of anticoagulation are recommended in all patients with CTEPH762
I
C
Antiphospholipid syndrome testing is recommended in patients with CTEPH
I
C
In patients with CTEPH and antiphospholipid syndrome, anticoagulation with VKAs is recommended103,764,765
I
C
It is recommended that all patients with CTEPH are reviewed by a CTEPH team for the assessment of multimodality management54
I
C
PEA is recommended as the treatment of choice for patients with CTEPH and ﬁbrotic obstructions within pulmonary arteries accessible by surgery54,102
I
B
BPA is recommended in patients who are technically inoperable or have residual PH after PEA and distal obstructions amenable to
BPA54,102,783,784,789,793,798,811
I
B
Riociguat is recommended for symptomatic patients with inoperable CTEPH or persistent/recurrent PH after PEA775
I
B
Long-term follow-up is recommended after PEA and BPA, as well as for patients with CTEPH established on medical therapy782,805,806,812
I
C
A multimodality approach should be considered for patients with persistent PH after PEA and for patients with inoperable CTEPH804,805,812
IIa
C
Treprostinil s.c. may be considered in patients in WHO-FC III–IV who have inoperable CTEPH or persistent/recurrent PH after PEA776
IIb
B
Off-label use of drugs approved for PAH may be considered in symptomatic patients who have inoperable CTEPH55,777–779,801
IIb
B
In patients with inoperable CTEPH, a combination of sGC stimulator/PDE5i, ERA,777 or parenteral prostacyclin analogues776 may be considered
IIb
C
BPA may be considered for technically operable patients with a high proportion of distal disease and an unfavourable risk:beneﬁt ratio for PEA
IIb
C
CTEPD without PH
In patients with CTEPD without PH, long-term anticoagulant therapy should be considered on an individual basisc
IIa
C
PEA or BPA should be considered in selected symptomatic patients with CTEPD without PH
IIa
C
© ESC/ERS 2022
3698
ESC/ERS Guidelines


<!-- PAGE 82 -->

### Page 82

### 11 Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5)

Pulmonary hypertension with unclear and/or multifactorial mechanisms (Table 24) includes several conditions that may be complicated by complex and sometimes overlapping pulmonary vascular involvement. Although group 5 PH represents less-studied forms of PH, it constitutes a signiﬁcant part of the worldwide burden of PH.1 Group 5 PH includes: haematological disorders, such as
SCD and chronic myeloproliferative neoplasms; systemic disorders, such as sarcoidosis; metabolic diseases, such as glycogen storage disease; and others, such as chronic renal failure, pulmonary tumour thrombotic microangiopathy, and ﬁbrosing mediastinitis.
A common feature of these diseases is that the mechanisms of
PH are poorly understood and contributing factors may include,
alone or in combination: hypoxic pulmonary vasoconstriction, pulmonary vascular remodelling, thrombosis, ﬁbrotic destruction and/
or extrinsic compression of pulmonary vasculature, pulmonary vasculitis, high-output cardiac failure, and left HF. These patients need careful assessment and treatment should be directed to the underlying condition.
11.1. Haematological disorders
In haemoglobinopathies and chronic haemolytic anaemias, including
SCD, PH has emerged as a major cause of morbidity and mortality.
The prevalence of PH conﬁrmed by RHC was 6–10% in studies of adult patients with stable SCD.93,94,813 Patients with SCD with precapillary PH are more commonly homozygous for haemoglobin S,
while some have S-β0 thalassaemia (S-β0 thal) or haemoglobin
SCD.814 Thrombotic lesions are a major component of PH related to SCD, more frequently in haemoglobin SCD.814 Patients with
PH and SCD should be followed by multidisciplinary SCD and PH
teams, since treatment of the anaemia is a key part of management.814 There is a lack of data to support the use of PAH drugs in patients with SCD-associated PH. In a study in patients with
SCD with TRV ≥2.7 m/s and a 6MWD of 150–500 m, sildenaﬁl showed no treatment effect on 6MWD, TRV, or NT-proBNP, but appeared to increase hospitalization rates for pain.815 Preliminary evidence supports the short- and long-term beneﬁts of chronic blood-exchange transfusions in patients with pre-capillary PH complicating SCD.816 Pre-capillary PH complicating SCD has an important impact on survival, with an overall death rate of 2.0–5.3% in different populations with similar follow-up (26 months and 18
months, respectively).94,817 In β-thalassaemia, invasive haemodynamic evaluation conﬁrmed pre-capillary PH in 2.1% of cases, while a post-capillary proﬁle was found in 0.3%.818 Potential treatment strategies are awaiting an enhanced understanding of the
Recommendation Table 24B
GRADE
Recommendations
Quality of evidence
Strength of recommendation
Classa
Levelb
In patients with CTEPH who are candidates for BPA, medical therapy should be considered prior to the intervention798
Very low
Conditional
IIa
B
© ESC/ERS 2022
BPA, balloon pulmonary angioplasty; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; ERA, endothelin receptor antagonist; PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; PEA, pulmonary endarterectomy; PE, pulmonary embolism; PH, pulmonary hypertension;
s.c., subcutaneous; sGC, soluble guanylate cyclase; VKA, vitamin K antagonist; WHO-FC, World Health Organization functional class.
aClass of recommendation.
bLevel of evidence.
cLong-term anticoagulant therapy is recommended when the risk of PE recurrence is intermediate or high,103 or when there is no history of venous thrombo-embolism.
Table 24
Pulmonary hypertension with unclear and/
or multifactorial mechanisms
Disorders associated with pulmonary hypertension
1 Haematological disorders
Inherited and acquired chronic haemolytic anaemia
• Sickle cell disease
• β-thalassaemia
• Spherocytosis
• Stomatocytosis
• Autoimmune disorders
Chronic myeloproliferative disorders
• Chronic myelogenous leukaemia
• Polycythaemia vera
• Idiopathic myeloﬁbrosis
• Essential thrombocytopenia
• Others
2 Systemic disorders
Sarcoidosis
Pulmonary Langerhans’s cell histiocytosis
Neuroﬁbromatosis type 1
3 Metabolic disorders
Glycogen storage disease
Gaucher disease
4 Chronic renal failure with/
without haemodialysis
5 Pulmonary tumour thrombotic microangiopathy
6 Fibrosis mediastinitis
© ESC/ERS 2022
ESC/ERS Guidelines
3699


<!-- PAGE 83 -->

### Page 83

pathophysiological mechanisms. In spherocytosis, splenectomy is a risk factor for CTEPH.819
Multiple causes of PH have been described in patients with chronic myeloproliferative disorders.820 In chronic myelogenous leukaemia,
spleen enlargement and anaemia can give rise to hyperkinetic syndrome. Hepatosplenic enlargement can also cause PoPH. Cases of potentially reversible DPAH have been described with dasatinib, bosutinib, and ponatinib. In polycythaemia vera and essential thrombocythaemia, there is an increased risk of venous thrombo-embolic disease and CTEPH; moreover, a blood clot within the hepatic veins can lead to Budd–Chiari syndrome and subsequent PoPH.
Pulmonary extramedullary haematopoiesis complicating idiopathic or secondary myeloﬁbrosis may also contribute to dyspnoea and PH.
Group 5 PH may be described in other haematological disorders,
such as common variable immunodeﬁciency; immunoglobulin G4
(IgG4)-related disease; Castleman disease; and polyneuropathy, organomegaly, endocrinopathy, monoclonal immunoglobulin, skin changes (POEMS) syndrome.821–823
11.2. Systemic disorders
The reported prevalence of PH in patients with sarcoidosis is 6–
20%.824 The causes are multifactorial, including ﬁbrosing lung disease,
granulomata in the PAs and/or pulmonary veins, ﬁbrosing mediastinitis and/or extrinsic compression by lymph nodes, pulmonary vasculitis, CTEPH, and PoPH.58,825 It is associated with signiﬁcant morbidity and increased mortality compared with sarcoidosis without PH.58,825 In a registry, factors independently associated with outcomes included physiological (forced expiratory volume in 1 s/FVC
ratio and DLCO) and functional (6MWD) parameters.58 In a large study of severe, sarcoidosis-associated PH, PAH drugs improved short-term pulmonary haemodynamics without improving
6MWD.59 Small RCTs have suggested efﬁcacy of PAH drugs in these patients,
which requires conﬁrmation in larger studies.826
Corticosteroids or immunosuppressive therapy may improve haemodynamics in selected patients with active granulomatous disease. Of note, when pulmonary vascular compression is suspected
(ﬁbrosing mediastinitis and/or extrinsic compression by lymph nodes), results from pulmonary angiography and PET scans provide additional information justifying endovascular and/or antiinﬂammatory approaches. Long-term survival remains poor in sarcoidosis-associated PH, which makes LTx a reasonable option for selected severe cases.
In pulmonary Langerhans’s cell histiocytosis, diminished exercise capacity does not appear to be due to ventilatory limitation but may be related to pulmonary vascular dysfunction. In 29 patients with PH associated with pulmonary Langerhans’s cell histiocytosis,
PAH drugs improved haemodynamics without worsening oxygen levels.827
Pulmonary hypertension associated with neuroﬁbromatosis type
1 is a rare but severe complication characterized by female predominance (female/male ratio 3.9:1).828 Speciﬁc pulmonary vascular involvement exists in these patients, and despite a potential short-term beneﬁt of PAH drugs, prognosis remains poor, and
LTx should be considered in selected patients with severe disease.
In the presence of dyspnoea, screening for ILD by non-contrast
CT and for PH by echocardiography is required.828
11.3. Metabolic disorders
Glycogen storage diseases are caused by genetic alterations of glycogen metabolism, and PH case reports have been related to glycogen storage disease type 1 and 2.829 The occurrence of PH has predominantly been described in glycogen storage disease type 1, where it may partly be due to vasoconstrictive amines such as serotonin.
Drugs for PAH have been used in some cases.830
Untreated patients with Gaucher disease may develop PH, which is caused by a combination of factors, including asplenia, plugging of the vasculature by abnormal macrophages, and pulmonary vascular remodelling. Treatment with enzyme-replacement therapy may improve PH.
11.4. Chronic kidney failure
Although commonly recognized in chronic renal failure, the pathogenesis of PH remains poorly understood and PH is observed in patients prior to and while receiving different dialysis modalities.831 A
recent RHC study of 3504 patients with chronic kidney disease found that CpcPH was the most common phenotype, and the phenotype with the highest mortality.832 Post-capillary PH has been described in 65% of patients receiving haemodialysis and 71%
of patients without kidney replacement.833
11.5. Pulmonary tumour thrombotic microangiopathy
Pulmonary tumour thrombotic microangiopathy describes tumourcell microemboli with occlusive ﬁbrointimal remodelling in small PAs,
pulmonary veins, and lymphatics. It is a rare cause of PH, which arises due to multiple mechanisms, but probably remains under-diagnosed,
as evidenced by autopsy ﬁndings.834 The disorder is associated with carcinomas, notably gastric carcinoma. Progressive vessel occlusion ultimately results in PH, which is often severe, of sudden onset, rapidly progressive, and accompanied by progressive hypoxaemia. Chest
CT may show patchy ground-glass and septal markings (masquerading as PVOD).
11.6. Fibrosing mediastinitis
Fibrosing mediastinitis is caused by ﬁbrous tissue proliferating in the mediastinum, encasing mediastinal viscera and compressing mediastinal bronchovascular structures.835 Pre- or post-capillary PH can complicate the course of ﬁbrosing mediastinitis due to extrinsic compression of the
PAs and/or pulmonary veins. Fibrosing mediastinitis can be idiopathic or caused by irradiation, infection (tuberculosis, histoplasmosis), and systemic diseases, such as sarcoidosis and IgG4-related disease, a ﬁbroinﬂammatory disease characterized by elevated serum IgG4 levels with inﬁltration of IgG4+ plasma cells and severe ﬁbrosis in affected tissues.821 Treatment should be directed to the underlying condition.
No clear clinical improvement has been described with PAH drugs.
Surgical and endovascular procedures have been proposed to de-obstruct or bypass the arterial and/or venous compressions.
In the absence of positive RCTs studying the use of PAH drugs for treating group 5 PH, treating the underlying disorder remains the standard of care.836 Importantly, some of the diseases described in
Table 24 may have a pulmonary venous component that could be made worse with PAH drugs, implying that off-label use of drugs approved for PAH should be considered with great caution, if at all.
3700
ESC/ERS Guidelines


<!-- PAGE 84 -->

### Page 84

Placebo-controlled, randomized trials are currently recruiting in well-phenotyped subgroups of PH with unclear and/or multifactorial mechanisms, such as sarcoidosis-associated PH.
12. Deﬁnition of a pulmonary hypertension centre
While PH is not an uncommon condition, severe forms of PH, especially PAH and CTEPH, require highly specialized management.
Since medical centres with multidisciplinary teams and a high volume of patients generally offer best standard of care, which translates into better clinical outcomes, establishing PH centres is clinically and economically highly desirable and is supported by patient organizations and scientiﬁc societies. The purpose of a
PH centre is to: receive new referrals; assess and investigate the cause of PH; carefully phenotype and routinely manage patients with medical, interventional, and surgical approaches; work closely with other health care providers to achieve the best outcomes for patients; undertake audits (reporting patient case mix and quality indicators); and be involved in clinical and translational research,
and education. The requirements—comprising deﬁnition, multidisciplinary structure, number of cases, procedures, and stafﬁng levels, as well as the skills and resources needed in a PH referral centre—are described below and in Figure 16. Criteria for paediatric and CTEPH centres are described elsewhere (Sections 7.8.3 and 10.3,
respectively).
Co-ordinated by a core MDT member responsible for the multidisciplinary approach
Core MDT
Extended MDT
Social worker
Study nurse
Paediatric cardiologist
Psychologist
Adult CHD specialist
Lung pathologist
Hepatologist
Physiotherapist
Rheumatologist
Intensive care specialist
Thoracic radiologist
Palliative care specialist
Cardiac radiologist
Lung transplant physician/surgeonc
Clinical geneticist/
Genetic counsellorc
At least 2 PH nurses
Nurse specialist
For diagnostic pulmonary angiography, embolization
Interventional radiologist/cardiologist
Cardiologist/Pneumologist
At least 2 surgeons
(ECMO)
Cardiothoracic surgeon
Case managerb
Responsible for data 
collection, analysis, and organization of audit meetings
Data manager
MDT meeting
Regular, to discuss multidisciplinary aspects of individual patient care
Patient empowerment and advocacy
Clear verbal, and written information for patients that describes diagnostic procedures and treatment options;
shared decision-making; collaboration with advocacy group
Interaction with external healthcare providers and other relevant stakeholders
GP, local specialist, social services, rehabilitation centres, national health services, labs,
insurers, school, work, sport club, psychologist, etc.
Quality control/Audits
Data collection/registration; monitoring of quality indicators; regular internal audits
Research, training, and education
Involvement in clinical and translational research: teaching courses on local, national, or international basis
Patient care pathway and clinical management protocol
Steps from diagnosis to follow-up including advanced disease, palliative stage, and end of life
At least 2 PH specialists treating a sufficient number of patientsa
Responsible for the co-ordination of care on patient level
Gynaecologist/
Obstetrician
Cardiothoracic 
anaesthetist
Processes
Pulmonary hypertension centre working 50% on PH care 
Figure 16 Pulmonary hypertension centre schematic. CHD, congenital heart disease; ECMO, extracorporeal membrane oxygenation; GP, general practitioner; MDT, multidisciplinary team; PH, pulmonary hypertension. aNumber adapted according to speciﬁc country characteristics. bCase manager can be a nurse specialist, social worker, physiotherapist, or administrative assistant in function of the centre organization. cCan be located in partner centres. Adapted from Biganzoli et al.846
ESC/ERS Guidelines
3701


<!-- PAGE 85 -->

### Page 85

12.1. Facilities and skills required for a pulmonary hypertension centre
Pulmonary hypertension centres care for a sufﬁcient number of patients on PH therapy, as well as new referrals, to warrant this status.
According to the 2015 ESC/ERS Guidelines for the diagnosis and treatment of PH and the European Reference Network on rare respiratory diseases (ERN-LUNG) competency requirements, the ideal number of patients seen by an adult centre each year is no fewer than 200, of which at least half have a ﬁnal diagnosis of PAH; a PH
centre follows at least 50 patients with PAH or CTEPH and receives at least two new referrals per month with documented PAH or
CTEPH.25,26,837–839 These numbers can be adapted according to speciﬁc country characteristics (small population, large geographical area) provided that strong working collaborations are established with high-volume centres. This is currently facilitated by the availability of secure virtual platforms (e.g. ERN clinical patient management system).840
Proper training of staff members includes core competencies, such as those outlined in the ERS Pulmonary Vascular Diseases Continuing
Professional Development framework,841 and builds on entrustable professional activities, described in the ESC Core Curriculum.842
Clinical, laboratory, and imaging facilities include: a ward where health care providers have expertise in PH; a specialist outpatient service; an intermediate/ICU; 24/7 emergency care; an interventional radiology unit; diagnostic investigations, including echocardiography,
CT scanning, nuclear medicine, MRI, exercise tests, and PFTs; a cardiac catheterization laboratory; access to genetic counselling and testing; and fast and easy access to cardiothoracic and vascular surgery. Key diagnostic procedures are performed in sufﬁcient numbers to guarantee expertise (e.g. ERN-LUNG requirements).837 In analogy with the ‘advanced heart failure units’,843 PH centres offer the full range of PAH therapies available in their country (including i.v./
s.c. prostacyclin derivatives) and have early referral protocols to
CTEPH, LTx, and rehabilitation centres. Since evaluation and early availability of new drugs and techniques are critical, PH centres participate in collaborative clinical research.
Regular multidisciplinary team meetings, including core members and on-demand invited members (extended multidisciplinary team)
as needed (Figure 16), are required to establish and adapt individual patient care pathways. Case management (co-ordination of individual patient pathways) should include administrative, social, and care support. Remote accessibility of the PH centre by phone, mail, or other is a vital part of the care. Strategies have to be implemented in order to improve health literacy and shared decision-making,
with the support of dedicated patient decision tools. Transitioning from a paediatric PH centre to an adult PH centre requires adequate planning to prevent gaps in care. Involving national and/or international patient associations helps to design patient-centric care and to spread medical knowledge among patients and their carers.
Pulmonary hypertension centres should record patients’ data using local, national, or international patient registries, and be able to report process indicators (compliance with diagnostic and treatment guidelines, including LTx) and outcome indicators, such as
WHO-FC, exercise capacity, haemodynamics, quality of life, complications, and survival. They should undergo regular audits to assess the quality of delivered care.
12.2. European Reference Network
In 2017, the European Commission launched European Reference
Networks (ERNs) for rare diseases that included the ERN-LUNG
with a PH core network. European Reference Networks are patientcentred networks of commissioned centres offering guidance and cross-border best standard of care in the European Union. The
PH network includes over 20 full members, contributing each year
≏1500 new patients with PAH or CTEPH.844 It also includes UK
supporting centres, and afﬁliated partners (who do not necessarily have to fulﬁl the minimum competency criteria of the ERN-LUNG
PH network). The ERN-LUNG requires and monitors standards for these centres.
12.3. Patient associations and patient empowerment
Pulmonary hypertension centres should inform patients about patient associations and encourage them to join such groups. Patient associations are a valuable resource for managing patients, as they provide educational and emotional support, and can have positive effects on coping, conﬁdence, and outlook.845 It is recommended that
PH centres collaborate with patient associations on initiatives to
Recommendation Table 25 — Recommendations for pulmonary hypertension centres
Recommendations
Classa
Levelb
It is recommended that PH centres provide care by a multidisciplinary team (cardiologist,
pneumologist, rheumatologist, nurse specialist,
radiologist, psychological and social work support,
and appropriate on-call expertise)
I
C
It is recommended that PH centres have direct links and quick referral patterns to other services
(such as genetic counselling, PEA/BPA, LTx, and adult congenital heart disease service)
I
C
It is recommended that PH centres maintain a patient registry
I
C
It is recommended that PH centres collaborate with patient associations
I
C
Accreditation of the PH centres should be considered (e.g. https://ec.europa.eu/health/ern/
assessment_en)
IIa
C
PH centres’ participation in collaborative clinical research should be considered
IIa
C
PH centres should follow-up a sufﬁcient number of patients to maintain expertise (at least 50
patients with PAH or CTEPH and at least two new referrals per month with documented PAH
or CTEPH), and consider establishing collaborations with high-volume centres
IIa
C
© ESC/ERS 2022
BPA, balloon pulmonary angioplasty; CTEPH, chronic thrombo-embolic pulmonary hypertension; LTx, lung transplantation; PAH, pulmonary arterial hypertension; PEA,
pulmonary endarterectomy; PH, pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
3702
ESC/ERS Guidelines


<!-- PAGE 86 -->

### Page 86

empower patients and improve the patient experience, addressing issues such as health literacy, digital skills, healthy lifestyles, mental health, and self-management. Health care can be delivered more effectively and efﬁciently if patients are full partners in the process.
13. Key messages
(1) The haemodynamic deﬁnition of PH has been updated as mPAP .20 mmHg. The deﬁnition of PAH also implies a PVR
.2 WU and PAWP ≤15 mmHg. These cut-off values better reﬂect the limits of normal ranges, but do not yet translate into new therapeutic recommendations, since the efﬁcacy of
PAH therapy in patients with PVD and an mPAP 21–
24 mmHg and/or PVR 2–3 WU is still unknown.
(2) The main diagnostic algorithm for PH has been simpliﬁed following a three-step approach, from suspicion by ﬁrst-line physicians, detection by echocardiography, and conﬁrmation with
RHC in PH centres. Warning signs associated with worse outcomes have been identiﬁed, which justify immediate referral and management in PH centres.
(3) Screening strategies for PAH in patients with SSc and in those at risk of HPAH are proposed based on the results of published cohort studies. Their implementation may shorten the time from symptom onset to diagnosis of PAH.
(4) An improved recognition of CT and echocardiographic signs of
CTEPH at the time of an acute PE event, together with a systematic follow-up of patients with acute PE, as indicated in the 2019 ESC/ERS Guidelines for the diagnosis and management of acute pulmonary embolism, should help to remediate the underdiagnosis of CTEPH.
(5) The three-strata risk-stratiﬁcation assessment in PAH has been reﬁned after being validated in multiple registries. The MRI and echocardiographic criteria have been added to the ESC/ERS table, reﬁning non-invasive evaluation at diagnosis.
(6) A four-strata risk stratiﬁcation, dividing the large, intermediate-risk group into intermediate–low and intermediate–high risk, is proposed at follow-up.
(7) The treatment algorithm for PAH has been simpliﬁed, with a clear focus on risk assessment, cardiopulmonary comorbidities,
and treatment goals. Initial combination therapy and treatment escalation at follow-up when appropriate are current standards.
(8) The Task Force has attempted to close the gap between paediatric and adult PAH care, with therapeutic and follow-up strategies based on risk stratiﬁcation and treatment response,
extrapolated from that in adults but adapted for age.
(9) The recommendations on sex-related issues in patients with
PAH, including pregnancy, have been updated, with information and shared decision-making as key points.
(10) The recommendations for rehabilitation and exercise programmes in PH have been updated following the release of additional supportive evidence.
(11) For the ﬁrst time, there is a recommendation for PH medical therapy in group 3 PH, based on a single positive RCT in patients with ILD.
(12) The concept of CTEPD with or without PH has been introduced, enabling further research on the natural history and management in the absence of PH.
(13) The treatment algorithm for CTEPH has been modiﬁed, including multimodal therapy with surgery, PH drugs, and BPA.
14. Gaps in evidence
14.1. Pulmonary arterial hypertension
(group 1)
• The efﬁcacy and safety of PAH drugs in group 1 patients with an mPAP 21–24 mmHg, PVR 2–3 WU, and exercise PH has to be established.
• The role of PAH drugs in different PAH subgroups, including schistosomiasis-associated PAH, needs to be explored.
• Risk-stratiﬁcation assessment in PAH needs to be further prospectively validated through goal-orientated outcome studies,
and optimized for patients with PAH and comorbidities.
• New PAH phenotypes observed in patients with signiﬁcant cardiopulmonary comorbidities are common and should be the focus of more research.
• The importance of PAH patient phenotypes and the relevance of comorbidities on treatment goals and outcomes must be further evaluated.
• The impact of PAH therapies and treatment strategies on survival needs to be further assessed.
• Pulmonary arterial hypertension drugs targeting novel pathways are emerging and the impact of add-on use of this medication on outcomes has to be evaluated in RCTs.
• The role of RV imaging techniques (echocardiography, cMRI) in diagnosing and stratifying risk in PAH needs to be further studied.
The proposed cut-off values for risk stratiﬁcation need to be properly validated in multicentre studies.
• The role of CPET in the early diagnosis of PAH in populations at risk of developing PAH, and in assessing prognosis in PAH on top of clinical and haemodynamic data, needs further investigation.
• The role of exercise echocardiography and exercise RHC in patients at risk of developing PAH, with abnormal CPET but normal rest echocardiogram, also needs further evaluation.
• The use of mechanical circulatory support, particularly in reversible PH or in patients with advanced right HF with an exit strategy
(such as LTx), has to be further studied.
• Differences in natural history and treatment response between adults and children should be further investigated.
• Further studies are needed on the effects of PADN in PAH and in other PH groups.
• The impact of centre volume, organization, and expertise on treatment outcome needs further investigation.
14.2. Pulmonary hypertension associated with left heart disease (group 2)
• The management of patients with group 2 PH needs further study with RCTs.
• Additional research is needed to facilitate non-invasive diagnosis of
HFpEF-associated PH and distinguishing it from PAH.
• The role of ﬂuid challenge and exercise testing to reveal left HF
needs further validation.
ESC/ERS Guidelines
3703


<!-- PAGE 87 -->

### Page 87

• Further studies focusing on PDE5is in patients with HFpEF and a
CpcPH phenotype are needed and currently underway.
• The effects that new HF medication (ARNIs, SGLT-2is) has on PH,
through reverse remodelling of the LV, need further investigation.
14.3. Pulmonary hypertension associated with lung diseases and/or hypoxia
(group 3)
• The management of patients with group 3 PH has to be further studied in RCTs.
• Reﬁning phenotypes will be crucial, as this will inform development of trials.
• Clinical relevance and therapeutic implications of severe PH in lung disease need to be investigated.
• Long-term data on the effects of inhaled treprostinil (and other
PAH drugs) in patients with PH associated with lung disease are needed.
• The impact of the hypobaric and hypoxic environment of the .150
million people living at .2500 m altitude has tobe clariﬁed, and studies need to be performed to assess potential treatment strategies for PH.
14.4. Chronic thrombo-embolic pulmonary hypertension (group 4)
• The differentiation between acute and chronic PE in imaging
(CTPA) has to be improved.
• In patients with suspected CTEPH, the diagnostic role of DECT or iodine subtraction mapping vs. V/Q lung scintigraphy has to be validated.
• The effect of drug therapy on the outcome of patients with
CTEPH needs to be established.
• The treatment goals in patients with CTEPH have to be clariﬁed, as it is still unclear if normalizing mPAP and PVR translates into improved outcomes.
• The role of BPA vs. PEA should be further clariﬁed: which treatment in which patient? Are they equivalent for the treatment of segmental/subsegmental disease?
• In inoperable CTEPH or persistent/recurrent PH after PEA, the potential role of combination therapy of PH drugs must be assessed.
• The role of medical treatments as bridges to interventional and operative treatments needs to be formally tested.
• Randomized controlled trials are needed to discriminate the effects of PEA and early follow-up rehabilitation.
• The effect of PEA, BPA, and medical therapy on patients with
CTEPD without PH is not established.
14.5. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5)
• Further research needs to inform management of group 5 PH,
such as SCD-associated PH and sarcoidosis-associated PH.
15. ‘What to do’ and ‘What not to do’ messages from the Guidelines
Recommendations
Classa
Levelb
Recommendations for right heart catheterization and vasoreactivity testing
Right heart catheterization
It is recommended that RHC is performed to conﬁrm the diagnosis of PH (especially PAH or CTEPH) and to support treatment decisions
I
B
In patients with suspected or known PH, it is recommended that RHC is performed in experienced centres
I
C
It is recommended that RHC comprises a complete set of haemodynamics and is performed following standardized protocols
I
C
Vasoreactivity testing
Vasoreactivity testing is recommended in patients with I/H/DPAH to detect those who can be treated with high doses of a CCB
I
B
It is recommended that vasoreactivity testing is performed at PH centres
I
C
It is recommended to consider a positive response to vasoreactivity testing by a reduction in mPAP ≥10 mmHg to reach an absolute value of mPAP ≤40 mmHg with an increased or unchanged COc
I
C
Inhaled nitric oxide, inhaled iloprost, or i.v. epoprostenol are recommended for performing vasoreactivity testing
I
C
Vasoreactivity testing, for identifying candidates for CCB therapy, is not recommended in patients with PAH other than I/H/DPAH and in PH groups 2, 3, 4, and 5
III
C
Continued
3704
ESC/ERS Guidelines


<!-- PAGE 88 -->

### Page 88

Recommendations for diagnostic strategy
Echocardiography
Echocardiography is recommended as the ﬁrst-line, non-invasive, diagnostic investigation in suspected PH
I
B
It is recommended to assign an echocardiographic probability of PH, based on an abnormal TRV and the presence of other echocardiographic signs suggestive of PH (see Table 10)
I
B
It is recommended to maintain the current threshold for TRV (.2.8 m/s) for echocardiographic probability of PH according to the updated haemodynamic deﬁnition
I
C
Imaging
Ventilation/perfusion or perfusion lung scan is recommended in patients with unexplained PH to assess for CTEPH
I
C
CT pulmonary angiography is recommended in the work-up of patients with suspected CTEPH
I
C
Routine biochemistry, haematology, immunology, HIV testing, and thyroid function tests are recommended in all patients with PAH, to identify associated conditions
I
C
Abdominal ultrasound is recommended for the screening of portal hypertension
I
C
Other diagnostic tests
Pulmonary function tests with DLCO are recommended in the initial evaluation of patients with PH
I
C
Open or thoracoscopic lung biopsy is not recommended in patients with PAH
III
C
Recommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension
Systemic sclerosis
In patients with SSc, an annual evaluation of the risk of having PAH is recommended
I
B
In adult patients with SSc with .3 years’ disease duration, an FVC ≥40%, and a DLCO ,60%, the DETECT algorithm is recommended to identify asymptomatic patients with PAH
I
B
In patients with SSc, where breathlessness remains unexplained following non-invasive assessment, RHC is recommended to exclude
PAH
I
C
CTEPH/CTEPD
In patients with persistent or new-onset dyspnoea or exercise limitation following PE, further diagnostic evaluation to assess for
CTEPH/CTEPD is recommended
I
C
For symptomatic patients with mismatched perfusion lung defects beyond 3 months of anticoagulation for acute PE, referral to a PH/
CTEPH centre is recommended after considering the results of echocardiography, BNP/NT-proBNP, and/or CPET
I
C
Other
Counselling regarding the risk of PAH and annual screening are recommended in individuals who test positive for PAH-causing mutations and in ﬁrst-degree relatives of patients with HPAH
I
B
In patients referred for liver transplantation, echocardiography is recommended as a screening test for PH
I
C
Recommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension
It is recommended to evaluate disease severity in patients with PAH with a panel of data derived from clinical assessment, exercise tests,
biochemical markers, echocardiography, and haemodynamic evaluations
I
B
Achieving and maintaining a low-risk proﬁle on optimized medical therapy is recommended as a treatment goal in patients with PAH
I
B
For risk stratiﬁcation at the time of diagnosis, the use of a three-strata model (low, intermediate, and high risk) is recommended, taking into account all available data including haemodynamics
I
B
For risk stratiﬁcation during follow-up, the use of a four-strata model (low, intermediate–low, intermediate–high, and high risk) based on
WHO-FC, 6MWD, and BNP/NT-proBNP is recommended, with additional variables taken into account as necessary
I
B
Continued
ESC/ERS Guidelines
3705


<!-- PAGE 89 -->

### Page 89

Recommendations for general measures and special circumstances
General measures
Supervised exercise training is recommended in patients with PAH under medical therapy
I
A
Psychosocial support is recommended in patients with PAH
I
C
Immunization of patients with PAH against SARS-CoV-2, inﬂuenza, and Streptococcus pneumoniae is recommended
I
C
Diuretic treatment is recommended in patients with PAH with signs of RV failure and ﬂuid retention
I
C
Long-term oxygen therapy is recommended in patients with PAH whose arterial blood oxygen pressure is ,8 kPa (60 mmHg)d
I
C
In the presence of iron-deﬁciency anaemia, correction of iron status is recommended in patients with PAH
I
C
The use of ACEis, ARBs, ARNIs, SGLT-2is, beta-blockers, or ivabradine is not recommended in patients with PAH unless required by comorbidities (i.e. high blood pressure, coronary artery disease, left HF, or arrhythmias)
III
C
Special circumstances
In-ﬂight oxygen administration is recommended for patients using oxygen or whose arterial blood oxygen pressure is ,8 kPa
(60 mmHg) at sea level
I
C
Recommendations for women of childbearing potential
It is recommended that women of childbearing potential with PAH are counselled at the time of diagnosis about the risks and uncertainties associated with becoming pregnant; this should include advice against becoming pregnant, and referral for psychological support where needed
I
C
It is recommended to provide women of childbearing potential with PAH with clear contraceptive advice, considering the individual needs of the woman but recognizing that the implications of contraceptive failure are signiﬁcant in PAH
I
C
It is recommended that women with PAH who consider pregnancy or who become pregnant receive prompt counselling in an experienced PH centre, to facilitate genetic counselling and shared decision-making, and to provide psychological support to the patients and their families where needed
I
C
For women with PAH having termination of pregnancy, it is recommended that this be performed in PH centres, with psychological support provided to the patients and their families
I
C
As teratogenic potential has been reported in pre-clinical models for endothelin receptor antagonists and riociguat, these drugs are not recommended during pregnancy
III
B
Recommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension
High doses of CCBs are recommended in patients with IPAH, HPAH, or DPAH who are responders to acute vasoreactivity testing
I
C
Close follow-up with complete reassessment after 3–4 months of therapy (including RHC) is recommended in patients with IPAH,
HPAH, or DPAH treated with high doses of CCBs
I
C
Continuing high doses of CCBs is recommended in patients with IPAH, HPAH, or DPAH in WHO-FC I or II with marked haemodynamic improvement (mPAP ,30 mmHg and PVR ,4 WU)
I
C
Initiating PAH therapy is recommended in patients who remain in WHO-FC III or IV or those without marked haemodynamic improvement after high doses of CCBs
I
C
CCBs are not recommended in patients without a vasoreactivity study or non-responders, unless prescribed for other indications (e.g.
Raynaud’s phenomenon)
III
C
Recommendations for initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension without cardiopulmonary comorbiditiese
Initial combination therapy with ambrisentan and tadalaﬁl is recommended
I
B
Initial combination therapy with macitentan and tadalaﬁl is recommended
I
B
Initial combination therapy with macitentan, tadalaﬁl, and selexipag is not recommended
III
B
Continued
3706
ESC/ERS Guidelines


<!-- PAGE 90 -->

### Page 90

Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension
General recommendation for sequential combination therapy
It is recommended to base treatment escalations on risk assessment and general treatment strategies (see treatment algorithm)
I
C
Evidence from studies with a composite morbidity/mortality endpoint as the primary outcome measure
The addition of macitentan to PDE5is or oral/inhaled prostacyclin analogues is recommended to reduce the risk of morbidity/mortality events
I
B
The addition of selexipag to ERAsf and/or PDE5is is recommended to reduce the risk of morbidity/mortality events
I
B
The addition of oral treprostinil to ERA or PDE5i/riociguat monotherapy is recommended to reduce the risk of morbidity/mortality events
I
B
The addition of bosentan to sildenaﬁl is not recommended to reduce the risk of morbidity/mortality events
III
B
Evidence from studies with change in 6MWD as the primary outcome measure
The addition of sildenaﬁl to epoprostenol is recommended to improve exercise capacity
I
B
Evidence from studies with safety of combination therapy as primary outcome measure
Combining riociguat and PDE5is is not recommendedg
III
B
Recommendations for intensive care management for pulmonary arterial hypertension
When managing patients with right HF in the ICU, it is recommended to involve physicians with expertise, treat causative factors, and use supportive measures, including inotropes and vasopressors, ﬂuid management, and PAH drugs, as appropriate
I
C
Recommendations for lung transplantation
It is recommended that potentially eligible candidates are referred for LTx evaluation when they have an inadequate response to oral combination therapy, indicated by an intermediate–high or high risk or by a REVEAL risk score .7
I
C
It is recommended to list patients for LTx who present with a high risk of death or with a REVEAL risk score ≥10 despite receiving optimized medical therapy including s.c. or i.v. prostacyclin analogues
I
C
Recommendations for pulmonary arterial hypertension associated with drugs or toxins
It is recommended to make a diagnosis of drug- or toxin-associated PAH in patients who had relevant exposure and in whom other causes of PH have been excluded
I
C
In patients with suspected drug- or toxin-associated PAH, it is recommended to immediately discontinue the causative agent whenever possible
I
C
Recommendations for pulmonary arterial hypertension associated with connective tissue disease
In patients with PAH associated with CTD, treatment of the underlying condition according to current guidelines is recommended
I
A
In patients with PAH associated with CTD, the same treatment algorithm as for patients with IPAH is recommended
I
C
Recommendations for pulmonary arterial hypertension associated with human immunodeﬁciency virus infection
In patients with PAH associated with HIV infection, antiretroviral treatment according to current guidelines is recommended
I
A
Recommendations for pulmonary arterial hypertension associated with portal hypertension
Echocardiography is recommended in patients with liver disease or portal hypertension with signs or symptoms suggestive of PH, and as a screening tool in patients evaluated for liver transplantation or transjugular portosystemic shunt
I
C
It is recommended that patients with PAH associated with portal hypertension are referred to centres with expertise in managing both conditions
I
C
Drugs approved for PAH are not recommended for patients with portal hypertension and unclassiﬁed PH (i.e. elevated mPAP, high CO,
and a normal PVR)
III
C
Continued
ESC/ERS Guidelines
3707


<!-- PAGE 91 -->

### Page 91

Recommendations for shunt closure in patients with pulmonary-systemic ﬂow ratio .1.5:1 based on calculated pulmonary vascular resistance
In patients with an ASD, VSD, or PDA and a PVR ,3 WU, shunt closure is recommended
I
C
In patients with an ASD and a PVR .5 WU despite PAH treatment, shunt closure is not recommended
III
C
Recommendations for pulmonary arterial hypertension associated with adult congenital heart disease
Risk assessment
Risk assessment is recommended for patients with persistent PAH after defect closure
I
C
Treatment
Bosentan is recommended in symptomatic patients with Eisenmenger syndrome to improve exercise capacity
I
B
In women with Eisenmenger syndrome, pregnancy is not recommended
III
C
In patients with Eisenmenger syndrome, routine phlebotomy to lower elevated haematocrit is not recommended
III
C
Recommendations for pulmonary arterial hypertension with signs of venous/capillary involvement
A combination of clinical and radiological ﬁndings, ABG, PFTs, and genetic testing is recommended to diagnose PAH with signs of venous and/or capillary involvement (PVOD/PCH)
I
A
Identiﬁcation of biallelic EIF2AK4 mutations is recommended to conﬁrm a diagnosis of heritable PVOD/PCH
I
A
Referral of eligible patients with PVOD/PCH to a transplant centre for evaluation is recommended as soon as the diagnosis is established
I
C
Lung biopsy is not recommended to conﬁrm a diagnosis of PVOD/PCH
III
C
Recommendations for paediatric pulmonary hypertension
Children
It is recommended to perform the diagnostic work-up, including RHC and acute vasoreactivity testing, and treat children with PH at centres with speciﬁc expertise in paediatric PH
I
C
In children with PH, a comprehensive work-up for conﬁrming diagnosis and speciﬁc aetiology is recommended (similar to that in adults,
but adapted for age)
I
C
For conﬁrming PH diagnosis, RHC is recommended, preferably before initiating any PAH therapy
I
C
In children with IPAH/HPAH, acute vasoreactivity testing is recommended to detect those who may beneﬁt from CCB therapy
I
C
It is recommended to similarly deﬁne a positive response to acute vasoreactivity testing in children and adults by a reduction in mPAP
≥10 mmHg to reach an absolute value of mPAP ≤40 mmHg, with an increased or unchanged CO
I
C
In children with PAH, a therapeutic strategy based on risk stratiﬁcation and treatment response is recommended, extrapolated from that in adults, but adapted for age
I
C
It is recommended to monitor the treatment response in children with PAH by serially assessing a panel of data derived from clinical assessment, echocardiographic evaluation, biochemical markers, and exercise tolerance tests
I
C
Infants
It is recommended to screen infants with bronchopulmonary dysplasia for PH
I
B
In infants with (or at risk of) bronchopulmonary dysplasia and PH, treating lung disease—including hypoxia, aspiration, and structural airway disease—and optimizing respiratory support is recommended before initiating PAH therapy
I
B
Recommendations for pulmonary hypertension associated with left heart disease
In patients with LHD, optimizing treatment of the underlying condition is recommended before considering assessment of suspected PH
I
A
RHC is recommended for suspected PH in patients with LHD, if it aids management decisions
I
C
Continued
3708
ESC/ERS Guidelines


<!-- PAGE 92 -->

### Page 92

RHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair
I
C
For patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV dysfunction, referral to a PH centre for a complete diagnostic work-up is recommended
I
C
In patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is recommended
I
C
When patients with PH and multiple risk factors for LHD, who have a normal PAWP at rest but an abnormal response to exercise or
ﬂuid challenge, are treated with PAH drugs, close monitoring is recommended
I
C
Drugs approved for PAH are not recommended in PH-LHDh
III
A
Recommendations for pulmonary hypertension associated with lung disease and/or hypoxia
If PH is suspected in patients with lung disease, it is recommended that echocardiographyi be performed and results interpreted in conjunction with ABG, PFTs including DLCO, and CT imaging
I
C
In patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where indicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation
I
C
In patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH, referral to a PH
centre is recommendedj
I
C
In patients with lung disease and severe PH, an individualized approach to treatment is recommended
I
C
It is recommended to refer eligible patients with lung disease and PH for LTx evaluation
I
C
In patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions
I
C
The use of ambrisentan is not recommended in patients with PH associated with IPF
III
B
The use of riociguat is not recommended in patients with PH associated with IIP
III
B
The use of PAH medication is not recommended in patients with lung disease and non-severe PHk
III
C
Recommendations for chronic thrombo-embolic pulmonary hypertension and chronic thrombo-embolic pulmonary disease without pulmonary hypertension
CTEPH
Lifelong, therapeutic doses of anticoagulation are recommended in all patients with CTEPH
I
C
Antiphospholipid syndrome testing is recommended in patients with CTEPH
I
C
In patients with CTEPH and antiphospholipid syndrome, anticoagulation with VKAs is recommended
I
C
It is recommended that all patients with CTEPH are reviewed by a CTEPH team for the assessment of multimodality management
I
C
PEA is recommended as the treatment of choice for patients with CTEPH and ﬁbrotic obstructions within pulmonary arteries accessible by surgery
I
B
BPA is recommended in patients who are technically inoperable or have residual PH after PEA and distal obstructions amenable to BPA
I
B
Riociguat is recommended for symptomatic patients with inoperable CTEPH or persistent/recurrent PH after PEA
I
B
Long-term follow-up is recommended after PEA and BPA, as well as for patients with CTEPH established on medical therapy
I
C
Recommendations for pulmonary hypertension centres
It is recommended that PH centres provide care by a multidisciplinary team (cardiologist, pneumologist, rheumatologist, nurse specialist,
radiologist, psychological and social work support, appropriate on-call expertise)
I
C
It is recommended that PH centres have direct links and quick referral patterns to other services (such as genetic counselling, PEA/BPA,
LTx, adult congenital heart disease service)
I
C
Continued
ESC/ERS Guidelines
3709


<!-- PAGE 93 -->

### Page 93

### 16 Quality indicators

Quality indicators (QIs) are tools that may be used to evaluate care quality, including structural, process, and outcomes of care.847 They may also serve as a mechanism for enhancing adherence to guideline recommendations through associated quality-improvement initiatives and benchmarking of care providers.848,849 As such, the role of QIs in improving care and outcomes for cardiovascular disease is increasingly being recognized by health care authorities, professional organizations, payers, and the public.847
The ESC understands the need for measuring and reporting quality and outcomes of cardiovascular care, and has established methods for developing the ESC QIs for the quantiﬁcation of care and outcomes for cardiovascular diseases.847 To date, the ESC has developed QI suites for a number of cardiovascular diseases850–852
and embedded these in respective ESC Clinical Practice guidelines.27,477,853,854 Furthermore, the ESC aims to integrate its QIs with clinical registries such as the EurObservational Research
Programme and the European Uniﬁed Registries On Heart Care
Evaluation and Randomized Trials (EuroHeart) project855 to provide real-world data about the patterns and outcomes of care for cardiovascular disease across Europe.
In parallel with the writing of this Clinical Practice Guideline, a process has been initiated to develop QIs for patients with PH using the
It is recommended that PH centres maintain a patient registry
I
C
It is recommended that PH centres collaborate with patient associations
I
C
© ESC/ERS 2022
6MWD, 6-minute walking distance; ABG, arterial blood gas analysis; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–
neprilysin inhibitor; ASD, atrial septal defect; BNP/NT-proBNP, brain natriuretic peptide/N-terminal pro-brain natriuretic peptide; BPA, balloon pulmonary angioplasty; CCB,
calcium channel blocker; CpcPH, combined post- and pre-capillary pulmonary hypertension; CPET, cardiopulmonary exercise testing; CT, computed tomography; CTD, connective tissue disease; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon monoxide; DPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; FVC, forced vital capacity; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HIV, human immunodeﬁciency virus; HPAH, heritable pulmonary arterial hypertension; ICU, intensive care unit; I/H/DPAH, idiopathic, heritable,
drug-associated pulmonary arterial hypertension; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; IPF, idiopathic pulmonary ﬁbrosis; i.v., intravenous; LHD, left heart disease; LTx, lung transplantation; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PAWP,
pulmonary arterial wedge pressure; PCH, pulmonary capillary haemangiomatosis; PDA, patent ductus arteriosus; PDE5i, phosphodiesterase 5 inhibitor; PE, pulmonary embolism;
PEA, pulmonary endarterectomy; PFTs, pulmonary function tests; PH, pulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVOD,
pulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right ventricular; s.c., subcutaneous; SGLT-2i, sodium–glucose cotransporter-2 inhibitor; SSc, systemic sclerosis; TRV, tricuspid regurgitation velocity; VKA, vitamin K antagonist; VSD, ventricular septal defect; WHO-FC, World Health
Organization functional class; WU, Wood units.
aClass of recommendation.
bLevel of evidence.
cTesting should also be performed in patients with a baseline mPAP ≤40 mmHg, in whom the same responder criteria apply.
dMeasured on at least two occasions.
eCardiopulmonary comorbidities are predominantly encountered in elderly patients and include risk factors for HFpEF such as obesity, diabetes, coronary heart disease, a history of hypertension, and/or a low DLCO.
fERA used in the GRIPHON study were bosentan and ambrisentan.
gThe PATENT plus study investigated the combination of sildenaﬁl and riociguat; however, combining riociguat with any PDE5i is contraindicated.
hSafety concerns have been identiﬁed when ERAs are used in patients with HF (HFpEF and HFrEF, with or without PH) and when sildenaﬁl is used in patients with persistent PH after correction of valvular heart disease.
iAssessments should ideally be made when the patient is clinically stable, as exacerbations can signiﬁcantly raise pulmonary artery pressure.
jThis recommendation does not apply to patients with end-stage lung disease who are not considered candidates for LTx.
kThis does not include inhaled treprostinil, which may be considered in patients with PH associated with ILD irrespective of PH severity.
‘What to do’ and ‘What not to do’ messages developed with GRADE Evidence to Decision framework
GRADE
Recommendations
Quality of evidence
Strength of recommendation
Classa
Levelb
In patients with IPAH/HPAH/DPAH who present at low or intermediate risk of death, initial combination therapy with a PDE5i and an ERA is recommended
Low
Conditional
I
B
The use of PDE5i in patients with HFpEF and isolated post-capillary PH is not recommended
Low
Conditional
III
C
The use of PDE5i in patients with ILD and non-severe PH is not recommended
Very low
Conditional
III
C
© ESC/ERS 2022
DPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; HPAH, heritable pulmonary arterial hypertension; HFpEF, heart failure with preserved ejection fraction; ILD, interstitial lung disease; PDE5i, phosphodiesterase 5 inhibitor; PH, pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
3710
ESC/ERS Guidelines


<!-- PAGE 94 -->

### Page 94

ESC methodology and through collaboration with domain experts and the Heart Failure Association of the ESC. Such QIs may be used for evaluating the quality of care for patients with PH, and enable important aspects of care delivery to be captured. These QIs,
alongside their speciﬁcations and development process, will be published separately.
17. Supplementary data
Supplementary data is available at European Heart Journal online including key narrative question (1-8) and PICO questions (I-IV).
18. Data availability statement
No new data were generated or analysed in support of this research.
19. Author information
Author/Task Force Member Afﬁliations: Marc Humbert*,
Faculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre,
France, Service de Pneumologie et Soins Intensifs Respiratoires,
Centre de Référence de l’Hypertension Pulmonaire, Hôpital
Bicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre,
France, INSERM UMR_S 999, Hôpital Marie-Lannelongue, Le
Plessis-Robinson, France; Gabor Kovacs, University Clinic of
Internal Medicine, Division of Pulmonology, Medical University of
Graz, Graz, Austria, Ludwig Boltzmann Institute for Lung Vascular
Research,
Graz,
Austria;
Marius
M.
Hoeper,
Respiratory
Medicine,
Hannover
Medical
School,
Hanover,
Germany,
Biomedical Research in End-stage and Obstructive Lung Disease
(BREATH), member of the German Centre of Lung Research
(DZL), Hanover, Germany; Roberto Badagliacca, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari,
Sapienza
Università
di
Roma,
Roma,
Italy,
Dipartimento
Cardio-Toraco-Vascolare e
Chirurgia dei
Trapianti d’Organo,
Policlinico Umberto I, Roma, Italy; Rolf M.F. Berger, Center for
Congenital Heart Diseases, Beatrix Children’s Hospital, Dept of
Paediatric
Cardiology,
University
Medical
Center
Groningen,
University of Groningen, Groningen, Netherlands; Margarita
Brida, Department of Sports and Rehabilitation Medicine, Medical
Faculty University of Rijeka, Rijeka, Croatia, Adult Congenital Heart
Centre and National Centre for Pulmonary Hypertension, Royal
Brompton & Hareﬁeld Hospitals, Guys & St Thomas’s NHS Trust,
London,
United
Kingdom;
Jørn
Carlsen,
Department of
Cardiology,
Copenhagen
University
Hospital,
Rigshospitalet,
Copenhagen, Denmark, Department of Clinical Medicine; Faculty of
Health and
Medical
Sciences,
University of
Copenhagen,
Copenhagen, Denmark; Andrew J.S. Coats, Faculty of Medicine,
University of Warwick, Coventry, United Kingdom, Faculty of
Medicine,
Monash
University
Melbourne,
Australia;
Pilar
Escribano-Subias, Pulmonary Hypertension Unit, Cardiology
Department, Hospital Universitario 12 de Octubre, Madrid, Spain,
CIBER-CV (Centro de Investigaciones Biomédicas En Red de enfermedades CardioVasculares), Instituto de Salud Carlos III, Madrid,
Spain, Facultad de Medicina, Universidad Complutense, Madrid,
Spain; Pisana Ferrari (Italy), ESC Patient Forum, Sophia Antipolis,
France, AIPI, Associazione Italiana Ipertensione Polmonare, Bologna,
Italy; Diogenes S. Ferreira, Alergia e Imunologia, Hospital de
Clinicas, Universidade Federal do Parana, Curitiba, Brazil; Hossein
Ardeschir
Ghofrani,
Department of
Internal
Medicine,
University
Hospital
Giessen,
Justus-Liebig
University,
Giessen,
Germany, Department of Pneumology, Kerckhoff Klinik, Bad
Nauheim, Germany, Department of Medicine, Imperial College
London, London, United Kingdom; George Giannakoulas,
Cardiology
Department,
Aristotle
University of
Thessaloniki,
AHEPA University Hospital, Thessaloniki, Greece; David G. Kiely,
Department of Infection, Immunity and Cardiovascular Disease,
University of
Shefﬁeld,
Shefﬁeld,
United
Kingdom,
Shefﬁeld
Pulmonary Vascular Disease Unit, Shefﬁeld Teaching Hospitals NHS
Foundation Trust, Shefﬁeld, United Kingdom, Insigneo Institute,
University of Shefﬁeld, Shefﬁeld, United Kingdom; Eckhard
Mayer,
Thoracic
Surgery,
Kerckhoff
Clinic,
Bad
Nauheim,
Germany; Gergely Meszaros (Hungary), ESC Patient Forum,
Sophia
Antipolis,
France,
European
Lung
Foundation
(ELF),
Shefﬁeld, United Kingdom; Blin Nagavci, Institute for Evidence in
Medicine, Faculty of Medicine and Medical Center, University of
Freiburg, Freiburg, Germany; Karen M. Olsson, Clinic of
Respiratory Medicine, Hannover Medical School, member of the
German Center of Lung Research (DZL), Hannover, Germany;
Joanna Pepke-Zaba, Pulmonary Vascular Diseases Unit, Royal
Papworth
Hospital,
Cambridge,
United
Kingdom;
Jennifer
K. Quint, NHLI, Imperial College London, London, United
Kingdom; Göran Rådegran, Department of Cardiology, Clinical
Sciences
Lund,
Faculty of
Medicine,
Lund,
Sweden,
The
Haemodynamic Lab, The Section for Heart Failure and Valvular
Disease, VO. Heart and Lung Medicine, Skåne University Hospital,
Lund, Sweden; Gerald Simonneau, Faculté Médecine, Université
Paris Saclay, Le Kremlin-Bicêtre, France, Centre de Référence de l’Hypertension
Pulmonaire,
Hopital
Marie-Lannelongue,
Le
Plessis-Robinson, France; Olivier Sitbon, Faculty of Medicine,
Université Paris-Saclay, Le Kremlin-Bicêtre, France, Service de
Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l’Hypertension Pulmonaire, Hôpital Bicêtre, Assistance Publique
Hôpitaux de Paris, Le Kremlin-Bicêtre, France, INSERM UMR_S
999,
Hôpital Marie-Lannelongue,
Le
Plessis-Robinson,
France;
Thomy Tonia, Institute of Social and Preventive Medicine,
University of Bern, Bern, Switzerland; Mark Toshner, Heart Lung
Research Institute, Dept of Medicine, University of Cambridge,
Cambridge,
United
Kingdom,
Royal
Papworth
NHS
Trust;
Jean-Luc Vachiery, Department of Cardiology, Pulmonary
Vascular Diseases and Heart Failure Clinic, HUB Hôpital Erasme,
Brussels, Belgium; and Anton Vonk Noordegraaf, Pulmonology,
Amsterdam UMC, Amsterdam, Netherlands.
* Marc Humbert is supported by the Investissement d’Avenir programme managed by the French National Research Agency under the grant contract ANR-18-RHUS-0006 (DESTINATION 2024).
20. Appendix
ESC/ERS Scientiﬁc Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
ESC/ERS Guidelines
3711


<!-- PAGE 95 -->

### Page 95

Document Reviewers: Markus Schwerzmann (ESC Review
Coordinator) (Switzerland), Anh-Tuan Dinh-Xuan (ERS Review
Coordinator)
(France),
Andy
Bush
(United
Kingdom),
Magdy
Abdelhamid (Egypt), Victor Aboyans (France), Eloisa Arbustini (Italy),
Riccardo Asteggiano (Italy), Joan-Albert Barberà (Spain), Maurice
Beghetti (Switzerland), Jelena Čelutkienė (Lithuania), Maja Cikes
(Croatia), Robin Condliffe (United Kingdom), Frances de Man
(Netherlands), Volkmar Falk (Germany), Laurent Fauchier (France),
Sean Gaine (Ireland), Nazzareno Galié (Italy), Wendy Gin-Sing
(United
Kingdom),
John
Granton
(Canada),
Ekkehard
Grünig
(Germany), Paul M. Hassoun (United States of America), Merel
Hellemons (Netherlands), Tiny Jaarsma (Sweden), Barbro Kjellström
(Sweden), Frederikus A. Klok (Netherlands), Aleksandra Konradi
(Russian Federation), Konstantinos C. Koskinas (Switzerland), Dipak
Kotecha (United Kingdom), Irene Lang (Austria), Basil S. Lewis
(Israel), Ales Linhart (Czech Republic), Gregory Y.H. Lip (United
Kingdom), Maja-Lisa Løchen (Norway), Alexander G. Mathioudakis
(United Kingdom), Richard Mindham (United Kingdom), Shahin
Moledina (United Kingdom), Robert Naeije (Belgium), Jens Cosedis
Nielsen (Denmark), Horst Olschewski (Austria), Isabelle Opitz
(Switzerland), Steffen E. Petersen (United Kingdom), Eva Prescott
(Denmark), Amina Rakisheva (Kazakhstan), Abilio Reis (Portugal),
Arsen D. Ristić (Serbia), Nicolas Roche (France), Rita Rodrigues
(Portugal), Christine Selton-Suty (France), Rogerio Souza (Brazil),
Andrew J. Swift (United Kingdom), Rhian M. Touyz (Canada/United
Kingdom), Silvia Ulrich (Switzerland), Martin R. Wilkins (United
Kingdom), and Stephen John Wort (United Kingdom).
ESC National Cardiac Societies actively involved in the review process of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Algeria: Algerian Society of
Cardiology,
Messaad
Krim;
Armenia:
Armenian Cardiologists
Association, Hamlet Hayrapetyan; Austria: Austrian Society of
Cardiology,
Irene
Lang;
Azerbaijan:
Azerbaijan
Society of
Cardiology, Oktay Musayev; Belarus: Belorussian Scientiﬁc Society of
Cardiologists,
Irina
Lazareva;
Bosnia and Herzegovina:
Association of Cardiologists of Bosnia and Herzegovina, Šekib
Sokolović; Bulgaria: Bulgarian Society of Cardiology, Vasil Velchev;
Croatia: Croatian Cardiac Society, Maja Cikes; Cyprus: Cyprus
Society of Cardiology, Ioannis Michaloliakos; Czechia: Czech Society of Cardiology, Pavel Jansa; Denmark: Danish Society of Cardiology,
Søren Mellemkjær; Egypt: Egyptian Society of Cardiology, Ahmed
Hassan; Estonia: Estonian Society of Cardiology, Ly Anton;
Finland: Finnish Cardiac Society, Markku Pentikäinen; France:
French Society of Cardiology, Nicolas Meneveau; Georgia: Georgian
Society of Cardiology, Mikheil Tsverava; Germany: German Cardiac
Society, Mareike Lankeit; Greece: Hellenic Society of Cardiology,
Athanasios Manginas; Hungary: Hungarian Society of Cardiology,
Istvan Hizoh; Ireland: Irish Cardiac Society, Vincent Maher; Israel:
Israel Heart Society, Rafael Hirsch; Italy: Italian Federation of
Cardiology,
Nazzareno
Galié;
Kazakhstan:
Association of
Cardiologists of Kazakhstan, Murat A. Mukarov; Kosovo (Republic of): Kosovo Society of Cardiology, Pranvera Ibrahimi; Kyrgyzstan:
Kyrgyz Society of Cardiology, Sooronbaev Talant, Latvia: Latvian
Society of Cardiology, Ainars Rudzitis; Lebanon: Lebanese Society of Cardiology, Ghassan Kiwan; Lithuania: Lithuanian Society of
Cardiology, Lina Gumbienė; Luxembourg: Luxembourg Society of
Cardiology, Andrei Codreanu; Malta: Maltese Cardiac Society, Josef
Micallef; Moldova (Republic of): Moldavian Society of Cardiology,
Eleonora
Vataman;
Montenegro:
Montenegro
Society of
Cardiology, Nebojsa Bulatovic; Morocco: Moroccan Society of
Cardiology, Said Chraibi; Netherlands: Netherlands Society of
Cardiology, Marco C. Post; North Macedonia: North Macedonian
Society of Cardiology, Elizabeta Srbinovska Kostovska; Norway:
Norwegian
Society of
Cardiology,
Arne
Kristian
Andreassen;
Poland:
Polish
Cardiac
Society,
Marcin
Kurzyna;
Portugal:
Portuguese Society of Cardiology, Rui Plácido; Romania: Romanian
Society of Cardiology, Ioan Mircea Coman; Russian Federation:
Russian Society of Cardiology, Oksana Vasiltseva; San Marino: San
Marino Society of Cardiology, Marco Zavatta; Serbia: Cardiology
Society of Serbia, Arsen D. Ristić; Slovakia: Slovak Society of
Cardiology,
Iveta
Šimkova;
Slovenia:
Slovenian
Society of
Cardiology, Gregor Poglajen; Spain: Spanish Society of Cardiology,
María Lázaro Salvador; Sweden: Swedish Society of Cardiology,
Stefan Söderberg; Switzerland: Swiss Society of Cardiology, Silvia
Ulrich; Syrian Arab Republic: Syrian Cardiovascular Association,
Mhd Yassin Bani Marjeh; Tunisia: Tunisian Society of Cardiology and Cardio-Vascular Surgery, Fatma Ouarda; Turkey: Turkish
Society of Cardiology, Bulent Mutlu; Ukraine: Ukrainian Association of Cardiology, Yuriy Sirenko; United Kingdom of Great Britain and Northern Ireland: British Cardiovascular Society, J. Gerry
Coghlan;
and
Uzbekistan:
Association of
Cardiologists of
Uzbekistan, Timur Abdullaev.
ESC Clinical Practice Guidelines (CPG) Committee: Colin
Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid (Egypt),
Victor Aboyans (France), Sotiris Antoniou (United Kingdom), Elena
Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas Baumbach
(United Kingdom), Michael A. Borger (Germany), Jelena Čelutkienė
(Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France),
Volkmar Falk (Germany), Laurent Fauchier (France), Chris P. Gale
(United
Kingdom),
Sigrun
Halvorsen
(Norway),
Bernard
Iung
(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian
Federation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha
(United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel),
Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Richard
Mindham (United Kingdom), Jens Cosedis Nielsen (Denmark),
Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark),
Amina Rakisheva (Kazakhstan), Marta Sitges (Spain), and Rhian
M. Touyz (Canada/ United Kingdom).
Independent Research Methodologists: Rebecca L. Morgan
(United States of America) and Kapeena Sivakumaran (Canada).
21. References
1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M,
et al. Haemodynamic deﬁnitions and updated clinical classiﬁcation of pulmonary hypertension. Eur Respir J 2019;53:1801913.
2. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines:
1. Introduction-GRADE evidence proﬁles and summary of ﬁndings tables. J Clin
Epidemiol 2011;64:383–394.
3. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M,
et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ 2016;353:i2089.
3712
ESC/ERS Guidelines


<!-- PAGE 96 -->

### Page 96

4. Nagavci B, Tonia T, Roche N, Genton C, Vaccaro V, Humbert M, et al. European
Respiratory Society clinical practice guidelines: methodological guidance. ERJ Open
Res 2022;8:0655–2021.
5. Schünemann HB, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group; 2013.
6. Miravitlles M, Tonia T, Rigau D, Roche N, Genton C, Vaccaro V, et al. New era for
European Respiratory Society clinical practice guidelines: joining efﬁciency and high methodological standards. Eur Respir J 2018;51:1800221.
7. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009;34:
888–894.
8. Kovacs G, Olschewski A, Berghold A, Olschewski H. Pulmonary vascular resistances during exercise in normal subjects: a systematic review. Eur Respir J 2012;
39:319–328.
9. Wolsk E, Bakkestrom R, Thomsen JH, Balling L, Andersen MJ, Dahl JS, et al. The inﬂuence of age on hemodynamic parameters during rest and exercise in healthy individuals. JACC Heart Fail 2017;5:337–346.
10. Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, et al.
Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans Affairs Clinical
Assessment, Reporting, and Tracking program. Circulation 2016;133:1240–1248.
11. Douschan P, Kovacs G, Avian A, Foris V, Gruber F, Olschewski A, et al. Mild elevation of pulmonary arterial pressure as a predictor of mortality. Am J Respir Crit Care
Med 2018;197:509–516.
12. Kolte D, Lakshmanan S, Jankowich MD, Brittain EL, Maron BA, Choudhary G. Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis. J Am Heart Assoc 2018;7:e009729.
13. Maron BA, Brittain EL, Hess E, Waldo SW, Baron AE, Huang S, et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension:
a retrospective cohort study. Lancet Respir Med 2020;8:873–884.
14. Xanthouli P, Jordan S, Milde N, Marra A, Blank N, Egenlauf B, et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new deﬁnition of pulmonary arterial hypertension. Ann Rheum Dis 2020;79:370–378.
15. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE,
et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur
Heart J 2007;28:2539–2550.
16. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA)
of the European Society of Cardiology (ESC). Eur Heart J 2019;40:3297–3317.
17. Zeder K, BanﬁC, Steinrisser-Allex G, Maron BA, Humbert M, Lewis GD, et al.
Diagnostic, prognostic and differential-diagnostic relevance of pulmonary hemodynamics during exercise - a systematic review. Eur Respir J 2022;2:103181.
18. Ho JE, Zern EK, Lau ES, Wooster L, Bailey CS, Cunningham T, et al. Exercise pulmonary hypertension predicts clinical outcomes in patients with dyspnea on effort.
J Am Coll Cardiol 2020;75:17–26.
19. Stamm A, Saxer S, Lichtblau M, Hasler ED, Jordan S, Huber LC, et al. Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. Eur
Respir J 2016;48:1658–1667.
20. Hasler ED, Muller-Mottet S, Furian M, Saxer S, Huber LC, Maggiorini M, et al.
Pressure-ﬂow during exercise catheterization predicts survival in pulmonary hypertension. Chest 2016;150:57–67.
21. Lewis GD, Murphy RM, Shah RV, Pappagianopoulos PP, Malhotra R, Bloch KD, et al.
Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes. Circ Heart Fail 2011;4:
276–285.
22. Zeder K, Avian A, Bachmaier G, Douschan P, Foris V, Sassmann T, et al. Exercise pulmonary resistances predict long-term survival in systemic sclerosis. Chest
2021;159:781–790.
23. Eisman AS, Shah RV, Dhakal BP, Pappagianopoulos PP, Wooster L, Bailey C, et al.
Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure. Circ Heart Fail 2018;11:e004750.
24. Bentley RF, Barker M, Esfandiari S, Wright SP, Valle FH, Granton JT, et al. Normal and abnormal relationships of pulmonary artery to wedge pressure during exercise.
J Am Heart Assoc 2020;9:e016339.
25. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint
Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the
European Society of Cardiology (ESC) and the European Respiratory Society
(ERS): Endorsed by: Association for European Paediatric and Congenital
Cardiology (AEPC), International Society for Heart and Lung Transplantation
(ISHLT). Eur Respir J 2015;46:903–975.
26. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint
Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the
European Society of Cardiology (ESC) and the European Respiratory Society
(ERS): Endorsed by: Association for European Paediatric and Congenital
Cardiology (AEPC), International Society for Heart and Lung Transplantation
(ISHLT). Eur Heart J 2016;37:67–119.
27. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Eur Heart J 2021;42:3599–3726.
28. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021
ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J
2022;43:561–632.
29. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A
global view of pulmonary hypertension. Lancet Respir Med 2016;4:306–322.
30. NHS Digital. National Audit of Pulmonary Hypertension 10th Annual Report,
Great Britain, 2018-19. https://digital.nhs.uk/data-and-information/publications/
statistical/national-pulmonary-hypertension-audit/2019# (24 March 2022, date last accessed 22 July 2022).
31. Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identiﬁcation of the most accurate estimates from a systematic literature review. Pulm Circ 2021;11:
2045894020977300.
32. Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol 2017;14:603–614.
33. Montani D, Girerd B, Jais X, Laveneziana P, Lau EMT, Bouchachi A, et al. Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. The Eur
Respir J 2020;58:2004229.
34. Certain MC, Chaumais MC, Jais X, Savale L, Seferian A, Parent F, et al.
Characteristics and long-term outcomes of pulmonary venoocclusive disease induced by mitomycin C. Chest 2021;159:1197–1207.
35. Cornet L, Khouri C, Roustit M, Guignabert C, Chaumais MC, Humbert M, et al.
Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. Eur Respir J 2019;53:1802472.
36. McGee M, Whitehead N, Martin J, Collins N. Drug-associated pulmonary arterial hypertension. Clin Toxicol 2018;56:801–809.
37. McGregor PC, Boosalis V, Aragam J. Carﬁlzomib-induced pulmonary hypertension with associated right ventricular dysfunction: A case report. SAGE Open Med Case
Rep 2021;9:2050313X21994031.
38. Montani D, Lau EM, Descatha A, Jais X, Savale L, Andujar P, et al. Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. Eur
Respir J 2015;46:1721–1731.
39. Savale L, Chaumais MC, Cottin V, Bergot E, Frachon I, Prevot G, et al. Pulmonary hypertension associated with benﬂuorex exposure. Eur Respir J 2012;40:
1164–1172.
40. Weatherald J, Bondeelle L, Chaumais MC, Guignabert C, Savale L, Jais X, et al.
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. Eur Respir J 2020;
56:2000279.
41. Philen RM, Posada M. Toxic oil syndrome and eosinophilia-myalgia syndrome: May
8–10, 1991, World Health Organization meeting report. Semin Arthritis Rheum
1993;23:104–124.
42. Hertzman PA, Clauw DJ, Kaufman LD, Varga J, Silver RM, Thacker HL, et al. The eosinophilia-myalgia syndrome: status of 205 patients and results of treatment 2
years after onset. Ann Intern Med 1995;122:851–855.
43. Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience.
Am Heart J 2006;152:521–526.
44. Chen SC, Dastamani A, Pintus D, Yau D, Aftab S, Bath L, et al. Diazoxide-induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: Recommendations from a multicentre study in the UK. Clin Endocrinol (Oxf) 2019;91:770–775.
45. Timlin MR, Black AB, Delaney HM, Matos RI, Percival CS. Development of pulmonary hypertension during treatment with diazoxide: a case series and literature review. Pediatr Cardiol 2017;38:1247–1250.
46. Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global
Burden of Disease Study 2013. Lancet 2015;386:743–800.
47. Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiery JL.
Left ventricular heart failure and pulmonary hypertension. Eur Heart J 2016;37:
942–954.
48. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redﬁeld MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009;53:1119–1126.
49. Tichelbacker T, Dumitrescu D, Gerhardt F, Stern D, Wissmuller M, Adam M, et al.
Pulmonary hypertension and valvular heart disease. Herz 2019;44:491–501.
ESC/ERS Guidelines
3713


<!-- PAGE 97 -->

### Page 97

50. Weber L, Rickli H, Haager PK, Joerg L, Weilenmann D, Brenner R, et al.
Haemodynamic mechanisms and long-term prognostic impact of pulmonary hypertension in patients with severe aortic stenosis undergoing valve replacement.
Eur J Heart Fail 2019;21:172–181.
51. Hurdman J, Condliffe R, Elliot CA, Swift A, Rajaram S, Davies C, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013;41:
1292–1301.
52. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al.
Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019;
53:1801914.
53. Naeije R. Pulmonary hypertension at high altitude. Eur Respir J 2019;53:1900985.
54. Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 2020;57:
2002828.
55. Kramm T, Wilkens H, Fuge J, Schäfers H-J, Guth S, Wiedenroth CB, et al. Incidence and characteristics of chronic thromboembolic pulmonary hypertension in
Germany. Clinical research in cardiology: ofﬁcial journal of the German Cardiac
Society 1–6 (2018) doi:10.1007/s00392-018-1215-5.
56. Swietlik EM, Ruggiero A, Fletcher AJ, Taboada D, Knightbridge E, Harlow L, et al.
Limitations of resting haemodynamics in chronic thromboembolic disease without pulmonary hypertension. Eur Respir J 2019;53:1801787.
57. Kalantari S, Gomberg-Maitland M. Group 5 pulmonary hypertension: the orphan’s orphan disease. Cardiol Clin 2016;34:443–449.
58. Shlobin OA, Kouranos V, Barnett SD, Alhamad EH, Culver DA, Barney J, et al.
Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. Eur Respir J 2020;55:
1901747.
59. Boucly A, Cottin V, Nunes H, Jais X, Tazi A, Prevot G, et al. Management and longterm outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J
2017;50:1700465.
60. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al.
Primary pulmonary hypertension. A national prospective study. Ann Intern Med
1987;107:216–223.
61. Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007;132:373–379.
62. Galiè N, Saia F, Palazzini M, Manes A, Russo V, Bacchi Reggiani ML, et al. Left main coronary artery compression in patients with pulmonary arterial hypertension and angina. J Am Coll Cardiol 2017;69:2808–2817.
63. Kovacs G, Avian A, Foris V, Tscherner M, Kqiku X, Douschan P, et al. Use of ECG
and other simple non-invasive tools to assess pulmonary hypertension. PLoS One
2016;11:e0168706.
64. Bonderman D, Wexberg P, Martischnig AM, Heinzl H, Lang MB, Sadushi R, et al. A
noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J
2011;37:1096–1103.
65. Klok FA, Surie S, Kempf T, Eikenboom J, van Straalen JP, van Kralingen KW, et al. A
simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Thromb
Res 2011;128:21–26.
66. Henkens IR, Mouchaers KT, Vonk-Noordegraaf A, Boonstra A, Swenne CA, Maan
AC, et al. Improved ECG detection of presence and severity of right ventricular pressure load validated with cardiac magnetic resonance imaging. Am J Physiol
Heart Circ Physiol 2008;294:H2150–H2157.
67. Rich JD, Thenappan T, Freed B, Patel AR, Thisted RA, Childers R, et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol 2013;167:669–676.
68. Remy-Jardin M, Ryerson CJ, Schiebler ML, Leung ANC, Wild JM, Hoeper MM, et al.
Imaging of pulmonary hypertension in adults: a position paper from the Fleischner
Society. Eur Respir J 2021;57:2004455.
69. Ascha M, Renapurkar RD, Tonelli AR. A review of imaging modalities in pulmonary hypertension. Ann Thorac Med 2017;12:61–73.
70. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al.
Deﬁnitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62:
D42–D50.
71. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 2003;41:1028–1035.
72. Meyer FJ, Ewert R, Hoeper MM, Olschewski H, Behr J, Winkler J, et al. Peripheral airway obstruction in primary pulmonary hypertension. Thorax 2002;57:473–476.
73. Alonso-Gonzalez R, Borgia F, Diller GP, Inuzuka R, Kempny A, Martinez-Naharro A,
et al. Abnormal lung function in adults with congenital heart disease: prevalence, relation to cardiac anatomy, and association with survival. Circulation 2013;127:882–890.
74. Hoeper MM, Dwivedi K, Pausch C, Lewis RA, Olsson KM, Huscher D, et al.
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet
Respir Med 2022. Jun
28:S2213-2600(22)00097-2. doi: 10.1016/S2213-2600(22)
00097-2. Epub ahead of print. PMID: 35777416
75. Hoeper MM, Meyer K, Rademacher J, Fuge J, Welte T, Olsson KM. Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. JACC Heart Fail 2016;4:441–449.
76. Olson TP, Johnson BD, Borlaug BA. Impaired pulmonary diffusion in heart failure with preserved ejection fraction. JACC Heart Fail 2016;4:490–498.
77. Olsson KM, Fuge J, Meyer K, Welte T, Hoeper MM. More on idiopathic pulmonary arterial hypertension with a low diffusing capacity. Eur Respir J 2017;50:1700354.
78. Trip P, Nossent EJ, de Man FS, van den Berk IA, Boonstra A, Groepenhoff H, et al.
Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension:
patient characteristics and treatment responses. Eur Respir J 2013;42:1575–1585.
79. Melot C, Naeije R. Pulmonary vascular diseases. Compr Physiol 2011;1:593–619.
80. Harbaum L, Fuge J, Kamp JC, Hennigs JK, Simon M, Sinning C, et al. Blood carbon dioxide tension and risk in pulmonary arterial hypertension. Int J Cardiol 2020;318:
131–137.
81. Jilwan FN, Escourrou P, Garcia G, Jais X, Humbert M, Roisman G. High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. Chest 2013;143:47–55.
82. Rudski LG, Lai WW, Aﬁlalo J, Hua L, Handschumacher MD, Chandrasekaran K,
et al. Guidelines for the echocardiographic assessment of the right heart in adults:
a report from the American Society of Echocardiography endorsed by the
European Association of Echocardiography, a registered branch of the European
Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc
Echocardiogr 2010;23:685–713.
83. Lang RM, Badano LP, Mor-Avi V, Aﬁlalo J, Armstrong A, Ernande L, et al.
Recommendations for cardiac chamber quantiﬁcation by echocardiography in adults:
an update from the American Society of Echocardiography and the European
Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233–270.
84. Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al.
Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantiﬁcation, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of
Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017;18:1301–1310.
85. Farber HW, Foreman AJ, Miller DP, McGoon MD. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail 2011;17:56–64.
86. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al.
Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:735–740.
87. Fisher MR, Forﬁa PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, et al.
Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009;179:615–621
88. D’Alto M, Di Maio M, Romeo E, Argiento P, Blasi E, Di Vilio A, et al.
Echocardiographic probability of pulmonary hypertension: a validation study.
Eur Respir J. 2022;2102548. doi:10.1183/13993003.02548-2021. Epub ahead of print.
89. Jankowich M, Maron BA, Choudhary G. Mildly elevated pulmonary artery systolic pressure on echocardiography: bridging the gap in current guidelines. Lancet
Respir Med 2021;9:1185–1191.
90. Huston JH, Maron BA, French J, Huang S, Thayer T, Farber-Eger EH, et al.
Association of mild echocardiographic pulmonary hypertension with mortality and right ventricular function. JAMA Cardiol 2019;4:1112–1121.
91. Gall H, Yogeswaran A, Fuge J, Sommer N, Grimminger F, Seeger W, et al. Validity of echocardiographic tricuspid regurgitation gradient to screen for new deﬁnition of pulmonary hypertension. E Clin Med 2021;34:100822.
92. D’Alto M, Romeo E, Argiento P, D’Andrea A, Vanderpool R, Correra A, et al.
Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension. Int J Cardiol 2013;168:4058–4062.
93. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 2012;
39:112–118.
94. Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011;365:44–53.
95. Grunig E, Henn P, D’Andrea A, Claussen M, Ehlken N, Maier F, et al. Reference values for and determinants of right atrial area in healthy adults by 2-dimensional echocardiography. Circ Cardiovasc Imaging 2013;6:117–124.
96. Tello K, Wan J, Dalmer A, Vanderpool R, Ghofrani HA, Naeije R, et al. Validation of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio for the assessment of right ventricular-arterial coupling in severe pulmonary hypertension. Circ Cardiovasc Imaging 2019;12:e009047.
97. Tello K, Axmann J, Ghofrani HA, Naeije R, Narcin N, Rieth A, et al. Relevance of the
TAPSE/PASP ratio in pulmonary arterial hypertension. Int J Cardiol 2018;266:
229–235.
98. Guazzi M, Dixon D, Labate V, Beussink-Nelson L, Bandera F, Cuttica MJ, et al. RV
contractile function and its coupling to pulmonary circulation in heart failure with
3714
ESC/ERS Guidelines


<!-- PAGE 98 -->

### Page 98

preserved ejection fraction: stratiﬁcation of clinical phenotypes and outcomes.
JACC Cardiovasc Imaging 2017;10:1211–1221.
99. Arkles JS, Opotowsky AR, Ojeda J, Rogers F, Liu T, Prassana V, et al. Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med 2011;183:268–276.
100. Takahama H, McCully RB, Frantz RP, Kane GC. Unraveling the RV ejection Doppler envelope: insight into pulmonary artery hemodynamics and disease severity. JACC
Cardiovasc Imaging 2017;10:1268–1277.
101. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, et al.
Heart J 2021;42:563–645.
102. Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019;53:1801915.
103. Konstantinides SV, Meyer G, Becattini C, Fauueno H, Bueno H, Geersing GJ, et al.
Eur Heart J 2020;41:543–603.
104. He J, Fang W, Lv B, He JG, Xiong CM, Liu ZH, et al. Diagnosis of chronic thromboembolic pulmonary hypertension: comparison of ventilation/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography. Nucl Med Commun 2012;33:459–463.
105. Tunariu N, Gibbs SJ, Win Z, Gin-Sing W, Graham A, Gishen P, et al.
Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007;48:680–684.
106. Giordano J, Khung S, Duhamel A, Hossein-Foucher C, Bellevre D, Lamblin N, et al.
Lung perfusion characteristics in pulmonary arterial hypertension (PAH) and peripheral forms of chronic thromboembolic pulmonary hypertension (pCTEPH):
dual-energy CT experience in 31 patients. Eur Radiol 2017;27:1631–1639.
107. Seferian A, Helal B, Jais X, Girerd B, Price LC, Gunther S, et al. Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. Eur Respir J 2012;40:75–83.
108. Swift AJ, Dwivedi K, Johns C, Garg P, Chin M, Currie BJ, et al. Diagnostic accuracy of
CT pulmonary angiography in suspected pulmonary hypertension. Eur Radiol 2020;
30:4918–4929.
109. Dong C, Zhou M, Liu D, Long X, Guo T, Kong X. Diagnostic accuracy of computed tomography for chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. PLoS One 2015;10:e0126985.
110. Rajaram S, Swift AJ, Capener D, Telfer A, Davies C, Hill C, et al. Diagnostic accuracy of contrast-enhanced MR angiography and unenhanced proton MR imaging compared with CT pulmonary angiography in chronic thromboembolic pulmonary hypertension. Eur Radiol 2012;22:310–317.
111. Ende-Verhaar YM, Meijboom LJ, Kroft LJM, Beenen LFM, Boon GJAM, Middeldorp
S, et al. Usefulness of standard computed tomography pulmonary angiography performed for acute pulmonary embolism for identiﬁcation of chronic thromboembolic pulmonary hypertension: results of the InShape III study. J Heart Lung
Transplant 2019;38:731–738.
112. Guerin L, Couturaud F, Parent F, Revel MP, Gillaizeau F, Planquette B, et al.
Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb
Haemost 2014;112:598–605.
113. Tamura M, Yamada Y, Kawakami T, Kataoka M, Iwabuchi Y, Sugiura H, et al.
Diagnostic accuracy of lung subtraction iodine mapping CT for the evaluation of pulmonary perfusion in patients with chronic thromboembolic pulmonary hypertension: correlation with perfusion SPECT/CT. Int J Cardiol 2017;243:538–543.
114. Masy M, Giordano J, Petyt G, Hossein-Foucher C, Duhamel A, Kyheng M, et al.
Dual-energy CT (DECT) lung perfusion in pulmonary hypertension: concordance rate with V/Q scintigraphy in diagnosing chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2018;28:5100–5110.
115. Hinrichs JB, Marquardt S, von Falck C, Hoeper MM, Olsson KM, Wacker FK, et al.
Comparison of C-arm computed tomography and digital subtraction angiography in patients with chronic thromboembolic pulmonary hypertension. Cardiovasc
Intervent Radiol 2016;39:53–63.
116. Hinrichs JB, Renne J, Hoeper MM, Olsson KM, Wacker FK, Meyer BC. Balloon pulmonary angioplasty: applicability of C-Arm CT for procedure guidance. Eur Radiol
2016;26:4064–4071.
117. Swift AJ, Lu H, Uthoff J, Garg P, Cogliano M, Taylor J, et al. A machine learning cardiac magnetic resonance approach to extract disease features and automate pulmonary arterial hypertension diagnosis. Eur Heart J Cardiovasc Imaging 2021;22:
236–245.
118. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med 2017;
377:2298.
119. Rosenkranz S, Howard LS, Gomberg-Maitland M, Hoeper MM. Systemic consequences of pulmonary hypertension and right-sided heart failure. Circulation
2020;141:678–693.
120. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 2001;104:429–435.
121. Boerrigter BG, Bogaard HJ, Trip P, Groepenhoff H, Rietema H, Holverda S, et al.
Ventilatory and cardiocirculatory exercise proﬁles in COPD: the role of pulmonary hypertension. Chest 2012;142:1166–1174.
122. Caravita S, Faini A, Deboeck G, Bondue A, Naeije R, Parati G, et al. Pulmonary hypertension and ventilation during exercise: role of the pre-capillary component.
J Heart Lung Transplant 2017;36:754–762.
123. Dumitrescu D, Nagel C, Kovacs G, Bollmann T, Halank M, Winkler J, et al.
Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. Heart 2017;103:774–782.
124. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The
2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 2016;35:1–23.
125. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al.
Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006;48:2546–2552.
126. Kovacs G, Avian A, Olschewski A, Olschewski H. Zero reference level for right heart catheterisation. Eur Respir J 2013;42:1586–1594.
127. Opotowsky AR, Hess E, Maron BA, Brittain EL, Baron AE, Maddox TM, et al.
Thermodilution vs estimated Fick cardiac output measurement in clinical practice:
an analysis of mortality from the Veterans Affairs Clinical Assessment, Reporting,
and Tracking (VA CART) Program and Vanderbilt University. JAMA Cardiol 2017;
2:1090–1099.
128. Viray MC, Bonno EL, Gabrielle ND, Maron BA, Atkins J, Amoroso NS, et al. Role of pulmonary artery wedge pressure saturation during right heart catheterization: a prospective study. Circ Heart Fail 2020;13:e007981.
129. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105–3111.
130. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A
comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am
Coll Cardiol 2000;35:176–182.
131. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, Hetzer R, et al.
Assessment of the vasodilator response in primary pulmonary hypertension.
Comparing prostacyclin and iloprost administered by either infusion or inhalation.
Eur Heart J 2003;24:356–365.
132. Jing ZC, Jiang X, Han ZY, Xu XQ, Wang Y, Wu Y, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009;33:
1354–1360.
133. Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, et al. An ofﬁcial
European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J 2017;50:1700578.
134. Claeys M, Claessen G, La Gerche A, Petit T, Belge C, Meyns B, et al. Impaired cardiac reserve and abnormal vascular load limit exercise capacity in chronic thromboembolic disease. JACC Cardiovasc Imaging 2019;12:1444–1456.
135. Guth S, Wiedenroth CB, Rieth A, Richter MJ, Gruenig E, Ghofrani HA, et al.
Exercise right heart catheterization before and after pulmonary endarterectomy in patients with chronic thromboembolic disease. Eur Respir J 2018;52:1800458.
136. Godinas L, Lau EM, Chemla D, Lador F, Savale L, Montani D, et al. Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure. Eur Respir J 2016;48:254–257.
137. Naeije R, Vanderpool R, Dhakal BP, Saggar R, Saggar R, Vachiery JL, et al.
Exercise-induced pulmonary hypertension: physiological basis and methodological concerns. Am J Respir Crit Care Med 2013;187:576–583.
138. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, et al.
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 2014;148:e1–e132.
139. Esfandiari S, Wright SP, Goodman JM, Sasson Z, Mak S. Pulmonary artery wedge pressure relative to exercise work rate in older men and women. Med Sci Sports
Exerc 2017;49:1297–1304.
140. Boerrigter BG, Waxman AB, Westerhof N, Vonk-Noordegraaf A, Systrom DM.
Measuring central pulmonary pressures during exercise in COPD: how to cope with respiratory effects. Eur Respir J 2014;43:1316–1325.
141. Andersen MJ, Wolsk E, Bakkestrom R, Thomsen JH, Balling L, Dahl JS, et al.
Hemodynamic response to rapid saline infusion compared with exercise in healthy participants aged 20–80 years. J Cardiac Failure 2019;25:902–910.
142. Vachiery JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al.
Pulmonary hypertension due to left heart disease. Eur Respir J 2019;53:1801897.
143. D’Alto M, Romeo E, Argiento P, Motoji Y, Correra A, Di Marco GM, et al. Clinical relevance of ﬂuid challenge in patients evaluated for pulmonary hypertension. Chest
2017;151:119–126.
ESC/ERS Guidelines
3715


<!-- PAGE 99 -->

### Page 99

144. van de Bovenkamp AA, Wijkstra N, Oosterveer FPT, Vonk Noordegraaf A,
Bogaard HJ, van Rossum AC, et al. The value of passive leg raise during right heart catheterization in diagnosing heart failure with preserved ejection fraction. Circ
Heart Fail 2022;15:e008935.
145. D’Alto M, Dimopoulos K, Coghlan JG, Kovacs G, Rosenkranz S, Naeije R. Right heart catheterization for the diagnosis of pulmonary hypertension: controversies and practical issues. Heart Fail Clin 2018;14:467–477.
146. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76–81.
147. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al.
Diagnosis and differential assessment of pulmonary arterial hypertension. J Am
Coll Cardiol 2004;43:40S–47S.
148. Morrell NW, Aldred MA, Chung WK, Elliott CG, Nichols WC, Soubrier F, et al.
Genetics and genomics of pulmonary arterial hypertension. Eur Respir J 2019;53:
1801899.
149. Graf S, Haimel M, Bleda M, Hadinnapola C, Southgate L, Li W, et al. Identiﬁcation of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat
Commun 2018;9:1416.
150. Zhu N, Swietlik EM, Welch CL, Pauciulo MW, Hagen JJ, Zhou X, et al. Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Med
2021;13:80.
151. Song J, Eichstaedt CA, Viales RR, Benjamin N, Harutyunova S, Fischer C, et al.
Identiﬁcation of genetic defects in pulmonary arterial hypertension by a new gene panel diagnostic tool. Clin Sci (Lond) 2016;130:2043–2052.
152. International PPHC, Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA
III, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81–84.
153. Bohnen MS, Ma L, Zhu N, Qi H, McClenaghan C, Gonzaga-Jauregui C, et al.
Loss-of-function ABCC8 mutations in pulmonary arterial hypertension. Circ
Genom Precis Med 2018;11:e002087.
154. Ma L, Roman-Campos D, Austin ED, Eyries M, Sampson KS, Soubrier F, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013;369:
351–361.
155. Nasim MT, Ogo T, Ahmed M, Randall R, Chowdhury HM, Snape KM, et al.
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 2011;32:1385–1389.
156. Garg A, Kircher M, Del Campo M, Amato RS, Agarwal AK, University of
Washington Center for Mendelian Genomics. Whole exome sequencing identiﬁes de novo heterozygous CAV1 mutations associated with a novel neonatal onset lipodystrophy syndrome. Am J Med Genet A 2015;167A:1796–1806.
157. Kerstjens-Frederikse WS, Bongers EM, Roofthooft MT, Leter EM, Douwes JM, Van
Dijk A, et al. TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension. J Med Genet 2013;50:500–506.
158. Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014;46:65–69.
159. Swietlik EM, Greene D, Zhu N, Megy K, Cogliano M, Rajaram S, et al. Bayesian inference associates rare KDR variants with speciﬁc phenotypes in pulmonary arterial hypertension. Circ Genom Precis Med 2020;14:e003155.
160. Chida A, Shintani M, Yagi H, Fujiwara M, Kojima Y, Sato H, et al. Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers. Am J
Cardiol 2012;110:586–593.
161. Hoeper MM, Pausch C, Grünig E, Klose H, Staehler G, Huscher D, et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transpl 2020;39:1435–1444.
162. Badagliacca R, Poscia R, Pezzuto B, Papa S, Nona A, Mancone M, et al. Pulmonary arterial dilatation in pulmonary hypertension: prevalence and prognostic relevance.
Cardiology 2012;121:76–82.
163. Santaniello A, Casella R, Vicenzi M, Rota I, Montanelli G, De Santis M, et al.
Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2020;59:
1581–1586.
164. Albrecht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V, Eckersley
R, et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999;353:1579–1583.
165. Cottin V, Le Pavec J, Prevot G, Mal H, Humbert M, Simonneau G, et al. Pulmonary hypertension in patients with combined pulmonary ﬁbrosis and emphysema syndrome. Eur Respir J 2010;35:105–111.
166. Galiè N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al.
Initial use of ambrisentan plus tadalaﬁl in pulmonary arterial hypertension. N Engl
J Med 2015;373:834–844.
167. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al.
Macitentan and morbidity and mortality in pulmonary arterial hypertension. N
Engl J Med 2013;369:809–818.
168. Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, et al.
Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet
Respir Med 2019;7:594–604.
169. Armstrong I, Billings C, Kiely DG, Yorke J, Harries C, Clayton S, et al. The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients. BMC Pulm Med 2019;19:67.
170. Strange G, Gabbay E, Kermeen F, Williams T, Carrington M, Stewart S, et al. Time from symptoms to deﬁnitive diagnosis of idiopathic pulmonary arterial hypertension: the delay study. Pulm Circ 2013;3:89–94.
171. Ivarsson B, Johansson A, Kjellstrom B. The odyssey from symptom to diagnosis of pulmonary hypertension from the patients and spouses perspective. J Prim Care
Community
Health
2021;12:21501327211029241.
doi:
10.1177/
21501327211029241
172. Kiely DG, Lawrie A, Humbert M. Screening strategies for pulmonary arterial hypertension. Eur Heart J Suppl 2019;21:K9–K20.
173. Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al.
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis:
the DETECT study. Ann Rheum Dis 2014;73:1340–1349.
174. Weatherald J, Montani D, Jevnikar M, Jais X, Savale L, Humbert M. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2019;28:
190023.
175. Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimbach JK, Ramsay MA, et al.
International Liver Transplant Society Practice Guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension.
Transplantation 2016;100:1440–1452.
176. Mancuso L, Scordato F, Pieri M, Valerio E, Mancuso A. Management of portopulmonary hypertension:
new perspectives.
World
J
Gastroenterol
2013;19:
8252–8257.
177. Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, RafﬁF, De Zuttere D, et al.
Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008;177:108–113.
178. Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P,
Mairuhu AT, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature.
Eur Respir J 2017;49:1601792.
179. Ende-Verhaar YM, Huisman MV, Klok FA. To screen or not to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism.
Thromb Res 2017;151:1–7.
180. Kiely DG, Doyle O, Drage E, Jenner H, Salvatelli V, Daniels FA, et al. Utilising artiﬁcial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension. Pulm Circ 2019;9:2045894019890549.
181. Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP):
a randomised, placebo-controlled phase 2b study. Lancet Respir Med 2019;7:
780–790.
182. Nagel C, Henn P, Ehlken N, D’Andrea A, Blank N, Bossone E, et al. Stress Doppler echocardiography for early detection of systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Res Ther 2015;17:165.
183. Semalulu T, Rudski L, Huynh T, Langleben D, Wang M, Canadian Scleroderma
Research Group, et al. An evidence-based strategy to screen for pulmonary arterial hypertension in systemic sclerosis. Semin Arthritis Rheum 2020;50:1421–1427.
184. Vandecasteele E, Drieghe B, Melsens K, Thevissen K, De Pauw M, Deschepper E,
et al. Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. Eur Respir J 2017;49:1602275.
185. Coghlan JG, Wolf M, Distler O, Denton CP, Doelberg M, Harutyunova S, et al.
Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J 2018;51:1701197.
186. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792–3800.
187. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011;63:3522–3530.
188. Thakkar V, Stevens W, Prior D, Youssef P, Liew D, Gabbay E, et al. The inclusion of
N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis
Res Ther 2013;15:R193.
189. Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 2015;17:7.
190. Morrisroe K, Stevens W, Sahhar J, Rabusa C, Nikpour M, Proudman S, et al.
Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. Arthritis Res
Ther 2017;19:42.
3716
ESC/ERS Guidelines


<!-- PAGE 100 -->

### Page 100

191. Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman SM, Nikpour M, et al. Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. BMC Pulm Med
2016;16:134.
192. Smith V, Vanhaecke A, Vandecasteele E, Guerra M, Paolino S, Melsens K, et al.
Nailfold videocapillaroscopy in systemic sclerosis-related pulmonary arterial hypertension: a systematic literature review. J Rheumatol 2020;47:888–895.
193. Larkin EK, Newman JH, Austin ED, Hemnes AR, Wheeler L, Robbins IM, et al.
Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:892–896.
194. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003;37:401–409.
195. Kim WR, Krowka MJ, Plevak DJ, Lee J, Rettke SR, Frantz RP, et al. Accuracy of
Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000;6:453–458.
196. Raevens S, Colle I, Reyntjens K, Geerts A, Berrevoet F, Rogiers X, et al.
Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: an analysis of cutoff values. Liver Transpl 2013;19:602–610.
197. Golpe
R,
Perez-de-Llano
LA,
Castro-Anon
O,
Vazquez-Caruncho
M,
Gonzalez-Juanatey C, Veres-Racamonde A, et al. Right ventricle dysfunction and pulmonary hypertension in hemodynamically stable pulmonary embolism. Respir
Med 2010;104:1370–1376.
198. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al.
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257–2264.
199. Simonneau G, Hoeper MM. Evaluation of the incidence of rare diseases: difﬁculties and uncertainties, the example of chronic thromboembolic pulmonary hypertension. Eur Respir J 2017;49:1602522.
200. Coquoz N, Weilenmann D, Stolz D, Popov V, Azzola A, Fellrath JM, et al.
Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism. Eur Respir J 2018;51:1702505.
201. Valerio LM, Mavromanoli AC, Barco S, Abele C, Becker D, Bruch L, et al.
FOCUS Investigators. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J 2022;43:
3387–3398.
202. Nijkeuter M, Hovens MM, Davidson BL, Huisman MV. Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review. Chest 2006;
129:192–197.
203. Sanchez O, Helley D, Couchon S, Roux A, Delaval A, Trinquart L, et al. Perfusion defects after pulmonary embolism: risk factors and clinical signiﬁcance. J Thromb
Haemost 2010;8:1248–1255.
204. Wartski M, Collignon MA. Incomplete recovery of lung perfusion after 3 months in patients with acute pulmonary embolism treated with antithrombotic agents.
THESEE Study Group. Tinzaparin ou heparin standard: evaluation dans l’Embolie
Pulmonaire study. J Nucl Med 2000;41:1043–1048.
205. Nilsson LT, Andersson T, Larsen F, Lang IM, Liv P, Soderberg S. Dyspnea after pulmonary embolism: a nation-wide population-based case-control study. Pulm Circ
2021;11:20458940211046831.
206. Boon G, Ende-Verhaar YM, Bavalia R, El Bouazzaoui LH, Delcroix M,
Dzikowska-Diduch O, et al. Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II
study. Thorax 2021;76:1002–1009.
207. Helmersen D, Provencher S, Hirsch AM, Van Dam A, Dennie C, de Perrot M, et al.
Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian
Thoracic Society clinical practice guideline update. Can J Respir Crit Care Sleep
Med 2019;3:177–198.
208. Delcroix M, Kerr K, Fedullo P. Chronic thromboembolic pulmonary hypertension.
Epidemiology and risk factors. Ann Am Thorac Soc 2016;13:S201–S206.
209. Klok FA, Tesche C, Rappold L, Dellas C, Hasenfuss G, Huisman MV, et al. External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Thromb Res 2015;135:796–801.
210. Barst RJ, Chung L, Zamanian RT, Turner M, McGoon MD. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest 2013;144:160–168.
211. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012;39:589–596.
212. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780–788.
213. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al.
Predicting survival in pulmonary arterial hypertension: insights from the Registry to
Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease
Management (REVEAL). Circulation 2010;122:164–172.
214. Humbert M, Sitbon O, Yaici A, Montani D, O’Callaghan DS, Jais X, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.
Eur Respir J 2010;36:549–555.
215. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, et al. Survival with
ﬁrst-line bosentan in patients with primary pulmonary hypertension. Eur Respir J
2005;25:244–249.
216. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012;39:589–596.
217. Amsallem M, Sweatt AJ, Aymami MC, Kuznetsova T, Selej M, Lu H, et al. Right heart end-systolic remodeling index strongly predicts outcomes in pulmonary arterial hypertension: comparison with validated models. Circ Cardiovasc Imaging 2017;
10:e005771.
218. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, et al.
Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214–1219.
219. Badagliacca R, Papa S, Valli G, Pezzuto B, Poscia R, Manzi G, et al. Echocardiography combined with cardiopulmonary exercise testing for the prediction of outcome in idiopathic pulmonary arterial hypertension. Chest 2016;150:1313–1322.
220. Badagliacca R, Papa S, Manzi G, Miotti C, Luongo F, Sciomer S, et al. Usefulness of adding echocardiography of the right heart to risk-assessment scores in prostanoid-treated pulmonary arterial hypertension. JACC Cardiovasc Imaging
2020;13:2054–2056.
221. Ernande L, Cottin V, Leroux PY, Girerd N, Huez S, Mulliez A, et al. Right isovolumic contraction velocity predicts survival in pulmonary hypertension. J Am Soc
Echocardiogr 2013;26:297–306.
222. Forﬁa PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et al.
Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J
Respir Crit Care Med 2006;174:1034–1041.
223. Ghio S, Mercurio V, Fortuni F, Forﬁa PR, Gall H, Ghofrani A, et al. A comprehensive echocardiographic method for risk stratiﬁcation in pulmonary arterial hypertension. Eur Respir J 2020;56:2000513.
224. Sachdev A, Villarraga HR, Frantz RP, McGoon MD, Hsiao JF, Maalouf JF, et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. Chest 2011;139:1299–1309.
225. Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR,
et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J 2019;53:1801900.
226. Batal O, Dardari Z, Costabile C, Gorcsan J, Arena VC, Mathier MA. Prognostic value of pericardial effusion on serial echocardiograms in pulmonary arterial hypertension. Echocardiography 2015;32:1471–1476.
227. Chen L, Larsen CM, Le RJ, Connolly HM, Pislaru SV, Murphy JG, et al. The prognostic signiﬁcance of tricuspid valve regurgitation in pulmonary arterial hypertension.
Clin Respir J 2018;12:1572–1580.
228. Fenstad ER, Le RJ, Sinak LJ, Maradit-Kremers H, Ammash NM, Ayalew AM, et al.
Pericardial effusions in pulmonary arterial hypertension: characteristics, prognosis,
and role of drainage. Chest 2013;144:1530–1538.
229. Badagliacca R, Poscia R, Pezzuto B, Papa S, Reali M, Pesce F, et al. Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. J Heart Lung Transpl 2018;37:195–205.
230. Badano LP, Addetia K, Pontone G, Torlasco C, Lang RM, Parati G, et al. Advanced imaging of right ventricular anatomy and function. Heart 2020;106:1469–1476.
231. Lewis RA, Johns CS, Cogliano M, Capener D, Tubman E, Elliot CA, et al.
Identiﬁcation of cardiac magnetic resonance imaging thresholds for risk stratiﬁcation in pulmonary arterial hypertension. Am J Respir Crit Care Med 2020;201:
458–466.
232. Swift AJ, Capener D, Johns C, Hamilton N, Rothman A, Elliot C, et al. Magnetic resonance imaging in the prognostic evaluation of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2017;196:228–239.
233. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ,
et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011;58:2511–2519.
234. van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG,
Spreeuwenberg MD, et al. Prognostic value of right ventricular mass, volume,
and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007;28:
1250–1257.
235. Alabed S, Shahin Y, Garg P, Alandejani F, Johns CS, Lewis RA, et al. Cardiac-MRI
predicts clinical worsening and mortality in pulmonary arterial hypertension: a systematic review and meta-analysis. JACC Cardiovasc Imaging 2021;14:931–942.
236. Swift AJ, Wilson F, Cogliano M, Kendall L, Alandejani F, Alabed S, et al. Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study.
Thorax 2021;76:1032–1035.
237. van der Bruggen CE, Handoko ML, Bogaard HJ, Marcus JT, Oosterveer FPT,
Meijboom LJ, et al. The value of hemodynamic measurements or cardiac MRI in
ESC/ERS Guidelines
3717


<!-- PAGE 101 -->

### Page 101

the follow-up of patients with idiopathic pulmonary arterial hypertension. Chest
2021;159:1575–1585.
238. Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, et al. Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension. Circulation 2018;137:693–704.
239. van Wolferen SA, van de Veerdonk MC, Mauritz GJ, Jacobs W, Marcus JT, Marques
KMJ, et al. Clinically signiﬁcant change in stroke volume in pulmonary hypertension.
Chest 2011;139:1003–1009.
240. Huis In ‘t Veld AE, Van de Veerdonk MC, Spruijt O, Groeneveldt JA, Marcus JT,
Westerhof N, et al. EXPRESS: preserving right ventricular function in patients with pulmonary arterial hypertension: single centre experience with a cardiac magnetic resonance imaging-guided treatment strategy.
Pulm
Circ
2019.
doi:10.1177/2045894018824553. Epub ahead of print.
241. van de Veerdonk MC, Huis In T Veld AE, Marcus JT, Westerhof N, Heymans MW,
Bogaard HJ, et al. Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension. Eur Respir J 2017;49:1700007.
242. van de Veerdonk MC, Marcus JT, Westerhof N, de Man FS, Boonstra A, Heymans
MW, et al. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest 2015;147:1063–1071.
243. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al.
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343–349.
244. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156–163.
245. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension:
the impact of epoprostenol therapy. Circulation 2002;106:1477–1482.
246. Provencher S, Chemla D, Herve P, Sitbon O, Humbert M, Simonneau G. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur
Respir J 2006;27:114–120.
247. Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, et al. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J
2015;46:152–164.
248. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratiﬁcation equation. Eur Respir J 2010;35:1079–1087.
249. Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE,
et al. Predicting survival in patients with pulmonary arterial hypertension: the
REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest 2019;156:323–337.
250. Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, et al.
The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 2012;141:354–362.
251. Savarese G, Paolillo S, Costanzo P, D’Amore C, Cecere M, Losco T, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol
2012;60:1192–1201.
252. Zelniker TA, Huscher D, Vonk-Noordegraaf A, Ewert R, Lange TJ, Klose H, et al.
The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. Clin Res Cardiol 2018;107:460–470.
253. Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance.
J Heart Lung Transpl 2015;34:362–368.
254. Heresi GA, Rao Y. Follow-up functional class and 6-minute walk distance identify long-term survival in pulmonary arterial hypertension. Lung 2020;198:933–938.
255. Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, et al. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: data from the randomized SERAPHIN trial. PLoS
One 2018;13:e0193226.
256. Halliday SJ, Wang L, Yu C, Vickers BP, Newman JH, Fremont RD, et al. Six-minute walk distance in healthy young adults. Respir Med 2020;165:105933.
257. Khirfan G, Naal T, Abuhalimeh B, Newman J, Heresi GA, Dweik RA, et al.
Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension. PLoS One 2018;13:e0191869.
258. Lewis RA, Billings CG, Hurdman JA, Smith IA, Austin M, Armstrong IJ, et al. Maximal exercise testing using the incremental shuttle walking test can be used to riskstratify patients with pulmonary arterial hypertension. Ann Am Thorac Soc 2021;
18:34–43.
259. Laveneziana P, Di Paolo M, Palange P. The clinical value of cardiopulmonary exercise testing in the modern era. Eur Respir Rev 2021;30:200187.
260. Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002;106:319–324.
261. Badagliacca R, Papa S, Poscia R, Valli G, Pezzuto B, Manzi G, et al. The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension. J Heart Lung Transpl 2019;38:306–314.
262. Deboeck G, Scoditti C, Huez S, Vachiery JL, Lamotte M, Sharples L, et al. Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension. Eur Respir J 2012;40:1410–1419.
263. Wensel R, Francis DP, Meyer FJ, Opitz CF, Bruch L, Halank M, et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol 2013;167:1193–1198.
264. Badagliacca R, Rischard F, Giudice FL, Howard L, Papa S, Valli G, et al. Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. J Heart Lung Transplant 2022;41:780–790.
265. Bouzina H, Rådegran G. Low plasma stem cell factor combined with high transforming growth factor-α identiﬁes high-risk patients in pulmonary arterial hypertension. ERJ Open Res 2018;4:00035-02018.
266. Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N, et al. Association of
N-terminal pro brain natriuretic peptide and long-term outcome in patients with pulmonary arterial hypertension: insights from the phase III GRIPHON study.
Circulation 2019;139:2440–2450.
267. Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, et al.
Baseline and serial brain natriuretic peptide level predicts 5-year overall survival in patients with pulmonary arterial hypertension: data from the REVEAL registry.
Chest 2018;154:126–135.
268. Harbaum L, Ghataorhe P, Wharton J, Jimenez B, Howard LSG, Gibbs JSR, et al.
Reduced plasma levels of small HDL particles transporting ﬁbrinolytic proteins in pulmonary arterial hypertension. Thorax 2019;74:380–389.
269. Naal T, Abuhalimeh B, Khirfan G, Dweik RA, Tang WHW, Tonelli AR. Serum chloride levels track with survival in patients with pulmonary arterial hypertension. Chest
2018;154:541–549.
270. Nikolic I, Yung LM, Yang P, Malhotra R, Paskin-Flerlage S, Dinter T, et al. Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension.
Am J Respir Crit Care Med 2019;199:891–902.
271. Rhodes CJ, Wharton J, Ghataorhe P, Watson G, Girerd B, Howard LS, et al. Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respir Med 2017;5:717–726.
272. Wetzl V, Tiede SL, Faerber L, Weissmann N, Schermuly RT, Ghofrani HA, et al.
Plasma MMP2/TIMP4 ratio at follow-up assessment predicts disease progression of idiopathic pulmonary arterial hypertension. Lung 2017;195:489–496.
273. Arvidsson M, Ahmed A, Bouzina H, Rådegran G. Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension. Pulm Circ 2019;9:
2045894019895414.
274. Kylhammar D, Hesselstrand R, Nielsen S, Scheele C, Radegran G. Angiogenic and inﬂammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension. Scand J Rheumatol 2018;47:319–324.
275. Saleby J, Bouzina H, Ahmed S, Lundgren J, Radegran G. Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation. ERJ
Open Res 2019;5:00037–02019.
276. van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, et al.
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl
J Med 2014;370:433–443.
277. Ferrer E, Dunmore BJ, Hassan D, Ormiston ML, Moore S, Deighton J, et al. A potential role for exosomal translationally controlled tumor protein export in vascular remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2018;59:
467–478.
278. Lavoie JR, Ormiston ML, Perez-Iratxeta C, Courtman DW, Jiang B, Ferrer E, et al.
Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension.
Circulation 2014;129:2125–2135.
279. Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur
Respir J 2008;32:503–512.
280. Hoeper M, Pausch C, Olsson K, Huscher D, Pittrow D, Grünig E, et al. COMPERA
2.0: a reﬁned 4-strata risk assessment model for pulmonary arterial hypertension.
Eur Respir J 2022;60:2102311.
281. Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev 2015;24:621–629.
282. Yorke J, Corris P, Gaine S, Gibbs JS, Kiely DG, Harries C, et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur
Respir J 2014;43:1106–1113.
283. McGoon MD, Ferrari P, Armstrong I, Denis M, Howard LS, Lowe G, et al. The importance of patient perspectives in pulmonary hypertension. Eur Respir J 2019;53:
1801919.
284. Twiss J, McKenna S, Ganderton L, Jenkins S, Ben-L’amri M, Gain K, et al.
Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension. BMC Pulm Med 2013;13:45.
3718
ESC/ERS Guidelines


<!-- PAGE 102 -->

### Page 102

285. Chen H, De Marco T, Kobashigawa EA, Katz PP, Chang VW, Blanc PD.
Comparison of cardiac and pulmonary-speciﬁc quality-of-life measures in pulmonary arterial hypertension. Eur Respir J 2011;38:608–616.
286. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge
Pulmonary
Hypertension
Outcome
Review
(CAMPHOR):
a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006;15:103–115.
287. Lewis RA, Armstrong I, Bergbaum C, Brewis MJ, Cannon J, Charalampopoulos A,
et al. EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. Eur Respir J 2021;57:2000124.
288. Bonner N, Abetz L, Meunier J, Sikirica M, Mathai SC. Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients. Health Qual Life Outcomes 2013;11:161.
289. McCollister D, Shaffer S, Badesch DB, Filusch A, Hunsche E, Schuler R, et al.
Development of the Pulmonary Arterial Hypertension-Symptoms and Impact
(PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH. Respir Res 2016;17:72.
290. McCabe C, Bennett M, Doughty N, MacKenzie Ross R, Sharples L, Pepke-Zaba J.
Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest 2013;144:522–530.
291. Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, et al. Prediction of health-related quality of life and hospitalization in pulmonary arterial hypertension:
the Pulmonary Hypertension Association Registry. Am J Respir Crit Care Med 2021;
203:761–764.
292. Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S, et al.
A comprehensive risk stratiﬁcation at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J 2018;39:4175–4181.
293. Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, et al.
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratiﬁcation model. Eur Respir J 2017;50:
1700740.
294. Hjalmarsson C, Kjellström B, Jansson K, Nisell M, Kylhammar D, Kavianipour M,
et al. Early risk prediction in patients with idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a reﬁned assessment.
ERJ Open Res 2021;7:00854-02020.
295. Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G, et al. Risk assessment,
prognosis and guideline implementation in pulmonary arterial hypertension. Eur
Respir J 2017;50:1700889.
296. Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL
Lite 2, for use in patients with pulmonary arterial hypertension. Chest 2021;159:
337–346.
297. Bouzina H, Rådegran G, Butler O, Hesselstrand R, Hjalmarsson C, Holl K, et al.
Longitudinal changes in risk status in pulmonary arterial hypertension. ESC Heart
Fail 2021;8:680–690.
298. D’Alto M, Badagliacca R, Lo Giudice F, Argiento P, Casu G, Corda M, et al.
Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan–tadalaﬁl in pulmonary arterial hypertension. J Heart Lung
Transpl 2020;39:1389–1397.
299. Hjalmarsson C, Rådegran G, Kylhammar D, Rundqvist B, Multing J, Nisell MD, et al.
Impact of age and comorbidity on risk stratiﬁcation in idiopathic pulmonary arterial hypertension. Eur Respir J 2018;51:1702310.
300. Humbert M, Farber HW, Ghofrani HA, Benza RL, Busse D, Meier C, et al. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J 2019;53:1802004.
301. Kuwana M, Blair C, Takahashi T, Langley J, Coghlan JG. Initial combination therapy of ambrisentan and tadalaﬁl in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modiﬁed intention-to-treat population of the AMBITION study: post hoc analysis. Ann Rheum Dis 2020;79:626–634.
302. Kylhammar D, Hjalmarsson C, Hesselstrand R, Jansson K, Kavianipour M,
Kjellstrom B, et al. Predicting mortality during long-term follow-up in pulmonary arterial hypertension. ERJ Open Res 2021;7:00837-02020.
303. Sitbon O, Chin KM, Channick RN, Benza RL, Di Scala L, Gaine S, et al. Risk assessment in pulmonary arterial hypertension: insights from the GRIPHON study. J
Heart Lung Transpl 2020;39:300–309.
304. Rhodes CJ, Wharton J, Swietlik EM, Harbaum L, Girerd B, Coghlan JG, et al. Using the plasma proteome for risk stratifying patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2022;205:1102–1111.
305. Benza RL, Lohmueller LC, Kraisangka J, Kanwar M. Risk assessment in pulmonary arterial hypertension patients: the long and short of it. Adv Pulm Hypertens 2018;
16:125–135.
306. Yogeswaran A, Richter MJ, Sommer N, Ghofrani HA, Seeger W, Tello K, et al.
Advanced risk stratiﬁcation of intermediate risk group in pulmonary arterial hypertension. Pulm Circ 2020;10:2045894020961739.
307. Zelt JGE, Hossain A, Sun LY, Mehta S, Chandy G, Davies RA, et al. Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension. J
Heart Lung Transplant 2020;39:675–685.
308. Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Prévot G, et al. External validation of a reﬁned 4-strata risk assessment score from the French pulmonary hypertension registry. Eur Respir J 2022;59:2102419.
309. Olsson KM, Richter MJ, Kamp JC, Gall H, Heine A, Ghofrani HA, et al. Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. J
Heart Lung Transplant 2019;38:748–756.
310. Tonelli AR, Sahay S, Gordon KW, Edwards LD, Allmon AG, Broderick M, et al.
Impact of inhaled treprostinil on risk stratiﬁcation with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies. Pulm Circ 2020;10:
2045894020977025.
311. Weatherald J, Boucly A, Launay D, Cottin V, Prévot G, Bourlier D, et al.
Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. Eur Respir J 2018;52:1800678.
312. Chan L, Chin LMK, Kennedy M, Woolstenhulme JG, Nathan SD, Weinstein AA,
et al. Beneﬁts of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. Chest 2013;143:
333–343.
313. de Man FS, Handoko ML, Groepenhoff H, van ‘t Hul AJ, Abbink J, Koppers RJ, et al.
Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2009;34:669–675.
314. Ehlken N, Lichtblau M, Klose H, Weidenhammer J, Fischer C, Nechwatal R, et al.
Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. Eur Heart J 2016;37:35–44.
315. Grunig E, MacKenzie A, Peacock AJ, Eichstaedt CA, Benjamin N, Nechwatal R, et al.
Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large
European multicentre randomized controlled trial. Eur Heart J 2021;42:2284–2295.
316. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, et al.
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006;114:
1482–1489.
317. Grunig E, Eichstaedt C, Barbera JA, Benjamin N, Blanco I, Bossone E, et al. ERS
statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. Eur Respir J 2019;53:1800332.
318. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006;130:545–552.
319. Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al.
Anticoagulation and survival in pulmonary arterial hypertension: results from the
Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary
Hypertension (COMPERA). Circulation 2014;129:57–65.
320. Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension
(PAH) in the Registry to Evaluate Early and Long-term PAH Disease
Management (REVEAL). Circulation 2015;132:2403–2411.
321. Khan MS, Usman MS, Siddiqi TJ, Khan SU, Murad MH, Mookadam F, et al. Is anticoagulation beneﬁcial in pulmonary arterial hypertension? Circ Cardiovasc Qual
Outcomes 2018;11:e004757.
322. Wang P, Hu L, Yin Y, Yan D, Zheng H, Zhang J, et al. Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis. Thromb Res 2020;196:251–256.
323. Stickel S, Gin-Sing W, Wagenaar M, Gibbs JSR. The practical management of ﬂuid retention in adults with right heart failure due to pulmonary arterial hypertension.
Eur Heart J Suppl 2019;21:K46–K53.
324. Sandoval J, Aguirre JS, Pulido T, Martinez-Guerra ML, Santos E, Alvarado P, et al.
Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J
Respir Crit Care Med 2001;164:1682–1687.
325. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;131:493–498.
326. Ulrich S, Saxer S, Hasler ED, Schwarz EI, Schneider SR, Furian M, et al. Effect of domiciliary oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomised, placebo-controlled trial. Eur Respir J 2019;54:1900276.
327. Ulrich S, Hasler ED, Saxer S, Furian M, Muller-Mottet S, Keusch S, et al. Effect of breathing oxygen-enriched air on exercise performance in patients with precapillary pulmonary hypertension: randomized, sham-controlled cross-over trial. Eur
Heart J 2017;38:1159–1168.
ESC/ERS Guidelines
3719


<!-- PAGE 103 -->

### Page 103

328. Adir Y, Humbert M, Chaouat A. Sleep-related breathing disorders and pulmonary hypertension. Eur Respir J 2021;57:2002258.
329. McDonagh T, Damy T, Doehner W, Lam CSP, Sindone A, van der Meer P, et al.
Screening, diagnosis and treatment of iron deﬁciency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur J Heart Fail 2018;20:1664–1672.
330. Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JS, et al. Iron deﬁciency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol 2011;58:300–309.
331. Ruiter G, Lankhorst S, Boonstra A, Postmus PE, Zweegman S, Westerhof N, et al.
Iron deﬁciency is common in idiopathic pulmonary arterial hypertension. Eur Respir
J 2011;37:1386–1391.
332. Ruiter G, Lanser IJ, de Man FS, van der Laarse WJ, Wharton J, Wilkins MR, et al. Iron deﬁciency in systemic sclerosis patients with and without pulmonary hypertension.
Rheumatology 2014;53:285–292.
333. Van De Bruaene A, Delcroix M, Pasquet A, De Backer J, De Pauw M, Naeije R, et al.
Iron deﬁciency is associated with adverse outcome in Eisenmenger patients. Eur
Heart J 2011;32:2790–2799.
334. Sonnweber T, Nairz M, Theurl I, Petzer V, Tymoszuk P, Haschka D, et al. The crucial impact of iron deﬁciency deﬁnition for the course of precapillary pulmonary hypertension. PLoS One 2018;13:e0203396.
335. Ruiter G, Manders E, Happe CM, Schalij I, Groepenhoff H, Howard LS, et al.
Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deﬁciency. Pulm Circ 2015;5:466–472.
336. Viethen T, Gerhardt F, Dumitrescu D, Knoop-Busch S, Ten Freyhaus H, Rudolph
TK, et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deﬁciency: a pilot study. Int J
Cardiol 2014;175:233–239.
337. Kramer T, Wissmuller M, Natsina K, Gerhardt F, Ten Freyhaus H, Dumitrescu D,
et al. Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deﬁciency: a long-term study. J Cachexia Sarcopenia Muscle 2021;12:
1501–1512.
338. Olsson KM, Fuge J, Brod T, Kamp JC, Schmitto J, Kempf T, et al. Oral iron supplementation with ferric maltol in patients with pulmonary hypertension. Eur Respir J
2020;56:2000616.
339. Howard LSGE, He J, Watson GMJ, Huang L, Wharton J, Luo Q, et al.
Supplementation with iron in pulmonary arterial hypertension. Two randomized crossover trials. Ann Am Thorac Soc 2021;18:981–988.
340. Larisch A, Neeb C, de Zwaan M, Pabst C, Tiede H, Ghofrani A, et al. Mental distress and wish for psychosomatic treatment of patients with pulmonary hypertension.
Psychother Psychosom Med Psychol 2014;64:384–389.
341. Olsson KM, Meltendorf T, Fuge J, Kamp JC, Park DH, Richter MJ, et al. Prevalence of mental disorders and impact on quality of life in patients with pulmonary arterial hypertension. Front Psychiatry 2021;31:667602.
342. Pfeuffer E, Krannich H, Halank M, Wilkens H, Kolb P, Jany B, et al. Anxiety, depression, and health-related QOL in patients diagnosed with PAH or CTEPH. Lung
2017;195:759–768.
343. Zhou X, Shi H, Yang Y, Zhang Z, Zhai Z, Wang C. Anxiety and depression in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: results from a Chinese survey. Exp Ther Med 2020;19:
3124–3132.
344. Kingman M, Hinzmann B, Sweet O, Vachiery JL. Living with pulmonary hypertension: unique insights from an international ethnographic study. BMJ Open 2014;4:
e004735.
345. Harzheim D, Klose H, Pinado FP, Ehlken N, Nagel C, Fischer C, et al. Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Res 2013;14:104.
346. Anand V, Vallabhajosyula S, Cheungpasitporn W, Frantz RP, Cajigas HR, Strand JJ,
et al. Inpatient palliative care use in patients with pulmonary arterial hypertension:
temporal trends, predictors, and outcomes. Chest 2020;158:2568–2578.
347. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:
487–497.
348. Kjellstrom B, Sandqvist A, Hjalmarsson C, Nisell M, Nasman P, Ivarsson B.
Adherence to disease-speciﬁc drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ERJ Open
Res 2020;6:00299-02020.
349. Shah NB, Mitchell RE, Proctor ST, Choi L, DeClercq J, Jolly JA, et al. High rates of medication adherence in patients with pulmonary arterial hypertension: an integrated specialty pharmacy approach. PLoS One 2019;14:e0217798.
350. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998;
31:1650–1657.
351. Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur
Heart J 2009;30:256–265.
352. Duarte AG, Thomas S, Safdar Z, Torres F, Pacheco LD, Feldman J, et al.
Management of pulmonary arterial hypertension during pregnancy: a retrospective,
multicenter experience. Chest 2013;143:1330–1336.
353. Jais X, Olsson KM, Barbera JA, Blanco I, Torbicki A, Peacock A, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur
Respir J 2012;40:881–885.
354. Kiely DG, Condliffe R, Webster V, Mills GH, Wrench I, Gandhi SV, et al. Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach. BJOG 2010;117:565–574.
355. Luo J, Shi H, Xu L, Su W, Li J. Pregnancy outcomes in patients with pulmonary arterial hypertension: a retrospective study. Medicine 2020;99:e20285.
356. Kamp JC, von Kaisenberg C, Greve S, Winter L, Park DH, Fuge J, et al. Pregnancy in pulmonary arterial hypertension: midterm outcomes of mothers and offspring. J
Heart Lung Transplant 2021;40:229–233.
357. Corbach N, Berlier C, Lichtblau M, Schwarz EI, Gautschi F, Groth A, et al. Favorable pregnancy outcomes in women with well-controlled pulmonary arterial hypertension. Front Med (Lausanne) 2021;8:689764.
358. Bostock S, Sheares K, Cannon J, Taboada D, Pepke-Zaba J, Toshner M. The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade. Eur Respir J 2017;50:1701141.
359. de Raaf MA, Beekhuijzen M, Guignabert C, Vonk Noordegraaf A, Bogaard HJ.
Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension. Reprod Toxicol 2015;56:45–51.
360. Dunn L, Greer R, Flenady V, Kumar S. Sildenaﬁl in pregnancy: a systematic review of maternal tolerance and obstetric and perinatal outcomes. Fetal Diagn Ther 2017;41:
81–88.
361. van Giersbergen PL, Halabi A, Dingemanse J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin
Pharmacol Ther 2006;44:113–118.
362. Meyer S, McLaughlin VV, Seyfarth HJ, Bull TM, Vizza CD, Gomberg-Maitland M,
et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J 2013;41:1302–1307.
363. Hassan HJ, Housten T, Balasubramanian A, Simpson CE, Damico RL, Mathai SC,
et al. A novel approach to perioperative risk assessment for patients with pulmonary hypertension. ERJ Open Res 2021;7:00257-02021.
364. Non-cardiac surgery: Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M,
Barbato E, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J 2022. https://doi.
org/10.1093/eurheartj/ehac270.
365. Burns RM, Peacock AJ, Johnson MK, Church AC. Hypoxaemia in patients with pulmonary arterial hypertension during simulated air travel. Respir Med 2013;107:
298–304.
366. Kylhammar D, Rådegran G. The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension. Acta Physiol 2017;219:728–756.
367. Code of Federal Regulations. Chapter I, Subchapter C, Part 25, Subpart D, Subjgrp -
Pressurization. Section 25.841 - Pressurized cabins. Washington, DC: US
Government Printing Ofﬁce; 2012.
368. Groth A, Saxer S, Bader PR, Lichtblau M, Furian M, Schneider SR, et al. Acute hemodynamic changes by breathing hypoxic and hyperoxic gas mixtures in pulmonary arterial and chronic thromboembolic pulmonary hypertension. Int J Cardiol 2018;
270:262–267.
369. Roubinian N, Elliott CG, Barnett CF, Blanc PD, Chen J, De Marco T, et al. Effects of commercial air travel on patients with pulmonary hypertension air travel and pulmonary hypertension. Chest 2012;142:885–892.
370. Schneider SR, Mayer LC, Lichtblau M, Berlier C, Schwarz EI, Saxer S, et al. Effect of normobaric hypoxia on exercise performance in pulmonary hypertension: randomized trial. Chest 2021;159:757–771.
371. Seccombe LM, Chow V, Zhao W, Lau EMT, Rogers PG, Ng ACC, et al. Right heart function during simulated altitude in patients with pulmonary arterial hypertension.
Open Heart 2017;4:e000532.
372. Thamm M, Voswinckel R, Tiede H, Lendeckel F, Grimminger F, Seeger W, et al. Air travel can be safe and well tolerated in patients with clinically stable pulmonary hypertension. Pulm Circ 2011;1:239–243.
373. Cramer D, Ward S, Geddes D. Assessment of oxygen supplementation during air travel. Thorax 1996;51:202–203.
374. Dubroff J, Melendres L, Lin Y, Beene DR, Ketai L. High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude.
Pulm Circ 2020;10:2045894019894534.
375. Fakhri S, Hannon K, Moulden K, Peterson R, Hountras P, Bull T, et al. Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary
Hypertension Association Registry. Pulm Circ 2020;10:2045894020964342.
3720
ESC/ERS Guidelines


<!-- PAGE 104 -->

### Page 104

376. Schneider SR, Mayer LC, Lichtblau M, Berlier C, Schwarz EI, Saxer S, et al. Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension:
randomised crossover trial. ERJ Open Res 2021;7:00314-02021.
377. Makowski CT, Rissmiller RW, Bullington WM. Riociguat: a novel new drug for treatment of pulmonary hypertension. Pharmacotherapy 2015;35:502–519.
378. Montani D, Savale L, Natali D, Jais X, Herve P, Garcia G, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur
Heart J 2010;31:1898–1907.
379. Galiè N, Ussia G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995;
75:55A–62A.
380. Clozel M, Maresta A, Humbert M. Endothelin receptor antagonists. Handb Exp
Pharmacol 2013;218:199–227.
381. Xing J, Cao Y, Yu Y, Li H, Song Z, Yu H. In vitro micropatterned human pluripotent stem cell test (microP-hPST) for morphometric-based teratogen screening. Sci Rep
2017;7:8491.
382. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al.
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind,
placebo-controlled, multicenter, efﬁcacy (ARIES) study 1 and 2. Circulation 2008;
117:3010–3019.
383. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896–903.
384. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of
European post-marketing surveillance of bosentan in pulmonary hypertension.
Eur Respir J 2007;30:338–344.
385. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenaﬁl when coprescribed in pulmonary hypertension. Br J Clin
Pharmacol 2005;60:107–112.
386. Weber C, Banken L, Birnboeck H, Schulz R. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J
Clin Pharmacol 1999;39:847–854.
387. Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI.
Pharmacokinetic interaction between tadalaﬁl and bosentan in healthy male subjects. J Clin Pharmacol 2008;48:610–618.
388. Ghofrani HA, Osterloh IH, Grimminger F. Sildenaﬁl: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006;5:
689–702.
389. Galiè N, Muller K, Scalise AV, Grunig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenaﬁl in pulmonary arterial hypertension. Eur
Respir J 2015;45:1314–1322.
390. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenaﬁl citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:
2148–2157.
391. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efﬁcacy of sildenaﬁl in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind,
crossover study. J Am Coll Cardiol 2004;43:1149–1153.
392. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, et al. Addition of sildenaﬁl to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521–530.
393. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al.
Tadalaﬁl therapy for pulmonary arterial hypertension. Circulation 2009;119:
2894–2903.
394. Schermuly RT, Janssen W, Weissmann N, Stasch JP, Grimminger F, Ghofrani HA.
Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig
Drugs 2011;20:567–576.
395. Ghofrani HA, Galiè N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:
330–340.
396. Galiè N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J
Respir Med 2003;2:123–137.
397. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995;48:
890–896.
398. Sitbon O, Delcroix M, Bergot E, Boonstra AB, Granton J, Langleben D, et al.
EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.
Am Heart J 2014;167:210–217.
399. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study
Group. N Engl J Med 1996;334:296–302.
400. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin
(epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112:485–491.
401. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al.
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med
2000;132:425–434.
402. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH.
Improvement in pulmonary hemodynamics during intravenous epoprostenol
(prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641–648.
403. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, et al. Prognostic factors for survival in human immunodeﬁciency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:1433–1439.
404. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858–1865.
405. Boucly A, O’Connell C, Savale L, O’Callaghan DS, Jais X, Montani D, et al. Tunnelled central venous line-associated infections in patients with pulmonary arterial hypertension treated with intravenous prostacyclin. Presse Med 2016;45:20–28.
406. Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL, et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008;(160):5–9.
407. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322–329.
408. Simonneau G, Barst RJ, Galiè N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J
Respir Crit Care Med 2002;165:800–804.
409. Bourge RC, Waxman AB, Gomberg-Maitland M, Shapiro SM, Tarver JH III, Zwicke
DL, et al. Treprostinil administered to treat pulmonary arterial hypertension using a fully implantable programmable intravascular delivery system: results of the
DelIVery for PAH trial. Chest 2016;150:27–34.
410. Richter MJ, Harutyunova S, Bollmann T, Classen S, Gall H, Gerhardt Md F, et al.
Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. J Heart Lung Transplant 2018;37:1235–1244.
411. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al.
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension:
a randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915–1922.
412. Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the
FREEDOM-C2 study): a randomized controlled trial. Chest 2013;144:952–958.
413. Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012;142:
1383–1390.
414. Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, et al. Efﬁcacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013;127:624–633.
415. White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY,
et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med 2020;
201:707–717.
416. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119–2125.
417. Galiè N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol
2002;39:1496–1502.
418. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galiè N, et al.
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012;40:874–880.
419. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015;373:2522–2533.
419a. McLaughlin V, Channick RN, Ghofrani H-A, Lemarié J-C, Naeije R, Packer M, et al.
Bosentan added to sildenaﬁl therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015;46:405–413.
420. Hoeper MM, McLaughlin VV, Barbera JA, Frost AE, Ghofrani HA, Peacock AJ, et al.
Initial combination therapy with ambrisentan and tadalaﬁl and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med 2016;4:894–901.
421. Chin KM, Sitbon O, Doelberg M, Feldman J, Gibbs JSR, Grunig E, et al. Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. J Am Coll Cardiol 2021;78:1393–1403.
ESC/ERS Guidelines
3721


<!-- PAGE 105 -->

### Page 105

422. Badagliacca R, D’Alto M, Ghio S, Argiento P, Bellomo V, Brunetti ND, et al. Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension. Am J Respir Crit Care Med 2021;203:484–492.
423. Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, et al.
Ambrisentan and tadalaﬁl up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;192:1102–1110.
424. Kirtania L, Maiti R, Srinivasan A, Mishra A. Effect of combination therapy of endothelin receptor antagonist and phosphodiesterase-5 inhibitor on clinical outcome and pulmonary haemodynamics in patients with pulmonary arterial hypertension: a meta-analysis. Clin Drug Investig 2019;39:1031–1044.
425. Montani D, Lau EM, Dorfmuller P, Girerd B, Jais X, Savale L, et al. Pulmonary veno-occlusive disease. Eur Respir J 2016;47:1518–1534.
426. Sitbon O, Jais X, Savale L, Cottin V, Bergot E, Macari EA, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014;
43:1691–1697.
427. D’Alto M, Badagliacca R, Argiento P, Romeo E, Farro A, Papa S, et al. Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension. Chest 2020;157:376–383.
428. Boucly A, Savale L, Jais X, Bauer F, Bergot E, Bertoletti L, et al. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension.
Am J Respir Crit Care Med 2021;204:842–854.
429. Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label,
randomised controlled trial. Lancet Respir Med 2021;9:573–584.
430. Sitbon O, Cottin V, Canuet M, Clerson P, Gressin V, Perchenet L, et al. Initial combination therapy of macitentan and tadalaﬁl in pulmonary arterial hypertension. Eur
Respir J 2020;56:2000673. doi:10.1183/13993003.00673-2020.
431. Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs 2018;18:37–47.
432. Lajoie AC, Lauziere G, Lega JC, Lacasse Y, Martin S, Simard S, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.
Lancet Respir Med 2016;4:291–305.
433. Hoeper MM, Pausch C, Grunig E, Staehler G, Huscher D, Pittrow D, et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.
Eur Respir J 2022;59:2102024. doi:10.1183/13993003.02024-2021.
434. Zelt JGE, Sugarman J, Weatherald J, Partridge ACR, Liang JC, Swiston J, et al.
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS Guideline Era. Eur Respir J 2022;59:2101552. doi:
10.1183/13993003.01552-2021.
435. Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, et al.
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017;50:
1602425.
436. Bartolome SD, Sood N, Shah TG, Styrvoky K, Torres F, Chin KM. Mortality in patients with pulmonary arterial hypertension treated with continuous prostanoids.
Chest 2018;154:532–540.
437. Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, et al. SERAPHIN
haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
Eur Heart J 2017;38:1147–1155.
438. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, et al. Long-term sildenaﬁl added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2014;33:689–697.
439. Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, et al.
Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary
Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung
Transplant 2011;30:1327–1333.
440. Rubin LJ, Galiè N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study
(PATENT-2). Eur Respir J 2015;45:1303–1313.
441. Hoeper MM, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, et al.
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691–694.
442. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al.
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257–1263.
443. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, et al. ARIES-3:
ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012;30:93–99.
444. Dardi F, Manes A, Palazzini M, Bachetti C, Mazzanti G, Rinaldi A, et al. Combining bosentan and sildenaﬁl in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J 2015;46:414–421.
445. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sondergaard L. Combination therapy with bosentan and sildenaﬁl in Eisenmenger syndrome: a randomized, placebocontrolled, double-blinded trial. Eur Heart J 2010;31:1124–1131.
446. Vizza CD, Jansa P, Teal S, Dombi T, Zhou D. Sildenaﬁl dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovasc Disord 2017;17:239.
447. Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, et al.
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013;168:871–880.
448. Khou V, Anderson JJ, Strange G, Corrigan C, Collins N, Celermajer DS, et al.
Diagnostic delay in pulmonary arterial hypertension: insights from the Australian and New Zealand pulmonary hypertension registry. Respirology 2020;25:863–871.
449. McLaughlin VV, Vachiery JL, Oudiz RJ, Rosenkranz S, Galiè N, Barbera JA, et al.
Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: results from the AMBITION trial. J Heart Lung Transplant 2019;38:
1286–1295.
450. Opitz CF, Hoeper MM, Gibbs JS, Kaemmerer H, Pepke-Zaba J, Coghlan JG, et al.
Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 2016;68:368–378.
451. Lewis RA, Thompson AAR, Billings CG, Charalampopoulos A, Elliot CA, Hamilton
N, et al. Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Eur Respir J 2020;55:2000041.
452. Valentin S, Maurac A, Sitbon O, Beurnier A, Gomez E, Guillaumot A, et al.
Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. Eur Respir J 2021;58:2004066.
453. Rosenkranz S, Channick R, Chin KM, Jenner B, Gaine S, Galiè N, et al. The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. Eur J Heart Fail 2022;24:205–214.
454. Khan MS, Memon MM, Amin E, Yamani N, Khan SU, Figueredo VM, et al. Use of balloon atrial septostomy in patients with advanced pulmonary arterial hypertension: a systematic review and meta-analysis. Chest 2019;156:53–63.
455. Sandoval J, Gaspar J, Pulido T, Bautista E, Martinez-Guerra ML, Zeballos M, et al.
Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment.
J Am Coll Cardiol 1998;32:297–304.
456. Aggarwal M, Grady RM, Choudhry S, Anwar S, Eghtesady P, Singh GK. Potts shunt improves right ventricular function and coupling with pulmonary circulation in children with suprasystemic pulmonary arterial hypertension. Circ Cardiovasc Imaging
2018;11:e007964.
457. Baruteau AE, Belli E, Boudjemline Y, Laux D, Levy M, Simonneau G, et al. Palliative
Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the ﬁrst 24 patients. Eur J Cardiothorac Surg 2015;
47:e105–e110.
458. Grady RM, Canter M, Shmalts A, Coleman R, Beghetti M, Berger RM, et al.
Pulmonary-to-systemic arterial shunt in children with severe pulmonary hypertension. J Am Coll Cardiol 2021;78:468–477.
459. Rosenzweig EB, Ankola A, Krishnan U, Middlesworth W, Bacha E, Bacchetta M. A
novel unidirectional-valved shunt approach for end-stage pulmonary arterial hypertension: early experience in adolescents and adults. J Thorac Cardiovasc Surg 2021;
161:1438–1446.e1432.
460. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P. Prognostic signiﬁcance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J
Respir Crit Care Med 2010;181:1269–1275.
461. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 2004;
110:1308–1312.
462. Juratsch CE, Jengo JA, Castagna J, Laks MM. Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature. Chest
1980;77:525–530.
463. Rothman A, Jonas M, Castel D, Tzafriri AR, Traxler H, Shav D, et al. Pulmonary artery denervation using catheter-based ultrasonic energy. EuroIntervention 2019;15:
722–730.
464. Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective,
ﬁrst-in-man PADN-1 study (ﬁrst-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol 2013;62:1092–1100.
465. Rothman AMK, Vachiery JL, Howard LS, Mikhail GW, Lang IM, Jonas M, et al.
Intravascular ultrasound pulmonary artery denervation to treat pulmonary arterial hypertension (TROPHY1): multicenter, early feasibility study. JACC Cardiovasc Interv
2020;13:989–999.
3722
ESC/ERS Guidelines


<!-- PAGE 106 -->

### Page 106

466. Sztrymf B, Souza R, Bertoletti L, Jais X, Sitbon O, Price LC, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J
2010;35:1286–1293.
467. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, et al.
Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J 2011;38:359–367.
468. Hoeper MM, Benza RL, Corris P, de Perrot M, Fadel E, Keogh AM, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J 2019;53:1801906.
469. Kapur NK, Esposito ML, Bader Y, Morine KJ, Kiernan MS, Pham DT, et al.
Mechanical circulatory support devices for acute right ventricular failure.
Circulation 2017;136:314–326.
470. Konstam MA, Kiernan MS, Bernstein D, Bozkurt B, Jacob M, Kapur NK, et al.
Evaluation and management of right-sided heart failure: a scientiﬁc statement from the American Heart Association. Circulation 2018;137:e578–e622.
471. Olsson KM, Richter MJ, Kamp JC, Gall H, Ghofrani HA, Fuge J, et al. Reﬁned risk stratiﬁcation in pulmonary arterial hypertension and timing of lung transplantation.
Eur Respir J 2022. doi:10.1183/13993003.03087-2021. Epub ahead of print.
472. Moser B, Jaksch P, Taghavi S, Murakozy G, Lang G, Hager H, et al. Lung transplantation for idiopathic pulmonary arterial hypertension on intraoperative and postoperatively prolonged extracorporeal membrane oxygenation provides optimally controlled reperfusion and excellent outcome. Eur J Cardiothorac Surg 2018;53:
178–185.
473. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F,
et al.
The
Registry of the
International
Society for
Heart and
Lung
Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart
Lung Transplant 2012;31:1073–1086.
474. Egan TM, Edwards LB. Effect of the lung allocation score on lung transplantation in the United States. J Heart Lung Transplant 2016;35:433–439.
475. Savale L, Le Pavec J, Mercier O, Mussot S, Jais X, Fabre D, et al. Impact of highpriority allocation on lung and heart-lung transplantation for pulmonary hypertension. Ann Thorac Surg 2017;104:404–411.
476. Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB,
et al.
The
Registry of the
International
Society for
Heart and
Lung
Transplantation:
Thirty-second
Ofﬁcial
Adult
Lung and
Heart-Lung
Transplantation Report–2015; Focus Theme: Early Graft Failure. J Heart Lung
Transplant 2015;34:1264–1277.
477. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al.
(EACTS): the Task Force for the diagnosis and management of atrial ﬁbrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;
42:373–498.
478. Wanamaker B, Cascino T, McLaughlin V, Oral H, Latchamsetty R, Siontis KC. Atrial arrhythmias in pulmonary hypertension: pathogenesis, prognosis and management.
Arrhythm Electrophysiol Rev 2018;7:43–48.
479. Andersen MO, Diederichsen SZ, Svendsen JH, Carlsen J. Assessment of cardiac arrhythmias using long-term continuous monitoring in patients with pulmonary hypertension. Int J Cardiol 2021;334:110–115.
480. Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial ﬂutter and ﬁbrillation in patients with pulmonary hypertension. Int J Cardiol 2013;167:2300–2305.
481. Wen L, Sun ML, An P, Jiang X, Sun K, Zheng L, et al. Frequency of supraventricular arrhythmias in patients with idiopathic pulmonary arterial hypertension. Am J
Cardiol 2014;114:1420–1425.
482. Luesebrink U, Fischer D, Gezgin F, Duncker D, Koenig T, Oswald H, et al. Ablation of typical right atrial ﬂutter in patients with pulmonary hypertension. Heart Lung
Circ 2012;21:695–699.
483. Santangeli P, Zado ES, Hutchinson MD, Riley MP, Lin D, Frankel DS, et al.
Prevalence and distribution of focal triggers in persistent and long-standing persistent atrial ﬁbrillation. Heart Rhythm 2016;13:374–382.
484. Ghigna MR, Guignabert C, Montani D, Girerd B, Jais X, Savale L, et al. BMPR2 mutation status inﬂuences bronchial vascular changes in pulmonary arterial hypertension. Eur Respir J 2016;48:1668–1681.
485. Rasciti E, Sverzellati N, Silva M, Casadei A, Attina D, Palazzini M, et al. Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension.
Radiol Med 2017;122:257–264.
486. Yang S, Wang J, Kuang T, Gong J, Ma Z, Shen YH, et al. Efﬁcacy and safety of bronchial artery embolization on hemoptysis in chronic thromboembolic pulmonary hypertension: a pilot prospective cohort study. Crit Care Med 2019;47:e182–e189.
487. Demerouti
EA,
Manginas
AN,
Athanassopoulos
GD,
Karatasakis
GT.
Complications leading to sudden cardiac death in pulmonary arterial hypertension.
Respir Care 2013;58:1246–1254.
488. Kreibich M, Siepe M, Kroll J, Hohn R, Grohmann J, Beyersdorf F. Aneurysms of the pulmonary artery. Circulation 2015;131:310–316.
489. Mak SM, Strickland N, Gopalan D. Complications of pulmonary hypertension: a pictorial review. Br J Radiol 2017;90:20160745.
490. Nuche J, Montero Cabezas JM, Alonso Charterina S, Escribano Subias P.
Management of incidentally diagnosed pulmonary artery dissection in patients with pulmonary arterial hypertension. Eur J Cardiothorac Surg 2019;56:210–212.
491. Russo V, Zompatori M, Galiè N. Extensive right pulmonary artery dissection in a young patient with chronic pulmonary hypertension. Heart 2012;98:265–266.
492. Zylkowska J, Kurzyna M, Florczyk M, Burakowska B, Grzegorczyk F, Burakowski J,
et al. Pulmonary artery dilatation correlates with the risk of unexpected death in chronic arterial or thromboembolic pulmonary hypertension. Chest 2012;142:
1406–1416.
493. Florczyk M, Wieteska M, Kurzyna M, Gosciniak P, Pepke-Zaba J, Biederman A, et al.
Acute and chronic dissection of pulmonary artery: new challenges in pulmonary arterial hypertension? Pulm Circ 2018;8:2045893217749114.
494. Velazquez Martin M, Montero Cabezas JM, Huertas S, Nuche J, Albarran A, Delgado
JF, et al. Clinical relevance of adding intravascular ultrasound to coronary angiography for the diagnosis of extrinsic left main coronary artery compression by a pulmonary artery aneurysm in pulmonary hypertension. Catheter Cardiovasc Interv
2021;98:691–700.
495. Torres F, Farber H, Ristic A, McLaughlin V, Adams J, Zhang J, et al. Efﬁcacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.
Eur Respir J 2019;54:1901030.
496. Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston
IR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J
Med 2021;384:1204–1215.
497. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 2006;130:1657–1663.
498. Zamanian RT, Hedlin H, Greuenwald P, Wilson DM, Segal JI, Jorden M, et al.
Features and outcomes of methamphetamine-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2018;197:788–800.
499. Savale L, Sattler C, Gunther S, Montani D, Chaumais MC, Perrin S, et al. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J 2014;44:
1627–1634.
500. Weatherald J, Chaumais MC, Savale L, Jais X, Seferian A, Canuet M, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a populationbased study. Eur Respir J 2017;50:1700217.
501. Cardio-Oncology: Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar
MC, Bergler-Klein J, et al. Guidelines on cardio-oncology. Eur Heart J 2022.
https://doi.org/10.1093/eurheartj/ehac244.
502. Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010;37:2290–2298.
503. Launay D, Montani D, Hassoun PM, Cottin V, Le Pavec J, Clerson P, et al. Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. PLoS One 2018;13:e0197112.
504. Launay D, Sobanski V, Hachulla E, Humbert M. Pulmonary hypertension in systemic sclerosis: different phenotypes. Eur Respir Rev 2017;26:170056.
505. Hachulla E, Jais X, Cinquetti G, Clerson P, Rottat L, Launay D, et al. Pulmonary arterial hypertension associated with systemic lupus erythematosus: results from the
French Pulmonary Hypertension Registry. Chest 2018;153:143–151.
506. Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O, et al.
Immunosuppressive therapy in lupusand mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008;58:521–531.
507. Qian J, Li M, Zhang X, Wang Q, Zhao J, Tian Z, et al. Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. Eur Respir J 2019;53:1800081.
508. Sanges S, Yelnik CM, Sitbon O, Benveniste O, Mariampillai K, Phillips-Houlbracq M,
et al. Pulmonary arterial hypertension in idiopathic inﬂammatory myopathies: data from the French pulmonary hypertension registry and review of the literature.
Medicine (Baltimore) 2016;95:e4911.
509. Wang J, Li M, Wang Q, Zhang X, Qian J, Zhao J, et al. Pulmonary arterial hypertension associated with primary Sjogren’s syndrome: a multicentre cohort study from
China. Eur Respir J 2020;56:1902157.
510. Montani D, Henry J, O’Connell C, Jais X, Cottin V, Launay D, et al. Association between rheumatoid arthritis and pulmonary hypertension: data from the French
Pulmonary Hypertension Registry. Respiration 2018;95:244–250.
511. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al.
Pulmonary arterial hypertension in France: results from a national registry. Am J
Respir Crit Care Med 2006;173:1023–1030.
512. Humbert M, Khaltaev N, Bousquet J, Souza R. Pulmonary hypertension: from an orphan disease to a public health problem. Chest 2007;132:365–367.
513. Gunther S, Jais X, Maitre S, Berezne A, Dorfmuller P, Seferian A, et al. Computed tomography ﬁndings of pulmonary venoocclusive disease in scleroderma patients
ESC/ERS Guidelines
3723


<!-- PAGE 107 -->

### Page 107

presenting with precapillary pulmonary hypertension. Arthritis Rheum 2012;64:
2995–3005.
514. Hsu S, Kokkonen-Simon KM, Kirk JA, Kolb TM, Damico RL, Mathai SC, et al. Right ventricular myoﬁlament functional differences in humans with systemic sclerosis-associated versus idiopathic pulmonary arterial hypertension. Circulation
2018;137:2360–2370.
515. Chauvelot L, Gamondes D, Berthiller J, Nieves A, Renard S, Catella-Chatron J, et al.
Hemodynamic response to treatment and outcomes in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis: data from a study identifying prognostic factors in pulmonary hypertension associated with interstitial lung disease. Arthritis Rheum 2021;73:
295–304.
516. Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 2013;72:1940–1946.
517. Ramjug S, Hussain N, Hurdman J, Billings C, Charalampopoulos A, Elliot CA, et al.
Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a comparison of demographic, hemodynamic, and MRI characteristics and outcomes.
Chest 2017;152:92–102.
518. Pan J, Lei L, Zhao C. Comparison between the efﬁcacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Clin Exp Rheumatol 2018;36:
1095–1102.
519. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest
2006;130:182–189.
520. Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, et al.
Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum
Dis 2017;76:422–426.
521. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE.
Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344–350.
522. Trombetta AC, Pizzorni C, Ruaro B, Paolino S, Sulli A, Smith V, et al. Effects of longterm treatment with bosentan and iloprost on nailfold absolute capillary number,
ﬁngertip blood perfusion, and clinical status in systemic sclerosis. J Rheumatol 2016;
43:2033–2041.
523. Pradere P, Tudorache I, Magnusson J, Savale L, Brugiere O, Douvry B, et al. Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study. J Heart Lung Transplant 2018;37:903–911.
524. Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.
Eur Respir J 2017;50:1602493.
525. Barbaro G, Lucchini A, Pellicelli AM, Grisorio B, Giancaspro G, Fauarbarini G, et al.
Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 2006;92:
1164–1166.
526. Degano B, Guillaume M, Savale L, Montani D, Jais X, Yaici A, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010;24:67–75.
527. Sitbon O. HIV-related pulmonary arterial hypertension: clinical presentation and management. AIDS 2008;22:S55–S62.
528. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS (London, England) 2008;22:S35–S40.
529. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, et al.
Platelet-derived growth factor expression in primary pulmonary hypertension:
comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;
11:554–559.
530. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000;118:1133–1141.
531. Zuber JP, Calmy A, Evison JM, Hasse B, Schiffer V, Wagels T, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004;38:1178–1185.
532. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, et al.
Bosentan for the treatment of human immunodeﬁciency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;170:1212–1217.
533. Degano B, Yaici A, Le Pavec J, Savale L, Jais X, Camara B, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur
Respir J 2009;33:92–98.
534. Carlsen J, Kjeldsen K, Gerstoft J. Sildenaﬁl as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 2002;16:1568–1569.
535. Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenaﬁl in HIV-related pulmonary hypertension. AIDS 2001;15:1747–1748.
536. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenaﬁl and saquinavir/ritonavir. Br J Clin Pharmacol 2000;50:
99–107.
537. Garraffo R, Lavrut T, Ferrando S, Durant J, Rouyrre N, MacGregor TR, et al. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalaﬁl in healthy volunteers. J Clin Pharmacol 2011;51:1071–1078.
538. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000;162:1846–1850.
539. Cea-Calvo L, Escribano Subias P, Tello de Menesses R, Lazaro Salvador M, Gomez
Sanchez MA, Delgado Jimenez JF, et al. Treatment of HIV-associated pulmonary hypertension with treprostinil. Rev Esp Cardiol 2003;56:421–425.
540. Ghofrani HA, Friese G, Discher T, Olschewski H, Schermuly RT, Weissmann N,
et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 2004;23:321–326.
541. Bigna JJ, Sime PS, Koulla-Shiro S. HIV related pulmonary arterial hypertension: epidemiology in Africa, physiopathology, and role of antiretroviral treatment. AIDS Res
Ther 2015;12:36.
542. Ryom L, Cotter A, De Miguel R, Beguelin C, Podlekareva D, Arribas JR, et al. 2019
update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV Med 2020;21:617–624.
543. Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, et al.
Portopulmonary hypertension: a report from the US-based REVEAL Registry.
Chest 2012;141:906–915.
544. Lazaro Salvador M, Quezada Loaiza CA, Rodriguez Padial L, Barbera JA,
Lopez-Meseguer M, Lopez-Reyes R, et al. Portopulmonary hypertension: prognosis and management in the current treatment era - results from the REHAP registry.
Intern Med J 2021;51:355–365.
545. Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, et al.
Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol 2020;73:130–139.
546. Baiges A, Turon F, Simon-Talero M, Tasayco S, Bueno J, Zekrini K, et al. Congenital extrahepatic portosystemic shunts (Abernethy malformation): an international observational study. Hepatology 2020;71:658–669.
547. Fussner LA, Iyer VN, Cartin-Ceba R, Lin G, Watt KD, Krowka MJ. Intrapulmonary vascular dilatations are common in portopulmonary hypertension and may be associated with decreased survival. Liver Transpl 2015;21:1355–1364.
548. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:502–508.
549. Olsson KM, Meyer K, Berliner D, Hoeper MM. Development of hepatopulmonary syndrome during combination therapy for portopulmonary hypertension. Eur
Respir J 2019;53:1801880.
550. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl
2000;6:443–450.
551. Cartin-Ceba R, Burger C, Swanson K, Vargas H, Aqel B, Keaveny AP, et al. Clinical outcomes after liver transplantation in patients with portopulmonary hypertension. Transplantation 2021;105:2283–2290.
552. Deroo R, Trepo E, Holvoet T, De Pauw M, Geerts A, Verhelst X, et al.
Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis. Hepatology 2020;72:
1701–1716.
553. Sadd CJ, Osman F, Li Z, Chybowski A, Decker C, Henderson B, et al. Long-term outcomes and survival in moderate-severe portopulmonary hypertension after liver transplant. Transplantation 2021;105:346–353.
554. Savale L, Sattler C, Coilly A, Conti F, Renard S, Francoz C, et al. Long-term outcome in liver transplantation candidates with portopulmonary hypertension. Hepatology
2017;65:1683–1692.
555. Diller GP, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Li W, et al. Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation 2015;132:
2118–2125.
556. van Riel AC, Schuuring MJ, van Hessen ID, Zwinderman AH, Cozijnsen L, Reichert
CL, et al. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classiﬁcation. Int J Cardiol
2014;174:299–305.
557. Lammers AE, Bauer LJ, Diller GP, Helm PC, Abdul-Khaliq H, Bauer UMM, et al.
Pulmonary hypertension after shunt closure in patients with simple congenital heart defects. Int J Cardiol 2020;308:28–32.
558. Ntiloudi D, Zanos S, Gatzoulis MA, Karvounis H, Giannakoulas G. How to evaluate patients with congenital heart disease-related pulmonary arterial hypertension.
Expert Rev Cardiovasc Ther 2019;17:11–18.
559. Dimopoulos K, Condliffe R, Tulloh RMR, Clift P, Alonso-Gonzalez R, Bedair R, et al.
Echocardiographic screening for pulmonary hypertension in congenital heart disease: JACC review topic of the week. J Am Coll Cardiol 2018;72:2778–2788.
3724
ESC/ERS Guidelines


<!-- PAGE 108 -->

### Page 108

560. Kempny A, Dimopoulos K, Fraisse A, Diller GP, Price LC, Raﬁq I, et al. Blood viscosity and its relevance to the diagnosis and management of pulmonary hypertension. J Am Coll Cardiol 2019;73:2640–2642.
561. Arvanitaki A, Giannakoulas G, Baumgartner H, Lammers AE. Eisenmenger syndrome: diagnosis, prognosis and clinical management. Heart 2020;106:1638–1645.
562. Diller GP, Korten MA, Bauer UM, Miera O, Tutarel O, Kaemmerer H, et al. Current therapy and outcome of Eisenmenger syndrome: data of the German National
Register for congenital heart defects. Eur Heart J 2016;37:1449–1455.
563. Kempny A, Hjortshoj CS, Gu H, Li W, Opotowsky AR, Landzberg MJ, et al.
Predictors of death in contemporary adult patients with Eisenmenger syndrome:
a multicenter study. Circulation 2017;135:1432–1440.
564. Arvind B, Relan J, Kothari SS. “Treat and repair” strategy for shunt lesions: a critical review. Pulm Circ 2020;10:2045894020917885.
565. Brida M, Nashat H, Gatzoulis MA. Pulmonary arterial hypertension: closing the gap in congenital heart disease. Curr Opin Pulm Med 2020;26:422–428.
566. van der Feen DE, Bartelds B, de Boer RA, Berger RMF. Assessment of reversibility in pulmonary arterial hypertension and congenital heart disease. Heart 2019;105:
276–282.
567. Becker-Grunig T, Klose H, Ehlken N, Lichtblau M, Nagel C, Fischer C, et al. Efﬁcacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol 2013;168:375–381.
568. Hartopo AB, Anggrahini DW, Nurdiati DS, Emoto N, Dinarti LK. Severe pulmonary hypertension and reduced right ventricle systolic function associated with maternal mortality in pregnant uncorrected congenital heart diseases. Pulm Circ 2019;
9:2045894019884516.
569. Li Q, Dimopoulos K, Liu T, Xu Z, Liu Q, Li Y, et al. Peripartum outcomes in a large population of women with pulmonary arterial hypertension associated with congenital heart disease. Eur J Prev Cardiol 2019;26:1067–1076.
570. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C,
Cifkova R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165–3241.
571. Blanche C, Alonso-Gonzalez R, Uribarri A, Kempny A, Swan L, Price L, et al. Use of intravenous iron in cyanotic patients with congenital heart disease and/or pulmonary hypertension. Int J Cardiol 2018;267:79–83.
572. Bertoletti L, Mismetti V, Giannakoulas G. Use of anticoagulants in patients with pulmonary hypertension. Hamostaseologie 2020;40:348–355.
573. Freisinger E, Gerss J, Makowski L, Marschall U, Reinecke H, Baumgartner H, et al.
Current use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44 000 patients. Eur
Heart J 2020;41:4168–4177.
574. Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48–54.
575. Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efﬁcace M, Gesang S, et al.
Evaluation of Macitentan in patients with Eisenmenger syndrome. Circulation
2019;139:51–63.
576. Zuckerman WA, Leaderer D, Rowan CA, Mituniewicz JD, Rosenzweig EB.
Ambrisentan for pulmonary arterial hypertension due to congenital heart disease.
Am J Cardiol 2011;107:1381–1385.
577. Nashat H, Kempny A, Harries C, Dormand N, Alonso-Gonzalez R, Price LC, et al. A
single-centre, placebo-controlled, double-blind randomised cross-over study of nebulised iloprost in patients with Eisenmenger syndrome: A pilot study. Int J
Cardiol 2020;299:131–135.
578. D’Alto M, Constantine A, Balint OH, Romeo E, Argiento P, Ablonczy L, et al. The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome. Eur Respir J 2019;54:1901401.
579. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galiè N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 2014;35:
716–724.
580. Savale L, Manes A. Pulmonary arterial hypertension populations of special interest:
portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease. Eur Heart J Suppl 2019;21:K37–K45.
581. Dimopoulos K, Diller GP, Opotowsky AR, D’Alto M, Gu H, Giannakoulas G, et al.
Deﬁnition and management of segmental pulmonary hypertension. J Am Heart
Assoc 2018;7:e008587.
582. Amedro P, Gavotto A, Abassi H, Picot MC, Matecki S, Malekzadeh-Milani S, et al.
Efﬁcacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design. ESC Heart Fail 2020;7:747–756.
583. Goldberg DJ, Zak V, Goldstein BH, Schumacher KR, Rhodes J, Penny DJ, et al.
Results of the FUEL Trial. Circulation 2020;141:641–651.
584. Ridderbos FS, Hagdorn QAJ, Berger RMF. Pulmonary vasodilator therapy as treatment for patients with a Fontan circulation: the Emperor’s new clothes? Pulm Circ
2018;8:2045894018811148.
585. Dimopoulos K, Muthiah K, Alonso-Gonzalez R, Banner NR, Wort SJ, Swan L, et al.
Heart or heart-lung transplantation for patients with congenital heart disease in
England. Heart 2019;105:596–602.
586. Lapa M, Dias B, Jardim C, Fernandes CJ, Dourado PM, Figueiredo M, et al.
Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation
2009;119:1518–1523.
587. KnaﬂD, Gerges C, King CH, Humbert M, Bustinduy AL. Schistosomiasis-associated pulmonary arterial hypertension: a systematic review. Eur Respir Rev 2020;29:190089.
588. Fernandes CJC, Piloto B, Castro M, Gavilanes Oleas F, Alves JL Jr, Lopes Prada LF,
et al. Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era. Eur Respir J 2018;51:1800307.
589. Weatherald J, Dorfmuller P, Perros F, Ghigna MR, Girerd B, Humbert M, et al.
Pulmonarycapillaryhaemangiomatosis: a distinct entity?Eur Respir Rev 2020;29:190168.
590. Humbert M, Guignabert C, Bonnet S, Dorfmuller P, Klinger JR, Nicolls MR, et al.
Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 2019;53:1801887.
591. Montani D, Girerd B, Jais X, Levy M, Amar D, Savale L, et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med 2017;5:125–134.
592. Perez-Olivares C, Segura de la Cal T, Flox-Camacho A, Nuche J, Tenorio J, Martinez
Menaca A, et al. The role of cardiopulmonary exercise test in identifying pulmonary veno-occlusive disease. Eur Respir J 2021;57:2100115.
593. Bergbaum C, Samaranayake CB, Pitcher A, Weingart E, Semple T, Kokosi M, et al. A
case series on the use of steroids and mycophenolate mofetil in idiopathic and heritable pulmonary veno-occlusive disease: is there a role for immunosuppression?
Eur Respir J 2021;57:2004354.
594. vanLoonRL,RoofthooftMT,HillegeHL,tenHarkelAD,vanOsch-GeversM,Delhaas
T, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 2011;124:1755–1764.
595. del Cerro Marin MJ, Sabate Rotes A, Rodriguez Ogando A, Mendoza Soto A,
Quero Jimenez M, Gavilan Camacho JL, et al. Assessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish registry. Am J Respir Crit
Care Med 2014;190:1421–1429.
596. Li L, Jick S, Breitenstein S, Hernandez G, Michel A, Vizcaya D. Pulmonary arterial hypertension in the USA: an epidemiological study in a large insured pediatric population. Pulm Circ 2017;7:126–136.
597. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012;379:537–546.
598. Abman SH, Mullen MP, Sleeper LA, Austin ED, Rosenzweig EB, Kinsella JP, et al.
Characterisation of paediatric pulmonary hypertensive vascular disease from the
PPHNet Registry. Eur Respir J 2021;59:2003337.
599. Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et al.
Paediatric pulmonary arterial hypertension: updates on deﬁnition, classiﬁcation,
diagnostics and management. Eur Respir J 2019;53:1801916.
600. Haarman MG, Kerstjens-Frederikse WS, Vissia-Kazemier TR, Breeman KTN,
Timens W, Vos YJ, et al. The genetic epidemiology of pediatric pulmonary arterial hypertension. J Pediatr 2020;225:65–73.e65.
601. Levy M, Eyries M, Szezepanski I, Ladouceur M, Nadaud S, Bonnet D, et al. Genetic analyses in a cohort of children with pulmonary hypertension. Eur Respir J 2016;48:
1118–1126.
602. Mourani PM, Abman SH. Pulmonary hypertension and vascular abnormalities in bronchopulmonary dysplasia. Clin Perinatol 2015;42:839–855.
603. van Loon RL, Roofthooft MT, van Osch-Gevers M, Delhaas T, Strengers JL, Blom
NA, et al. Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatr 2009;155:176–182.e171.
604. Arjaans S, Zwart EAH, Ploegstra MJ, Bos AF, Kooi EMW, Hillege HL, et al.
Identiﬁcation of gaps in the current knowledge on pulmonary hypertension in extremely preterm infants: a systematic review and meta-analysis. Paediatr Perinatal
Epidemiol 2018;32:258–267.
604a. Haarman MG, Do JM, Ploegstra MJ, Roofthooft MTR, Vissia-Kazemier TR, Hillege
HL, et al. The clinical value of proposed risk stratiﬁcation tools in pediatric pulmonary arterial hypertension. Am J Respir Crit Care Med 2019;200:1312–1315.
605. Beghetti M, Schulze-Neick I, Berger RM, Ivy DD, Bonnet D, Weintraub RG, et al.
Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension). Int J Cardiol 2016;203:
325–330.
606. Ploegstra MJ, Zijlstra WMH, Douwes JM, Hillege HL, Berger RMF. Prognostic factors in pediatric pulmonary arterial hypertension: a systematic review and meta-analysis. Int J Cardiol 2015;184:198–207.
607. Ivy DD, Rosenzweig EB, Lemarie JC, Brand M, Rosenberg D, Barst RJ. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol 2010;106:1332–1338.
608. Zijlstra WMH, Douwes JM, Rosenzweig EB, Schokker S, Krishnan U, Roofthooft
MTR, et al. Survival differences in pediatric pulmonary arterial hypertension: clues
ESC/ERS Guidelines
3725


<!-- PAGE 109 -->

### Page 109

to a better understanding of outcome and optimal treatment strategies. J Am Coll
Cardiol 2014;63:2159–2169.
609. Ploegstra MJ, Douwes JM, Roofthooft MT, Zijlstra WM, Hillege HL, Berger RM.
Identiﬁcation of treatment goals in paediatric pulmonary arterial hypertension.
Eur Respir J 2014;44:1616–1626.
610. Singh Y, Lakshminrusimha S. Pathophysiology and management of persistent pulmonary hypertension of the newborn. Clin Perinatol 2021;48:595–618.
611. Arjaans S, Haarman MG, Roofthooft MTR, Fries MWF, Kooi EMW, Bos AF, et al.
Fate of pulmonary hypertension associated with bronchopulmonary dysplasia beyond 36 weeks postmenstrual age. Arch Dis Child Fetal Neonatal Ed 2021;106:
45–50.
612. Goss KN, Beshish AG, Barton GP, Haraldsdottir K, Levin TS, Tetri LH, et al. Early pulmonary vascular disease in young adults born preterm. Am J Respir Crit Care Med
2018;198:1549–1558.
613. Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, et al. STARTS-2:
long-term survival with oral sildenaﬁl monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation 2014;129:1914–1923.
614. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A randomized,
double-blind, placebo-controlled, dose-ranging study of oral sildenaﬁl citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012;
125:324–334.
615. Ivy D, Bonnet D, Berger R, Meyer G, Baygani S, Li B. Efﬁcacy and safety of tadalaﬁl in a pediatric population with pulmonary arterial hypertension: phase 3 randomized,
double-blind placebo-controlled study. Pulm Circ 2021;11:20458940211024955.
616. Small D, Ferguson-Sells L, Dahdah N, Bonnet D, Landry J, Li B. Pharmacokinetics and safety of tadalaﬁl in a paediatric population with pulmonary arterial hypertension: a multiple ascending-dose study. Br J Clin Pharmacol 2019;85:2302–2309.
617. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al.
Pharmacokinetics, safety, and efﬁcacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003;73:372–382.
618. Beghetti M, Haworth SG, Bonnet D, Barst RJ, Acar P, Fraisse A, et al.
Pharmacokinetic and clinical proﬁle of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol
2009;68:948–955.
619. Berger RM, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Galiè N, et al. FUTURE-2:
results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int J
Cardiol 2016;202:52–58.
620. Berger RMF, Gehin M, Beghetti M, Ivy D, Kusic-Pajic A, Cornelisse P, et al. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. Br J Clin Pharmacol 2017;83:
1734–1744.
621. Ivy D, Beghetti M, Juaneda-Simian E, Miller D, Lukas M, Ioannou C, et al. A randomized study of safety and efﬁcacy of two doses of ambrisentan to treat pulmonary arterial hypertension in pediatric patients aged 8 years up to 18 years. J Pediatr
2020;5:100055.
622. Takatsuki S, Rosenzweig EB, Zuckerman W, Brady D, Calderbank M, Ivy DD.
Clinical safety, pharmacokinetics, and efﬁcacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol 2013;48:27–34.
623. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999;99:1197–1208.
624. Hopper RK, Wang Y, DeMatteo V, Santo A, Kawut SM, Elci OU, et al. Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension. Pulm Circ 2018;8:2045894018759247.
625. Lammers AE, Hislop AA, Flynn Y, Haworth SG. Epoprostenol treatment in children with severe pulmonary hypertension. Heart 2007;93:739–743.
626. Douwes JM, Zijlstra WM, Rosenzweig EB, Ploegstra MJ, Krishnan US, Haarman MG,
et al. Parenteral prostanoids in pediatric pulmonary arterial hypertension: start early, dose high, combine. Ann Am Thorac Soc 2022;19:227–237.
627. Tella JB, Kulik TJ, McSweeney JE, Sleeper LA, Lu M, Mullen MP. Prostanoids in pediatric pulmonary hypertension: clinical response, time-to-effect, and dose-response.
Pulm Circ 2020;10:2045894020944858.
628. Krishnan U, Feinstein JA, Adatia I, Austin ED, Mullen MP, Hopper RK, et al.
Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. J Pediatr 2017;188:24–34.e21.
629. Vayalthrikkovil S, Vorhies E, Stritzke A, Bashir RA, Mohammad K, Kamaluddeen M,
et al. Prospective study of pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Pediatr Pulmonol 2019;54:171–178.
630. Abman SH, Collaco JM, Shepherd EG, Keszler M, Cuevas-Guaman M, Welty SE,
et al. Interdisciplinary care of children with severe bronchopulmonary dysplasia. J
Pediatr 2017;181:12–28.e11.
631. Bermejo J, Gonzalez-Mansilla A, Mombiela T, Fernandez AI, Martinez-Legazpi P,
Yotti R, et al. Persistent pulmonary hypertension in corrected valvular heart disease: hemodynamic insights and long-term survival. J Am Heart Assoc 2021;10:
e019949.
632. Caravita S, Dewachter C, Soranna D, D’Araujo SC, Khaldi A, Zambon A, et al.
Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis. Eur Respir J 2018;51:1702427.
633. Crawford TC, Leary PJ, Fraser CD III, Suarez-Pierre A, Magruder JT, Baumgartner
WA, et al. Impact of the new pulmonary hypertension deﬁnition on heart transplant outcomes: expanding the hemodynamic risk proﬁle. Chest 2020;157:
151–161.
634. O’Sullivan CJ, Wenaweser P, Ceylan O, Rat-Wirtzler J, Stortecky S, Heg D, et al.
Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classiﬁcation. Circ Cardiovasc Interv 2015;8:e002358.
635. Vanderpool RR, Saul M, Nouraie M, Gladwin MT, Simon MA. Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol 2018;3:298–306.
636. Murali S, Kormos RL, Uretsky BF, Schechter D, Reddy PS, Denys BG, et al.
Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience. Am Heart J 1993;126:896–904.
637. Zimpfer D, Zrunek P, Roethy W, Czerny M, Schima H, Huber L, et al. Left ventricular assist devices decrease ﬁxed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg 2007;133:689–695.
638. Al-Naamani N, Preston IR, Paulus JK, Hill NS, Roberts KE. Pulmonary arterial capacitance is an important predictor of mortality in heart failure with a preserved ejection fraction. JACC Heart Fail 2015;3:467–474.
639. Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail 2013;1:290–299.
640. Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 2010;106:284–286.
641. Shah AM, Shah SJ, Anand IS, Sweitzer NK, O’Meara E, Heitner JF, et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline
ﬁndings from the echocardiographic study of the Treatment of Preserved
Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart
Fail 2014;7:104–115.
642. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001;37:
183–188.
643. Tampakakis E, Leary PJ, Selby VN, De Marco T, Cappola TP, Felker GM, et al. The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail 2015;3:9–16.
644. Naeije R, Gerges M, Vachiery JL, Caravita S, Gerges C, Lang IM. Hemodynamic phenotyping of pulmonary hypertension in left heart failure. Circ Heart Fail 2017;10:
e004082.
645. Guazzi M, Naeije R. Pulmonary hypertension in heart failure: pathophysiology,
pathobiology, and emerging clinical perspectives. J Am Coll Cardiol 2017;69:
1718–1734.
646. Zlotnick DM, Ouellette ML, Malenka DJ, DeSimone JP, Leavitt BJ, Helm RE, et al.
Effect of preoperative pulmonary hypertension on outcomes in patients with severe aortic stenosis following surgical aortic valve replacement. Am J Cardiol
2013;112:1635–1640.
647. Melby SJ, Moon MR, Lindman BR, Bailey MS, Hill LL, Damiano RJ Jr. Impact of pulmonary hypertension on outcomes after aortic valve replacement for aortic valve stenosis. J Thorac Cardiovasc Surg 2011;141:1424–1430.
648. Lucon A, Oger E, Bedossa M, Boulmier D, Verhoye JP, Eltchaninoff H, et al.
Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: study from the
FRANCE 2 Registry. Circ Cardiovasc Interv 2014;7:240–247.
649. Faggiano P, Antonini-Canterin F, Ribichini F, D’Aloia A, Ferrero V, Cervesato E,
et al. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol 2000;85:204–208.
650. Zuern CS, Eick C, Rizas K, Stoleriu C, Woernle B, Wildhirt S, et al. Prognostic value of mild-to-moderate pulmonary hypertension in patients with severe aortic valve stenosis undergoing aortic valve replacement. Clin Res Cardiol 2012;101:81–88.
651. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE
multinational database of 19030 patients. Eur J Cardiothorac Surg 1999;15:
816–822; discussion 822–813.
652. Chandrashekhar Y, Westaby S, Narula J. Mitral stenosis. Lancet 2009;374:
1271–1283.
653. Dreyfus GD, Martin RP, Chan KM, Dulguerov F, Alexandrescu C. Functional tricuspid regurgitation: a need to revise our understanding. J Am Coll Cardiol 2015;65:
2331–2336.
3726
ESC/ERS Guidelines


<!-- PAGE 110 -->

### Page 110

654. Muraru D, Parati G, Badano L. The importance and the challenges of predicting the progression of functional tricuspid regurgitation. JACC Cardiovasc Imaging 2020;13:
1652–1654.
655. Andersen MJ, Hwang SJ, Kane GC, Melenovsky V, Olson TP, Fetterly K, et al.
Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction. Circ Heart Fail
2015;8:542–550.
656. Tedford RJ, Hassoun PM, Mathai SC, Girgis RE, Russell SD, Thiemann DR, et al.
Pulmonary capillary wedge pressure augments right ventricular pulsatile loading.
Circulation 2012;125:289–297.
657. Bosch L, Lam CSP, Gong L, Chan SP, Sim D, Yeo D, et al. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. Eur J
Heart Fail 2017;19:1664–1671.
658. Obokata M, Reddy YNV, Melenovsky V, Pislaru S, Borlaug BA. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart J 2019;40:689–697.
659. D’Alto M, Romeo E, Argiento P, Pavelescu A, Melot C, D’Andrea A, et al.
Echocardiographic prediction of pre- versus postcapillary pulmonary hypertension.
J Am Soc Echocardiogr 2015;28:108–115.
660. D’Alto M, Romeo E, Argiento P, Pavelescu A, D’Andrea A, Di Marco GM, et al. A
simple echocardiographic score for the diagnosis of pulmonary vascular disease in heart failure. J Cardiovasc Med 2017;18:237–243.
661. Hoeper MM, Lam CSP, Vachiery JL, Bauersachs J, Gerges C, Lang IM, et al.
Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. Eur Heart J 2017;38:2869–2873.
662. Churchill TW, Li SX, Curreri L, Zern EK, Lau ES, Liu EE, et al. Evaluation of 2 existing diagnostic scores for heart failure with preserved ejection fraction against a comprehensively phenotyped cohort. Circulation 2021;143:289–291.
663. Reddy YNV, Carter RE, Obokata M, Redﬁeld MM, Borlaug BA. A simple, evidencebased approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018;138:861–870.
664. Andersen MJ, Ersboll M, Bro-Jeppesen J, Gustafsson F, Hassager C, Kober L, et al.
Exercise hemodynamics in patients with and without diastolic dysfunction and preserved ejection fraction after myocardial infarction. Circ Heart Fail 2012;5:444–451.
665. Andersen MJ, Olson TP, Melenovsky V, Kane GC, Borlaug BA. Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure. Circ Heart Fail 2015;8:41–48.
666. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redﬁeld MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ
Heart Fail 2010;3:588–595.
667. Fujimoto N, Borlaug BA, Lewis GD, Hastings JL, Shafer KM, Bhella PS, et al.
Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation 2013;127:55–62.
668. Ho JE, Zern EK, Wooster L, Bailey CS, Cunningham T, Eisman AS, et al. Differential clinical proﬁles, exercise responses, and outcomes associated with existing HFpEF
deﬁnitions. Circulation 2019;140:353–365.
669. Baratto C, Caravita S, Soranna D, Faini A, Dewachter C, Zambon A, et al. Current limitations of invasive exercise hemodynamics for the diagnosis of heart failure with preserved ejection fraction. Circ Heart Fail 2021;14:e007555.
670. Fox BD, Shimony A, Langleben D, Hirsch A, Rudski L, Schlesinger R, et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension.
Eur Respir J 2013;42:1083–1091.
671. Lewis GD, Bossone E, Naeije R, Grunig E, Saggar R, Lancellotti P, et al. Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases.
Circulation 2013;128:1470–1479.
672. Maor E, Grossman Y, Balmor RG, Segel M, Fefer P, Ben-Zekry S, et al. Exercise haemodynamics may unmask the diagnosis of diastolic dysfunction among patients with pulmonary hypertension. Eur J Heart Fail 2015;17:151–158.
673. Robbins IM, Hemnes AR, Pugh ME, Brittain EL, Zhao DX, Piana RN, et al. High prevalence of occult pulmonary venous hypertension revealed by ﬂuid challenge in pulmonary hypertension. Circ Heart Fail 2014;7:116–122.
674. Borlaug BA. Invasive assessment of pulmonary hypertension: time for a more ﬂuid approach? Circ Heart Fail 2014;7:2–4.
675. Selim AM, Wadhwani L, Burdorf A, Raichlin E, Lowes B, Zolty R. Left ventricular assist devices in pulmonary hypertension group 2 with signiﬁcantly elevated pulmonary vascular resistance: a bridge to cure. Heart Lung Circ 2019;28:946–952.
676. Al-Kindi SG, Farhoud M, Zacharias M, Ginwalla MB, ElAmm CA, Benatti RD, et al.
Left ventricular assist devices or inotropes for decreasing pulmonary vascular resistance in patients with pulmonary hypertension listed for heart transplantation.
J Card Fail 2017;23:209–215.
677. Imamura T, Chung B, Nguyen A, Rodgers D, Sayer G, Adatya S, et al. Decoupling between diastolic pulmonary artery pressure and pulmonary capillary wedge pressure as a prognostic factor after continuous ﬂow ventricular assist device implantation. Circ Heart Fail 2017;10:e003882.
678. Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension–a multi-center randomized study. Cardiology 2008;109:273–280.
679. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, et al.
Sildenaﬁl improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007;116:1555–1562.
680. Dumitrescu D, Seck C, Mohle L, Erdmann E, Rosenkranz S. Therapeutic potential of sildenaﬁl in patients with heart failure and reactive pulmonary hypertension. Int J
Cardiol 2012;154:205–206.
681. Wu X, Yang T, Zhou Q, Li S, Huang L. Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. Eur J Heart Fail 2014;16:444–453.
682. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliﬂozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–1461.
683. Koller B, Steringer-Mascherbauer R, Ebner CH, Weber T, Ammer M, Eichinger J,
et al. Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-trial). Heart Lung Circ 2017;26:
433–441.
684. Vachiery JL, Delcroix M, Al-Hiti H, Efﬁcace M, Hutyra M, Lack G, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 2018;51:
1701886.
685. Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, et al.
Effects of sildenaﬁl on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015;36:2565–2573.
686. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a
1-year study. Circulation 2011;124:164–174.
687. Kramer T, Dumitrescu D, Gerhardt F, Orlova K, Ten Freyhaus H, Hellmich M, et al.
Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. Int J Cardiol 2019;283:152–158.
688. Obokata M, Reddy YNV, Shah SJ, Kaye DM, Gustafsson F, Hasenfubeta G, et al.
Effects of interatrial shunt on pulmonary vascular function in heart failure with preserved ejection fraction. J Am Coll Cardiol 2019;74:2539–2550.
689. Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction
(REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.
Lancet 2022;399:1130–1140.
690. Borlaug BA, Blair J, Bergmann MW, Bugger H, Burkhoff D, Bruch L, et al. Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure. Circulation 2022;145:1592–1604.
691. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB,
et al. Sustained efﬁcacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 2016;387:453–461.
692. Angermann CE, Assmus B, Anker SD, Asselbergs FW, Brachmann J, Brett ME, et al.
Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure
(MEMS-HF). Eur J Heart Fail 2020;22:1891–1901.
693. Shavelle DM, Desai AS, Abraham WT, Bourge RC, Raval N, Rathman LD, et al.
Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: one-year outcomes from the
CardioMEMS Post-Approval Study. Circ Heart Fail 2020;13:e006863.
694. Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, et al.
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet 2021;398:991–1001.
695. Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, et al.
Empagliﬂozin effects on pulmonary artery pressure in patients with heart failure:
results from the EMBRACE-HF trial. Circulation 2021;143:1673–1686.
696. Tran JS, Havakuk O, McLeod JM, Hwang J, Kwong HY, Shavelle D, et al. Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Fail 2021;8:1706–1710.
697. Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, et al.
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail 2019;21:337–341.
698. Wachter R, Fonseca AF, Balas B, Kap E, Engelhard J, Schlienger R, et al. Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany.
Eur J Heart Fail 2019;21:588–597.
699. Gaemperli O, Moccetti M, Surder D, Biaggi P, Hurlimann D, Kretschmar O, et al.
Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart 2012;98:126–132.
700. Tigges E, Blankenberg S, von Bardeleben RS, Zurn C, Bekeredjian R, Ouarrak T,
et al. Implication of pulmonary hypertension in patients undergoing MitraClip
ESC/ERS Guidelines
3727


<!-- PAGE 111 -->

### Page 111

therapy: results from the German transcatheter mitral valve interventions (TRAMI)
registry. Eur J Heart Fail 2018;20:585–594.
701. Bermejo J, Yotti R, Garcia-Orta R, Sanchez-Fernandez PL, Castano M,
Segovia-Cubero J, et al. Sildenaﬁl for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter,
double-blind, randomized clinical trial. Eur Heart J 2018;39:1255–1264.
702. Chorin E, Rozenbaum Z, Topilsky Y, Konigstein M, Ziv-Baran T, Richert E, et al.
Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc
Imaging 2020;21:157–165.
703. Topilsky Y, Nkomo VT, Vatury O, Michelena HI, Letourneau T, Suri RM, et al.
Clinical outcome of isolated tricuspid regurgitation. JACC Cardiovasc Imaging
2014;7:1185–1194.
704. Lurz P, Orban M, Besler C, Braun D, Schlotter F, Noack T, et al. Clinical characteristics, diagnosis, and risk stratiﬁcation of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair. Eur Heart J
2020;41:2785–2795.
705. Brener MI, Lurz P, Hausleiter J, Rodes-Cabau J, Fam N, Kodali SK, et al. Right ventricular-pulmonary arterial coupling and afterload reserve in patients undergoing transcatheter tricuspid valve repair. J Am Coll Cardiol 2022;79:448–461.
706. Cao JY, Wales KM, Cordina R, Lau EMT, Celermajer DS. Pulmonary vasodilator therapies are of no beneﬁt in pulmonary hypertension due to left heart disease:
A meta-analysis. Int J Cardiol 2018;273:213–220.
707. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, et al.
“Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001;164:219–224.
708. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A,
Charpentier C, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995;107:
1193–1198.
709. Thurnheer R, Ulrich S, Bloch KE. Precapillary pulmonary hypertension and sleepdisordered breathing: is there a link? Respiration 2017;93:65–77.
710. Leon-Velarde F, Maggiorini M, Reeves JT, Aldashev A, Asmus I, Bernardi L, et al.
Consensus statement on chronic and subacute high altitude diseases. High Alt
Med Biol 2005;6:147–157.
711. Freitas CSG, Baldi BG, Jardim C, Araujo MS, Sobral JB, Heiden GI, et al. Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method. Orphanet J Rare Dis
2017;12:74.
712. Zeder K, Avian A, Bachmaier G, Douschan P, Foris V, Sassmann T, et al. Elevated pulmonary vascular resistance predicts mortality in COPD patients. Eur Respir J
2021;58:2100944.
713. Olsson KM, Hoeper MM, Pausch C, Grunig E, Huscher D, Pittrow D, et al.
Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. Eur Respir J 2021;58:2101483.
714. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 2005;172:189–194.
715. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary ﬁbrosis. Chest
2006;129:746–752.
716. Medrek SK, Sharafkhaneh A, Spiegelman AM, Kak A, Pandit LM. Admission for
COPD exacerbation is associated with the clinical diagnosis of pulmonary hypertension: results from a Retrospective Longitudinal Study of a Veteran Population.
COPD 2017;14:484–489.
717. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:158–164.
718. Vizza CD, Hoeper MM, Huscher D, Pittrow D, Benjamin N, Olsson KM, et al.
Pulmonary hypertension in patients with COPD: results from COMPERA. Chest
2021;160:678–689.
719. Dauriat G, Reynaud-Gaubert M, Cottin V, Lamia B, Montani D, Canuet M, et al.
Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a prospective French multicenter cohort. J Heart Lung Transplant 2021;
40:1009–1018.
720. Kovacs G, Agusti A, Barbera JA, Celli B, Criner G, Humbert M, et al. Pulmonary vascular involvement in COPD - is there a pulmonary vascular phenotype? Am J Respir
Crit Care Med 2018;198:1000–1011.
721. Andersen KH, Iversen M, Kjaergaard J, Mortensen J, Nielsen-Kudsk JE, Bendstrup E,
et al. Prevalence, predictors, and survival in pulmonary hypertension related to endstage chronic obstructive pulmonary disease. J Heart Lung Transplant 2012;31:
373–380.
722. Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, et al.
Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005;127:1531–1536.
723. Carlsen J, Hasseriis Andersen K, Boesgaard S, Iversen M, Steinbruchel D, Bogelund
Andersen C. Pulmonary arterial lesions in explanted lungs after transplantation correlate with severity of pulmonary hypertension in chronic obstructive pulmonary disease. J Heart Lung Transplant 2013;32:347–354.
724. Bunel V, Guyard A, Dauriat G, Danel C, Montani D, Gauvain C, et al. Pulmonary arterial histologic lesions in patients with COPD with severe pulmonary hypertension. Chest 2019;156:33–44.
725. Kovacs G, Avian A, Douschan P, Foris V, Olschewski A, Olschewski H. Patients with pulmonary arterial hypertension less represented in clinical trials - who are they and how are they? Am J Respir Crit Care Med 2016;193:A3979.
726. Torres-Castro R, Gimeno-Santos E, Vilaro J, Roque-Figuls M, Moises J,
Vasconcello-Castillo L, et al. Effect of pulmonary hypertension on exercise tolerance in patients with COPD: a prognostic systematic review and meta-analysis.
Eur Respir Rev 2021;30:200321.
727. Nathan SD, Shlobin OA, Barnett SD, Saggar R, Belperio JA, Ross DJ, et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary ﬁbrosis. Respir Med 2008;102:1305–1310.
728. Bax S, Bredy C, Kempny A, Dimopoulos K, Devaraj A, Walsh S, et al. A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease. ERJ Open Res 2018;4:00124-2017.
729. Bax S, Jacob J, Ahmed R, Bredy C, Dimopoulos K, Kempny A, et al. Right ventricular to left ventricular ratio at CT pulmonary angiogram predicts mortality in interstitial lung disease. Chest 2020;157:89–98.
730. Chin M, Johns C, Currie BJ, Weatherley N, Hill C, Elliot C, et al. Pulmonary artery size in interstitial lung disease and pulmonary hypertension: association with interstitial lung disease severity and diagnostic utility. Front Cardiovasc Med 2018;5:53.
731. Kiely DG, Levin D, Hassoun P, Ivy DD, Jone PN, Bwika J, et al. Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute
(PVRI). Pulm Circ 2019;9:2045894019841990.
732. Johns CS, Rajaram S, Capener DA, Oram C, Elliot C, Condliffe R, et al. Non-invasive methods for estimating mPAP in COPD using cardiovascular magnetic resonance imaging. Eur Radiol 2018;28:1438–1448.
733. Pynnaert C, Lamotte M, Naeije R. Aerobic exercise capacity in COPD patients with and without pulmonary hypertension. Respir Med 2010;104:121–126.
734. Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A,
et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease.
N Engl J Med 2021;384:325–334.
735. Kovacs G, Avian A, Pienn M, Naeije R, Olschewski H. Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. Am J Respir Crit Care Med 2014;190:252–257.
736. Blanco I, Santos S, Gea J, Guell R, Torres F, Gimeno-Santos E, et al. Sildenaﬁl to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J
2013;42:982–992.
737. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N,
et al. Sildenaﬁl for treatment of lung ﬁbrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895–900.
738. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B,
Grimminger F, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung ﬁbrosis. Am J Respir Crit Care Med 1999;160:600–607.
739. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619–628.
740. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of idiopathic pulmonary ﬁbrosis with ambrisentan: a parallel, randomized trial. Ann Intern
Med 2013;158:641–649.
741. Goudie AR, Lipworth BJ, Hopkinson PJ, Wei L, Struthers AD. Tadalaﬁl in patients with chronic obstructive pulmonary disease: a randomised, double-blind,
parallel-group, placebo-controlled trial. Lancet Respir Med 2014;2:293–300.
742. Lederer DJ, Bartels MN, Schluger NW, Brogan F, Jellen P, Thomashow BM, et al.
Sildenaﬁl for chronic obstructive pulmonary disease: a randomized crossover trial.
COPD 2012;9:268–275.
743. Vitulo P, Stanziola A, Confalonieri M, Libertucci D, Oggionni T, Rottoli P, et al.
Sildenaﬁl in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. J Heart
Lung Transplant 2017;36:166–174.
744. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, et al.
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary ﬁbrosis. Am J Respir Crit Care Med 2008;177:75–81.
745. King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary ﬁbrosis. Am J
Respir Crit Care Med 2011;184:92–99.
746. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M,
Anstrom KJ, Collard HR, Flaherty KR, et al. A controlled trial of sildenaﬁl in advanced idiopathic pulmonary ﬁbrosis. N Engl J Med 2010;363:620–628.
3728
ESC/ERS Guidelines


<!-- PAGE 112 -->

### Page 112

747. Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, et al. Nintedanib plus sildenaﬁl in patients with idiopathic pulmonary ﬁbrosis. N Engl J Med 2018;379:
1722–1731.
748. Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parﬁtt L, et al. Bosentan in pulmonary hypertension associated with ﬁbrotic idiopathic interstitial pneumonia.
Am J Respir Crit Care Med 2014;190:208–217.
749. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, et al. Sildenaﬁl preserves exercise capacity in patients with idiopathic pulmonary ﬁbrosis and rightsided ventricular dysfunction. Chest 2013;143:1699–1708.
750. Raghu G, Nathan SD, Behr J, Brown KK, Egan JJ, Kawut SM, et al. Pulmonary hypertension in idiopathic pulmonary ﬁbrosis with mild-to-moderate restriction. Eur
Respir J 2015;46:1370–1377.
751. Nathan SD, Tapson VF, Elwing J, Rischard F, Mehta J, Shapiro S, et al. Efﬁcacy of inhaled treprostinil on multiple disease progression events in patients with pulmonary hypertension due to parenchymal lung disease in the INCREASE trial. Am J
Respir Crit Care Med 2022;205:198–207.
752. Gall H, Felix JF, Schneck FK, Milger K, Sommer N, Voswinckel R, et al. The Giessen pulmonary hypertension registry: survival in pulmonary hypertension subgroups. J
Heart Lung Transplant 2017;36:957–967.
753. Hoeper MM, Behr J, Held M, Grunig E, Vizza CD, Vonk-Noordegraaf A, et al.
Pulmonary hypertension in patients with chronic ﬁbrosing idiopathic interstitial pneumonias. PLoS One 2015;10:e0141911.
754. Klok FA, Delcroix M, Bogaard HJ. Chronic thromboembolic pulmonary hypertension from the perspective of patients with pulmonary embolism. J Thromb Haemost
2018;16:1040–1051.
755. Klok FA, Dzikowska-Diduch O, Kostrubiec M, Vliegen HW, Pruszczyk P, Hasenfuss
G, et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost 2016;14:
121–128.
756. Bonderman D, Wilkens H, Wakounig S, Schafers HJ, Jansa P, Lindner J, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009;
33:325–331.
757. Narechania S, Renapurkar R, Heresi GA. Mimickers of chronic thromboembolic pulmonary hypertension on imaging tests: a review. Pulm Circ 2020;10:
2045894019882620.
758. Xi XY, Gao W, Gong JN, Guo XJ, Wu JY, Yang YH, et al. Value of (18)F-FDG PET/
CT in differentiating malignancy of pulmonary artery from pulmonary thromboembolism: a cohort study and literature review. Int J Cardiovasc Imaging 2019;35:
1395–1403.
759. Lasch F, Karch A, Koch A, Derlin T, Voskrebenzev A, Alsady TM, et al. Comparison of MRI and VQ-SPECT as a screening test for patients with suspected CTEPH:
CHANGE-MRI study design and rationale. Front Cardiovasc Med 2020;7:51.
760. Nagel C, Prange F, Guth S, Herb J, Ehlken N, Fischer C, et al. Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension. PLoS One 2012;7:e41603.
761. Nagel C, Nasereddin M, Benjamin N, Egenlauf B, Harutyunova S, Eichstaedt CA,
et al. Supervised exercise training in patients with chronic thromboembolic pulmonary hypertension as early follow-up treatment after pulmonary endarterectomy: a prospective cohort study. Respiration 2020;99:577–588.
762. Bunclark K, Newnham M, Chiu YD, Ruggiero A, Villar SS, Cannon JE, et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2020;18:114–122.
763. Humbert MS, Simonneau G, Pittrow D, Delcroix M, Pepke-Zaba J, Langleben D,
et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2022;41:716–721.
764. Ordi-Ros
J,
Saez-Comet L, Perez-Conesa M, Vidal X, Riera-Mestre
A,
Castro-Salomo A, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 2019;171:
685–694.
765. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018;132:
1365–1371.
766. Hsieh WC, Jansa P, Huang WC, Niznansky M, Omara M, Lindner J. Residual pulmonary hypertension after pulmonary endarterectomy: a meta-analysis. J Thorac
Cardiovasc Surg 2018;156:1275–1287.
767. Madani MM, Auger WR, Pretorius V, Sakakibara N, Kerr KM, Kim NH, et al.
Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg 2012;94:97–103; discussion 103.
768. Lankeit M, Krieg V, Hobohm L, Kolmel S, Liebetrau C, Konstantinides S, et al.
Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension.
J Heart Lung Transplant 2018;37:250–258.
769. Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D’Armini AM, Snijder R, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation 2016;133:859–871.
770. Newnham M, Bunclark K, Abraham N, Ali S, Amaral-Almeida L, Cannon JE, et al.
CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. Eur Respir J
2020;56:1902096.
771. Vuylsteke A, Sharples L, Charman G, Kneeshaw J, Tsui S, Dunning J, et al.
Circulatory arrest versus cerebral perfusion during pulmonary endarterectomy surgery (PEACOG): a randomised controlled trial. Lancet 2011;378:1379–1387.
772. D’Armini AM, Morsolini M, Mattiucci G, Grazioli V, Pin M, Valentini A, et al.
Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2014;148:1005–1011.
773. Quadery SR, Swift AJ, Billings CG, Thompson AAR, Elliot CA, Hurdman J, et al. The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. Eur Respir J 2018;52:1800589.
774. Taboada D, Pepke-Zaba J, Jenkins DP, Berman M, Treacy CM, Cannon JE, et al.
Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J 2014;44:1635–1645.
775. Ghofrani HA, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al.
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
N Engl J Med 2013;369:319–329.
776. Sadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, Campean IA, et al.
Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med 2019;7:239–248.
777. Ghofrani HA, Simonneau G, D’Armini AM, Fedullo P, Howard LS, Jais X, et al.
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised,
double-blind, placebo-controlled study. Lancet Respir Med 2017;5:785–794.
778. Jais X, D’Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension:
BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol
2008;52:2127–2134.
779. Reichenberger F, Voswinckel R, Enke B, Rutsch M, El Fechtali E, Schmehl T, et al.
Long-term treatment with sildenaﬁl in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007;30:922–927.
780. Guth S, D’Armini AM, Delcroix M, Nakayama K, Fadel E, Hoole SP, et al. Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. ERJ Open Res 2021;7:00850–02020.
781. Brenot P, Jais X, Taniguchi Y, Garcia Alonso C, Gerardin B, Mussot S, et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J 2019;53:1802095.
782. Darocha S, Pietura R, Pietrasik A, Norwa J, Dobosiewicz A, Pilka M, et al.
Improvement in quality of life and hemodynamics in chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty. Circ J 2017;81:
552–557.
783. Fukui S, Ogo T, Morita Y, Tsuji A, Tateishi E, Ozaki K, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J 2014;43:1394–1402.
784. Kataoka M, Inami T, Hayashida K, Shimura N, Ishiguro H, Abe T, et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012;5:756–762.
785. Kriechbaum SD, Wiedenroth CB, Peters K, Barde MA, Ajnwojner R, Wolter JS,
et al. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension. Biomarkers 2020;25:578–586.
786. Kriechbaum SD, Scherwitz L, Wiedenroth CB, Rudolph F, Wolter JS, Haas M, et al.
Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH. ERJ Open Res 2020;6:00356-02020.
787. Lang I, Meyer BC, Ogo T, Matsubara H, Kurzyna M, Ghofrani HA, et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Eur
Respir Rev 2017;26:160119.
788. Mahmud E, Behnamfar O, Ang L, Patel MP, Poch D, Kim NH. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Interv Cardiol
Clin 2018;7:103–117.
789. Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H. Reﬁned balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012;5:748–755.
790. Ogawa A, Matsubara H. After the dawn-balloon pulmonary angioplasty for patients with chronic thromboembolic pulmonary hypertension. Circ J 2018;82:1222–1230.
791. Olsson KM, Wiedenroth CB, Kamp JC, Breithecker A, Fuge J, Krombach GA, et al.
Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J
2017;49:1602409.
792. Roller FC, Kriechbaum S, Breithecker A, Liebetrau C, Haas M, Schneider C, et al.
Correlation of native T1 mapping with right ventricular function and pulmonary
ESC/ERS Guidelines
3729


<!-- PAGE 113 -->

### Page 113

haemodynamics in patients with chronic thromboembolic pulmonary hypertension before and after balloon pulmonary angioplasty. Eur Radiol 2019;29:1565–1573.
793. Sugimura K, Fukumoto Y, Satoh K, Nochioka K, Miura Y, Aoki T, et al. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 2012;76:485–488.
794. Ogawa A, Satoh T, Fukuda T, Sugimura K, Fukumoto Y, Emoto N, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: results of a multicenter registry. Circ Cardiovasc Qual Outcomes 2017;10:e004029.
795. Inami T, Kataoka M, Yanagisawa R, Ishiguro H, Shimura N, Fukuda K, et al.
Long-term outcomes after percutaneous transluminal pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.
Circulation
2016;134:
2030–2032.
796. Ejiri K, Ogawa A, Fujii S, Ito H, Matsubara H. Vascular injury is a major cause of lung injury after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2018;11:e005884.
797. Shimokawahara H, Ogawa A, Mizoguchi H, Yagi H, Ikemiyagi H, Matsubara H.
Vessel stretching is a cause of lumen enlargement immediately after balloon pulmonary angioplasty: intravascular ultrasound analysis in patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2018;11:e006010.
798. Jaïs X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med
2022. doi:10.1016/S2213-2600(22)00214-4.
799. Wiedenroth CB, Olsson KM, Guth S, Breithecker A, Haas M, Kamp JC, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease. Pulm Circ 2018;8:2045893217753122.
800. Romanov A, Cherniavskiy A, Novikova N, Edemskiy A, Ponomarev D, Shabanov V,
et al. Pulmonary artery denervation for patients with residual pulmonary hypertension after pulmonary endarterectomy. J Am Coll Cardiol 2020;76:916–926.
801. Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, et al.
Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 2004;23:595–600.
802. Nagaya N, Sasaki N, Ando M, Ogino H, Sakamaki F, Kyotani S, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003;123:338–343.
803. Reesink HJ, Surie S, Kloek JJ, Tan HL, Tepaske R, Fedullo PF, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2010;139:85–91.
804. Araszkiewicz A, Darocha S, Pietrasik A, Pietura R, Jankiewicz S, Banaszkiewicz M,
et al. Balloon pulmonary angioplasty for the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomy. Int J Cardiol 2019;278:
232–237.
805. Shimura N, Kataoka M, Inami T, Yanagisawa R, Ishiguro H, Kawakami T, et al.
Additional percutaneous transluminal pulmonary angioplasty for residual or recurrent pulmonary hypertension after pulmonary endarterectomy. Int J Cardiol 2015;
183:138–142.
806. Cannon JE, Su L, Kiely DG, Page K, Toshner M, Swietlik E, et al. Dynamic risk stratiﬁcation of patient long-term outcome after pulmonary endarterectomy: results
From the UK National Cohort. Circulation 2016;133:1761–1771.
807. Wiedenroth CB, Liebetrau C, Breithecker A, Guth S, Lautze HJ, Ortmann E, et al.
Combined pulmonary endarterectomy and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. J Heart Lung
Transplant 2016;35:591–596.
808. Delcroix M, Staehler G, Gall H, Grunig E, Held M, Halank M, et al. Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. Eur
Respir J 2018;52:1800248.
809. Benza RL, Farber HW, Frost A, Grunig E, Hoeper MM, Busse D, et al. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. J Heart Lung Transplant 2018;37:836–843.
810. Mayer E, Jenkins D, Lindner J, D’Armini A, Kloek J, Meyns B, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg
2011;141:702–710.
811. Andreassen AK, Ragnarsson A, Gude E, Geiran O, Andersen R. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Heart 2013;99:1415–1420.
812. Wiedenroth CB, Ghofrani HA, Adameit MSD, Breithecker A, Haas M, Kriechbaum
S, et al. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulm
Circ 2018;8:2045894018783996.
813. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA 2012;307:1254–1256.
814. Savale L, Habibi A, Lionnet F, Maitre B, Cottin V, Jais X, et al. Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. Eur
Respir J 2019;54:1900585.
815. Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, et al.
Hospitalization for pain in patients with sickle cell disease treated with sildenaﬁl for elevated TRV and low exercise capacity. Blood 2011;118:855–864.
816. Turpin M, Chantalat-Auger C, Parent F, Driss F, Lionnet F, Habibi A, et al. Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. Eur Respir J 2018;52:1800272.
817. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J
Med 2004;350:886–895.
818. Derchi G, Galanello R, Bina P, Cappellini MD, Piga A, Lai ME, et al. Prevalence and risk factors for pulmonary arterial hypertension in a large group of beta-thalassemia patients using right heart catheterization: a Webthal study. Circulation 2014;129:
338–345.
819. Jais X, Ioos V, Jardim C, Sitbon O, Parent F, Hamid A, et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 2005;60:1031–1034.
820. Adir Y, Humbert M. Pulmonary hypertension in patients with chronic myeloproliferative disorders. Eur Respir J 2010;35:1396–1406.
821. Takanashi S, Akiyama M, Suzuki K, Otomo K, Takeuchi T. IgG4-related ﬁbrosing mediastinitis diagnosed with computed tomography-guided percutaneous needle biopsy: two case reports and a review of the literature. Medicine 2018;97:e10935.
822. Montani D, Achouh L, Marcelin AG, Viard JP, Hermine O, Canioni D, et al.
Reversibility of pulmonary arterial hypertension in
HIV/HHV8-associated
Castleman’s disease. Eur Respir J 2005;26:969–972.
823. Jouve P, Humbert M, Chauveheid MP, Jais X, Papo T. POEMS syndrome-related pulmonary hypertension is steroid-responsive. Respir Med 2007;101:353–355.
824. Savale L, Huitema M, Shlobin O, Kouranos V, Nathan SD, Nunes H, et al. WASOG
statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. Eur Respir Rev 2022;31:210165.
825. Bandyopadhyay D, Humbert M. An update on sarcoidosis-associated pulmonary hypertension. Curr Opin Pulm Med 2020;26:582–590.
826. Baughman RP, Shlobin OA, Gupta R, Engel PJ, Stewart JI, Lower EE, et al. Riociguat for sarcoidosis-associated pulmonary hypertension: results of a 1-year doubleblind, placebo-controlled trial. Chest 2022;161:448–457.
827. Le Pavec J, Lorillon G, Jais X, Tcherakian C, Feuillet S, Dorfmuller P, et al. Pulmonary
Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012;142:
1150–1157.
828. Jutant EM, Jais X, Girerd B, Savale L, Ghigna MR, Perros F, et al. Phenotype and outcomes of pulmonary hypertension associated with neuroﬁbromatosis type 1. Am J
Respir Crit Care Med 2020;202:843–852.
829. Oliveros, E, Vaidya, A. Metabolic disorders of pulmonary hypertension. Adv Pulm
Hypertens 2021;20:35–39.
830. Humbert M, Labrune P, Simonneau G. Severe pulmonary arterial hypertension in type 1 glycogen storage disease. Eur J Pediatr 2002;161:S93–S96.
831. Kawar B, Ellam T, Jackson C, Kiely DG. Pulmonary hypertension in renal disease:
epidemiology, potential mechanisms and implications. Am J Nephrol 2013;37:
281–290.
832. Edmonston DL, Parikh KS, Rajagopal S, Shaw LK, Abraham D, Grabner A, et al.
Pulmonary hypertension subtypes and mortality in CKD. Am J Kidney Dis 2020;
75:713–724.
833. Pabst S, Hammerstingl C, Hundt F, Gerhardt T, Grohe C, Nickenig G, et al.
Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. PLoS One 2012;7:e35310.
834. Price LC, Seckl MJ, Dorfmuller P, Wort SJ. Tumoral pulmonary hypertension. Eur
Respir Rev 2019;28:180065.
835. Seferian A, Steriade A, Jais X, Planche O, Savale L, Parent F, et al. Pulmonary hypertension complicating ﬁbrosing mediastinitis. Medicine 2015;94:e1800.
836. Baughman RP, Culver DA, Cordova FC, Padilla M, Gibson KF, Lower EE, et al.
Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 2014;145:810–817.
837. Humbert MG, Galié N, Meszaros G. Competency requirements for ERN-lung
PH centres. https://ern-lung.eu/inhalt/wp-content/uploads/2020/10/PH-MCC.pdf.
(24 June 2022, date last accessed 22 July 2022).
838. Doyle-Cox C, Nicholson G, Stewart T, Gin-Sing W. Current organization of specialist pulmonary hypertension clinics: results of an international survey. Pulm Circ
2019;9:2045894019855611.
839. Saunders H, Helgeson SA, Abdelrahim A, Rottman-Pietrzak K, Reams V, Zeiger TK,
et al. Comparing diagnosis and treatment of pulmonary hypertension patients at a pulmonary hypertension center versus community centers. Diseases 2022;10:5.
840. European Reference Network. Clinical Patient Management System (CPMS).
https://ern-euro-nmd.eu/clinical-patient-management-system/ (24 March 2022,
date last accessed 22 July 2022).
3730
ESC/ERS Guidelines


<!-- PAGE 114 -->

### Page 114

841. ERS. Continuing Professional Development - Pulmonary Vascular Diseases. https://
www.ersnet.org/wp-content/uploads/2021/02/Continuing-professional-developmentPulmonary-Vascular-Diseases.pdf (24 March 2022, date last accessed 22 July 2022).
842. Tanner FC, Brooks N, Fox KF, Goncalves L, Kearney P, Michalis L, et al. ESC core curriculum for the cardiologist. Eur Heart J 2020;41:3605–3692.
843. Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al.
Advanced heart failure: a position statement of the Heart Failure Association of the
European Society of Cardiology. Eur J Heart Fail 2018;20:1505–1535.
844. Google Maps. ERN-LUNG reference centres. https://www.google.com/maps/d/
viewer?mid=1VVJW2YWYN1q6NYMWPdk78nltgTOptt4C&ll=50.
878853000000014%2C4.6743529999999955&z=8 (24 March 2022, date last accessed 22 July 2022).
845. Giri PC, Stevens GJ, Merrill-Henry J, Oyoyo U, Balasubramanian VP. Participation in pulmonary hypertension support group improves patient-reported health quality outcomes: a patient and caregiver survey. Pulm Circ 2021;11:20458940211013258.
846. Biganzoli L, Cardoso F, Beishon M, Cameron D, Cataliotti L, Coles CE, et al. The requirements of a specialist breast centre. Breast 2020;51:65–84.
847. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, et al. European Society of Cardiology methodology for the development of quality indicators for the quantiﬁcation of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes
2022;8:4–13.
848. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the UK
after removal of ﬁnancial incentives. N Engl J Med 2018;379:948–957.
849. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality
8 years into global payment. N Engl J Med 2019;381:252–263.
850. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, et al. Quality indicators for the care and outcomes of adults with atrial ﬁbrillation. Europace 2021;23:
494–495.
851. Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet JP, et al. 2020 Update of the quality indicators for acute myocardial infarction: a position paper of the
Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group. Eur Heart J Acute Cardiovasc
Care 2021;10:224–233.
852. Aktaa S, Abdin A, Arbelo E, Burri H, Vernooy K, Blomstrom-Lundqvist C, et al.
European Society of Cardiology quality indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality
Indicators in collaboration with the European Heart Rhythm Association of the
European Society of Cardiology. Europace 2022;24:165–172.
853. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.
Heart J 2021;42:3427–3520.
854. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, et al. 2020
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:
1289–1367.
855. Batra G, Aktaa S, Wallentin L, Maggioni AP, Wilkinson C, Casadei B, et al.
Methodology for the development of international clinical data standards for common cardiovascular conditions: European Uniﬁed Registries for Heart Care
Evaluation and Randomised Trials (EuroHeart). Eur Heart J Qual Care Clin
Outcomes 2021. doi:10.1093/ehjqcco/qcab052. Epub ahead of print.
ESC/ERS Guidelines
3731
